pyrimethamine has been researched along with Malaria in 1388 studies
Maloprim: contains above 2 cpds
Malaria: A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas." | 9.69 | Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023) |
| "Coverage of antenatal iron and folic acid (IFA) supplementation and malaria chemoprophylaxis remains low in many low-income and middle-income settings." | 9.69 | Improving coverage of antenatal iron and folic acid supplementation and malaria prophylaxis through targeted information and home deliveries in Côte d'Ivoire: a cluster randomised controlled trial. ( Dao, D; Fink, G; Koné, S; Probst-Hensch, N; Utzinger, J, 2023) |
| "Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-piperaquine was superior at preventing malaria infection, but not at improving birthweight." | 9.34 | Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. ( Chico, RM; Desai, M; Dorsey, G; Glymour, MM; Gosling, R; Gutman, J; Kajubi, R; Kakuru, A; Kamya, MR; Kuile, FOT; L'Ianziva, A; Rerolle, F; Roh, ME; Shiboski, S, 2020) |
| "Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) significantly reduces the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (SP), the current standard of care, but its impact on the incidence of malaria during infancy is unknown." | 9.34 | Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial. ( Chandramohan, D; Clark, TD; Dorsey, G; Havlir, DV; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Nakalembe, M; Ochieng, T; Ochokoru, H; Ruel, T; Staedke, SG, 2020) |
| "We investigated whether adding community scheduled malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHWs) to standard intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) would improve maternal and infant health." | 9.30 | Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial. ( , 2019) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) and SP plus azithromycin (SPAZ) reduces low birthweight (<2,500 g) in women without malarial and reproductive tract infections." | 9.30 | Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection. ( Anuan, AA; Beeson, JG; Buffet, C; Hansa, AP; Hasang, W; Karl, S; Mueller, I; Ome-Kaius, M; Randall, L; Rogerson, SJ; Stock, SJ; Teo, A; Unger, HW, 2019) |
| "To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV." | 9.27 | Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018) |
| "Chloroquine administered as intermittent therapy did not provide better protection from malaria and related adverse effects compared with intermittent sulfadoxine-pyrimethamine in a setting of high resistance to sulfadoxine-pyrimethamine." | 9.27 | Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. ( Boudová, S; Divala, TH; Goswami, J; Kanjala, M; Kennedy, J; Laufer, MK; Masonga, R; Mawindo, PM; Mbilizi, Y; Muehlenbachs, A; Mungwira, RG; Muwalo, F; Mvula, P; Ndaferankhande, M; Ndovie, L; Nyirenda, OM; Potter, GE; Tomoka, T; Tsirizani, LE; Wylie, BJ, 2018) |
| "Sulfadoxine/pyrimethamine is recommended for intermittent preventative treatment of malaria during pregnancy." | 9.24 | Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery. ( Adam, I; Barnes, KI; de Kock, M; Denti, P; Nyunt, MM; Tarning, J; Workman, L, 2017) |
| "Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa." | 9.22 | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016) |
| " We conducted a trial to evaluate the efficacy and safety of scheduled intermittent screening with malaria rapid diagnostic tests (RDTs) and treatment of RDT-positive women with dihydroartemisinin-piperaquine (DP) as an alternative strategy to IPTp-SP." | 9.22 | Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Tr ( Ali, D; Faragher, B; Kalilani, L; Kang'ombe, A; Khairallah, C; Levitt, B; Madanitsa, M; Meshnick, S; Mwapasa, V; Pace, C; Smedley, J; Taylor, SM; Ter Kuile, FO; Thwai, KL; van Eijk, AM; Wang, D, 2016) |
| "It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season." | 9.22 | Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. ( Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016) |
| "Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women." | 9.20 | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. ( Abdulla, S; Aponte, J; Cot, M; Desai, M; Fernandes, S; González, R; Hanson, K; Katana, A; Kremsner, P; Kuwawenaruwa, A; Macete, E; Massougbodgi, A; Menéndez, C; Mombo-Ngoma, G; Ramharter, M; Sicuri, E; Slustker, L, 2015) |
| "The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)." | 9.20 | Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. ( Compaore, YD; Greenwood, B; Milligan, P; Nosten, F; Ouedraogo, JB; Rosenthal, PJ; Some, AF; Sutherland, C; Tarning, J; Zongo, I, 2015) |
| "We did this open-label, three-group, randomised controlled superiority trial at four sites in western Kenya with high malaria transmission and sulfadoxine-pyrimethamine resistance." | 9.20 | Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-lab ( Desai, M; Gutman, J; Juma, E; Kariuki, S; Katana, A; L'lanziva, A; Laserson, K; Otieno, K; Ouma, P; ter Kuile, FO; Were, V; Williamson, J, 2015) |
| "Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children." | 9.20 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. ( Alifrangis, M; Baraka, V; Carneiro, I; Chandramohan, D; Gesase, S; Gosling, R; Hashim, R; Ishengoma, D; Mosha, J; Poirot, E; Vittinghoff, E, 2015) |
| "Malaria intermittent preventive treatment of malaria in infant with sulphadoxine-pyrimethamine (IPTi-SP) reduced the incidence of malaria and anaemia by 30% and 20% respectively." | 9.16 | The implementation of malaria intermittent preventive trialtreatment with sulphadoxine-pyrimethamine in infants reduced all-cause mortality in the district of Kolokani, Mali: results from a cluster randomized control. ( Dicko, A; Doumbo, O; Konare, M; Rogier, C; Salamon, R; Testa, J; Traore, D, 2012) |
| "New regimens for intermittent preventive treatment in pregnancy (IPTp) against malaria are needed as the effectiveness of the standard two-dose sulfadoxine-pyrimethamine (SP) regimen is under threat." | 9.16 | The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial. ( Ashorn, P; Cheung, YB; Kulmala, T; Luntamo, M; Maleta, K; Meshnick, SR; Rantala, AM, 2012) |
| "In 2003, Mali introduced intermittent preventive therapy in pregnancy (ITPp) with sulfadoxine-pyrimethamine (SP) for the control of malaria in pregnancy, consisting of 2 doses of SP given in the 2nd and 3rd trimester." | 9.15 | Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trial. ( Bougoudogo, F; Coulibaly, S; Danis, M; Dara, A; Diakite, OS; Diallo, M; Djimde, A; Doumbo, OK; Doumbo, S; Doumtabé, D; Guindo, O; Karim, DM; Kayentao, K; Maiga, OM; Ongoiba, A; Ter Kuile, FO; Traoré, B; Traoré, BT; Traoré, M; Traoré, MS, 2011) |
| "Pregnant women with non-severe, slide proven, falciparum malaria were randomised to one of 4 regimes: sulfadoxine-pyrimethamine [SP]; chlorproguanil-dapsone [CD]; SP+amodiaquine [SP+AQ] or amodiaquine+artesunate [AQ+AS]." | 9.14 | Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. ( Briceño, M; Drakeley, C; Greenwood, BM; Mutabingwa, TK; Muze, K; Ord, R; Whitty, CJ, 2009) |
| "In the context of the increasing resistance to sulfadoxine-pyrimethamine (SP), we evaluated the efficacy of mefloquine (MQ) for intermittent preventive treatment during pregnancy (IPTp)." | 9.14 | Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. ( Ayemonna, P; Bottero, J; Briand, V; Cordel, H; Cot, M; Fayomi, B; Fievet, N; Guerra, J; Kossou, H; Masse, V; Massougbodji, A; Noël, H, 2009) |
| "Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated malaria, but there is widespread resistance." | 9.14 | Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. ( Bell, DJ; Chimpeni, P; Hughes, DA; Kayange, N; Lalloo, DG; Molyneux, ME; Montgomery, J; Mukaka, M; Ward, SA; Winstanley, PA; Wootton, D, 2009) |
| "The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria but no studies of its use for prevention have been done in Africa." | 9.14 | Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. ( Cairns, M; Cames, C; Cheng, Y; Cisse, B; Faye, B; Faye, E; Faye, O; Gaye, O; Greenwood, B; Lô, AC; Milligan, P; NDiaye, JL; NDiaye, M; NDiaye, O; Simondon, K; Trape, JF, 2009) |
| "In the context of a trial studying intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Lambaréné, Gabon, children aged 18-30 months were followed up after having received their last dose at an age of 15 months." | 9.14 | No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. ( Aponte, JJ; Borchert, LB; Doernemann, J; Gabor, JJ; Grobusch, MP; Issifou, S; Koester, KB; Kremsner, PG; Kurth, F; Lell, B; Poetschke, M; Pongratz, P; Profanter, K; Schuster, K; Schwarz, NG, 2009) |
| "To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital." | 9.14 | Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009) |
| "Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious regimen for intermittent preventive treatment to prevent malaria in children (IPTc), but the amodiaquine component is not always well tolerated." | 9.14 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. ( Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010) |
| "To evaluate the effect of seasonal IPT with sulphadoxine pyrimethamine (SP) on incidence of malaria disease in area of seasonal transmission, 262 children 6 months-10 years in Kambila, Mali were randomized to receive either IPT with SP twice at eight weeks interval or no IPT during the transmission season of 2002 and were followed up for 12 months." | 9.13 | Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. ( Diallo, AI; Dicko, A; Doumbo, OK; Guindo, O; Kone, M; Sacko, M; Sagara, I; Sissoko, MS; Toure, OB, 2008) |
| "The in vivo therapeutic efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination was evaluated in the treatment of uncomplicated Plasmodium falciparum malaria and of chloroquine for P." | 9.13 | [Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006]. ( Cortés, LJ; Guerra, AP; Knudson, A; Nicholls, RS; Pérez, MA; Usta, C, 2008) |
| "Sulfadoxine-pyrimethamine (SP) inhibits folate metabolism by the malaria parasite." | 9.13 | Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria. ( Ayisi, JG; Hamel, MJ; Kager, PA; Kariuki, S; Otieno, K; Ouma, PO; Parise, M; Slutsker, L; Ter Kuile, FO; van Eijk, AM; Williamson, J, 2008) |
| "In Malawi, there has been a return of Plasmodium falciparum sensitivity to chloroquine (CQ) since sulfadoxine-pyrimethamine (SP) replaced CQ as first line treatment for uncomplicated malaria." | 9.13 | Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. ( Bell, DJ; Molyneux, ME; Mukaka, M; Nyirongo, SK; Plowe, CV; Ward, SA; Winstanley, PA; Zijlstra, EE, 2008) |
| "The study design was an open randomized control trial comparing anaemia incidence among pregnant women on intermittent presumptive treatment of malaria with SP with those on chloroquine (CQ)." | 9.13 | Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women. ( Abiona, TC; Asa, OO; Fatusi, AO; Ijadunola, KT; Onayade, AA, 2008) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 9.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas." | 9.12 | Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 9.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| " The high endemicity of malaria in Africa may impact on the efficacy of artemisinin-based combination therapy." | 9.11 | Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. ( Bakyaita, N; Banek, K; Dorsey, G; Kamya, MR; Kilian, A; Kironde, F; Nsobya, SL; Reingold, A; Rosenthal, PJ; Slater, M; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2005) |
| "In Malawi, trimethoprim-sulfamethoxazole (TS) is the recommended first-line treatment for children with Integrated Management of Childhood Illness dual classifications of malaria and pneumonia, and sulfadoxine-pyrimethyamine (SP) plus five days of treatment with erythromycin (SP plus E) is the recommended second-line treatment." | 9.11 | Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. ( Bloland, P; Chizani, N; Hamel, MJ; Holtz, T; Kaimila, N; Kazembe, P; Kublin, J; Mkandala, C; Steketee, R, 2005) |
| "Between 1993 and 1999, we monitored the efficacy of sulfadoxine-pyrimethamine in 1175 children aged <24 months receiving 2789 treatments for falciparum malaria in western Kenya using a widely deployed age-based dose regimen: infants, 125 plus 6." | 9.10 | Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. ( Courval, JM; Hawley, WA; Kariuki, SK; Kolczak, MS; Kuile, FO; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; Terlouw, DJ, 2003) |
| "Treatment of malaria with sulfadoxine/pyrimethamine and of presumed bacterial infections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assessed to see if either increases the carriage of cotrimoxazole-resistant Streptococcus pneumoniae in Malawian children." | 9.09 | Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. ( Barat, LM; Bloland, PB; Dowell, SF; Feikin, DR; Graf, C; Huebner, RE; Kazembe, PN; Klugman, KP; Nwanyanwu, OC; Schwartz, B; Ziba, C, 2000) |
| "In a controlled trial of weekly malaria chemoprophylaxis with chloroquine and pyrimethamine there were no significant differences in type and frequency of severe morbidity during chemoprophylaxis." | 9.07 | Severe morbidity among children in a trial malaria chemoprophylaxis with pyrimethamine or chloroquine in Ibarapa, Nigeria. ( Asuzu, MC; Bamgboye, A; Ogunba, EO; Osunkoya, BO; Oyediran, AB; Topley, E; Williams, AI, 1993) |
| "Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1." | 9.07 | Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ( Chongsuphajaisiddhi, T; Edstein, M; Luxemburger, C; Nosten, F; Phaipun, L; ter Kuile, F; Thew, KL; Webster, HK; White, NJ, 1991) |
| "To compare the efficacy and side-effects of two therapeutic regimens for chloroquine-resistant falciparum malaria, a randomized study was carried out in 69 patients in Maputo Central Hospital in 1986-1987." | 9.06 | [Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique]. ( Dinis, DV; Schapira, A, 1990) |
| "In Nigeria chloroquine remains the drug of choice for the treatment of falciparum malaria since chloroquine resistance is not yet a problem." | 9.06 | Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria. ( Aina Adio, R; Fadeke Aderounmu, A; Laoye, AJ; Modupe Makinde, J; Salako, LA, 1988) |
| "After treatment with chloroquine and pyrimethamine/sulfadoxine, 118 school children aged 6 to 10 years living near the Kenyan coast were enrolled in a malaria chemoprophylaxis study and followed up for 20 weeks." | 9.06 | Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. ( Brandling-Bennett, AD; Gilles, HM; Howells, RE; Koech, DK; Oloo, AJ; Watkins, WM, 1987) |
| "A randomized double blind study in long term malaria chemoprophylaxis was performed to compare the tolerability of Fansimef (1 tablet containing 250 mg mefloquine + 500 mg sulfadoxine + 25 mg pyrimethamine per week) with chloroquine (300 mg per week)." | 9.06 | Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria. ( Kollaritsch, H; Kollaritsch, R; Kremsner, P; Leimer, R; Mailer, H; Stemberger, H; Wiedermann, G, 1988) |
| " Fifty cases of falciparum malaria were treated with 1800 mg amodiaquine for 3 days: the cure rate was 65." | 9.06 | Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China. ( Cai, XZ; Fu, SG; Huang, JK; Huang, OL; Ouyang, WC; Pang, XJ; Wang, XF; Wu, Z; Zhang, KY; Zhou, JX, 1988) |
| "As malaria caused by Plasmodium falciparum has become resistant to chloroquine alternative drug regimens need to be developed." | 9.06 | Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. ( Bygbjerg, IC; Fogh, S; Gøtzsche, PC; Jepsen, S; Kuijlen, K; Mordhorst, CH; Ravn, P; Rønn, A; Schapira, A, 1988) |
| "The standard chloroquine treatment for Plasmodium falciparum malaria is 25 mg (base)/kg (C25) given over 3 days." | 9.06 | Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children. ( Bugilimfura, L; Deloron, P; Neill, M; Ntilivamunda, A; Sexton, JD, 1988) |
| "A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP)." | 9.06 | Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose. ( Bunnag, D; Charoenlarp, P; Chitamas, S; Harinasuta, T; Sheth, UK; Suntharasmai, P; Vanijanond, S; Wernsdorfer, WH, 1987) |
| "A total of 100 male Zambian patients with symptomatic falciparum malaria were treated with either two tablets of mefloquine plus sulfadoxine-pyrimethamine (Fansimef) or three tablets of sulfadoxine-pyrimethamine (Fansidar) as a single dose." | 9.06 | A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. ( Ekue, JM; Mukunyandela, M; Phiri, DE; Sheth, UK, 1987) |
| "Three different regimens were compared for treatment of falciparum malaria in displaced Kampucheans living in encampments on the Thai-Kampuchean border in 1983: single dose 750 mg mefloquine, 1." | 9.06 | Treatment of falciparum malaria with quinne and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border. ( Doberstyn, EB; Gaüzère, BA; Meek, SR; Nordlander, E; Phuphaisan, S; Thanapanich, C, 1986) |
| "A trial of drug regimens for treating Plasmodium falciparum malaria was conducted in a refugee camp in eastern Thailand where extensive 'Fansidar' (pyrimethamine-sulfadoxine) resistance had been demonstrated." | 9.05 | Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980. ( Brandling-Bennett, AD; Campbell, CC; Doberstyn, EB; Freeman, J; Reacher, M, 1981) |
| "A prospective trial in 80 patients randomly allocated to four antimalarial treatment regimens--mefloquine plus pyrimethamine-sulfadoxine ('Fansidar'); mefloquine plus qinghaosu; mefloquine, fansidar, and qinghaosu; and qinghaosu alone--was carried out on Hainan Island, China, in patients with chloroquine-resistant falciparum malaria." | 9.05 | Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. ( Arnold, K; Fu, LC; Guo, XB; Jian, HX; Li, GQ, 1984) |
| "A study was carried out to assess the efficacy of a modified 7 day course of quinine in children with falciparum malaria, in comparison with those of a 7 day course of quinine at standard dosage and a combination of a 7 day course of quinine and sulfadoxine-pyrimethamine, and in relation to the MIC, and to the serum levels of quinine during the course of treatment." | 9.05 | Treatment of quinine resistant falciparum malaria in Thai children. ( Attanath, P; Chongsuphajaisiddhi, T; Sabchareon, A, 1983) |
| "Falciparum malaria in 104 Thai patients was treated with either Mefloquine or Fansidar and patients were examined for parasitaemia for the next 28 days." | 9.05 | A comparative trial of Mefloquine and Fansidar in the treatment of falciparum malaria: failure of Fansidar. ( Dixon, KE; Phintuyothin, P; Pitaktong, U; Pongsupat, T; Williams, RG, 1982) |
| "Fifty-two patients with severe chloroquine resistant Plasmodium falciparum malaria were treated in a randomized double blind study with either quinine and a single dose of pyrimethamine-sulfadoxine (Fansidar) or quinine alone." | 9.05 | Quinine alone versus quinine plus a pyrimethamine-sulfadoxine combination in the treatment of Plasmodium faliciparum cerebral malaria. ( Adler, J; Englehard, D; Naparstek, Y; Sack, J; Shemer, J; Spira, DT; Weiler-Ravell, D, 1981) |
| "Chloroquine-resistant Plasmodium falciparum malaria is increasing in prevelance in Papua New Guinea and alternative therapies for acute malaria are being sought." | 9.05 | Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. ( Alpers, M; Darlow, B; Gibney, S; Jolley, D; Stace, J; Vrbova, H, 1982) |
| " In one trial mefloquine was compared with chloroquine in 40 patients with Plasmodium vivax malaria and in the other one mefloquine was compared with MSP in 40 patients with P falciparum malaria." | 9.05 | Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria. ( Bunnag, D; Harinasuta, T; Lasserre, R; Leimer, R; Vinijanont, S, 1985) |
| "The clinical and parasitological response of adult male patients to mefloquine and to a combination of quinine and sulfadoxine-pyrimethamine during the treatment of falciparum malaria was compared." | 9.05 | An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil. ( de Oliveira, RM; de Souza, JM; de Souza, SD; Roulet, H; Sheth, UK, 1985) |
| "Two field trials to detect chloroquine-resistant malaria were conducted according to WHO recommendations in a malaria free area near Rangoon." | 9.04 | Chloroquine-resistant malaria in Burma. ( Hlaing, N; Htun Nyun, R; Kyi, KK; Myint, T; Tin, F; U, T, 1975) |
| "5 g) of mefloquine hydrochloride cured all of 37 patients with falciparum malaria, and a single dose of pyrimethamine (75 mg) plus sulfadoxine (1." | 9.04 | Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine. ( Doberstyn, EB; Noeypatimanondh, S; Phintuyothin, P; Teerakiartkamjorn, C, 1979) |
| "A trial of suppression of malaria by administration of combined sulphadoxine-pyrimethamine tablets every 28 days was undertaken in West Malaysia during 1972." | 9.04 | Suppression of malaria with monthly administration of combined sulphadoxine and pyrimethamine. ( Lewis, AN; Ponnampalam, JT, 1975) |
| " One hundred and seventy inhabitants of the Ilorin area, Nigeria, were observed over a period of five months during the season of maximum malaria transmission while taking pyrimethamine-sulphormethoxine weekly, fortnightly and every four weeks." | 9.04 | Comparative efficiency of pyrimethamine-sulphormethoxine in malaria suppression given as single weekly, fortnightly and monthly doses. ( Shafei, AZ, 1975) |
| "Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy." | 9.01 | A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. ( Esu, E; Meremikwu, M; Oduwole, O; Okusanya, BO; Olaleye, A, 2019) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 8.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| "Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the standard 2-dose regimen." | 8.89 | Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. ( Ashorn, P; Doumbo, OK; Garner, P; Kayentao, K; Luntamo, M; MacArthur, JR; Mulokozi, A; Naidoo, I; Roper, C; ter Kuile, FO; van Eijk, AM, 2013) |
| " falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)." | 8.85 | Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009) |
| "Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral malaria, birth weight, and hemoglobin level/anemia were independently abstracted by 2 investigators." | 8.84 | Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. ( Filler, SJ; ter Kuile, FO; van Eijk, AM, 2007) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "A meta-analysis study evaluating the efficacy and safety of chloroquine and alternative antimalarial drugs used in six African countries including Ethiopia, Kenya, Uganda, Cote D'Ivoire, Gambia and Nigeria is presented." | 8.80 | Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ( Makonnen, E; Mengesha, T, 1999) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 8.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 8.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "The effectiveness of community delivery of intermittent preventive treatment (C-IPT) of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine has been evaluated in selected areas of the Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria." | 8.31 | Prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation. ( Arikpo, I; Bissombolo, D; Doderer-Lang, C; Figueroa-Romero, A; González, R; Lemba, E; Llach, M; Ma, L; Maly, C; Mayor, A; Menard, D; Menéndez, C; Meremikwu, M; Nhama, A; Pagnoni, F; Pons-Duran, C; Rakotosaona, R; Ratsimbasoa, A; Roman, E; Sacoor, C; Sanz, S, 2023) |
| "Intermittent preventive treatment of malaria in pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) tablets is one of the recommended interventions to reduce the burden of malaria on both the pregnant woman and the unborn child." | 8.12 | Intermittent Preventive Treatment of Malaria in Pregnancy with Sulphadoxine-Pyrimethamine and its Associated Factors in the Atwima Kwanwoma District, Ghana. ( Adom, J; Ankomah, SE; Duvor, F; Fusheini, A; Karikari, AK; Kokuro, C; Kumah, E; Otchere, G, 2022) |
| "In spite of the missed opportunities of sulfadoxine-pyrimethamine (IPTp-SP) in Uganda, scanty literature exist on malaria in pregnancy." | 8.12 | Uptake of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) in Uganda: a national survey. ( Ameyaw, EK, 2022) |
| "Intermittent preventive treatment of malaria among pregnant women with sulfadoxine-pyrimethamine (IPTp-SP), is one of the three recommended interventions for the prevention of malaria in pregnancy (MiP) in sub-Sahara Africa." | 8.02 | An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context. ( Aberese-Ako, M; Ampofo, GD; Ansah, E; Gyapong, M; Magnussen, P; Tagbor, H, 2021) |
| " At least three doses of sulphadoxine pyrimethamine for intermittent preventive treatment of malaria in pregnancy (IPTp-SP) is recommended for optimal benefit." | 8.02 | Determinants of the uptake of intermittent preventive treatment of malaria in pregnancy with sulphadoxine pyrimethamine in Sabatia Sub County, Western Kenya. ( Adipo, LB; Mutanyi, JA; Ogolla, SO; Onguru, DO, 2021) |
| "Malawi adopted the 2012 updated Word Health Organization (WHO) Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) policy in 2013." | 7.96 | Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health Organization policy: an analysis of demographic and health survey 2015-2016. ( Azizi, SC, 2020) |
| "In 2012, the World Health Organization recommended that pregnant women in malaria-endemic countries complete at least three (optimal) doses of intermittent preventive treatment (IPTp) using sulfadoxine-pyrimethamine (SP) to prevent malaria and related adverse events during pregnancy." | 7.96 | Correlates of uptake of optimal doses of sulfadoxine-pyrimethamine for prevention of malaria during pregnancy in East-Central Uganda. ( Allen, K; Bernard, K; Damazo, KT; Dathan, BM; Godfrey, A; Keith, B; Martin, MK; Patricia, N; Rogers, T; Venantius, KB, 2020) |
| "Intermittent presumptive treatment in pregnancy (IPTp) of malaria using sulfadoxine-pyrimethamine (SP) was introduced in Nigeria in 2005 to reduce the burden of malaria in pregnancy." | 7.96 | Inequities in the use of sulphadoxine-pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. ( Anitube, O; Ezeoke, U; Mbachu, C; Ndu, A, 2020) |
| "Innovative community strategies to increase intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) coverage is advocated particularly in rural areas, where health infrastructure is weakest and malaria transmission highest." | 7.96 | Reaching the unreached: effectiveness and satisfaction with community-directed distribution of sulfadoxine-pyrimethamine for preventing malaria in pregnancy in rural South-East, Nigeria. ( Abateneh, DD; Agu, AP; Akamike, IC; Alo, CN; Ndukwe, CD; Nzeh, CB; Okedo-Alex, IN; Okoro, OO; Uneke, CJ, 2020) |
| "Sulfadoxine-pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC)." | 7.91 | Markers of sulfadoxine-pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention. ( Badio, C; Bakula, E; Bousema, T; Cibenda, D; Grignard, L; Lanke, K; Lassovski, M; Okell, L; Ouabo, A; Piriou, E; Rao, B; Roper, C; van der Meulen, R; van Lenthe, M, 2019) |
| "This study highlights low adherence to the new 3-dose regimen of sulfadoxine-pyrimethamine-based intermittent preventive treatment in the Cotonou health zone II and III, but it reflects its potential to contribute to the reduction of the risk of low birth weight." | 7.91 | [Sulfadoxine-pyrimethamine-based intermittent preventive treatment in pregnant women and its effect on birth weight: application of 3-dosing regimen in the urban area of South Benin in 2017]. ( Ayivi-Vinz, G; Azandjèmé, C; Biaou, COA; Glèlè-Ahanhanzo, Y; Kpozehouen, A; Ouro-Koura, AR, 2019) |
| "Mefloquine was evaluated as an alternative for intermittent preventive treatment of malaria in pregnancy (IPTp) due to increasing resistance against the first-line drug sulfadoxine-pyrimethamine (SP)." | 7.91 | Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon. ( Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019) |
| "In 2006, because of the chloroquine-resistance and following the World Health Organization (WHO) recommendations, Côte d'Ivoire adopted a new policy for the prevention of malaria during pregnancy by intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)." | 7.91 | [Evaluation of the knowledge of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine in Ivory Coast]. ( Amari, ASG; Assemian, A; Assi, SB; Balayssac, E; Kamagaté, M; Kouamé, R; Yavo, JC, 2019) |
| " Structured interview and antenatal clinic cards were used to obtain data including the use of intermittent preventive therapy in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP)." | 7.91 | Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region. ( Aklillu, E; Kamuhabwa, AAR; Mikomangwa, WP; Oms, M, 2019) |
| "To investigate whether high-dosed folate supplements might diminish the efficacy of malaria intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) in a cohort of pregnant women in Benin, where malaria is holoendemic." | 7.88 | High folate levels are not associated with increased malaria risk but with reduced anaemia rates in the context of high-dosed folate supplements and intermittent preventive treatment against malaria in pregnancy with sulphadoxine-pyrimethamine in Benin. ( Accrombessi, M; Cot, M; Moya-Alvarez, V; Ouédraogo, S, 2018) |
| "5% of the pregnant women received at least one (1) dose of sulphadoxine pyrimethamine during the current pregnancy with 71% receiving optimal (at least 3 doses) doses of sulphadoxine pyrimethamine for intermittent preventive treatment of malaria in pregnancy at the time of study." | 7.85 | Factors influencing uptake of intermittent preventive treatment of malaria in pregnancy using sulphadoxine pyrimethamine in Sunyani Municipality, Ghana. ( Apanga, PA; Bachan, EG; Ibrahim, H; Issah, K; Maya, ET; Noora, CL, 2017) |
| "In Lusaka, Zambia, where malaria prevalence is low, national guidelines continue to recommend that all pregnant women receive sulfadoxine-pyrimethamine (SP) for malaria prophylaxis monthly at every scheduled antenatal care visit after 16 weeks of gestation." | 7.85 | Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region. ( Chi, BH; Kumwenda, A; Smid, M; Stoner, MC; Stringer, E; Stringer, JS; Vwalika, B, 2017) |
| "Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate." | 7.85 | Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. ( Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017) |
| "Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucial." | 7.83 | Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. ( Ades, V; Arinaitwe, E; Chaluluka, E; Coulibaly, SO; Desai, M; Doumbo, O; Edgar, D; Gutman, J; Kalilani, L; Kamuliwo, M; Kayentao, K; Khairallah, C; Mace, KE; Magnussen, P; Mathanga, DP; Meshnick, S; Otieno, K; Ouma, P; Shi, YP; Skarbinski, J; Taylor, SM; Ter Kuile, FO; Wiegand, RE, 2016) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 7.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "Intermittent preventive treatment of malaria in pregnancy with 3+ doses of sulfadoxine-pyrimethamine (IPTp-SP) reduces maternal mortality and stillbirths in malaria endemic areas." | 7.83 | Scaling-up the use of sulfadoxine-pyrimethamine for the preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme impact from three local government areas in Sokoto State, Nigeria. ( Abdul-Azeez, J; Abegunde, D; Austin, AM; Beal, K; Fapohunda, B; Ganiyu, H; Ibrahim, M; Mohammed, Z; Nanbol, Z; Orobaton, N, 2016) |
| " Sulfadoxine/pyrimethamine-the current intermittent preventive treatment of malaria in pregnancy (IPTp)-has proven in vitro activity against group B Streptococcus (GBS)." | 7.81 | Evaluation of intermittent preventive treatment of malaria against group B Streptococcus colonization in pregnant women: a nested analysis of a randomized controlled clinical trial of sulfadoxine/pyrimethamine versus mefloquine. ( Adegnika, AA; Agnandji, ST; Akerey-Diop, D; Basra, A; Bélard, S; Capan-Melser, M; González, R; Groger, M; Kremsner, PG; Lötsch, F; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo Ngoma, G; Ramharter, M; Rehman, K; Schipulle, U; Schwing, J; Würbel, H; Zoleko-Manego, R, 2015) |
| "Sulphadoxine-Pyrimethamine (SP) is still the only recommended antimalarial for use in intermittent preventive treatment of malaria during pregnancy (IPTp) in some malaria endemic countries including Ghana." | 7.81 | Glucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort Study. ( Amu, A; Anyorigiya, T; Asante, KP; Awini, E; Bart-Plange, C; Dosoo, D; Gyapong, M; Hodgson, A; Jakpa, G; Mahama, E; Oduro, AR; Ofei, E; Owusu, R; Owusu-Agyei, S; Segbaya, S, 2015) |
| "Persistence of sulfadoxine-pyrimethamine (SP) resistance has been described in an urban setting in Malawi where malaria transmission is relatively low." | 7.81 | The effect of local variation in malaria transmission on the prevalence of sulfadoxine-pyrimethamine resistant haplotypes and selective sweep characteristics in Malawi. ( Artimovich, E; Brown, S; Escalante, AA; Joshi, S; Kapito-Tembo, A; Laufer, MK; Mathanga, D; Nyirenda, O; Pensulo, P; Takala-Harrison, S; Taylor, TE, 2015) |
| "Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) has been adopted as policy by most countries in sub-Saharan Africa." | 7.81 | Prevalence of intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) use during pregnancy and other associated factors in Sekondi-Takoradi, Ghana. ( Acquah, S; Afoakwah, R; Boampong, JN; Iriemenam, NC; Nwaefuna, E; Onyeabor, OS; Orish, VN; Sanyaolu, AO, 2015) |
| "The effectiveness of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment during pregnancy for malaria is well established." | 7.80 | Factors associated with utilization of sulphadoxine-pyrimethamine during pregnancy among women in Kenya: a cross-sectional study. ( Chertok, IR; Gurka, KK; Haile, ZT; Sambamoorthi, U, 2014) |
| "Intermittent preventive treatment during pregnancy (IPTp) with optimal doses (two+) of sulphadoxine-pyrimethamine (SP) protects pregnant women from malaria-related adverse outcomes." | 7.80 | Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania. ( Exavery, A; Kinyonge, IP; Kweka, H; Makemba, A; Mbaruku, G; Mbuyita, S, 2014) |
| "A study of health facility (HF) data on women receiving sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria during pregnancy (IPTp) was carried out at antenatal care clinics in Mkuranga and Mufindi districts." | 7.80 | Health facility-based data on women receiving sulphadoxine-pyrimethamine during pregnancy in Tanzania: lessons to learn from a cross-sectional survey in Mkuranga and Mufindi districts and other national survey reports. ( Bloch, P; Bygbjerg, IC; Byskov, J; Ijumba, JN; Magnussen, P; Marero, M; Mboera, LE; Molteni, F; Mubyazi, GM, 2014) |
| "The WHO recommends supervised administration of sulphadoxine-pyrimethamine (SP) as intermittent preventive treatment for malaria (IPTp) during pregnancy." | 7.80 | Intermittent use of sulphadoxine-pyrimethamine for malaria prevention: a cross-sectional study of knowledge and practices among Ugandan women attending an urban antenatal clinic. ( Bisaso, RK; Byamugisha, J; Obua, C; Odongo, CO, 2014) |
| "Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is widely recommended in sub-Saharan Africa to reduce the risk of malaria and improve birth outcomes." | 7.79 | Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda. ( Ades, V; Arinaitwe, E; Chang, M; Dorsey, G; Filler, S; Kamya, MR; Mugagga, O; Nasr, S; Ninsiima, B; Patil, TS; Schwartz, A; Walakira, A, 2013) |
| "To investigate the characteristics of women in Nigeria who are likely to take sulfadoxine/pyrimethamine (SP) as recommended for the prevention of malaria in pregnancy to reduce maternal and child mortality rates." | 7.79 | Characteristics of Nigerian women taking sulfadoxine/pyrimethamine twice during pregnancy for the prevention of malaria. ( Brieger, WR; Okeibunor, JC; Onyeneho, NG; Orji, BC, 2013) |
| "Our findings show that intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine may predispose to gametocyte carriage in pregnant women resident in the hyperendemic malaria region of southwest Nigeria." | 7.78 | Intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine may promote Plasmodium falciparum gametocytogenesis. ( Adeoye, SB; Balogun, ST; Fehintola, FA, 2012) |
| "To assess the effect of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) on birth weight in sites with varying degrees of drug resistance." | 7.78 | Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC). ( D'Alessandro, U; Dramaix, MW; Likwela, JL; Lokwa, BL; Meuris, S, 2012) |
| "The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei." | 7.78 | The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine. ( Aldana, I; Bertani, S; Deharo, E; Garavito, G; Quiliano, M; Valentin, A, 2012) |
| "Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTpSP) is one of the major strategies of malaria control in most African countries where malaria is endemic." | 7.77 | Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges. ( Agomo, CO; Oyibo, WA, 2011) |
| "Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown." | 7.77 | Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011) |
| "Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi)." | 7.77 | Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination. ( Jansen, FH, 2011) |
| " Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) reduces the incidence of malaria and aims to prevent mortality in infants, children, and pregnant women." | 7.77 | Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance. ( Borrmann, S; Friesen, J; Matuschewski, K, 2011) |
| "The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa." | 7.77 | Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. ( Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Kanhon, S; Kone, M; Kouakou, F; Menan, H; Sloan, C; Vanga-Bosson, HA, 2011) |
| "The effectiveness of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) against malaria and anemia is unclear because of the spread of SP-resistant Plasmodium falciparum." | 7.77 | Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria and anemia in pregnant women. ( Adjei, AA; Anderson, WA; Ceesay, FK; Gyasi, RK; Lucchi, NW; Ndjakani, Y; Obed, SA; Rodney, P; Stiles, JK; Wilson, NO, 2011) |
| "Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) given during routine vaccinations is efficacious in preventing malaria disease and shows no interaction with the vaccines." | 7.76 | Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. ( Barry, A; Coulibaly, OM; Dama, S; de Sousa, A; Diallo, AI; Dicko, A; Dicko, M; Djimdé, AA; Doumbo, OK; Rogier, C; Sagara, I; Touré, SO; Traore, M, 2010) |
| "Pyrimethamine is an antimalarial drug that has also been used successfully to treat autoimmune diseases such as lymphoproliferative syndrome." | 7.76 | Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: a novel immunomodulatory mechanism of action for an old antimalarial drug? ( Legorreta-Herrera, M; Narváez, V; Retana-Ugalde, R; Ventura-Gallegos, JL, 2010) |
| "For monitoring efficacy of sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy, data obtained from studies of children seemed inadequate." | 7.76 | Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy. ( Bertin, G; Briand, V; Cot, M; Deloron, P; Massougbodji, A, 2010) |
| "To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome." | 7.75 | Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009) |
| "The use of most anti-malarial medications is restricted during pregnancy, but two doses of sulphadoxine-pyrimethamine are recommended after the first trimester as intermittent preventive treatment in pregnancy (IPTp)." | 7.75 | Rural Gambian women's reliance on health workers to deliver sulphadoxine-pyrimethamine as recommended intermittent preventive treatment for malaria in pregnancy. ( Brabin, L; Dumbaya, I; Owens, S; Stokes, E, 2009) |
| "To investigate how delayed introduction of sulfadoxine-pyrimethamine (Fansidar) and arthemeter-lumefantrine (Coartem) as first-line drugs for malaria in KwaZulu-Natal contributed to the reported epidemics of 1985-1988 and 1997-2001." | 7.75 | Impact of delayed introduction of sulfadoxine-pyrimethamine and arthemeter-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa. ( Anyachebelu, EJ; Geddes, R; Knight, SE; Maharaj, R, 2009) |
| "Having reliable forecasts is critical now for producers, malaria-endemic countries and agencies in order to adapt production and procurement of the artemisinin-based combination treatments (ACTs), the new first-line treatments of malaria." | 7.74 | Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs). ( D'Altilia, JP; Kindermans, JM; Olliaro, P; Vandenbergh, D; Vreeke, E, 2007) |
| " Anti-malaria drug policy (2007) of the NVBDC recommends chloroquine (CQ) as the first line of drug for the treatment of all malarias." | 7.74 | Battling the malaria iceberg with chloroquine in India. ( Sharma, VP, 2007) |
| "To appraise the prevalence of malaria and anaemia in antenatal mothers; and explore the factors influencing coverage of intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) under operational conditions in the national programme for malaria control in pregnancy." | 7.74 | Appraisal on the prevalence of malaria and anaemia in pregnancy and factors influencing uptake of intermittent preventive therapy with sulfadoxine-pyrimethamine in Kibaha district, Tanzania. ( Tarimo, SD, 2007) |
| "In malaria endemic areas intermittent treatment with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in pregnancy." | 7.73 | Perceptions on use of sulfadoxine-pyrimethamine in pregnancy and the policy implications for malaria control in Uganda. ( Magnussen, P; Mbonye, AK; Neema, S, 2006) |
| "There has been a constant increase in the level of therapeutic failure of the sulfadoxine-pyrimethamine (SP) combination for treating uncomplicated Plasmodium falciparum malaria." | 7.73 | [Blood levels of sulfadoxine and pyrimethamine, according to the malaria-treatment response, in two municipalities of Antioquia, Colombia]. ( Blair, S; Carmona, J; López, C; Márquez, D; Morales, G; Pabón, A, 2005) |
| "This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria." | 7.72 | Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. ( Courval, JM; Kager, PA; Kolczak, MS; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; ter Kuile, FO; Terlouw, DJ, 2003) |
| "Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance." | 7.72 | The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. ( , 2003) |
| "To monitor the effectiveness of intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) for the control of malaria in pregnancy at delivery in the Provincial Hospital in Kisumu, Kenya, and to assess the effect of IPT in participants in a cohort study." | 7.72 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "Mefloquine and pyrimethamine-sulfadoxine combination are recommended, as is quinine, for self-administered malaria prophylaxis." | 7.71 | [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine]. ( Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001) |
| "Prior to policy change from chloroquine (CQ) to sulphadoxine/pyrimethamine (S/P; Fansidar) we assessed the perception of CQ efficacy and the alternative treatment options for malaria in children among parents/guardians (N=527) of under-fives attending first level health facilities on account of fever." | 7.71 | Perception of chloroquine efficacy and alternative treatments for uncomplicated malaria in children in a holoendemic area of Tanzania: implications for the change of treatment policy. ( Bygbjerg, IC; Minjas, JN; Tarimo, DS, 2001) |
| "Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase-thymidylate synthase (DHFR-TS)." | 7.70 | Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. ( Chan, C; Dascombe, MJ; Douglas, KT; Hyde, JE; McKie, JH; Read, M; Roser, SA; Sirawaraporn, W; Yates, R; Yuthavong, Y, 1998) |
| "Data were collected from two separate prospective cohorts to ascertain the safety of chloroquine-proguanil, sulfadoxine-pyrimethamine (SP), and mefloquine taken in the first trimester of pregnancy." | 7.70 | Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. ( Edwards, R; Fuchs, E; Kerr, L; Phillips-Howard, PA; Schildknecht, J; Steffen, R; Vanhauwere, B, 1998) |
| "A fever case management (CM) approach using sulfadoxine-pyrimethamine (SP) was compared with two presumptive intertmittent SP treatment regimens in the second and third trimesters in pregnant primigravidae and secundigravidae in an area of intense Plasmodium falciparum malaria transmission in western Kenya." | 7.70 | Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. ( Ayisi, JG; Misore, A; Muga, R; Nahlen, BL; Oloo, AJ; Parise, ME; Roberts, JM; Schultz, LJ; Steketee, RW, 1998) |
| "Proguanil and pyrimethamine are antifolate drugs with distinct chemical structures that are used commonly in the prophylaxis and treatment of Plasmodium falciparum malaria." | 7.68 | Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. ( Milhous, WK; Peterson, DS; Wellems, TE, 1990) |
| "The pharmacokinetics of mefloquine (M) were studied in 59 male Thai patients with falciparum malaria." | 7.68 | Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria. ( Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1990) |
| "Proguanil 200mg daily and chloroquine base 300mg weekly along with maloprim 1 tablet weekly was used as malaria chemoprophylaxis for 140 Hong Kong based soliders on a seven-week jungle exercise in a holoendemic malarial area of Papua New Guinea." | 7.67 | Malaria chemoprophylaxis with a proguanil-chloroquine-maloprim combination in Papua New Guinea. ( Heap, BJ, 1988) |
| "The relative risks of non-specific upper respiratory tract infections were studied in two well matched groups of military recruits to see whether dapsone-pyrimethamine (Maloprim) given as antimalarial prophylaxis was associated with immunosuppression." | 7.67 | Risk of acute non-specific upper respiratory tract infections in healthy men taking dapsone-pyrimethamine for prophylaxis against malaria. ( Lau, EY; Lee, PS, 1988) |
| "A reversed-phase high performance liquid chromatography method was developed to simultaneously estimate serum concentrations of dapsone (DDS), monoacetyldapsone (MADDS), and pyrimethamine (PYR) in 34 young adult Chinese men after they had taken the sixth weekly dose of Maloprim for malaria prophylaxis." | 7.67 | Simultaneous estimation of serum concentrations of dapsone, monoacetyldapsone, and pyrimethamine in Chinese men on maloprim for malaria prophylaxis using reversed-phase high performance liquid chromatography. ( Lee, HS; Lee, PS; Ti, TY; Yap, CL, 1985) |
| "There are no published haematological data on the long-term (more than one year) use of dapsone-pyrimethamine (Maloprim, Folaprim; one tablet a week) for malarial prophylaxis." | 7.67 | Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine. ( Cook, IF; Kish, MY, 1985) |
| "The duration of protection from blood-stage malarial challenge following single injections of pyrimethamine pamoate was assessed in mice and monkeys." | 7.67 | Long-acting, repository antimalarial agents. Duration of protection in mice and monkeys following administration of pyrimethamine pamoate. ( Jacobs, RL; Steinkampf, RW; Werbel, LM; Worth, DF, 1984) |
| "A 16-year old girl with insulin-dependent diabetes mellitus (8 years' duration) developed tropic malaria 7 weeks after her return from Kenya despite a longtime prophylaxis using pyrimethamine and sulfadoxine (Fansidar)." | 7.67 | [Chloroquine and pyrimethamine/sulfadoxine resistant malaria tropica in a child with diabetes mellitus]. ( Bienzle, U; Burger, W; Kroll, MH; Weber, B, 1984) |
| "Chloroquine-resistant Plasmodium falciparum malaria has been described in East, Central and West Africa." | 7.67 | Probable chloroquine-resistant Plasmodium falciparum malaria in south-western Africa. ( Blumenfeld, AM; Davidson, A; Isaäcson, M; Sieling, WL, 1984) |
| "One hundred and ten consecutive patients with falciparum malaria were treated with Fansidar and primaquine." | 7.67 | Clinical efficacy of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Sabah, Malaysia. ( Tan, HS; Tan, PE, 1984) |
| "In the face of an increasing prevalence of Plasmodium falciparum resistant to chloroquine and to pyrimethamine-sulphonamide or -sulphone mixtures, the need for a new, effective blood schizontocide for treatment of acute malaria is urgent." | 7.67 | The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. ( Peters, W; Robinson, BL, 1984) |
| "A 39-year-old Japanese male engineer who stayed in Nigeria from August 17, 1987 through January 22, 1988, presented chloroquine-resistant Plasmodium falciparum malaria." | 7.67 | [Chloroquine-resistant Plasmodium falciparum malaria confirmed by semi-micro sensitivity test for chloroquine seen in a person returned from Nigeria to Japan]. ( Kano, S; Matsuoka, Y; Obana, M; Suzuki, M; Waki, S; Yamakawa, H, 1989) |
| "The seleno-organic compound ebselen showed anti-malarial activity in vitro against the murine Plasmodium berghei and the human P." | 7.67 | Antimalarial properties of ebselen. ( Hüther, AM; Parnham, MJ; Sauer, A; Zhang, Y, 1989) |
| "The triple combination of pyronaridine, sulfadoxine and pyrimethamine which has been proven to be efficient in delaying emergence of drug resistance of rodent malarial parasites was further studied for potential application to malaria control." | 7.67 | Antimalarial and toxic effect of triple combination of pyronaridine, sulfadoxine and pyrimethamine. ( Ha, SH; Huang, J; Huang, ZS; Meng, F; Shao, BR; Shi, XH; Ye, XY; Zhan, CQ, 1989) |
| "The disposition of sulfadoxine was studied in the presence of pyrimethamine in 18 healthy Thai subjects who had been suffering from falciparum malaria in the 6 months prior to the study, and in 12 Thai patients with acute malaria." | 7.67 | Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects. ( Keschamrus, N; Kölle, EU; Leimer, R; Noeypatimanond, S; Sarikabhuti, B; Weidekamm, E; Wernsdorfer, W, 1988) |
| "In a field study conducted in Burma, 54 semi-immune adults suffering from falciparum malaria (mean parasite count, 15 328/mm(3) before treatment) were given a single dose of a fixed combination of 750 mg mefloquine base, 1500 mg sulfadoxine, and 75 mg pyrimethamine (3 tablets of Fansimef)." | 7.67 | Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma. ( Hlaing, N; Lasserre, R; Tin, F; Tun, T; Win, S, 1985) |
| "The elimination of the antimalarial drug pyrimethamine was studied in isolated liver preparations from young rats (80-100 g) infected with merozoites of Plasmodium berghei two weeks earlier." | 7.67 | Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ( Date, NM; Mihaly, GW; Newman, KT; Smallwood, RA; Veenendaal, JR, 1987) |
| "Six imported cases of chloroquine-resistant Falciparum malaria have been studied since October 1984." | 7.67 | Imported cases of chloroquine-resistant falciparum malaria in Iran. ( Afshar, A; Edrissian, GH; Emadi, AM; Ghorbani, M; Hajseyed-Javadi, J; Khaleghian, B; Pishva, E; Saghari, H; Shahabi, S, 1986) |
| "Seven patients (one black African and six white Europeans) developed chloroquine-resistant falciparum malaria in East Africa." | 7.67 | Chloroquine-resistant falciparum malaria from East Africa. ( Bhattacharya, DN; Hall, AP, 1986) |
| "Sixty-eight cases of vivax and 30 cases of falciparum malaria patients were treated with a combination of sulfamonomethoxine-pyrimethamine (MP tablet with 500 mg of sulfamonomethoxine and 25 mg of pyrimethamine) and the results were compared with those with chloroquine, Fansidar and quinine." | 7.67 | A combination of sulfamonomethoxine and pyrimethamine versus other drugs for the treatment of malaria. ( Ebisawa, I; Ohara, H, 1986) |
| "Mefloquine-sulphadoxine-pyrimethamine (MSP) in combination has proved effective against multiple-drug-resistant falciparum malaria, but nothing is known about mefloquine absorption when it is given in this formulation." | 7.67 | Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ( Back, DJ; Karbwang, J; Looareesuwan, S; Molyneux, ME; Nagachinta, B; Phillips, RE; Warrell, DA; Wattanagoon, Y, 1987) |
| "A fatal case of Stevens-Johnson syndrome associated with Fansidar and chloroquine is reported in a 5-year-old boy." | 7.67 | Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine. ( Bamber, MG; Elder, AT; Gray, JA; Minns, RA, 1986) |
| "An American Peace Corps volunteer contracted chloroquine-resistant Plasmodium falciparum malaria while serving in Malawi and taking regular chloroquine prophylaxis." | 7.67 | Chloroquine-resistant falciparum malaria in northern Malawi. ( Ainsworth, B; Breman, JG; Patchen, LC; Teklehaimanot, A; Wolfe, MS, 1985) |
| "We report a patient who developed agranulocytosis following exposure to three drugs: amodiaquine, pyrimethamine and dipyrone." | 7.67 | Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum. ( Douer, D; Ramot, B; Schwartz, E; Shaked, N, 1985) |
| "The efficacy of chloroquine and pyrimethamine as malaria chemoprophylactics was investigated in young Nigerian children." | 7.67 | A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children. ( Akintunde, A; Attai, ED; Bartlett, A; Bidwell, DE; Bradley, AK; Bradley-Moore, AM; Fleming, AF; Greenwood, BM; Kirkwood, BR; Voller, A, 1985) |
| " Many of the thioquinazolines (VIII) showed suppressive antimalarial activity comparable with or superior to chloroquine, cycloguanil, and pyrimethamine against drug-sensitive lines of Plasmodium berghei in mice and Plasmodium gallinaceum in chicks, and several displayed potent prophylactic activity with P." | 7.66 | Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects. ( Elslager, EF; Jacob, P; Johnson, J; Rane, L; Werbel, LM; Worth, DF, 1978) |
| "Since it was first introduced 'Fansidar' (pyrimethamine 25 mg, sulfadoxine 500 mg) has been the preferred treatment for uncomplicated chloroquine-resistant Plasmodium falciparum malaria in Thailand." | 7.66 | Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand. ( Campbell, CC; Hurwitz, ES; Johnson, D, 1981) |
| "The first two cases from East Africa of RII chloroquine- and Fansidar-resistant falciparum malaria are described." | 7.66 | Combined chloroquine/Fansidar-resistant falciparum malaria appears in East Africa. ( Hess, U; Jones, M; Timmermans, PM, 1983) |
| "The effect of pyrimethamine and the combination of pyrimethamine-sulfadoxine (Fansidar) upon the termination of the acute attack of vivax malaria was studied in Thailand." | 7.66 | Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. ( Andre, RG; Doberstyn, EB; Noeypatimanondh, S; Phintuyothin, P; Teerakiartkamjorn, C, 1979) |
| "Quinine (at least four doses given at intervals of eight to 12 hours) followed by a single dose of sulfadoxine-pyrimethamine (Fansidar) is the most effective treatment of chloroquine-resistant falciparum malaria." | 7.65 | Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine. ( Doberstyn, EB; Hall, AP; Mettaprakong, V; Sonkom, P, 1975) |
| "Chlorproguanil is one of the antimalarial drugs developed in recent years which have shown promise for field use in malaria eradication campaigns." | 7.64 | Field trials with chlorproguanil in the prophylaxis of malaria in Ghana. ( CHARLES, LJ, 1961) |
| "The authors describe a two-year investigation carried out on a group of Nigerian schoolchildren with the object of assessing the effect of suppressing malaria infection with pyrimethamine on the physical development of the African child." | 7.63 | Suppression of malaria with pyrimethamine in Nigerian schoolchildren. ( ARCHIBALD, HM; BRUCE-CHWATT, LJ, 1956) |
| "The authors present the results of a study carried out to determine the efficacy of chloroquine- and pyrimethamine-salt mixtures as a suppressive against sporozoite-induced vivax malaria (Chesson strain)." | 7.63 | Chloroquine or pyrimethamine in salt as a supressive against sporozoite-induced vivax malaria (Chesson strain). ( BURGESS, RW; COATNEY, GR; MICKELSEN, O; PIRKLE, CI; YOUNG, MD, 1958) |
| "We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth." | 7.30 | The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Fan, YM; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2023) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 7.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 7.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration." | 7.01 | Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. ( Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023) |
| "Malaria is one of the most serious global problems." | 6.82 | The efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine vs artemisinin-based drugs for malaria: a systematic review and meta-analysis. ( Chen, N; Chu, X; Feng, L; Li, M; Liu, Y; Wang, Q; Wang, S; Yan, P; Yang, K; Zhang, N; Zhang, Z, 2022) |
| " We developed population pharmacokinetic (PK) models to describe the distribution of sulfadoxine (SDX) and pyrimethamine (PYM) in children with uncomplicated malaria in Malawi." | 6.76 | Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. ( Bell, DJ; Molyneux, ME; Mukaka, M; Nyirongo, SK; Ward, SA; Winstanley, PA, 2011) |
| "In conclusion it seems possible to treat falciparum malaria in semi-immune adults, weighing less than 60 kg, with a single dose of 500 mg mefloquine base, 1000 mg sulfadoxine and 50 mg pyrimethamine (2 tablets), instead of the higher dose (3 tablets) currently recommended." | 6.66 | Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma. ( Lasserre, R; Lim, MA; Tin, F; Win, S, 1987) |
| "Pyrimethamine alone was ineffective." | 6.64 | Single-dose therapy of Falciparum malaria using pyrimethamine in combination with diformyldapsone or sulfadoxine. ( Doberstyn, EB; Hall, AP; Sonkon, P; Vetvutanapibul, K, 1976) |
| " Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP." | 6.55 | Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. ( Dorsey, G; Gutman, J; Kovacs, S; Stergachis, A; Ter Kuile, FO, 2017) |
| "Pregnancy is also associated with the risk of neural tube defects (NTDs), especially in women with low folate status, and folic acid supplementation is recommended in pregnancy to lower the risk of NTDs." | 6.50 | Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate. ( Molloy, AM; Nzila, A; Okombo, J, 2014) |
| "Low birth weight is a public health problem in Africa with the cause attributable to malaria in pregnancy." | 5.72 | Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model. ( Afagbedzi, S; Guure, C, 2022) |
| "To determine if more effective malaria chemoprevention in mothers and their children results in better neurodevelopment, 305 pregnant women were randomly assigned to 3 doses of sulfadoxine-pyrimethamine, 3 doses of dihydroartemisinin-piperaquine (DP), or monthly DP during pregnancy, and their 293 children were assigned to DP every 3 months or monthly DP from 2 to 24 months of age." | 5.69 | Effect of Malaria and Malaria Chemoprevention Regimens in Pregnancy and Childhood on Neurodevelopmental and Behavioral Outcomes in Children at 12, 24, and 36 Months: A Randomized Clinical Trial. ( Apayi, C; Bangirana, P; Conroy, AL; Dorsey, GM; Georgieff, MK; Havlir, D; Jang, JH; John, CC; Kakuru, A; Kamya, MR; Muhindo, MK; Opoka, RO; Semrud-Clikeman, M, 2023) |
| "Adequate prevention regimen with monthly sulfadoxine-pyrimethamine given to all pregnant women has been proved to reduce the risk of LBW in malaria endemic areas." | 5.69 | Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial. ( Derra, K; Donnen, P; Dramaix, M; Kaboré, B; Lingani, M; Robert, A; Rouamba, T; Samadoulougou, S; Sanou, M; Somé, G; Sorgho, H; Tahita, MC; Tinto, H; Valéa, I; Zango, SH, 2023) |
| "Coverage of antenatal iron and folic acid (IFA) supplementation and malaria chemoprophylaxis remains low in many low-income and middle-income settings." | 5.69 | Improving coverage of antenatal iron and folic acid supplementation and malaria prophylaxis through targeted information and home deliveries in Côte d'Ivoire: a cluster randomised controlled trial. ( Dao, D; Fink, G; Koné, S; Probst-Hensch, N; Utzinger, J, 2023) |
| "Intermittent preventive treatment during pregnancy using sulphadoxine-pyrimethamine is one way of reducing the effect of the disease on pregnancy outcomes." | 5.62 | Late ANC initiation and factors associated with sub-optimal uptake of sulphadoxine-pyrimethamine in pregnancy: a preliminary study in Cape Coast Metropolis, Ghana. ( Amoako, BK; Anto, F, 2021) |
| " Also, three or more dosing was associated (p < 0." | 5.56 | Coverage and effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) on adverse pregnancy outcomes in the Mount Cameroon area, South West Cameroon. ( Achidi, EA; Anchang-Kimbi, JK; Apinjoh, TO; Dionne-Odom, J; Kalaji, LN; Mbacham, HF; Ngole Sumbele, IU; Tita, ATN; Wepnje, GB, 2020) |
| " Sulfadoxine-pyrimethamine (SP), given for intermittent preventive therapy of malaria in pregnancy (IPTp), is one of few existing interventions that improves outcomes of both mother and baby despite widespread SP-resistant malaria." | 5.51 | The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens. ( Bartelt, LA; Carroll, I; Chinkhumba, J; Gutman, JR; Itoh, M; Juliano, JJ; Kayange, M; Mathanga, DP; McQuade, ETR; Meshnick, SR; Mzembe, E; Operario, DJ; Puerto-Meredith, SM; Waltmann, A, 2022) |
| "Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) provides greater protection from placental malaria than sulfadoxine-pyrimethamine (SP)." | 5.51 | The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria. ( Andronescu, LR; Chinkhumba, J; Gutman, JR; Kachepa, W; Kachingwe, M; Laufer, MK; Liang, Y; Mathanga, DP; Peterson, I; Sharma, A, 2022) |
| "Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) is recommended as a chemoprevention therapy." | 5.48 | Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) among postpartum women in Zomba District, Malawi: a cross-sectional study. ( Azizi, SC; Chipukuma, H; Chongwe, G; Jacobs, C; Michelo, C; Zgambo, J, 2018) |
| "Malaria is still one of the most serious diseases in tropical regions." | 5.46 | A novel prediction approach for antimalarial activities of Trimethoprim, Pyrimethamine, and Cycloguanil analogues using extremely randomized trees. ( Hannongbua, S; Khamsemanan, N; Lawtrakul, L; Nattee, C; Toochinda, P, 2017) |
| "Malaria in pregnancy is a major health problem that can cause maternal anaemia, stillbirth, spontaneous abortion, low birth weight and intra-uterine stunting." | 5.38 | Validity of self-reported use of sulphadoxine-pyrimethamine intermittent presumptive treatment during pregnancy (IPTp): a cross-sectional study. ( Kironde, F; Mirembe, F; Namusoke, F; Ntale, M; Wahlgren, M, 2012) |
| "Trials of intermittent preventive treatment (IPTp) of malaria in pregnant women that compared dihydroartemisinin-piperaquine with the standard of care, sulfadoxine-pyrimethamine, showed dihydroartemisinin-piperaquine was superior at preventing malaria infection, but not at improving birthweight." | 5.34 | Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis. ( Chico, RM; Desai, M; Dorsey, G; Glymour, MM; Gosling, R; Gutman, J; Kajubi, R; Kakuru, A; Kamya, MR; Kuile, FOT; L'Ianziva, A; Rerolle, F; Roh, ME; Shiboski, S, 2020) |
| "Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) significantly reduces the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (SP), the current standard of care, but its impact on the incidence of malaria during infancy is unknown." | 5.34 | Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial. ( Chandramohan, D; Clark, TD; Dorsey, G; Havlir, DV; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, MR; Nakalembe, M; Ochieng, T; Ochokoru, H; Ruel, T; Staedke, SG, 2020) |
| "Malaria is a leading cause of death in Sub-Saharan Africa." | 5.33 | How sulfadoxine-pyrimethamine (SP) was perceived in some rural communities after phasing out chloroquine (CQ) as a first-line drug for uncomplicated malaria in Tanzania: lessons to learn towards moving from monotherapy to fixed combination therapy. ( Nsimba, SE, 2006) |
| "We investigated whether adding community scheduled malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHWs) to standard intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) would improve maternal and infant health." | 5.30 | Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial. ( , 2019) |
| "The intermittent preventive treatment in infants (IPTi) trial that took place in Papua New Guinea showed an overall reduction of 29% of the risk of malaria when delivering single-dose sulfadoxine-pyrimethamine (SP) associated to 3 days of amodiaquine (AQ) every three months to children during the first year of life." | 5.30 | Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial. ( Csajka, C; Décosterd, L; Genton, B; Guidi, M; Mueller, I; Schneider, M; Senn, N; Sottas, O; Thieffry, B, 2019) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) and SP plus azithromycin (SPAZ) reduces low birthweight (<2,500 g) in women without malarial and reproductive tract infections." | 5.30 | Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection. ( Anuan, AA; Beeson, JG; Buffet, C; Hansa, AP; Hasang, W; Karl, S; Mueller, I; Ome-Kaius, M; Randall, L; Rogerson, SJ; Stock, SJ; Teo, A; Unger, HW, 2019) |
| "We enrolled 1320 pregnant Malawian women in a randomized trial and treated them with two doses of sulfadoxine-pyrimethamine (control) or monthly sulfadoxine-pyrimethamine as IPTp against malaria, or monthly sulfadoxine-pyrimethamine and two doses of azithromycin (AZI-SP) as IPTp against malaria and reproductive tract infections." | 5.30 | The impact of maternal antenatal treatment with two doses of azithromycin and monthly sulphadoxine-pyrimethamine on child weight, mid-upper arm circumference and head circumference: A randomized controlled trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Hallamaa, L; Kulmala, T; Luntamo, M; Mangani, C, 2019) |
| "001) serum concentrations of PYR were found in Papua New Guineans than in Caucasians at both sampling times, an observation which may reflect differences in the bioavailability of PYR between the two racial groups." | 5.27 | Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis. ( Cochrane, JP; Cook, IF; Edstein, MD, 1986) |
| "We enrolled 1320 pregnant Malawian women in a randomized trial and treated them for malaria and other infections with either 2 doses of sulfadoxine-pyrimethamine (SP) (control), monthly SP, or monthly sulfadoxine-pyrimethamine and 2 doses of azithromycin (AZI-SP)." | 5.27 | Child Health Outcomes After Presumptive Infection Treatment in Pregnant Women: A Randomized Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Gladstone, M; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2018) |
| "To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV." | 5.27 | Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018) |
| "Chloroquine administered as intermittent therapy did not provide better protection from malaria and related adverse effects compared with intermittent sulfadoxine-pyrimethamine in a setting of high resistance to sulfadoxine-pyrimethamine." | 5.27 | Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial. ( Boudová, S; Divala, TH; Goswami, J; Kanjala, M; Kennedy, J; Laufer, MK; Masonga, R; Mawindo, PM; Mbilizi, Y; Muehlenbachs, A; Mungwira, RG; Muwalo, F; Mvula, P; Ndaferankhande, M; Ndovie, L; Nyirenda, OM; Potter, GE; Tomoka, T; Tsirizani, LE; Wylie, BJ, 2018) |
| "Pyrimethamine-sulfadoxine has been associated with severe and fatal cutaneous reactions as well as transient liver damage." | 5.27 | Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). ( Alexander, J; Howrie, DL; Kuritsky, JN; Miller, KD; Perez, TH; Taylor, S; Van Thiel, DH; Zitelli, BJ, 1987) |
| "A clinical case of Black Water Fever following Plasmodium falciparum infection is reported." | 5.27 | A case of black water fever treated with peritoneal dialysis and artemether (quinghaosu derivative). ( , 1987) |
| "When sulfalene was administered during malaria, this difference was no longer apparent." | 5.26 | The influence of acetylator phenotype on the response to sulfalene in individuals with chloroquine-resistant falciparum malaria. ( Carson, PE; Frischer, H; Rieckmann, KH; Trenholme, GM; Williams, RL, 1978) |
| "Sulfadoxine/pyrimethamine is recommended for intermittent preventative treatment of malaria during pregnancy." | 5.24 | Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery. ( Adam, I; Barnes, KI; de Kock, M; Denti, P; Nyunt, MM; Tarning, J; Workman, L, 2017) |
| " A total of 2400 children aged 3-59 months received either: (i) a short-acting ACT for case management of malaria (artemether-lumefantrine, AL) plus placebo SMC, or (ii) a long-acting ACT (dihydroartemisinin-piperaquine, DP) for case management plus placebo SMC or (iii) AL for case management plus active SMC with sulphadoxine-pyrimethamine and amodiaquine." | 5.22 | Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. ( Acheampong, PR; Antwi, GD; Bart Plange, C; Cairns, M; Chandramohan, D; Tagbor, H, 2016) |
| "Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa." | 5.22 | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016) |
| " We conducted a trial to evaluate the efficacy and safety of scheduled intermittent screening with malaria rapid diagnostic tests (RDTs) and treatment of RDT-positive women with dihydroartemisinin-piperaquine (DP) as an alternative strategy to IPTp-SP." | 5.22 | Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Tr ( Ali, D; Faragher, B; Kalilani, L; Kang'ombe, A; Khairallah, C; Levitt, B; Madanitsa, M; Meshnick, S; Mwapasa, V; Pace, C; Smedley, J; Taylor, SM; Ter Kuile, FO; Thwai, KL; van Eijk, AM; Wang, D, 2016) |
| "It is recommended that children aged 3 months to five years of age living in areas of seasonal transmission in the sub-Sahel should receive Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ) during the malaria transmission season." | 5.22 | Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial. ( Ba, EH; Cairns, M; Cissé, B; Fall, FB; Faye, B; Gaye, O; Gomis, JF; Greenwood, BM; Kouevijdin, E; Milligan, PJ; Molez, JF; NDiaye, JL; Ndour, CT; Niane, FK; Rogier, C; Sokhna, C; Trape, JF, 2016) |
| "Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ), given each month during the transmission season, is recommended for children living in areas of the Sahel where malaria transmission is highly seasonal." | 5.22 | Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. ( Ba, EH; Cairns, M; Cissé, B; Dial, Y; Fall, FB; Faye, B; Faye, E; Faye, O; Faye, OK; Faye, S; Flach, C; Gaye, O; Gomis, JF; Greenwood, B; Konate, L; Kouevijdin, E; Lo, A; Milligan, P; NDiaye, JL; NDiaye, M; Pitt, C; Sokhna, C; Sutherland, C; Sy, O; Thior, PM; Tine, R; Trape, JF, 2016) |
| "Sulfadoxine-pyrimethamine (SP) plus azithromycin (AZ) (SPAZ) has the potential for intermittent preventive treatment of malaria in pregnancy (IPTp), but its use could increase circulation of antibiotic-resistant bacteria associated with severe pediatric infections." | 5.20 | Impact of intermittent preventive treatment in pregnancy with azithromycin-containing regimens on maternal nasopharyngeal carriage and antibiotic sensitivity of Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus: a cross-sectional ( Aho, C; Greenhill, AR; Hanieh, S; Jack, W; Lafana, A; Michael, A; Mueller, I; Ome-Kaius, M; Rogerson, SJ; Siba, P; Umbers, AJ; Unger, HW; Wangnapi, RA, 2015) |
| "Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in HIV-negative women to avert malaria, while this relies on cotrimoxazole prophylaxis (CTXp) in HIV-positive women." | 5.20 | Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy. ( Abdulla, S; Aponte, J; Cot, M; Desai, M; Fernandes, S; González, R; Hanson, K; Katana, A; Kremsner, P; Kuwawenaruwa, A; Macete, E; Massougbodgi, A; Menéndez, C; Mombo-Ngoma, G; Ramharter, M; Sicuri, E; Slustker, L, 2015) |
| "The WHO recommends that children living in areas of highly seasonal malaria transmission in the Sahel subregion should receive seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine (SPAQ)." | 5.20 | Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. ( Compaore, YD; Greenwood, B; Milligan, P; Nosten, F; Ouedraogo, JB; Rosenthal, PJ; Some, AF; Sutherland, C; Tarning, J; Zongo, I, 2015) |
| "The efficacy of intermittent preventive treatment for malaria with sulfadoxine-pyrimethamine (IPTp-SP) in pregnancy is threatened in parts of Africa by the emergence and spread of resistance to SP." | 5.20 | A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy. ( Abubakar, I; Akor, F; Awine, T; Bationo, R; Bojang, K; Cairns, M; Chandramohan, D; Coulibaly, SO; Dabira, E; Djimdé, M; Doumbo, O; Greenwood, B; Guirou, E; Hodgson, A; Kayentao, K; Magnussen, P; Meshnick, S; Milligan, P; Mohammed, K; Njie, F; Oduro, A; Ordi, J; Quaye, S; Soulama, A; Tagbor, H; Taylor, S; ter Kuile, F; Williams, J; Woukeu, A, 2015) |
| "We did this open-label, three-group, randomised controlled superiority trial at four sites in western Kenya with high malaria transmission and sulfadoxine-pyrimethamine resistance." | 5.20 | Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-lab ( Desai, M; Gutman, J; Juma, E; Kariuki, S; Katana, A; L'lanziva, A; Laserson, K; Otieno, K; Ouma, P; ter Kuile, FO; Were, V; Williamson, J, 2015) |
| "Chlorproguanil-dapsone (CD) has been linked to hemolysis in symptomatic glucose-6-phosphate dehydrogenase deficient (G6PDd) children." | 5.20 | Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants. ( Alifrangis, M; Baraka, V; Carneiro, I; Chandramohan, D; Gesase, S; Gosling, R; Hashim, R; Ishengoma, D; Mosha, J; Poirot, E; Vittinghoff, E, 2015) |
| "Monthly chemoprevention with dihydroartemisinin-piperaquine was well tolerated and associated with a significant reduction in malaria in young HIV-exposed children." | 5.19 | Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. ( Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Jagannathan, P; Kakuru, A; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Rosenthal, PJ, 2014) |
| "Intermittent preventive treatment in infants (IPTi) is the administration of sulfadoxine-pyrimethamine (SP) at 2, 3, and 9 months of age to prevent malaria." | 5.17 | A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania. ( Alonso, P; Kaur, H; Lupala, C; Manzi, F; Mshinda, H; Ord, R; Pearce, RJ; Roper, C; Schellenberg, D; Schellenberg, J; Shirima, K; Tanner, M, 2013) |
| "Malaria intermittent preventive treatment of malaria in infant with sulphadoxine-pyrimethamine (IPTi-SP) reduced the incidence of malaria and anaemia by 30% and 20% respectively." | 5.16 | The implementation of malaria intermittent preventive trialtreatment with sulphadoxine-pyrimethamine in infants reduced all-cause mortality in the district of Kolokani, Mali: results from a cluster randomized control. ( Dicko, A; Doumbo, O; Konare, M; Rogier, C; Salamon, R; Testa, J; Traore, D, 2012) |
| "To investigate the consequences of intermittent preventive treatment (IPTp) timing on birth weight, we pooled data from two studies conducted in Benin between 2005 and 2010: a prospective cohort of 1037 pregnant women and a randomised trial comparing sulfadoxine-pyrimethamine (SP) to mefloquine in 1601 women." | 5.16 | Consequences of gestational malaria on birth weight: finding the best timeframe for intermittent preventive treatment administration. ( Borgella, S; Briand, V; Cot, M; Deloron, P; Fievet, N; Huynh, BT; Massougbodji, A, 2012) |
| "New regimens for intermittent preventive treatment in pregnancy (IPTp) against malaria are needed as the effectiveness of the standard two-dose sulfadoxine-pyrimethamine (SP) regimen is under threat." | 5.16 | The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial. ( Ashorn, P; Cheung, YB; Kulmala, T; Luntamo, M; Maleta, K; Meshnick, SR; Rantala, AM, 2012) |
| "During the 2008 malaria transmission season, 1,277 children under five years of age resident in villages within the rural Farafenni demographic surveillance system (DSS) in North Bank Region, The Gambia were randomized to receive monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of amodiaquine (AQ) or SP and AQ placebos given by village health workers (VHWs) on three occasions during the months of September, October and November, in a double-blind trial." | 5.15 | A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia. ( Bojang, KA; Greenwood, BM; Milligan, P; Sesay, S; Sowe, M; Touray, E; Webb, EL, 2011) |
| " Three rounds of treatment with sulphadoxine pyrimethamine plus amodiaquine or placebos were given at monthly intervals during the malaria transmission season." | 5.15 | Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. ( Chandramohan, D; Cousens, S; Diallo, DA; Diarra, A; Gansané, A; Greenwood, B; Kaboré, Y; Kangoyé, DT; Konaté, AT; Milligan, PJ; Ouédraogo, A; Ouédraogo, AZ; Ouédraogo, E; Ouédraogo, IN; Sirima, SB; Soulama, I; Tiono, AB; Yaro, JB, 2011) |
| "Intermittent preventive treatment of malaria in infants (IPTi) consists of the administration of a treatment dose of sulphadoxine-pyrimethamine (SP) at the time of routine vaccinations." | 5.15 | Evaluating the effectiveness of IPTi on malaria using routine health information from sentinel health centres in southern Tanzania. ( Alonso, P; Armstrong Schellenberg, JR; Chemba, M; Maokola, W; Mshinda, H; Schellenberg, D; Shirima, K; Tanner, M; Willey, BA, 2011) |
| "In 2003, Mali introduced intermittent preventive therapy in pregnancy (ITPp) with sulfadoxine-pyrimethamine (SP) for the control of malaria in pregnancy, consisting of 2 doses of SP given in the 2nd and 3rd trimester." | 5.15 | Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trial. ( Bougoudogo, F; Coulibaly, S; Danis, M; Dara, A; Diakite, OS; Diallo, M; Djimde, A; Doumbo, OK; Doumbo, S; Doumtabé, D; Guindo, O; Karim, DM; Kayentao, K; Maiga, OM; Ongoiba, A; Ter Kuile, FO; Traoré, B; Traoré, BT; Traoré, M; Traoré, MS, 2011) |
| "Sulphadoxine-pyrimethamine, in combination with artesunate or amodiaquine, is recommended for the treatment of uncomplicated malaria and is being evaluated for intermittent preventive treatment." | 5.15 | Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali. ( Barnes, KI; Beavogui, AH; Djimde, AA; Doumbo, OK; Evans, A; Fredericks, A; Maiga, H; Sangare, CP; Smith, P; Tekete, MM; Toure, S; Traore, ZI, 2011) |
| "A cohort of 129 children aged 1-10 years in Kampala, Uganda, were treated with amodiaquine plus sulfadoxine-pyrimethamine for 396 episodes of uncomplicated malaria over a 29-month period as part of a longitudinal clinical trial." | 5.14 | Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. ( Clark, TD; Dorsey, G; Greenhouse, B; Hubbard, A; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Slater, M; Staedke, SG, 2009) |
| "Intermittent preventive treatment in infants with sulfadoxine-pyrimethamine (IPTi-SP) reduces malaria episodes by 20 to 59% across Africa." | 5.14 | Reduced efficacy of intermittent preventive treatment of malaria in malnourished children. ( Bienzle, U; Danquah, I; Dietz, E; Mockenhaupt, FP; Reither, K; Zanger, P; Ziniel, P, 2009) |
| "Malaria preventive strategies in pregnancy were assessed in a health center randomized trial comparing intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) with and without community based promotional activities in rural Burkina Faso." | 5.14 | Community-based promotional campaign to improve uptake of intermittent preventive antimalarial treatment in pregnancy in Burkina Faso. ( Brabin, BJ; Coulibaly, SO; D'Alessandro, U; Gies, S; Ky, C; Ouattara, FT, 2009) |
| "Pregnant women with non-severe, slide proven, falciparum malaria were randomised to one of 4 regimes: sulfadoxine-pyrimethamine [SP]; chlorproguanil-dapsone [CD]; SP+amodiaquine [SP+AQ] or amodiaquine+artesunate [AQ+AS]." | 5.14 | Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. ( Briceño, M; Drakeley, C; Greenwood, BM; Mutabingwa, TK; Muze, K; Ord, R; Whitty, CJ, 2009) |
| "In the context of the increasing resistance to sulfadoxine-pyrimethamine (SP), we evaluated the efficacy of mefloquine (MQ) for intermittent preventive treatment during pregnancy (IPTp)." | 5.14 | Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. ( Ayemonna, P; Bottero, J; Briand, V; Cordel, H; Cot, M; Fayomi, B; Fievet, N; Guerra, J; Kossou, H; Masse, V; Massougbodji, A; Noël, H, 2009) |
| "Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated malaria, but there is widespread resistance." | 5.14 | Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. ( Bell, DJ; Chimpeni, P; Hughes, DA; Kayange, N; Lalloo, DG; Molyneux, ME; Montgomery, J; Mukaka, M; Ward, SA; Winstanley, PA; Wootton, D, 2009) |
| "The long terminal half life of piperaquine makes it suitable for intermittent preventive treatment for malaria but no studies of its use for prevention have been done in Africa." | 5.14 | Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. ( Cairns, M; Cames, C; Cheng, Y; Cisse, B; Faye, B; Faye, E; Faye, O; Gaye, O; Greenwood, B; Lô, AC; Milligan, P; NDiaye, JL; NDiaye, M; NDiaye, O; Simondon, K; Trape, JF, 2009) |
| "In the context of a trial studying intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Lambaréné, Gabon, children aged 18-30 months were followed up after having received their last dose at an age of 15 months." | 5.14 | No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon. ( Aponte, JJ; Borchert, LB; Doernemann, J; Gabor, JJ; Grobusch, MP; Issifou, S; Koester, KB; Kremsner, PG; Kurth, F; Lell, B; Poetschke, M; Pongratz, P; Profanter, K; Schuster, K; Schwarz, NG, 2009) |
| "To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital." | 5.14 | Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009) |
| "Sulfadoxine-pyrimethamine with amodiaquine (SP-AQ) is a highly efficacious regimen for intermittent preventive treatment to prevent malaria in children (IPTc), but the amodiaquine component is not always well tolerated." | 5.14 | Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. ( Ba, EH; Cairns, M; Cames, C; Cisse, B; Gaye, O; Greenwood, BM; Milligan, PJ; Simondon, K; Sokhna, C; Trape, JF, 2010) |
| "Between March 2004 and March 2008, in an area of western Kenya with year round malaria transmission with high seasonal intensity and high usage of insecticide-treated nets, we conducted a randomized, double-blind placebo-controlled trial with SP plus 3 days of artesunate (SP-AS3), 3 days of amodiaquine-artesunate (AQ3-AS3), or 3 days of short-acting chlorproguanil-dapsone (CD3) administered at routine expanded programme of immunization visits (10 weeks, 14 weeks and 9 months)." | 5.14 | Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial. ( Hamel, MJ; Kariuki, S; Lindblade, K; Newman, RD; Odhiambo, FO; Otieno, P; Peterson, E; Slutsker, L; ter Kuile, FO; Vulule, J; Williamson, J, 2010) |
| "During the 2003 and 2004 malaria transmission seasons, 1200 Gambian children with moderate or severe anaemia (Hb concentration <7 g/dL) were randomised to receive either monthly sulfadoxine-pyrimethamine (SP) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial." | 5.14 | Prevention of the recurrence of anaemia in Gambian children following discharge from hospital. ( Abubakr, I; Bojang, KA; Conway, DJ; Greenwood, B; Jallow, M; Milligan, PJ; Njie, F; Nwakanma, DC; Sisay-Joof, F, 2010) |
| " Children were randomized upon their first episode, and then treated for all episodes of uncomplicated malaria with amodiaquine/sulfadoxine-pyrimethamine (AQ/SP), artesunate/amodiaquine (AS/AQ), or artemether/lumefantrine (AL)." | 5.14 | Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. ( Clark, TD; Dorsey, G; Greenhouse, B; Kamya, MR; Maiteki-Sebuguzi, C; Njama-Meya, D; Nzarubara, B; Rosenthal, PJ; Staedke, SG, 2010) |
| "Intermittent preventive treatment in infants with sulphadoxine-pyrimethamine (IPTi-SP) reduces malaria morbidity by 20% to 33%." | 5.14 | Multiplicity of Plasmodium falciparum infection following intermittent preventive treatment in infants. ( Abruquah, HH; Buchholz, U; Danquah, I; Grobusch, MP; Kobbe, R; May, J; Mockenhaupt, FP; Reither, K; Zanger, P; Ziniel, P, 2010) |
| "The effectiveness of intermittent preventive treatment of malaria in pregnancy (IPTp) may be compromised by the spread of resistance to sulphadoxine/pyrimethamine (SP) across Africa." | 5.14 | Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial. ( Agbo, M; Bruce, J; Chandramohan, D; Greenwood, B; Tagbor, H, 2010) |
| "To evaluate the effect of seasonal IPT with sulphadoxine pyrimethamine (SP) on incidence of malaria disease in area of seasonal transmission, 262 children 6 months-10 years in Kambila, Mali were randomized to receive either IPT with SP twice at eight weeks interval or no IPT during the transmission season of 2002 and were followed up for 12 months." | 5.13 | Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali. ( Diallo, AI; Dicko, A; Doumbo, OK; Guindo, O; Kone, M; Sacko, M; Sagara, I; Sissoko, MS; Toure, OB, 2008) |
| "The in vivo therapeutic efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination was evaluated in the treatment of uncomplicated Plasmodium falciparum malaria and of chloroquine for P." | 5.13 | [Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006]. ( Cortés, LJ; Guerra, AP; Knudson, A; Nicholls, RS; Pérez, MA; Usta, C, 2008) |
| "Sulfadoxine-pyrimethamine (SP) inhibits folate metabolism by the malaria parasite." | 5.13 | Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria. ( Ayisi, JG; Hamel, MJ; Kager, PA; Kariuki, S; Otieno, K; Ouma, PO; Parise, M; Slutsker, L; Ter Kuile, FO; van Eijk, AM; Williamson, J, 2008) |
| "Monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% CI: 63%, 74%) and anaemia by 45% (95% CI: 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% CI: 14%,33%) and anaemia by 30% (95% CI: 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% CI: 6%, 27%) and anaemia by 32% (95% CI: 7%, 50%) compared to placebo." | 5.13 | Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. ( Adjuik, M; Binka, F; Chandramohan, D; Greenwood, B; Kweku, M; Liu, D; Seidu, M, 2008) |
| "Intermittent preventive treatment with three doses of sulfadoxine-pyrimethamine is a more effective strategy to prevent maternal anemia during pregnancy in Burkina Faso." | 5.13 | [Comparative impact of three malaria preventive regimens during pregnancy on maternal anemia due to malaria in Burkina Faso]. ( Bougouma, EC; Diarra, A; Konaté, AT; Nébié, I; Ouédraogo, A; Sirima, SB; Tiono, AB, 2008) |
| "In Malawi, there has been a return of Plasmodium falciparum sensitivity to chloroquine (CQ) since sulfadoxine-pyrimethamine (SP) replaced CQ as first line treatment for uncomplicated malaria." | 5.13 | Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. ( Bell, DJ; Molyneux, ME; Mukaka, M; Nyirongo, SK; Plowe, CV; Ward, SA; Winstanley, PA; Zijlstra, EE, 2008) |
| "The study design was an open randomized control trial comparing anaemia incidence among pregnant women on intermittent presumptive treatment of malaria with SP with those on chloroquine (CQ)." | 5.13 | Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women. ( Abiona, TC; Asa, OO; Fatusi, AO; Ijadunola, KT; Onayade, AA, 2008) |
| "To assess whether traditional birth attendants, drug-shop vendors, community reproductive-health workers, or adolescent peer mobilizers could administer intermittent preventive treatment (IPTp) for malaria with sulfadoxine-pyrimethamine to pregnant women." | 5.13 | Intermittent preventive treatment of malaria in pregnancy: a new delivery system and its effect on maternal health and pregnancy outcomes in Uganda. ( Bygbjerg, IC; Magnussen, P; Mbonye, AK, 2008) |
| "We undertook a trial of artesunate + amodiaquine (AS + AQ) and artesunate + sulphadoxine-pyrimethamine (AS + SP) in 180 children of age 6-59 months with uncomplicated malaria in Democratic Republic of Congo." | 5.12 | Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes. ( Kayembe, G; Montgomery, J; Pota, H; Roper, C; Swarthout, TD; van den Broek, IV, 2006) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas." | 5.12 | Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007) |
| "Sulfadoxine-pyrimethamine (SP) is among the most commonly used antimalarial drugs during pregnancy, yet the pharmacokinetics of SP are unknown in pregnant women." | 5.12 | Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. ( Ayisi, JG; Green, MD; Kager, PA; Nahlen, BL; Nettey, H; Parise, ME; Steketee, R; van Eijk, AM; van Ter Kuile, FO, 2007) |
| " falciparum gametocytes may persist after treatment with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) and contribute considerably to malaria transmission." | 5.12 | Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. ( Alifrangis, M; Bousema, T; Drakeley, C; Enevold, A; Gosling, R; Mosha, F; Ndaro, A; Sauerwein, R; Shekalaghe, S; van Meegeren, M, 2007) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 5.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "In Mali, IPT with SP appears more efficacious than weekly chloroquine chemoprophylaxis in preventing malaria during pregnancy." | 5.11 | Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. ( Coulibaly, D; Doumbo, O; Doumtabe, D; Kayentao, K; Keita, AS; Kodio, M; Maiga, B; Maiga, H; Mungai, M; Newman, RD; Ongoiba, A; Parise, ME, 2005) |
| " The high endemicity of malaria in Africa may impact on the efficacy of artemisinin-based combination therapy." | 5.11 | Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. ( Bakyaita, N; Banek, K; Dorsey, G; Kamya, MR; Kilian, A; Kironde, F; Nsobya, SL; Reingold, A; Rosenthal, PJ; Slater, M; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A, 2005) |
| "In Malawi, trimethoprim-sulfamethoxazole (TS) is the recommended first-line treatment for children with Integrated Management of Childhood Illness dual classifications of malaria and pneumonia, and sulfadoxine-pyrimethyamine (SP) plus five days of treatment with erythromycin (SP plus E) is the recommended second-line treatment." | 5.11 | Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. ( Bloland, P; Chizani, N; Hamel, MJ; Holtz, T; Kaimila, N; Kazembe, P; Kublin, J; Mkandala, C; Steketee, R, 2005) |
| "To evaluate the effects of intermittent preventive treatment for malaria in infants (IPTi) with sulfadoxine-pyrimethamine in an area of intense, seasonal transmission." | 5.11 | Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. ( Amponsa-Achiano, K; Awine, T; Baiden, R; Binka, F; Carneiro, I; Chandramohan, D; Greenwood, B; Hodgson, A; Jaffar, S; Mensah, N; Owusu-Agyei, S, 2005) |
| "Between 1993 and 1999, we monitored the efficacy of sulfadoxine-pyrimethamine in 1175 children aged <24 months receiving 2789 treatments for falciparum malaria in western Kenya using a widely deployed age-based dose regimen: infants, 125 plus 6." | 5.10 | Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing. ( Courval, JM; Hawley, WA; Kariuki, SK; Kolczak, MS; Kuile, FO; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; Terlouw, DJ, 2003) |
| "In 1996, Zambia's Ministry of Health made sulfadoxine-pyrimethamine (SP) available as a second-line antimalarial." | 5.09 | A community perspective on the efficacy of malaria treatment options for children in Lundazi district, Zambia. ( Hightower, A; Kachur, SP; Mphande, PC; Nalwamba, NC; Simoonga, C; Williams, HA, 1999) |
| "Treatment of malaria with sulfadoxine/pyrimethamine and of presumed bacterial infections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assessed to see if either increases the carriage of cotrimoxazole-resistant Streptococcus pneumoniae in Malawian children." | 5.09 | Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. ( Barat, LM; Bloland, PB; Dowell, SF; Feikin, DR; Graf, C; Huebner, RE; Kazembe, PN; Klugman, KP; Nwanyanwu, OC; Schwartz, B; Ziba, C, 2000) |
| "In a controlled trial of weekly malaria chemoprophylaxis with chloroquine and pyrimethamine there were no significant differences in type and frequency of severe morbidity during chemoprophylaxis." | 5.07 | Severe morbidity among children in a trial malaria chemoprophylaxis with pyrimethamine or chloroquine in Ibarapa, Nigeria. ( Asuzu, MC; Bamgboye, A; Ogunba, EO; Osunkoya, BO; Oyediran, AB; Topley, E; Williams, AI, 1993) |
| "Mefloquine is the treatment of choice for uncomplicated multiresistant falciparum malaria, and in combination with sulphadoxine and pyrimethamine (MSP) at a single dose of 15/30/1." | 5.07 | Mefloquine-resistant falciparum malaria on the Thai-Burmese border. ( Chongsuphajaisiddhi, T; Edstein, M; Luxemburger, C; Nosten, F; Phaipun, L; ter Kuile, F; Thew, KL; Webster, HK; White, NJ, 1991) |
| "We have reviewed a malaria chemoprophylaxis programme in which Maloprim (pyrimethamine and dapsone) has been administered fortnightly by village health workers (VHWs) to approximately 1500 children each year aged 6-59 months resident in 15 primary health care villages in a rural area of The Gambia over 5 years." | 5.06 | Compliance with malaria chemoprophylaxis over a five-year period among children in a rural area of The Gambia. ( Allen, SJ; Greenwood, BM; Menon, A; Snow, RW, 1990) |
| "A battalion of Royal Thai Marine militia was assigned to take either 50 mg or 100 mg of doxycycline daily or pyrimethamine/dapsone weekly for malaria prophylaxis on the Thai-Kampuchean border for a 17 week period." | 5.06 | Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border. ( Karwacki, JJ; Phintuyothin, P; Pilungkasa, S; Shanks, D; Singharaj, P; Suriyamongkol, V; Wasuwat, P; Watanasook, C, 1989) |
| "Two drug strategies for the control of malaria in children aged 3-59 months have been compared in a rural area of The Gambia--treatment of presumptive episodes of clinical malaria with chloroquine by village health workers, and treatment combined with fortnightly chemoprophylaxis with 'Maloprim' (pyrimethamine/dapsone) which was also given by village health workers." | 5.06 | Comparison of two strategies for control of malaria within a primary health care programme in the Gambia. ( Bradley, AK; Byass, P; Greenwood, AM; Greenwood, BM; Hayes, RJ; N'Jie, AB; Snow, RW, 1988) |
| "A cohort of 48 Gambian children was protected against malaria by fortnightly administration of Maloprim (pyrimethamine and dapsone) for 2 years between their 3 and 5 birthdays." | 5.06 | Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis. ( Byass, P; Greenwood, BM; Menon, A; Otoo, LN; Snow, RW, 1988) |
| "A double-blind comparative study of Fanismef-mefloquine/sulfadoxine/pyrimethamine (MSP) and Lariam-mefloquine (MEF) for the treatment of falciparum malaria, was carried out at malaria clinics in Kanchanaburi, in western Thailand, in the years 1987 and 1988." | 5.06 | Phase III double-blind comparative study of Fansimef and Lariam for the curative treatment of Plasmodium falciparum infections in Thailand. ( Malikul, S; Pinichpongse, S; Rooney, W; Tansophalaks, S; Thimasarn, K, 1990) |
| "To compare the efficacy and side-effects of two therapeutic regimens for chloroquine-resistant falciparum malaria, a randomized study was carried out in 69 patients in Maputo Central Hospital in 1986-1987." | 5.06 | [Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique]. ( Dinis, DV; Schapira, A, 1990) |
| "New studies on the suppressive and curative effects of the anti-malarial drug pyrimethamine in pregnant women from Ilorin, Nigeria showed both ineffective prophylaxis and suppression, and parasite resistance." | 5.06 | Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women. ( Adetoro, O; Akintunde, A; Alakija, T; Breman, JG; Edungbola, LD; Nahlen, BL; Nguyen-Dinh, P; Ogunbode, O, 1989) |
| "In Nigeria chloroquine remains the drug of choice for the treatment of falciparum malaria since chloroquine resistance is not yet a problem." | 5.06 | Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria. ( Aina Adio, R; Fadeke Aderounmu, A; Laoye, AJ; Modupe Makinde, J; Salako, LA, 1988) |
| "After treatment with chloroquine and pyrimethamine/sulfadoxine, 118 school children aged 6 to 10 years living near the Kenyan coast were enrolled in a malaria chemoprophylaxis study and followed up for 20 weeks." | 5.06 | Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. ( Brandling-Bennett, AD; Gilles, HM; Howells, RE; Koech, DK; Oloo, AJ; Watkins, WM, 1987) |
| "A randomized double blind study in long term malaria chemoprophylaxis was performed to compare the tolerability of Fansimef (1 tablet containing 250 mg mefloquine + 500 mg sulfadoxine + 25 mg pyrimethamine per week) with chloroquine (300 mg per week)." | 5.06 | Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria. ( Kollaritsch, H; Kollaritsch, R; Kremsner, P; Leimer, R; Mailer, H; Stemberger, H; Wiedermann, G, 1988) |
| " Fifty cases of falciparum malaria were treated with 1800 mg amodiaquine for 3 days: the cure rate was 65." | 5.06 | Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China. ( Cai, XZ; Fu, SG; Huang, JK; Huang, OL; Ouyang, WC; Pang, XJ; Wang, XF; Wu, Z; Zhang, KY; Zhou, JX, 1988) |
| "In Nigeria chloroquine remains the drug of choice for the treatment of falciparum malaria, since chloroquine resistance is not yet a problem." | 5.06 | Sensitivity of Plasmodium falciparum to mefloquine-sulphadoxine-pyrimethamine (Fansimef) in vivo and to mefloquine alone in vitro in Nigeria. ( Aderounmu, AF; Adio, RA; Laoye, JO; Makinde, JM; Salako, LA, 1988) |
| "As malaria caused by Plasmodium falciparum has become resistant to chloroquine alternative drug regimens need to be developed." | 5.06 | Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. ( Bygbjerg, IC; Fogh, S; Gøtzsche, PC; Jepsen, S; Kuijlen, K; Mordhorst, CH; Ravn, P; Rønn, A; Schapira, A, 1988) |
| "The standard chloroquine treatment for Plasmodium falciparum malaria is 25 mg (base)/kg (C25) given over 3 days." | 5.06 | Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children. ( Bugilimfura, L; Deloron, P; Neill, M; Ntilivamunda, A; Sexton, JD, 1988) |
| "A total of 89 adult male Thai patients who had acute, uncomplicated falciparum malaria were treated in a double-blind randomized trial with a single oral dose of two or three tablets, each consisting of 250 mg mefloquine, 500 mg sulfadoxine, and 25 mg pyrimethamine (MSP)." | 5.06 | Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose. ( Bunnag, D; Charoenlarp, P; Chitamas, S; Harinasuta, T; Sheth, UK; Suntharasmai, P; Vanijanond, S; Wernsdorfer, WH, 1987) |
| "A total of 100 male Zambian patients with symptomatic falciparum malaria were treated with either two tablets of mefloquine plus sulfadoxine-pyrimethamine (Fansimef) or three tablets of sulfadoxine-pyrimethamine (Fansidar) as a single dose." | 5.06 | A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria. ( Ekue, JM; Mukunyandela, M; Phiri, DE; Sheth, UK, 1987) |
| "Three different regimens were compared for treatment of falciparum malaria in displaced Kampucheans living in encampments on the Thai-Kampuchean border in 1983: single dose 750 mg mefloquine, 1." | 5.06 | Treatment of falciparum malaria with quinne and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border. ( Doberstyn, EB; Gaüzère, BA; Meek, SR; Nordlander, E; Phuphaisan, S; Thanapanich, C, 1986) |
| "The effects of chloroquine, amodiaquine and pyrimethamine-sulfadoxine (SP) (Fansidar) on the infection rate and density of Plasmodium falciparum gametocytes were studied in 198 patients with falciparum malaria from an area in the Punjab where malaria is endemic but seasonally transmitted." | 5.06 | Effects of chloroquine, amodiaquine and pyrimethamine-sulfadoxine on Plasmodium falciparum gametocytemia. ( Fox, E; Khaliq, AA; Macdonald, M; Sarwar, M; Strickland, GT, 1986) |
| "A trial of drug regimens for treating Plasmodium falciparum malaria was conducted in a refugee camp in eastern Thailand where extensive 'Fansidar' (pyrimethamine-sulfadoxine) resistance had been demonstrated." | 5.05 | Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980. ( Brandling-Bennett, AD; Campbell, CC; Doberstyn, EB; Freeman, J; Reacher, M, 1981) |
| "A prospective trial in 80 patients randomly allocated to four antimalarial treatment regimens--mefloquine plus pyrimethamine-sulfadoxine ('Fansidar'); mefloquine plus qinghaosu; mefloquine, fansidar, and qinghaosu; and qinghaosu alone--was carried out on Hainan Island, China, in patients with chloroquine-resistant falciparum malaria." | 5.05 | Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria. ( Arnold, K; Fu, LC; Guo, XB; Jian, HX; Li, GQ, 1984) |
| "A randomized double-blind study was performed to compare the side effects of long-term chemoprophylaxis of malaria with Fansidar (1 tablet a week) with those of a 300-mg weekly chloroquine regimen." | 5.05 | Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria. ( Leimer, R; Stemberger, H; Wiedermann, G, 1984) |
| "Mefloquine was compared with sulfadoxine-pyrimethamine for safety and efficacy in a randomized, double-blind clinical trial in adult males from a malaria-endemic area of Brazil." | 5.05 | A phase II clinical trial of mefloquine in Brazilian male subjects. ( de Souza, JM, 1983) |
| "A study was carried out to assess the efficacy of a modified 7 day course of quinine in children with falciparum malaria, in comparison with those of a 7 day course of quinine at standard dosage and a combination of a 7 day course of quinine and sulfadoxine-pyrimethamine, and in relation to the MIC, and to the serum levels of quinine during the course of treatment." | 5.05 | Treatment of quinine resistant falciparum malaria in Thai children. ( Attanath, P; Chongsuphajaisiddhi, T; Sabchareon, A, 1983) |
| "Falciparum malaria in 104 Thai patients was treated with either Mefloquine or Fansidar and patients were examined for parasitaemia for the next 28 days." | 5.05 | A comparative trial of Mefloquine and Fansidar in the treatment of falciparum malaria: failure of Fansidar. ( Dixon, KE; Phintuyothin, P; Pitaktong, U; Pongsupat, T; Williams, RG, 1982) |
| "The effect of various dosages of mefloquine hydrochloride (WR 142,490) and sulfadoxine-pyrimethamine in the suppression of malaria infections was studied in an area of northeastern Thailand highly endemic for both chloroquine-resistant Plasmodium falciparum and for P." | 5.05 | Chemosuppressive field trials in Thailand. IV. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by mefloquine (WR 142,490, A 4-quinolinemethanol). ( Canfield, CJ; Doberstyn, EB; Kennedy, RS; Pearlman, EJ; Sudsok, S; Thiemanun, W, 1980) |
| "Fifty-two patients with severe chloroquine resistant Plasmodium falciparum malaria were treated in a randomized double blind study with either quinine and a single dose of pyrimethamine-sulfadoxine (Fansidar) or quinine alone." | 5.05 | Quinine alone versus quinine plus a pyrimethamine-sulfadoxine combination in the treatment of Plasmodium faliciparum cerebral malaria. ( Adler, J; Englehard, D; Naparstek, Y; Sack, J; Shemer, J; Spira, DT; Weiler-Ravell, D, 1981) |
| "Fifty-eight Nigerian children with Plasmodium falciparum malaria were allocated randomly into two groups and treated with either chloroquine (25 mg/kg over three days) or Fansidar (35 mg sulphadoxin (+ 1/20 pyrimethamine) per kg single dose))." | 5.05 | The in vivo sensitivity of Plasmodium falciparum to chloroquine and to sulphadoxine-pyrimethamine combination in Ibadan, Nigeria. ( Olatunde, A; Salako, LA; Walker, O, 1981) |
| "Chloroquine-resistant Plasmodium falciparum malaria is increasing in prevelance in Papua New Guinea and alternative therapies for acute malaria are being sought." | 5.05 | Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum. ( Alpers, M; Darlow, B; Gibney, S; Jolley, D; Stace, J; Vrbova, H, 1982) |
| " In one trial mefloquine was compared with chloroquine in 40 patients with Plasmodium vivax malaria and in the other one mefloquine was compared with MSP in 40 patients with P falciparum malaria." | 5.05 | Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria. ( Bunnag, D; Harinasuta, T; Lasserre, R; Leimer, R; Vinijanont, S, 1985) |
| "The clinical and parasitological response of adult male patients to mefloquine and to a combination of quinine and sulfadoxine-pyrimethamine during the treatment of falciparum malaria was compared." | 5.05 | An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil. ( de Oliveira, RM; de Souza, JM; de Souza, SD; Roulet, H; Sheth, UK, 1985) |
| "Two field trials to detect chloroquine-resistant malaria were conducted according to WHO recommendations in a malaria free area near Rangoon." | 5.04 | Chloroquine-resistant malaria in Burma. ( Hlaing, N; Htun Nyun, R; Kyi, KK; Myint, T; Tin, F; U, T, 1975) |
| "5 g) of mefloquine hydrochloride cured all of 37 patients with falciparum malaria, and a single dose of pyrimethamine (75 mg) plus sulfadoxine (1." | 5.04 | Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine. ( Doberstyn, EB; Noeypatimanondh, S; Phintuyothin, P; Teerakiartkamjorn, C, 1979) |
| "A trial of suppression of malaria by administration of combined sulphadoxine-pyrimethamine tablets every 28 days was undertaken in West Malaysia during 1972." | 5.04 | Suppression of malaria with monthly administration of combined sulphadoxine and pyrimethamine. ( Lewis, AN; Ponnampalam, JT, 1975) |
| "In an area of Thailand where chloroquine-resistant falciparum malaria is known to exist, a chemosuppressive field trial was undertaken to test the efficacy of the preparation diformyldapsone (DFD) combined with pyrimethamine (Py) in suppressing falciparum and vivax parasitemias." | 5.04 | Chemosuppressive field trials in Thailand. II. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by a diformyldapsone-pyrimethamine combination. ( Castaneda, BF; Pearlman, EJ; Thiemanun, W, 1975) |
| " One hundred and seventy inhabitants of the Ilorin area, Nigeria, were observed over a period of five months during the season of maximum malaria transmission while taking pyrimethamine-sulphormethoxine weekly, fortnightly and every four weeks." | 5.04 | Comparative efficiency of pyrimethamine-sulphormethoxine in malaria suppression given as single weekly, fortnightly and monthly doses. ( Shafei, AZ, 1975) |
| "Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy." | 5.01 | A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. ( Esu, E; Meremikwu, M; Oduwole, O; Okusanya, BO; Olaleye, A, 2019) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "The World Health Organization currently recommends quinine+clindamycin for use against malaria in the first trimester." | 4.95 | Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. ( Clark, RL, 2017) |
| "In 2012, WHO changed its recommendation for intermittent preventive treatment of malaria during pregnancy (IPTp) from two doses to monthly doses of sulfadoxine-pyrimethamine during the second and third trimesters, but noted the importance of a cost-effectiveness analysis to lend support to the decision of policy makers." | 4.91 | Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data. ( Akazili, J; Fernandes, S; Hanson, K; Hill, J; Kayentao, K; Madanitsa, M; Sicuri, E; ter Kuile, FO; van Eijk, AM; Webster, J; Were, V, 2015) |
| " Chemopreventive strategies have been increasingly deployed in Africa, notably intermittent sulfadoxine-pyrimethamine treatment in pregnancy, and monthly amodiaquine-sulfadoxine-pyrimethamine during the rainy season months in children aged between 3 months and 5 years across the sub-Sahel." | 4.90 | Malaria. ( Dondorp, AM; Faiz, MA; Hien, TT; Mokuolu, OA; Pukrittayakamee, S; White, NJ, 2014) |
| "We searched PubMed and EMBASE for randomised controlled trials (RCTs) and cohort studies on the effect of CPT on incidence of malaria and mortality in children and extracted data on the prevalence of sulphadoxine-pyrimethamine resistance-conferring point mutations." | 4.90 | Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. ( Davies, MA; Egger, M; Mbeye, NM; Phiri, KS; ter Kuile, FO; Wandeler, G, 2014) |
| "Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the standard 2-dose regimen." | 4.89 | Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis. ( Ashorn, P; Doumbo, OK; Garner, P; Kayentao, K; Luntamo, M; MacArthur, JR; Mulokozi, A; Naidoo, I; Roper, C; ter Kuile, FO; van Eijk, AM, 2013) |
| "The intermittent preventive treatment of malaria in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) has been a key component of the focused antenatal care package for nearly a decade, reducing the burden of low birthweight attributable to malaria in sub-Saharan Africa." | 4.87 | Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. ( Chandramohan, D; Chico, RM, 2011) |
| "Intermittent preventive treatment of infants (IPTi) with sulphadoxine pyrimethamine (SP) is recommended as an additional malaria control intervention in high transmission areas of sub-Saharan Africa, provided its protective efficacy is not compromised by SP resistance." | 4.87 | Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. ( Naidoo, I; Roper, C, 2011) |
| " falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)." | 4.85 | Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009) |
| "Plasmodium falciparum resistance to chloroquine and sulphadoxine-pyrimethamine has led to the recent adoption of artemisinin-based combination therapies (ACTs) as the first line of treatment against malaria." | 4.85 | Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. ( Eastman, RT; Fidock, DA, 2009) |
| "Data on the efficacy of IPT with sulfadoxine-pyrimethamine on placental and peripheral malaria, birth weight, and hemoglobin level/anemia were independently abstracted by 2 investigators." | 4.84 | Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review. ( Filler, SJ; ter Kuile, FO; van Eijk, AM, 2007) |
| "Drug resistance is one of the major factors contributing to the resurgence of malaria, especially resistance to the most affordable drugs such as chloroquine and Fansidar, a combination drug of pyrimethamine and sulfadoxine." | 4.82 | Genetic and biochemical aspects of drug resistance in malaria parasites. ( Hayton, K; Su, XZ, 2004) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.81 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2001) |
| "A meta-analysis study evaluating the efficacy and safety of chloroquine and alternative antimalarial drugs used in six African countries including Ethiopia, Kenya, Uganda, Cote D'Ivoire, Gambia and Nigeria is presented." | 4.80 | Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries. ( Makonnen, E; Mengesha, T, 1999) |
| "Amodiaquine and chloroquine give fast relief from malaria symptoms, particularly fever." | 4.80 | Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria. ( McIntosh, HM, 2000) |
| "Mefloquine, a quinoline-methanol antimalarial, is effective single dose therapy for all species of malaria infecting humans, including multi-drug-resistant Plasmodium falciparum." | 4.78 | Clinical pharmacokinetics of mefloquine. ( Karbwang, J; White, NJ, 1990) |
| "The widespread emergence of chloroquine-resistant Plasmodium falciparum led to the formulation of an effective, fixed combination of two antimalarial agents, pyrimethamine and the long-acting sulfonamide sulfadoxine, for prophylaxis and treatment." | 4.77 | Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii. ( Hewlett, EL; Pearson, RD, 1987) |
| "Intermittent preventive treatment (IPTp) for pregnant women with sulfadoxine-pyrimethamine (SP) is widely implemented for the prevention of malaria in pregnancy and adverse birth outcomes." | 4.31 | Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast. ( Amadi, D; Bejon, P; Berkley, JA; Kamau, A; Musau, M; Mwakio, S; Nyaguara, A; Seale, AC; Snow, RW, 2023) |
| "Between December, 2015, and March, 2016, and between December, 2017, and March, 2018, immediately following the 2015 and 2017 malaria transmission seasons, community surveys were done among children younger than 5 years and individuals aged 10-30 years in districts implementing seasonal malaria chemoprevention with sulfadoxine-pyrimethamine and amodiaquine in Burkina Faso, Chad, Guinea, Mali, Nigeria, Niger and The Gambia." | 4.31 | Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study. ( Bazie, T; Beshir, KB; Bojang, K; Cairns, M; Ceesay, S; Diallo, A; Dicko, A; Doumagoum, D; Eloike, T; Gamougam, K; Kessely, H; Kolie, F; Lamine, MM; Laminou, IM; Loua, K; Maiga, H; Mansukhani, R; Merle, CS; Milligan, P; Moroso, D; Muwanguzi, J; Nader, J; NDiaye, JL; Ogboi, SJ; Ouedraogo, JB; Razafindralambo, L; Sagara, I; Scott, S; Snell, P; Sutherland, CJ; Traore, A; Zongo, I, 2023) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine is recommended at each antenatal care clinic visit in high-moderate transmission areas." | 4.31 | The impact of community delivery of intermittent preventive treatment of malaria in pregnancy on its coverage in four sub-Saharan African countries (Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria): a quasi-experimental multicentre e ( Arikpo, I; Cirera, L; Figueroa-Romero, A; González, R; LIach, M; Macete, E; Maly, C; Manun'Ebo, MF; Mbombo Ndombe, D; Menéndez, C; Meremikwu, M; Pagnoni, F; Pons-Duran, C; Rabeza, VR; Ramananjato, R; Ramírez, M; Roman, E; Sacoor, C; Sanz, S, 2023) |
| "Intermittent preventive therapy during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended in areas of moderate to high malaria transmission intensity." | 4.31 | Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda. ( Abram, A; Alruwaili, M; Eckert, E; Gutman, JR; Mbituyumuremyi, A; Munguti, K; Murindahabi, M; Piercefield, E; Sethi, R; Sullivan, DJ; Umulisa, N; Uwimana, A, 2023) |
| "The effectiveness of community delivery of intermittent preventive treatment (C-IPT) of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine has been evaluated in selected areas of the Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria." | 4.31 | Prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation. ( Arikpo, I; Bissombolo, D; Doderer-Lang, C; Figueroa-Romero, A; González, R; Lemba, E; Llach, M; Ma, L; Maly, C; Mayor, A; Menard, D; Menéndez, C; Meremikwu, M; Nhama, A; Pagnoni, F; Pons-Duran, C; Rakotosaona, R; Ratsimbasoa, A; Roman, E; Sacoor, C; Sanz, S, 2023) |
| "Using data from a trial of medication to prevent malaria in pregnancy that randomized 600 women to receive chloroquine or sulfadoxine-pyrimethamine during pregnancy, we conducted a NCC study assessing the role of prospectively collected AEs, as exposure of interest, on treatment non-adherence and study non-completion." | 4.12 | Effect of adverse events on non-adherence and study non-completion in malaria chemoprevention during pregnancy trial: A nested case control study. ( Chirwa, T; Divala, T; Kazembe, L; Laufer, MK; Mathanga, D; Mukaka, M; Patson, N; Peterson, I, 2022) |
| "Intermittent preventive treatment of malaria in pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) tablets is one of the recommended interventions to reduce the burden of malaria on both the pregnant woman and the unborn child." | 4.12 | Intermittent Preventive Treatment of Malaria in Pregnancy with Sulphadoxine-Pyrimethamine and its Associated Factors in the Atwima Kwanwoma District, Ghana. ( Adom, J; Ankomah, SE; Duvor, F; Fusheini, A; Karikari, AK; Kokuro, C; Kumah, E; Otchere, G, 2022) |
| "The World Health Organization recommends a minimum of three doses of quality-assured sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy (IPTp), in moderate to high malaria transmission areas in sub-Saharan Africa." | 4.12 | Retrospective evaluation of referral by community health workers on the uptake of intermittent preventive treatment of Malaria in pregnancy in Ohaukwu, Ebonyi State, Nigeria. ( Afolabi, K; Anoke, C; Bryce, E; Enne, J; Njoku, E; Odio, B; Ogbulafor, NC; Oliveras, E; Oniyire, A; Onuoha, HE; Orji, BC; Otolorin, E; Ugwa, E, 2022) |
| "Sulfadoxine-pyrimethamine (SP) is recommended in Africa in several antimalarial preventive regimens including Intermittent Preventive Treatment in pregnant women (IPTp), Intermittent Preventive Treatment in infants (IPTi) and Seasonal Malaria Chemoprevention (SMC)." | 4.12 | Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990-2020. ( Barnes, KI; Dahlström Otienoburu, S; Flegg, JA; Guerin, PJ; Hopkins Sibley, C; Humphreys, GS; Jacome-Meza, ZJ; Montanez, B; Raman, J; Strickland, T, 2022) |
| "In spite of the missed opportunities of sulfadoxine-pyrimethamine (IPTp-SP) in Uganda, scanty literature exist on malaria in pregnancy." | 4.12 | Uptake of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) in Uganda: a national survey. ( Ameyaw, EK, 2022) |
| "A significant gap exists between high rates of antenatal care attendance and low uptake of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) in Senegal." | 4.12 | Were Women Staying on Track with Intermittent Preventive Treatment for Malaria in Antenatal Care Settings? A Cross-Sectional Study in Senegal. ( Cao, J; Huang, J; Liang, D; Zhang, D; Zhang, K, 2022) |
| "Despite its effectiveness, the optimal use of the combination of insecticide-treated nets (ITN) and intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) remains low in malaria-endemic areas." | 4.12 | Variations in the use of malaria preventive measures among pregnant women in Guinea: a secondary analysis of the 2012 and 2018 demographic and health surveys. ( Barry, I; Beavogui, AH; Camara, AY; Cherif, MS; Cisse, D; Delamou, A; Diallo, A; Diawara, F; Doumbia, L; Doumbia, S; Magassouba, AS; Sangho, O; Sylla, Y; Tounkara, M; Toure, AA, 2022) |
| "Although studies in Nigeria showed the efficacy of intermittent preventive treatment using sulfadoxine-pyrimethamine (IPT-SP) in preventing malaria in pregnancy among Nigerian women there is still poor implementation of the intervention in Nigeria." | 4.12 | Factors influencing intermittent preventive treatment for malaria prevention among pregnant women accessing antenatal care in selected primary health care facilities of Bwari Area Council, Abuja Nigeria. ( Naidoo, M; Peters, GO, 2022) |
| "Intermittent preventive treatment of malaria among pregnant women with sulfadoxine-pyrimethamine (IPTp-SP), is one of the three recommended interventions for the prevention of malaria in pregnancy (MiP) in sub-Sahara Africa." | 4.02 | An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context. ( Aberese-Ako, M; Ampofo, GD; Ansah, E; Gyapong, M; Magnussen, P; Tagbor, H, 2021) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) is a comprehensive treatment protocol of anti-malarial drugs administered to pregnant women to prevent malaria, started at the fourth pregnancy month, with at least three doses of sulfadoxine-pyrimethamine (SP), taken as directly observed treatment (DOT) every 30 days at intervals until childbirth, in combination with other preventive measures." | 4.02 | The provider's checklist to improve pregnant women coverage by intermittent preventive malaria treatment in Mali: a pilot implementation study. ( Bennis, I; Diakalia, K; Doumbia, I; Seydou, F, 2021) |
| "Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is a key malaria prevention strategy in areas with moderate to high transmission." | 4.02 | Coverage of intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries: findings from household surveys. ( Arikpo, I; González, R; Llach, M; Macete, E; Manun'Ebo, MF; Mbombo Ndombe, D; Méndez, S; Menéndez, C; Meremikwu, M; Pagnoni, F; Pons-Duran, C; Rabeza, VR; Ramananjato, R; Ramírez, M; Roman, E; Sacoor, C; Sanz, S; Tholandi, M, 2021) |
| "Artemisinin is the frontline fast-acting anti-malarial against P." | 4.02 | Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India. ( Das, S; Hati, AK; Kar, A; Mandal, S; Manna, S; Saha, B, 2021) |
| "While the use of sulphadoxine pyrimethamine (SP) is effective in preventing malaria infection during pregnancy, there are challenges limiting its uptake in Nigeria." | 4.02 | Malaria intermittent preventive treatment in Nigeria: a qualitative study to explore barriers. ( Assan, A; Majdzadeh, R; Muhammad, FM; Nedjat, S; Parsaeian, M; Sajadi, HS, 2021) |
| "In malaria endemic regions, intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is recommended for all pregnant women during prenatal consultation, from the fourth month of pregnancy up to the time of delivery." | 4.02 | Determinants of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey. ( Beebe, M; Doumbia, S; Sangho, O; Tounkara, M; Whiting-Collins, LJ; Winch, PJ, 2021) |
| "Although malaria in pregnancy is preventable with the use of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP), it still causes maternal morbidity and mortality, in sub-Saharan Africa and Nigeria in particular." | 4.02 | Decomposition of socioeconomic inequalities in the uptake of intermittent preventive treatment of malaria in pregnancy in Nigeria: evidence from Demographic Health Survey. ( Hajizadeh, M; Khanam, R; Okoli, CI; Rahman, MM, 2021) |
| "Hence, this study was therefore aimed at evaluating the antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in mice infected with chloroquine sensitive Plasmodium berghei ANKA." | 4.02 | In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA. ( Achidi, EA; Bila, RB; Feugaing Sofeu, DD; Ivo, EP; Taiwe, GS; Tatsinkou Fossi, B; Toukam, LL, 2021) |
| " At least three doses of sulphadoxine pyrimethamine for intermittent preventive treatment of malaria in pregnancy (IPTp-SP) is recommended for optimal benefit." | 4.02 | Determinants of the uptake of intermittent preventive treatment of malaria in pregnancy with sulphadoxine pyrimethamine in Sabatia Sub County, Western Kenya. ( Adipo, LB; Mutanyi, JA; Ogolla, SO; Onguru, DO, 2021) |
| "Pyrimethamine-loaded nanomicelles showed potent antimalarial activity and can be considered as a potential candidate for further examination of their suitability as an antimalarial drug." | 3.96 | A new effective antiplasmodial compound: Nanoformulated pyrimethamine. ( Bide, VZ; Kalani, H; Nematolahy, P; Pestehchian, N; Vafaei, MR; Varshosaz, J; Yousefi, HA, 2020) |
| " Interviews focused on perception of purpose of ANC pharmaceuticals (particularly iron supplements, sulfadoxine-pyrimethamine as intermittent prevention of malaria and antiretroviral therapy for HIV), beliefs regarding efficacy and risk, and understanding of dosage and regimen." | 3.96 | "They Merely Prescribe and I Merely Swallow": Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali. ( Doumbia, SO; Hurley, EA; Searle, AR; Winch, PJ, 2020) |
| "A cross-sectional study was conducted of 426 pregnant mothers on IPTp with sulphadoxine-pyrimethamine against malaria who presented in labor, at National Hospital Abuja, Nigeria between January and June 2017." | 3.96 | The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria. ( Agboghoroma, CO; Iregbu, KC; Umemmuo, MU, 2020) |
| "31% from mothers who took intermittent preventive treatment in pregnancy with Sulfadoxine-Pyrimethamine, all (100%) from mothers using the insecticide-treated mosquito nets and 7." | 3.96 | Prevalence of Congenital Malaria in Kisangani, A Stable Malaria Transmission Area in Democratic Republic of the Congo. ( Alongo Mike-Antoine, M; Bosunga Gedeon, K; Likwela Joris, L; Mukonkole Jean-Paulin, M; Nguma Jean-Didier, B; Okenge Jean-Pascal, M; Otuli Noël, L, 2020) |
| "Malawi adopted the 2012 updated Word Health Organization (WHO) Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) policy in 2013." | 3.96 | Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health Organization policy: an analysis of demographic and health survey 2015-2016. ( Azizi, SC, 2020) |
| "In 2012, the World Health Organization recommended that pregnant women in malaria-endemic countries complete at least three (optimal) doses of intermittent preventive treatment (IPTp) using sulfadoxine-pyrimethamine (SP) to prevent malaria and related adverse events during pregnancy." | 3.96 | Correlates of uptake of optimal doses of sulfadoxine-pyrimethamine for prevention of malaria during pregnancy in East-Central Uganda. ( Allen, K; Bernard, K; Damazo, KT; Dathan, BM; Godfrey, A; Keith, B; Martin, MK; Patricia, N; Rogers, T; Venantius, KB, 2020) |
| "Intermittent presumptive treatment in pregnancy (IPTp) of malaria using sulfadoxine-pyrimethamine (SP) was introduced in Nigeria in 2005 to reduce the burden of malaria in pregnancy." | 3.96 | Inequities in the use of sulphadoxine-pyrimethamine for malaria prophylaxis during pregnancy in Nigeria. ( Anitube, O; Ezeoke, U; Mbachu, C; Ndu, A, 2020) |
| "In high malaria transmission settings, the use of sulfadoxine-pyrimethamine-based intermittent preventive treatment during pregnancy (IPTp-SP) has resulted in decreased antibody (Ab) levels to VAR2CSA." | 3.96 | Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon. ( Djontu, JC; Leke, RGF; Lloyd, YM; Megnekou, R; Salanti, A; Seumko'o, RMN; Taylor, DW, 2020) |
| "Innovative community strategies to increase intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) coverage is advocated particularly in rural areas, where health infrastructure is weakest and malaria transmission highest." | 3.96 | Reaching the unreached: effectiveness and satisfaction with community-directed distribution of sulfadoxine-pyrimethamine for preventing malaria in pregnancy in rural South-East, Nigeria. ( Abateneh, DD; Agu, AP; Akamike, IC; Alo, CN; Ndukwe, CD; Nzeh, CB; Okedo-Alex, IN; Okoro, OO; Uneke, CJ, 2020) |
| "Intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) is recommended to prevent malaria in pregnancy." | 3.91 | Using Short Message Service Alerts to Increase Antenatal Care and Malaria Prevention: Findings from Implementation Research Pilot in Guinea. ( Bangoura, L; Colaço, R; Fitch, ER; Flueckiger, RM; Fofana, A; Guilavogui, T; Reithinger, R; Taton, JL; Thierno, DM, 2019) |
| "Despite the effectiveness of intermittent preventive treatment in pregnancy using sulphadoxine-pyrimethamine (IPTp-SP), the uptake and coverage in southwest Nigeria are low." | 3.91 | Determinants of intermittent preventive treatment of malaria among women attending antenatal clinics in primary health care centers in Ogbomoso, Oyo State, Nigeria. ( Adewole, AO; Ajayi, I; Ajumobi, O; Fawole, O; Nguku, P; Oladimeji, A; Waziri, E; Yusuf, B, 2019) |
| " Optimum use of Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (IPTp-SP) and immunization against tetanus among pregnant women during antenatal care (ANC) visits are recommended strategies to prevent these issues." | 3.91 | Antenatal visits are positively associated with uptake of tetanus toxoid and intermittent preventive treatment in pregnancy in Ivory Coast. ( Bishwajit, G; Buh, A; Kota, K; Yaya, S, 2019) |
| " Intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) is one of the main strategies for prevention of malaria in pregnancy." | 3.91 | Factors influencing adherence to the new intermittent preventive treatment of malaria in pregnancy policy in Keta District of the Volta region, Ghana. ( Akamah, J; Jerela, JY; Manu, A; Maya, ET; Peprah, NY; Titiati, P; Torpey, K; Vandy, AO, 2019) |
| "Despite the clinically proven advantages of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), utilisation has been low in many African countries." | 3.91 | High uptake of Intermittent Preventive Treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana. ( Anang, AK; Asare, GQ; Coleman, N; Cot, M; Cottrell, G; Deloron, P; Escriou, G; Fobil, J; Houze, P; Kusi, KA; Laar, A; Ndam, NT; Ofori, MF; Quakyi, I; Tornyigah, B, 2019) |
| "Sulfadoxine-pyrimethamine (SP) is a cornerstone of malaria chemoprophylaxis and is considered for programmes in the Democratic Republic of Congo (DRC)." | 3.91 | Markers of sulfadoxine-pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention. ( Badio, C; Bakula, E; Bousema, T; Cibenda, D; Grignard, L; Lanke, K; Lassovski, M; Okell, L; Ouabo, A; Piriou, E; Rao, B; Roper, C; van der Meulen, R; van Lenthe, M, 2019) |
| "This study highlights low adherence to the new 3-dose regimen of sulfadoxine-pyrimethamine-based intermittent preventive treatment in the Cotonou health zone II and III, but it reflects its potential to contribute to the reduction of the risk of low birth weight." | 3.91 | [Sulfadoxine-pyrimethamine-based intermittent preventive treatment in pregnant women and its effect on birth weight: application of 3-dosing regimen in the urban area of South Benin in 2017]. ( Ayivi-Vinz, G; Azandjèmé, C; Biaou, COA; Glèlè-Ahanhanzo, Y; Kpozehouen, A; Ouro-Koura, AR, 2019) |
| "Mefloquine was evaluated as an alternative for intermittent preventive treatment of malaria in pregnancy (IPTp) due to increasing resistance against the first-line drug sulfadoxine-pyrimethamine (SP)." | 3.91 | Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon. ( Akerey-Diop, D; Basra, A; Geditz, M; Gonzalez, R; Hofmann, U; Kerb, R; Kremsner, PG; Lehr, T; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo-Ngoma, G; Ramharter, M; Schwab, M; Wojtyniak, JG; Würbel, H; Zoleko Manego, R, 2019) |
| " Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPT-SP) is recommended for preventing malaria in pregnancy (MiP)." | 3.91 | Access to and use of preventive intermittent treatment for Malaria during pregnancy: A qualitative study in the Chókwè district, Southern Mozambique. ( Arnaldo, P; Cambe, MI; Chicumbe, S; Enosse, SM; Magaço, A; Rosanas-Urgell, A; Rovira-Vallbona, E, 2019) |
| " Whether the addition of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seasonal malaria chemoprevention could reduce mortality and morbidity among African children was unclear." | 3.91 | Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. ( Barry, A; Cairns, M; Chandramohan, D; Coumare, S; Diarra, M; Dicko, A; Doumbo, O; Greenwood, B; Kuepfer, I; Milligan, P; Nikiema, F; Ouedraogo, JB; Sagara, I; Tapily, A; Thera, I; Tinto, H; Traore, A; Yerbanga, S; Zongo, I, 2019) |
| "In 2006, because of the chloroquine-resistance and following the World Health Organization (WHO) recommendations, Côte d'Ivoire adopted a new policy for the prevention of malaria during pregnancy by intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)." | 3.91 | [Evaluation of the knowledge of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine in Ivory Coast]. ( Amari, ASG; Assemian, A; Assi, SB; Balayssac, E; Kamagaté, M; Kouamé, R; Yavo, JC, 2019) |
| "Intermittent preventive treatment in pregnancy (IPTp) with 3 or more doses of sulfadoxine-pyrimethamine (SP) is recommended by the World Health Organization to prevent malaria in pregnant women living in high-risk areas." | 3.91 | Factors Associated with Intermittent Preventive Treatment of Malaria During Pregnancy in Mali. ( Diakité, M; Diarra, SS; Diawara, SI; Doumbia, S; Konaté, D; Tall, M, 2019) |
| "In Ghana, intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) is recommended for the prevention of malaria-related adverse outcomes." | 3.91 | Intermittent preventive treatment of pregnant women in Kintampo area of Ghana with sulphadoxine-pyrimethamine (SP): trends spanning 2011 and 2015. ( Adda, R; Amenga-Etego, S; Anane, EA; Asante, KP; Dosoo, DK; Gyaase, S; Nettey, OEA; Oppong, FB; Owusu-Agyei, S; Zandoh, C, 2019) |
| " Structured interview and antenatal clinic cards were used to obtain data including the use of intermittent preventive therapy in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP)." | 3.91 | Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region. ( Aklillu, E; Kamuhabwa, AAR; Mikomangwa, WP; Oms, M, 2019) |
| "The study was conducted to investigate malaria prevalence among a group of women in the Democratic Republic of Congo (DRC) who received intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP)." | 3.88 | Investigation of pregnancy-associated malaria by microscopy, rapid diagnostic test and PCR in Bandundu, the Democratic Republic of Congo. ( Bateko, JP; Imir, T; Ruh, E; Taylan-Ozkan, A, 2018) |
| "To investigate whether high-dosed folate supplements might diminish the efficacy of malaria intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) in a cohort of pregnant women in Benin, where malaria is holoendemic." | 3.88 | High folate levels are not associated with increased malaria risk but with reduced anaemia rates in the context of high-dosed folate supplements and intermittent preventive treatment against malaria in pregnancy with sulphadoxine-pyrimethamine in Benin. ( Accrombessi, M; Cot, M; Moya-Alvarez, V; Ouédraogo, S, 2018) |
| "Despite the development of resistance to Plasmodium falciparum malaria, sulfadoxine-pyrimethamine is still effective for intermittent preventive treatment of malaria in pregnancy (IPTp)." | 3.88 | A decade since sulfonamide-based anti-malarial medicines were limited for intermittent preventive treatment of malaria among pregnant women in Tanzania. ( Kilonzi, M; Marealle, AI; Mbwambo, DP; Mikomangwa, WP; Mlyuka, HJ; Mutagonda, RF, 2018) |
| "Malaria during pregnancy is associated with poor maternal and pregnancy outcome and the World Health Organization recommends the administration of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) and distribution of insecticide-treated mosquito nets (ITNs) to all pregnant women attending antenatal care (ANC) services." | 3.85 | Assessment of coverage of preventive treatment and insecticide-treated mosquito nets in pregnant women attending antenatal care services in 11 districts in Mozambique in 2011: the critical role of supply chain. ( Gudo, ES; Sacarlal, J; Salomão, C, 2017) |
| "5% of the pregnant women received at least one (1) dose of sulphadoxine pyrimethamine during the current pregnancy with 71% receiving optimal (at least 3 doses) doses of sulphadoxine pyrimethamine for intermittent preventive treatment of malaria in pregnancy at the time of study." | 3.85 | Factors influencing uptake of intermittent preventive treatment of malaria in pregnancy using sulphadoxine pyrimethamine in Sunyani Municipality, Ghana. ( Apanga, PA; Bachan, EG; Ibrahim, H; Issah, K; Maya, ET; Noora, CL, 2017) |
| "In Lusaka, Zambia, where malaria prevalence is low, national guidelines continue to recommend that all pregnant women receive sulfadoxine-pyrimethamine (SP) for malaria prophylaxis monthly at every scheduled antenatal care visit after 16 weeks of gestation." | 3.85 | Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region. ( Chi, BH; Kumwenda, A; Smid, M; Stoner, MC; Stringer, E; Stringer, JS; Vwalika, B, 2017) |
| "Mefloquine (MQ) has been used for the treatment of malaria since the mid-1980s, first as monotherapy or as fixed combination with sulfadoxine-pyrimethamine (MSP) and since the mid-1990s in combination with artesunate." | 3.85 | Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. ( Lee, SJ; Luxemburger, C; Nosten, F; Price, RN; Ter Kuile, FO, 2017) |
| "Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with SP is crucial." | 3.83 | Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. ( Ades, V; Arinaitwe, E; Chaluluka, E; Coulibaly, SO; Desai, M; Doumbo, O; Edgar, D; Gutman, J; Kalilani, L; Kamuliwo, M; Kayentao, K; Khairallah, C; Mace, KE; Magnussen, P; Mathanga, DP; Meshnick, S; Otieno, K; Ouma, P; Shi, YP; Skarbinski, J; Taylor, SM; Ter Kuile, FO; Wiegand, RE, 2016) |
| "In 1993, Malawi changed its first-line anti-malarial treatment for uncomplicated malaria from chloroquine to sulfadoxine-pyrimethamine (SP), and in 2007, it changed from SP to lumefantrine-artemether." | 3.83 | Malaria research and its influence on anti-malarial drug policy in Malawi: a case study. ( de Jager, C; Hongoro, C; Longwe, H; Mutero, CM; Mwendera, C; Phiri, K, 2016) |
| "Intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is recommended for malaria prevention during pregnancy." | 3.83 | [Factors associated with the failure of Intermittent Preventive Treatment for malaria among pregnant women in Yaounde]. ( de Nguefack, MA; Eko, FE; Enow, RM; Essiben, F; Foumane, P; Mboudou, ET; Njotang, PN, 2016) |
| "Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), provided as part of routine antenatal care (ANC), is one of three malaria-in-pregnancy prevention and control mechanisms recommended by the World Health Organization (WHO)." | 3.83 | Assessing supply-side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative study and document and record review in two regions of Uganda. ( Graham, K; Gudoi, SS; King, R; Meier, J; Mufubenga, P; Rassi, C, 2016) |
| "To identify factors contributing to low uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) in rural Mali." | 3.83 | Underreporting and Missed Opportunities for Uptake of Intermittent Preventative Treatment of Malaria in Pregnancy (IPTp) in Mali. ( Diarra, NH; Diop, SI; Doumbia, SO; Harvey, SA; Hurley, EA; Klein, MC; Rao, N, 2016) |
| "The Uganda National Malaria Control Programme recommends the use of intermittent preventive therapy in pregnancy with sulfadoxine/pyrimethamine (SP) to prevent malaria, however, there is overwhelming evidence of low uptake of this intervention." | 3.83 | The challenge of using intermittent preventive therapy with sulfadoxine/pyrimethamine among pregnant women in Uganda. ( Katamba, H; Okullo, AE; Rubahika, D; Wanzira, H, 2016) |
| "Faced with intense levels of chloroquine (CQ) resistance in Plasmodium falciparum malaria, Rwanda replaced CQ with amodiaquine (AQ)+sulfadoxine-pyrimethamine (SP) in 2001, and subsequently with artemether-lumefantrine (AL) in 2006, as first-line treatments for uncomplicated malaria." | 3.83 | Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. ( Grobusch, MP; Hakizimana, E; Kateera, F; Kumar, N; Mens, PF; Mutesa, L; Nsobya, SL; Tukwasibwe, S; van Vugt, M, 2016) |
| "Intermittent preventive treatment of malaria in pregnancy with 3+ doses of sulfadoxine-pyrimethamine (IPTp-SP) reduces maternal mortality and stillbirths in malaria endemic areas." | 3.83 | Scaling-up the use of sulfadoxine-pyrimethamine for the preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme impact from three local government areas in Sokoto State, Nigeria. ( Abdul-Azeez, J; Abegunde, D; Austin, AM; Beal, K; Fapohunda, B; Ganiyu, H; Ibrahim, M; Mohammed, Z; Nanbol, Z; Orobaton, N, 2016) |
| " Sulfadoxine/pyrimethamine-the current intermittent preventive treatment of malaria in pregnancy (IPTp)-has proven in vitro activity against group B Streptococcus (GBS)." | 3.81 | Evaluation of intermittent preventive treatment of malaria against group B Streptococcus colonization in pregnant women: a nested analysis of a randomized controlled clinical trial of sulfadoxine/pyrimethamine versus mefloquine. ( Adegnika, AA; Agnandji, ST; Akerey-Diop, D; Basra, A; Bélard, S; Capan-Melser, M; González, R; Groger, M; Kremsner, PG; Lötsch, F; Mackanga, JR; Matsiegui, PB; Menendez, C; Mombo Ngoma, G; Ramharter, M; Rehman, K; Schipulle, U; Schwing, J; Würbel, H; Zoleko-Manego, R, 2015) |
| "Tanzania adopted Intermittent-preventive treatment of malaria in pregnancy (IPTp) policy in 2000; the guidelines at the time of the study recommended the timing of the first dose of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) (IPTp-SP) at 20-24 weeks and the timing of the second dose at 28-32 weeks." | 3.81 | Predictors for uptake of intermittent preventive treatment of malaria in pregnancy (IPTp) in Tanzania. ( Hines, CS; Kibusi, SM; Kimunai, E, 2015) |
| "Nearly 20 years after the adoption by the government of Malawi of the provision of intermittent preventive treatment in pregnancy (IPTp) for malaria, only 55% of pregnant women received at least two doses of sulfadoxine-pyrimethamine (SP) in 2010." | 3.81 | Perspectives of health care providers on the provision of intermittent preventive treatment in pregnancy in health facilities in Malawi. ( Eckert, E; Moran, A; Nsabagasani, X; Yé, Y; Yoder, PS, 2015) |
| "Sulphadoxine-Pyrimethamine (SP) is still the only recommended antimalarial for use in intermittent preventive treatment of malaria during pregnancy (IPTp) in some malaria endemic countries including Ghana." | 3.81 | Glucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort Study. ( Amu, A; Anyorigiya, T; Asante, KP; Awini, E; Bart-Plange, C; Dosoo, D; Gyapong, M; Hodgson, A; Jakpa, G; Mahama, E; Oduro, AR; Ofei, E; Owusu, R; Owusu-Agyei, S; Segbaya, S, 2015) |
| "Persistence of sulfadoxine-pyrimethamine (SP) resistance has been described in an urban setting in Malawi where malaria transmission is relatively low." | 3.81 | The effect of local variation in malaria transmission on the prevalence of sulfadoxine-pyrimethamine resistant haplotypes and selective sweep characteristics in Malawi. ( Artimovich, E; Brown, S; Escalante, AA; Joshi, S; Kapito-Tembo, A; Laufer, MK; Mathanga, D; Nyirenda, O; Pensulo, P; Takala-Harrison, S; Taylor, TE, 2015) |
| "Intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) has been adopted as policy by most countries in sub-Saharan Africa." | 3.81 | Prevalence of intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) use during pregnancy and other associated factors in Sekondi-Takoradi, Ghana. ( Acquah, S; Afoakwah, R; Boampong, JN; Iriemenam, NC; Nwaefuna, E; Onyeabor, OS; Orish, VN; Sanyaolu, AO, 2015) |
| "The effectiveness of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment during pregnancy for malaria is well established." | 3.80 | Factors associated with utilization of sulphadoxine-pyrimethamine during pregnancy among women in Kenya: a cross-sectional study. ( Chertok, IR; Gurka, KK; Haile, ZT; Sambamoorthi, U, 2014) |
| "Intermittent preventive treatment during pregnancy (IPTp) with optimal doses (two+) of sulphadoxine-pyrimethamine (SP) protects pregnant women from malaria-related adverse outcomes." | 3.80 | Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania. ( Exavery, A; Kinyonge, IP; Kweka, H; Makemba, A; Mbaruku, G; Mbuyita, S, 2014) |
| "A study of health facility (HF) data on women receiving sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria during pregnancy (IPTp) was carried out at antenatal care clinics in Mkuranga and Mufindi districts." | 3.80 | Health facility-based data on women receiving sulphadoxine-pyrimethamine during pregnancy in Tanzania: lessons to learn from a cross-sectional survey in Mkuranga and Mufindi districts and other national survey reports. ( Bloch, P; Bygbjerg, IC; Byskov, J; Ijumba, JN; Magnussen, P; Marero, M; Mboera, LE; Molteni, F; Mubyazi, GM, 2014) |
| "Intermittent Preventive Treatment in pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) is widely used for the control of malaria in pregnancy in Africa." | 3.80 | Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study. ( Barry, B; Bationo, R; Coulibaly, SO; Dabira, E; Diakite, H; Djimde, M; Doumbo, OK; Guindo, N; Guirou, EA; Kayentao, K; Keita, M; Khairallah, C; Konate, S; Magnussen, P; Meshnick, SR; Niangaly, M; Soulama, A; Taylor, S; ter Kuile, FO; Traore, B, 2014) |
| "WHO recommends intermittent-preventive-treatment (IPTp) with sulphadoxine-pyrimethamine (SP) and insecticide-treated-nets (ITNs) to prevent malaria in pregnancy in sub-Saharan Africa, however uptake remains unacceptably low." | 3.80 | Effectiveness of antenatal clinics to deliver intermittent preventive treatment and insecticide treated nets for the control of malaria in pregnancy in Mali: a household survey. ( Bruce, J; Diarwara, S; Doumbo, OK; Hill, J; Kayentao, K; Smedley, J; ter Kuile, FO; Touré, M; Webster, J, 2014) |
| "At least 39 sub-Saharan African countries have policies on preventing malaria in pregnancy (MIP), including use of long-lasting insecticidal nets (LLINs), intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) and case management." | 3.80 | Assessment of the consistency of national-level policies and guidelines for malaria in pregnancy in five African countries. ( Andre, ZH; Dickerson, A; Eckert, E; Gomez, PP; Gutman, J; Hamel, MJ; Roman, E; Youll, S, 2014) |
| "The WHO recommends supervised administration of sulphadoxine-pyrimethamine (SP) as intermittent preventive treatment for malaria (IPTp) during pregnancy." | 3.80 | Intermittent use of sulphadoxine-pyrimethamine for malaria prevention: a cross-sectional study of knowledge and practices among Ugandan women attending an urban antenatal clinic. ( Bisaso, RK; Byamugisha, J; Obua, C; Odongo, CO, 2014) |
| "The World Health Organization (WHO) recommends that intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and insecticide treated bed nets (ITNs) must be provided during antenatal care (ANC) visits for malaria prevention during pregnancy." | 3.79 | Antenatal care visit attendance, intermittent preventive treatment and bed net use during pregnancy in Gabon. ( Bouyou-Akotet, MK; Kombila, M; Mawili-Mboumba, DP, 2013) |
| "Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is widely recommended in sub-Saharan Africa to reduce the risk of malaria and improve birth outcomes." | 3.79 | Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda. ( Ades, V; Arinaitwe, E; Chang, M; Dorsey, G; Filler, S; Kamya, MR; Mugagga, O; Nasr, S; Ninsiima, B; Patil, TS; Schwartz, A; Walakira, A, 2013) |
| "To investigate the characteristics of women in Nigeria who are likely to take sulfadoxine/pyrimethamine (SP) as recommended for the prevention of malaria in pregnancy to reduce maternal and child mortality rates." | 3.79 | Characteristics of Nigerian women taking sulfadoxine/pyrimethamine twice during pregnancy for the prevention of malaria. ( Brieger, WR; Okeibunor, JC; Onyeneho, NG; Orji, BC, 2013) |
| "Few women in Uganda access intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP)." | 3.79 | A new strategy and its effect on adherence to intermittent preventive treatment of malaria in pregnancy in Uganda. ( Birungi, J; Magnussen, P; Mbonye, AK; Yanow, S, 2013) |
| "Evidence on healthcare managers' experience on operational feasibility of malaria intermittent preventive treatment for malaria during pregnancy (IPTp) using sulphadoxine-pyrimethamine (SP) in Africa is systematically inadequate." | 3.79 | Feasibility and coverage of implementing intermittent preventive treatment of malaria in pregnant women contacting private or public clinics in Tanzania: experience-based viewpoints of health managers in Mkuranga and Mufindi districts. ( Bloch, P; Byskov, J; Magnussen, P; Mubyazi, GM, 2013) |
| "5% of women used at least one method of malaria prevention; 12% used four methods (insecticides, bednets, indoor residual spraying and Sulphadoxine Pyrimethamine) in combination." | 3.79 | Utilization of malaria prevention methods by pregnant women in Yaounde. ( Bisong, CE; Dongmo, CM, 2013) |
| "Widespread resistance to chloroquine was the mainstay to implement artemisinin-based combination therapy (ACT) in the year 2007 in few malaria endemic states in India including Jharkhand as the first line of treatment for uncomplicated Plasmodium falciparum malaria." | 3.79 | Insights following change in drug policy: a descriptive study for antimalarial prescription practices in children of public sector health facilities in Jharkhand state of India. ( Anvikar, AR; Das, MK; Gupta, R; Mishra, N; Rana, R; Shahi, B; Singh, S; Valecha, N, 2013) |
| " She was reported to have taken sulphadoxine-pyrimethamine for malaria prophylaxis during the pregnancy but did not use insecticide-treated net." | 3.78 | Congenital malaria in newborn twins. ( Opare, DA, 2012) |
| "Our findings show that intermittent preventive treatment in pregnancy with sulphadoxine-pyrimethamine may predispose to gametocyte carriage in pregnant women resident in the hyperendemic malaria region of southwest Nigeria." | 3.78 | Intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine may promote Plasmodium falciparum gametocytogenesis. ( Adeoye, SB; Balogun, ST; Fehintola, FA, 2012) |
| "Intermittent preventive treatment in infants (IPTi) is a malaria control strategy currently recommended by WHO for implementation at scale in Africa, consisting of administration of sulphadoxine-pyrimethamine (SP) coupled with routine immunizations offered to children under 1 year." | 3.78 | Acceptability of coupling intermittent preventive treatment in infants with the expanded programme on immunization in three francophone countries in Africa. ( Adovohekpe, P; Affo, A; de Sousa, A; Guidetti, F; Hassan, J; Lambo, N; Ndiaye, JL; Ndyiae, M; Rabarijaona, LP; Recht, J; Sow, D, 2012) |
| "To assess the effect of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) on birth weight in sites with varying degrees of drug resistance." | 3.78 | Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC). ( D'Alessandro, U; Dramaix, MW; Likwela, JL; Lokwa, BL; Meuris, S, 2012) |
| " The questionnaire elicited information on their: knowledge about malaria, attitude, chemotherapy and chemoprophylaxis using pyrimethamine, chloroquine proguanil as well as IPTp with sulphadoxine-pyrimethamine (SP)." | 3.78 | Patterns of case management and chemoprevention for malaria-in-pregnancy by public and private sector health providers in Enugu state, Nigeria. ( Onwujekwe, O; Onwujekwe, OC; Shu, E; Soremekun, RO; Uzochukwu, B, 2012) |
| "The effectiveness of methylene blue (MB) combined with pyrimethamine (PYR), chloroquine (CQ) or quinine (Q) was examined in a classical four-day suppressive test against a causative agent of rodent malaria, Plasmodium berghei." | 3.78 | The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine. ( Aldana, I; Bertani, S; Deharo, E; Garavito, G; Quiliano, M; Valentin, A, 2012) |
| "Meeting sessions included: updated policy recommendations on the use of sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of malaria in pregnancy, as well as the use of single dose primaquine as a Plasmodium falciparum gametocytocide; the need to develop a Global Technical Strategy for Malaria Control and Elimination 2016- 2025 and a global strategy for control of Plasmodium vivax; the Affordable Medicines Facility for malaria independent evaluation and promoting malaria case management in the private sector; updates from the Technical Expert Group on drug resistance and containment and the Evidence Review Group on malaria burden estimation; update on the RTS,S/AS01 malaria vaccine; progress on the policy setting process for malaria vector control; and the process for updating the WHO Guidelines for the Treatment of Malaria." | 3.78 | Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. ( , 2012) |
| "Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTpSP) is one of the major strategies of malaria control in most African countries where malaria is endemic." | 3.77 | Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges. ( Agomo, CO; Oyibo, WA, 2011) |
| "Naphthoquine (NQ), as a component of ARCO® which composed of NQ and artemisinin, is a new 4-aminoquinoline antimalarial synthesized by our institute." | 3.77 | Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model. ( Bei, ZC; Cao, WC; Wang, H; Wang, JY, 2011) |
| "Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown." | 3.77 | Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011) |
| "Insecticide-treated nets and intermittent preventive treatment with sulfadoxine-pyrimethamine are recommended for the control of malaria during pregnancy in endemic areas in Africa, but there has been no analysis of coverage data at a subnational level." | 3.77 | Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data. ( Alegana, VA; Gething, PW; Hill, J; Kirui, V; Snow, RW; ter Kuile, FO; van Eijk, AM, 2011) |
| "Recent publications put a serious warning regarding the inefficacy of sulphadoxine-pyrimethamine (SP) for the intermittent preventive treatment of malaria in young children (IPTi)." | 3.77 | Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination. ( Jansen, FH, 2011) |
| " Intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) reduces the incidence of malaria and aims to prevent mortality in infants, children, and pregnant women." | 3.77 | Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance. ( Borrmann, S; Friesen, J; Matuschewski, K, 2011) |
| "Sulphadoxine and pyrimethamine are anti-folate drugs that show synergistic anti-malarial effect." | 3.77 | Molecular epidemiology of Plasmodium vivax anti-folate resistance in India. ( Dev, V; Dua, VK; Joshi, H; Prajapati, SK, 2011) |
| "The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa." | 3.77 | Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. ( Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Kanhon, S; Kone, M; Kouakou, F; Menan, H; Sloan, C; Vanga-Bosson, HA, 2011) |
| "Intermittent preventive treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP) is recommended by WHO where malaria incidence in infancy is high and SP resistance is low." | 3.77 | Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children. ( Anto, F; Asoala, V; Cairns, M; Carneiro, I; Chandramohan, D; Ghani, A; Gosling, R; Greenwood, B; Milligan, P; Okell, L; Owusu-Agyei, S, 2011) |
| "The effectiveness of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) against malaria and anemia is unclear because of the spread of SP-resistant Plasmodium falciparum." | 3.77 | Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria and anemia in pregnant women. ( Adjei, AA; Anderson, WA; Ceesay, FK; Gyasi, RK; Lucchi, NW; Ndjakani, Y; Obed, SA; Rodney, P; Stiles, JK; Wilson, NO, 2011) |
| "Millions of African women receive sulfadoxine-pyrimethamine (SP) as intermittent preventive treatment during pregnancy (IPTp) to avoid poor outcomes that result from malaria." | 3.77 | Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. ( Duffy, PE; Fried, M; Harrington, WE; Kabyemela, E; Mutabingwa, TK, 2011) |
| "The currently recommended approach for preventing malaria in pregnancy (MiP), intermittent preventive treatment with sulphadoxine-pyrimethamine (SP-IPT), has been questioned due to the spread of resistance to SP." | 3.77 | Evaluating health workers' potential resistance to new interventions: a role for discrete choice experiments. ( Antwi, G; Chandramohan, D; Greenwood, B; Jones, C; Lagarde, M; Smith Paintain, L; Tagbor, H; Webster, J, 2011) |
| "In 2007, Malawi replaced the first-line medication for uncomplicated malaria, sulfadoxine-pyrimethamine-a single-dose regimen-with artemether-lumefantrine (AL)-a 6-dose, 3-day regimen." | 3.77 | Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. ( Ali, D; Filler, SJ; Jafali, J; Kachur, SP; Luka, M; Mace, KE; Mathanga, DP; Mwandama, D; Sande, J; Skarbinski, J, 2011) |
| " First line anti-malarial was Amodiaquine plus sulphadoxine-pyrimethamine (AQ+SP) bi-therapy." | 3.77 | Management of uncomplicated malaria in children under 13 years of age at a district hospital in Senegal: from official guidelines to usual practices. ( Cissé, M; Lalou, R; Le Hesran, JY; Sarrassat, S, 2011) |
| " Refugees received pre-departure antimalarial treatment with sulfadoxine-pyrimethamine (SP), partially supervised (three/six doses) artemether-lumefantrine (AL), or fully supervised AL." | 3.77 | Presumptive treatment to reduce imported malaria among refugees from east Africa resettling in the United States. ( Arguin, PM; Doney, AC; Galev, A; Green, M; Kapella, BK; Mekonnen, L; Phares, CR; Stauffer, WM; Weinberg, M, 2011) |
| " In 2010, artesunate + sulphadoxine-pyrimethamine became the universal first-line treatment for confirmed Plasmodium falciparum malaria and was deployed at full scale." | 3.77 | Prescription practices and availability of artemisinin monotherapy in India: where do we stand? ( Anvikar, AR; Das, MK; Dash, AP; Gupta, P; Gupta, YK; Kamal, VK; Kumar, H; Mishra, N; Pradhan, K; Shah, NK; Sharma, SK; Srivastava, HC; Valecha, N, 2011) |
| "Drug resistance against dihydrofolate reductase (DHFR) inhibitors-such as pyrimethamine (PM)-has now spread to almost all regions where malaria is endemic, rendering antifolate-based malaria treatments highly ineffective." | 3.76 | Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate. ( Brun, R; Chitnumsub, P; Dartois, V; Diagana, TT; Goh, A; Kamchonwongpaisan, S; Keller, TH; Kiara, SM; Lakshminarayana, SB; Ma, NL; Maneeruttanarungroj, C; Nzila, A; Rottmann, M; Taweechai, S; Weaver, M; Wittlin, S; Wong, J; Yeung, BK; Yuthavong, Y; Zou, B, 2010) |
| "Less than a year after the introduction of amodiaquine (AQ)/sulfadoxine-pyrimethamine (SP) as the first-line antimalarial treatment in Senegal, our study aimed to assess patients' drug intake and check its correspondence with nurses' prescription-adherence, the national guidelines regimen and theoretical dosage." | 3.76 | Child age or weight: difficulties related to the prescription of the right dosage of antimalarial combinations to treat children in Senegal. ( Lalou, R; Le Hesran, JY; Senghor, P; Souares, A, 2010) |
| "Intermittent preventive treatment in infants (IPTi) with sulphadoxine-pyrimethamine (SP) given during routine vaccinations is efficacious in preventing malaria disease and shows no interaction with the vaccines." | 3.76 | Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. ( Barry, A; Coulibaly, OM; Dama, S; de Sousa, A; Diallo, AI; Dicko, A; Dicko, M; Djimdé, AA; Doumbo, OK; Rogier, C; Sagara, I; Touré, SO; Traore, M, 2010) |
| "Pyrimethamine is an antimalarial drug that has also been used successfully to treat autoimmune diseases such as lymphoproliferative syndrome." | 3.76 | Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: a novel immunomodulatory mechanism of action for an old antimalarial drug? ( Legorreta-Herrera, M; Narváez, V; Retana-Ugalde, R; Ventura-Gallegos, JL, 2010) |
| "The relationship between antenatal care (ANC) visits and coverage of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), and barriers to IPTp-SP access were examined." | 3.76 | Intermittent preventive treatment of malaria in pregnancy (IPTp): do frequent antenatal care visits ensure access and compliance to IPTp in Ugandan rural communities? ( Katamanywa, J; Ndyomugyenyi, R, 2010) |
| "Data on antenatal attendance, uptake of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP), birthweight, malaria, anaemia, for 2,152 primigravidae." | 3.76 | Trends in pregnancy outcomes in Malawian adolescents receiving antimalarial and hematinic supplements. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, P; Msyamboza, K; Savage, E, 2010) |
| " We recorded demographic data, antenatal prescription of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine and bed net use, and examined finger-prick blood for malaria parasites and hemoglobin concentration." | 3.76 | Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets. ( Chaluluka, E; Feng, G; Molyneux, ME; Rogerson, SJ; Simpson, JA, 2010) |
| "For monitoring efficacy of sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy, data obtained from studies of children seemed inadequate." | 3.76 | Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy. ( Bertin, G; Briand, V; Cot, M; Deloron, P; Massougbodji, A, 2010) |
| "Anti-malarial drug resistance in Kenya prompted two drug policy changes within a decade: sulphadoxine-pyrimethamine (SP) replaced chloroquine (CQ) as the first-line anti-malarial in 1998 and artemether-lumefantrine (AL) replaced SP in 2004." | 3.76 | Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. ( Akala, HM; Bedno, SA; Coldren, RL; Eyase, FL; Moss, WJ; Prigge, ST; Spalding, MD; Waters, NC, 2010) |
| "To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome." | 3.75 | Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009) |
| "The use of most anti-malarial medications is restricted during pregnancy, but two doses of sulphadoxine-pyrimethamine are recommended after the first trimester as intermittent preventive treatment in pregnancy (IPTp)." | 3.75 | Rural Gambian women's reliance on health workers to deliver sulphadoxine-pyrimethamine as recommended intermittent preventive treatment for malaria in pregnancy. ( Brabin, L; Dumbaya, I; Owens, S; Stokes, E, 2009) |
| "To estimate the cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) using sulfadoxine-pyrimethamine (SP)." | 3.75 | Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania. ( Alonso, P; Hutton, G; Kahigwa, E; Macete, E; Mas, X; Menendez, C; Schellenberg, D; Sigauque, B; Tanner, M; Tediosi, F; Trapero, M; Trilla, A, 2009) |
| "Burkina Faso has recently changed the antimalarial drug policy to artesunate/amodiaquine or artemether/lumefantrine as the first-line antimalarial drug and sulfadoxine/pyrimethamine for the intermittent preventive treatment in pregnant woman." | 3.75 | [Change of antimalarial first-line treatment in Burkina Faso in 2005]. ( Diarra, A; Gansané, A; Konaté, AT; Nébié, I; Ouédraogo, A; Sirima, BS; Soulama, I; Tiono, A, 2009) |
| "To investigate how delayed introduction of sulfadoxine-pyrimethamine (Fansidar) and arthemeter-lumefantrine (Coartem) as first-line drugs for malaria in KwaZulu-Natal contributed to the reported epidemics of 1985-1988 and 1997-2001." | 3.75 | Impact of delayed introduction of sulfadoxine-pyrimethamine and arthemeter-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa. ( Anyachebelu, EJ; Geddes, R; Knight, SE; Maharaj, R, 2009) |
| "One year after the adoption of artesunate-amodiaquine (AS/AQ) as first-line therapy for the treatment of uncomplicated malaria, this study was designed to assess the treatment practices regarding anti-malarial drugs at health facilities in four rural areas in southern Cameroon." | 3.75 | Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon. ( Bley, D; Gausseres, M; Malvy, D; Millet, P; Sayang, C; Vernazza-Licht, N, 2009) |
| " Different techniques used to measure compliance were compared among children treated by the anti-malarial amodiaquine/sulphadoxine-pyrimethamine (AQ/SP) combination therapy, in use in Senegal between 2004 and 2006." | 3.75 | Self-reported data: a major tool to assess compliance with anti-malarial combination therapy among children in Senegal. ( Carlotti, MP; Lalou, R; Le Hesran, JY; Moulin, P; Sarrassat, S; Souares, A, 2009) |
| "Trials of intermittent preventive treatment against malaria in infants (IPTi) using sulphadoxine-pyrimethamine (SP) have shown a positive, albeit variable, protective efficacy against clinical malaria episodes." | 3.74 | Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants. ( Carneiro, I; Greenwood, B; Maire, N; Penny, M; Ross, A; Schellenberg, D; Smith, T; Studer, A; Tanner, M, 2008) |
| "Intermittent preventive treatment of malaria in infants (IPTi) using sulphadoxine-pyrimethamine and linked to the expanded programme on immunization (EPI) is a promising strategy for malaria control in young children." | 3.74 | Development of behaviour change communication strategy for a vaccination-linked malaria control tool in southern Tanzania. ( Alonso, P; Manzi, F; Mbuya, C; Mponda, H; Mrisho, M; Mshinda, H; Mushi, AK; Pool, R; Schellenberg, D; Schellenberg, J; Tanner, M, 2008) |
| "To assess the knowledge of dispensers in private pharmacies on new malaria treatment guidelines which involved switching from chloroquine (CQ) to sulfadoxine pyrimethamine (SP) and from SP to artemether-lumefantrine." | 3.74 | Poor knowledge on new malaria treatment guidelines among drug dispensers in private pharmacies in Tanzania: the need for involving the private sector in policy preparations and implementation. ( Haule, AF; Minzi, OM, 2008) |
| "RBx11160 (OZ277) is a promising antimalarial drug candidate that Ranbaxy Laboratories Limited and Medicines for Malaria Venture (MMV) are currently developing as a fixed combination with piperaquine." | 3.74 | In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. ( Chollet, J; Santo-Tomas, J; Scheurer, C; Snyder, C; Wittlin, S, 2007) |
| "The antifolate drugs sulfadoxine and pyrimethamine are commonly used to treat Plasmodium falciparum malaria." | 3.74 | Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum. ( Alam, MT; Bharti, PK; Bora, H; Das, B; Das, MK; Dash, AP; Dev, V; Kumar, A; Saifi, MA; Sharma, YD; Singh, N, 2007) |
| "Chloroquine (CLQ) and Pyrimethamine (PYR) are used for the treatment of malaria and some autoimmune diseases; although their mechanism of action is only partially understood, their therapeutic effectiveness in the second case has been attributed to their ability to increase apoptosis of T lymphocytes." | 3.74 | Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice. ( Legorreta-Herrera, M; Machuca-Rodríguez, C; Moreno-Altamirano, MM; Narváez, V; Ramos-Avila, A; Ventura-Gallegos, JL; Zentella-Dehesa, A, 2007) |
| "Anaemia [haemoglobin (Hb) <11 g/dl), severe anaemia (Hb <8 g/dl) and placental malaria were compared among women with known HIV status who delivered at a provincial hospital after study enrolment in the third trimester during three consecutive periods: period 1, no routine intervention (reference); period 2, routine haematinic supplementation (60 mg elementary iron three times/day, folic acid 5 mg once daily) and period 3, haematinics and IPT with SP." | 3.74 | Effect of haematinic supplementation and malaria prevention on maternal anaemia and malaria in western Kenya. ( Ayisi, JG; Kager, PA; Nahlen, BL; Otieno, JA; Rosen, DH; Shi, YP; Slutsker, L; Steketee, RW; Ter Kuile, FO; van Eijk, AM, 2007) |
| "To assess whether traditional birth attendants, drug-shop vendors, community reproductive health workers and adolescent peer mobilizers can administer intermittent preventive treatment (IPT) with sulfadoxine-pyremethamine to pregnant women, and reach those most at risk of malaria and increase access and compliance to it." | 3.74 | Intermittent preventive treatment of malaria in pregnancy: the effect of new delivery approaches on access and compliance rates in Uganda. ( Bygbjerg, IB; Magnussen, P; Mbonye, AK, 2007) |
| "Having reliable forecasts is critical now for producers, malaria-endemic countries and agencies in order to adapt production and procurement of the artemisinin-based combination treatments (ACTs), the new first-line treatments of malaria." | 3.74 | Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs). ( D'Altilia, JP; Kindermans, JM; Olliaro, P; Vandenbergh, D; Vreeke, E, 2007) |
| " Anti-malaria drug policy (2007) of the NVBDC recommends chloroquine (CQ) as the first line of drug for the treatment of all malarias." | 3.74 | Battling the malaria iceberg with chloroquine in India. ( Sharma, VP, 2007) |
| "Prior to the introduction of artemisinin-based combination antimalarial therapy in Mpumalanga province, South Africa, a pharmacovigilance strategy was developed to pilot locally relevant surveillance methods for detecting serious adverse drug reactions (ADRs) and signals related to artesunate plus sulfadoxine/pyrimethamine." | 3.74 | Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa. ( Allen, E; Barnes, KI; Blumberg, L; Durrheim, D; Mabuza, A; Mehta, U, 2007) |
| "Intermittent preventive treatment (IPTi) with sulphadoxine-pyrimethamine (SP) in infants resulted in different estimates of clinical malaria protection in two trials that used the same protocol in Ifakara, Tanzania, and Manhiça, Mozambique." | 3.74 | Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. ( Aide, P; Alonso, PL; Aponte, JJ; Kahigwa, E; Macete, E; Menendez, C; Mshinda, H; Sacarlal, J; Sanz, S; Schellenberg, D; Tanner, M, 2007) |
| "In November 2001, the National Health Ministry of Rwanda advocated a new therapeutic protocol replacing chloroquine by an amodiaquine+sulfadoxine-pyrimethamine combination for the treatment of uncomplicated malaria." | 3.74 | [Assessing the application of Rwanda's national protocol for uncomplicated malaria treatment in healthcare institutions in Kigali City, Rwanda]. ( Freund, RJ; Lombrail, P; Malvy, D; Millet, P; Nzayirambaho, M; Potel, G, 2008) |
| "To appraise the prevalence of malaria and anaemia in antenatal mothers; and explore the factors influencing coverage of intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) under operational conditions in the national programme for malaria control in pregnancy." | 3.74 | Appraisal on the prevalence of malaria and anaemia in pregnancy and factors influencing uptake of intermittent preventive therapy with sulfadoxine-pyrimethamine in Kibaha district, Tanzania. ( Tarimo, SD, 2007) |
| "To reduce the intolerable burden of malaria in pregnancy, the Ministry of Health in Uganda improved the antenatal care package by including a strong commitment to increase distribution of insecticide-treated nets (ITNs) and introduction of intermittent preventive treatment with sulphadoxine-pyrimethamine for pregnant women (IPTp-SP) as a national policy in 2000." | 3.74 | Use of antenatal care, maternity services, intermittent presumptive treatment and insecticide treated bed nets by pregnant women in Luwero district, Uganda. ( Kiwuwa, MS; Mufubenga, P, 2008) |
| "To assess whether traditional birth attendants, drug-shop vendors, community reproductive health workers and adolescent peer mobilizers can administer IPTp with sulphadoxine-pyrimethamine (SP) to pregnant women, reach those at greatest risk of malaria, and increase access and compliance with IPTp." | 3.74 | Effect of a community-based delivery of intermittent preventive treatment of malaria in pregnancy on treatment seeking for malaria at health units in Uganda. ( Bygbjerg, IC; Magnussen, P; Mbonye, AK; Schultz Hansen, K, 2008) |
| "In malaria endemic areas intermittent treatment with sulfadoxine-pyrimethamine (SP) is recommended for malaria prevention in pregnancy." | 3.73 | Perceptions on use of sulfadoxine-pyrimethamine in pregnancy and the policy implications for malaria control in Uganda. ( Magnussen, P; Mbonye, AK; Neema, S, 2006) |
| "There has been a constant increase in the level of therapeutic failure of the sulfadoxine-pyrimethamine (SP) combination for treating uncomplicated Plasmodium falciparum malaria." | 3.73 | [Blood levels of sulfadoxine and pyrimethamine, according to the malaria-treatment response, in two municipalities of Antioquia, Colombia]. ( Blair, S; Carmona, J; López, C; Márquez, D; Morales, G; Pabón, A, 2005) |
| "To evaluate treatment practices for uncomplicated malaria after the policy change from chloroquine to sulfadoxine-pyrimethamine and to artemether-lumefantrine in Zambia." | 3.73 | Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study. ( Hamer, DH; Ndhlovu, M; Rowe, AK; Snow, RW; Thea, DM; Zurovac, D, 2005) |
| "The anti-malarial agent chloroquine has activity against HIV." | 3.73 | Impact of chloroquine on viral load in breast milk. ( Aldrovandi, G; Ghosh, M; Kankasa, C; Kasonde, P; Kuhn, L; Semrau, K; Shutes, E; Sinkala, M; Thea, DM; Vwalika, C, 2006) |
| "The World Health Organization recommends that pregnant women in malaria-endemic areas receive >or= 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp/SP) in the second and third trimesters of pregnancy to prevent maternal anemia, placental parasitemia, and low birth weight (LBW)." | 3.73 | Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso. ( Asamoa, K; Bougouma, EC; Cotte, AH; Diarra, A; Konaté, A; Moran, AC; Newman, RD; Ouédraogo, A; Parise, ME; Sirima, SB, 2006) |
| "This study retrospectively studied amendable determinants of sulfadoxine-pyrimethamine (SP) efficacy involving 2869 treatments among 1072 Kenyan children <5 years old who had uncomplicated malaria." | 3.72 | Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya. ( Courval, JM; Kager, PA; Kolczak, MS; Lal, AA; Nahlen, BL; Oloo, AJ; Rosenberg, OS; ter Kuile, FO; Terlouw, DJ, 2003) |
| "WHO proposal of a new strategy for the control of malaria, intermittent treatment using sulfadoxine-pyrimethamine, encounters various conceptual and logistic problems." | 3.72 | [Limits and weaknesses of intermittent treatment in malaria prevention]. ( Chippaux, JP; Cot, M; Le Hesran, JY; Massougbodji, A, 2003) |
| "Between 1998 and 2001, Kenya, Uganda, Tanzania, Zanzibar, Rwanda and Burundi changed antimalarial drug policy, in the face of widespread chloroquine resistance." | 3.72 | The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. ( , 2003) |
| "To monitor the effectiveness of intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) for the control of malaria in pregnancy at delivery in the Provincial Hospital in Kisumu, Kenya, and to assess the effect of IPT in participants in a cohort study." | 3.72 | Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study. ( Ayisi, JG; Kager, PA; Misore, AO; Nahlen, BL; Odondi, JO; Otieno, JA; Rosen, DH; Steketee, RW; ter Kuile, FO; van Eijk, AM, 2004) |
| "Mefloquine and pyrimethamine-sulfadoxine combination are recommended, as is quinine, for self-administered malaria prophylaxis." | 3.71 | [Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine]. ( Granier, H; Laborde, JP; Martin, J; Nicolas, X; Talarmin, F, 2001) |
| "Prior to policy change from chloroquine (CQ) to sulphadoxine/pyrimethamine (S/P; Fansidar) we assessed the perception of CQ efficacy and the alternative treatment options for malaria in children among parents/guardians (N=527) of under-fives attending first level health facilities on account of fever." | 3.71 | Perception of chloroquine efficacy and alternative treatments for uncomplicated malaria in children in a holoendemic area of Tanzania: implications for the change of treatment policy. ( Bygbjerg, IC; Minjas, JN; Tarimo, DS, 2001) |
| "Access to effective treatment would substantially reduce the burden of malaria in sub-Saharan Africa, but resistance to chloroquine, the most commonly used first line drug, is now widespread." | 3.71 | Changing the first line drug for malaria treatment--cost-effectiveness analysis with highly uncertain inter-temporal trade-offs. ( Coleman, PG; Goodman, CA; Mills, AJ, 2001) |
| "Pyrimethamine acts by selectively inhibiting malarial dihydrofolate reductase-thymidylate synthase (DHFR-TS)." | 3.70 | Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria. ( Chan, C; Dascombe, MJ; Douglas, KT; Hyde, JE; McKie, JH; Read, M; Roser, SA; Sirawaraporn, W; Yates, R; Yuthavong, Y, 1998) |
| "To study the mechanism of antimalarial action of nitroquine." | 3.70 | [Effect of nitroquine on the membrane phospholipid of intraerythrocytic Plasmodium yoelii in vitro]. ( Deng, S; Hu, Y, 1999) |
| "Sulfadoxine-pyrimethamine preparations are used commonly for the treatment and or prevention of malaria in the endemic regions of Sub-Sahara Africa." | 3.70 | Effect of intramuscular sulfadoxine-pyrimethamine on pregnant Wistar rats. ( Uche-Nwachi, EO, 1998) |
| "Data were collected from two separate prospective cohorts to ascertain the safety of chloroquine-proguanil, sulfadoxine-pyrimethamine (SP), and mefloquine taken in the first trimester of pregnancy." | 3.70 | Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy. ( Edwards, R; Fuchs, E; Kerr, L; Phillips-Howard, PA; Schildknecht, J; Steffen, R; Vanhauwere, B, 1998) |
| "A fever case management (CM) approach using sulfadoxine-pyrimethamine (SP) was compared with two presumptive intertmittent SP treatment regimens in the second and third trimesters in pregnant primigravidae and secundigravidae in an area of intense Plasmodium falciparum malaria transmission in western Kenya." | 3.70 | Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. ( Ayisi, JG; Misore, A; Muga, R; Nahlen, BL; Oloo, AJ; Parise, ME; Roberts, JM; Schultz, LJ; Steketee, RW, 1998) |
| "The spectrum of antimalarial activity of the new macrolide antibiotic azithromycin was evaluated against blood- and sporozoite-induced infections with a chloroquine-resistant strain of Plasmodium yoelii nigeriensis (N-67) in Swiss mice and with simian parasite Plasmodium cynomolgi B in rhesus monkeys." | 3.70 | Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. ( Puri, SK; Singh, N, 2000) |
| "The stage-dependent sensitivity of Plasmodium vinckei petteri to the antimalarial drugs quinine, mefloquine, and pyrimethamine was investigated using single subcurative doses and 2 different tests: a prepatency test evidencing the extension of the prepatent period according to the stage at which the drug was administered, and a patency test showing the morphological alterations of the parasites and the modifications of the parasitic pattern following drug treatment." | 3.69 | Stage sensitivity of Plasmodium vinckei petteri to quinine, mefloquine, and pyrimethamine. ( Beauté-Lafitte, A; Caillard, V; Chabaud, A; Ginsburg, H; Landau, I, 1995) |
| "A pyrimethamine-resistant line of Plasmodium berghei was derived by treating infected mice with high doses of pyrimethamine and selecting for recrudescence." | 3.69 | Effect of pyrimethamine resistance on sporogony in a Plasmodium berghei/Anopheles stephensi model. ( Lanners, HN; Lowrie, RC; Shinondo, CJ; Wiser, MF, 1994) |
| "Groups of about 30 children in each of five villages were given pyrimethamine-sulfadoxine to clear their malaria parasitaemia, and they were followed up with fortnightly blood slides." | 3.68 | Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. Part 4. Effects on incidence of malaria infection. ( Curtis, CF; Msuya, FH, 1991) |
| "In 1983, the first African cases of malaria due to Plasmodium falciparum resistant to sulfadoxine/pyrimethamine, were described." | 3.68 | [Plasmodium falciparum resistant to sulfadoxine/pyrimethamine in Senegal]. ( Botella de Maglia, J; Espacio Casanovas, A; Martínez Paz, ML; Valls Ferrer, JM, 1991) |
| " falciparum to pyronaridine/sulfadoxine/pyrimethamine has been carried out in Diaoluo area in Hainan Province where chloroquine-resistant falciparum malaria is endemic, covering an area of 406 square kilometers, with a population of 3745 in 1986." | 3.68 | A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province. ( Huang, ZS; Meng, F; Shao, BR; Shi, XH, 1991) |
| "A simplified in-vivo test system was applied to detect chloroquine resistance in malaria patients in Shahjahanpur district (Uttar Pradesh) in India." | 3.68 | Application of a simplified in-vivo test system for determining chloroquine resistance in Plasmodium falciparum. ( Prasad, H; Prasad, RN; Sharma, VP; Virk, KJ, 1990) |
| "Forty-seven new acridone alkaloid derivatives (SA compounds) were tested for antimalarial activity in vitro." | 3.68 | Activities of new acridone alkaloid derivatives against Plasmodium yoelii in vitro. ( Fujimura, K; Fujioka, H; Fujita, M; Kato, N; Nishiyama, Y, 1990) |
| "Proguanil and pyrimethamine are antifolate drugs with distinct chemical structures that are used commonly in the prophylaxis and treatment of Plasmodium falciparum malaria." | 3.68 | Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. ( Milhous, WK; Peterson, DS; Wellems, TE, 1990) |
| "Pyronaridine, a highly effective antimalarial drug, was synthesized and developed by this institute." | 3.68 | [Combined action of pyronaridine and sulfadoxine/pyrimethamine against Plasmodium berghei ANKA strain in mice]. ( Shao, BR; Shi, XH; Ye, XY, 1990) |
| "Selection of the rodent malaria Plasmodium chabaudi with low levels of the antifolate drug pyrimethamine has previously been shown by us to result in duplication of the dihydrofolate reductase-thymidylate synthase (DHFR-TS) gene by a duplication of chromosome 7 and subsequent rearrangements." | 3.68 | Chromosomal rearrangements and point mutations in the DHFR-TS gene of Plasmodium chabaudi under antifolate selection. ( Cowman, AF; Lew, AM, 1990) |
| "The pharmacokinetics of mefloquine (M) were studied in 59 male Thai patients with falciparum malaria." | 3.68 | Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria. ( Back, DJ; Breckenridge, AM; Bunnag, D; Karbwang, J, 1990) |
| "Two soldiers continued weekly prophylaxis with 300 mg chloroquine base on their return to Australia from Papua New Guinea but were not protected against Plasmodium vivax malaria." | 3.67 | Plasmodium vivax resistance to chloroquine? ( Davis, DR; Hutton, DC; Rieckmann, KH, 1989) |
| "Proguanil 200mg daily and chloroquine base 300mg weekly along with maloprim 1 tablet weekly was used as malaria chemoprophylaxis for 140 Hong Kong based soliders on a seven-week jungle exercise in a holoendemic malarial area of Papua New Guinea." | 3.67 | Malaria chemoprophylaxis with a proguanil-chloroquine-maloprim combination in Papua New Guinea. ( Heap, BJ, 1988) |
| "The relative risks of non-specific upper respiratory tract infections were studied in two well matched groups of military recruits to see whether dapsone-pyrimethamine (Maloprim) given as antimalarial prophylaxis was associated with immunosuppression." | 3.67 | Risk of acute non-specific upper respiratory tract infections in healthy men taking dapsone-pyrimethamine for prophylaxis against malaria. ( Lau, EY; Lee, PS, 1988) |
| "A reversed-phase high performance liquid chromatography method was developed to simultaneously estimate serum concentrations of dapsone (DDS), monoacetyldapsone (MADDS), and pyrimethamine (PYR) in 34 young adult Chinese men after they had taken the sixth weekly dose of Maloprim for malaria prophylaxis." | 3.67 | Simultaneous estimation of serum concentrations of dapsone, monoacetyldapsone, and pyrimethamine in Chinese men on maloprim for malaria prophylaxis using reversed-phase high performance liquid chromatography. ( Lee, HS; Lee, PS; Ti, TY; Yap, CL, 1985) |
| "Several drugs are used for malaria chemoprophylaxis: 4 amino-quinolines, antifolics, combinations of sulfonamides and antifolics, and new anti-malarial agents, including mefloquine." | 3.67 | [Malaria chemoprophylaxis. Resistance problems]. ( Danis, M; Gentilini, M, 1985) |
| "There are no published haematological data on the long-term (more than one year) use of dapsone-pyrimethamine (Maloprim, Folaprim; one tablet a week) for malarial prophylaxis." | 3.67 | Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine. ( Cook, IF; Kish, MY, 1985) |
| "The duration of protection from blood-stage malarial challenge following single injections of pyrimethamine pamoate was assessed in mice and monkeys." | 3.67 | Long-acting, repository antimalarial agents. Duration of protection in mice and monkeys following administration of pyrimethamine pamoate. ( Jacobs, RL; Steinkampf, RW; Werbel, LM; Worth, DF, 1984) |
| "The antiplasmodial effect of a single dose treatment with a sulfadoxine/pyrimethamine combination as compared to a sulfalene/pyrimethamine combination against falciparum malaria was assessed in semi-immune populations in Burma in early 1980." | 3.67 | Comparative drug trial of a sulfadoxine/pyrimethamine and a sulfalene/pyrimethamine combination against Plasmodium falciparum infections in semi-immune populations of Burma. ( Tin, F, 1984) |
| "A 16-year old girl with insulin-dependent diabetes mellitus (8 years' duration) developed tropic malaria 7 weeks after her return from Kenya despite a longtime prophylaxis using pyrimethamine and sulfadoxine (Fansidar)." | 3.67 | [Chloroquine and pyrimethamine/sulfadoxine resistant malaria tropica in a child with diabetes mellitus]. ( Bienzle, U; Burger, W; Kroll, MH; Weber, B, 1984) |
| "Chloroquine-resistant Plasmodium falciparum malaria has been described in East, Central and West Africa." | 3.67 | Probable chloroquine-resistant Plasmodium falciparum malaria in south-western Africa. ( Blumenfeld, AM; Davidson, A; Isaäcson, M; Sieling, WL, 1984) |
| "Eighteen patients with Plasmodium falciparum infection were studied in Port-au-Prince, Haiti, to monitor the response of the malaria parasite to sulfadoxine-pyrimethamine." | 3.67 | Plasmodium falciparum in Haiti: susceptibility to pyrimethamine and sulfadoxine-pyrimethamine. ( Magloire, R; Nguyen-Dinh, P; Zevallos-Ipenza, A, 1984) |
| "One hundred and ten consecutive patients with falciparum malaria were treated with Fansidar and primaquine." | 3.67 | Clinical efficacy of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Sabah, Malaysia. ( Tan, HS; Tan, PE, 1984) |
| "In the face of an increasing prevalence of Plasmodium falciparum resistant to chloroquine and to pyrimethamine-sulphonamide or -sulphone mixtures, the need for a new, effective blood schizontocide for treatment of acute malaria is urgent." | 3.67 | The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'. ( Peters, W; Robinson, BL, 1984) |
| "The antimalarial drugs chloroquine and pyrimethamine were observed to afford protection to mice treated with these agents." | 3.67 | Protection against Plasmodium berghei yoelii in chloroquine- and pyrimethamine-treated mice. ( Pradhan, VR; Renapurkar, DM, 1984) |
| " The usefulness of this type of analysis for in vitro studies of antimalarial agents was demonstrated using three such agents--cyclosporin A, chloroquine, and pyrimethamine." | 3.67 | Microscopic and flow cytophotometric analysis of parasitemia in cultures of Plasmodium falciparum vitally stained with Hoechst 33342--application to studies of antimalarial agents. ( Brun, R; Franklin, RM; Grieder, A, 1986) |
| "A 39-year-old Japanese male engineer who stayed in Nigeria from August 17, 1987 through January 22, 1988, presented chloroquine-resistant Plasmodium falciparum malaria." | 3.67 | [Chloroquine-resistant Plasmodium falciparum malaria confirmed by semi-micro sensitivity test for chloroquine seen in a person returned from Nigeria to Japan]. ( Kano, S; Matsuoka, Y; Obana, M; Suzuki, M; Waki, S; Yamakawa, H, 1989) |
| "Rhodamine 123 (Rh 123) was used as a fluorescent probe for the mitochondria of the malarial parasite Plasmodium falciparum." | 3.67 | Mitochondria as the site of action of tetracycline on Plasmodium falciparum. ( Kiatfuengfoo, R; Prapunwattana, P; Suthiphongchai, T; Yuthavong, Y, 1989) |
| "The seleno-organic compound ebselen showed anti-malarial activity in vitro against the murine Plasmodium berghei and the human P." | 3.67 | Antimalarial properties of ebselen. ( Hüther, AM; Parnham, MJ; Sauer, A; Zhang, Y, 1989) |
| "The in vivo sensitivity of Plasmodium falciparum for chloroquine, quinine and pyrimethamine-sulfadoxine has been evaluated in 3 of 14 sentinel antimalarial drugs sensitivity surveillance centres between October 1986 and July 1987." | 3.67 | [Comparative efficacy of alternative treatments in Plasmodium falciparum infections in Zaire]. ( Disu, MM; Kalonji, MW; Mbudi, PK; Pela, NN, 1989) |
| "The sulfadoxine-pyrimethamine combination has not been recommended for the prophylaxis of malaria since 1985 following serious accidents in the USA." | 3.67 | [Plasmodium falciparum drug resistance and sulfadoxine-pyrimethamine in Africa]. ( Charmot, G; Coulaud, JP; Le Bras, J; Randriamanjaka, JR, 1989) |
| "Three standard antimalarials pyrimethamine, primaquine and quinine were tested against P." | 3.67 | Gametocytocidal and sporontocidal activity of some standard antimalarials on P. berghei (NK 65) infection M. natalensis. ( Pal, NL; Rastogi, M; Sen, AB, 1989) |
| "The triple combination of pyronaridine, sulfadoxine and pyrimethamine which has been proven to be efficient in delaying emergence of drug resistance of rodent malarial parasites was further studied for potential application to malaria control." | 3.67 | Antimalarial and toxic effect of triple combination of pyronaridine, sulfadoxine and pyrimethamine. ( Ha, SH; Huang, J; Huang, ZS; Meng, F; Shao, BR; Shi, XH; Ye, XY; Zhan, CQ, 1989) |
| "A patient developed eosinophilic peripheral pulmonary infiltrates while receiving malaria prophylaxis with sulfadoxine-pyrimethamine (Fansidar)." | 3.67 | Sulfadoxine specific lymphocyte transformation in a patient with eosinophilic pneumonia induced by sulfadoxine-pyrimethamine (Fansidar). ( Berg, PA; Daniel, PT; Holzschuh, J, 1989) |
| "The disposition of sulfadoxine was studied in the presence of pyrimethamine in 18 healthy Thai subjects who had been suffering from falciparum malaria in the 6 months prior to the study, and in 12 Thai patients with acute malaria." | 3.67 | Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects. ( Keschamrus, N; Kölle, EU; Leimer, R; Noeypatimanond, S; Sarikabhuti, B; Weidekamm, E; Wernsdorfer, W, 1988) |
| "A 12-year-old boy developed a phototoxic rash with subsequent progression to Stevens-Johnson syndrome due to prophylactic ingestion of antimalarials (chloroquine and sulfadoxine-pyrimethamine; Fansidar)." | 3.67 | An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy. ( Hönigsmann, H; Ortel, B; Sivayathorn, A, 1989) |
| "In a field study conducted in Burma, 54 semi-immune adults suffering from falciparum malaria (mean parasite count, 15 328/mm(3) before treatment) were given a single dose of a fixed combination of 750 mg mefloquine base, 1500 mg sulfadoxine, and 75 mg pyrimethamine (3 tablets of Fansimef)." | 3.67 | Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma. ( Hlaing, N; Lasserre, R; Tin, F; Tun, T; Win, S, 1985) |
| "The elimination of the antimalarial drug pyrimethamine was studied in isolated liver preparations from young rats (80-100 g) infected with merozoites of Plasmodium berghei two weeks earlier." | 3.67 | Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver. ( Date, NM; Mihaly, GW; Newman, KT; Smallwood, RA; Veenendaal, JR, 1987) |
| "We present two cases of Plasmodium falciparum malaria contracted in Douala despite adequate prophylaxis by Fansidar for one and by chloroquine for the other." | 3.67 | [2 cases of multiresistant Plasmodium falciparum malaria contracted in Douala with atypical clinical presentation]. ( Charmot, G; Le Bras, J; Simon, F, 1987) |
| "Fansidar (SP), a combination of sulfadoxine and pyrimethamine, was evaluated for its usefulness as a curative agent for treating individual malaria patients and for reducing the community reservoir of Plasmodium falciparum in 4 villages near Lahore, Pakistan, where resistance of 4-aminoquinolines has recently been reported." | 3.67 | Effects of Fansidar on chloroquine-resistant Plasmodium falciparum in Pakistan. ( Fox, E; Hassan, H; Khaliq, AA; Pervez, M; Sarwar, M; Strickland, GT, 1986) |
| "We have selected eight pyrimethamine resistant mutants of a cloned, drug sensitive, Plasmodium falciparum malaria parasite, strain FCR3." | 3.67 | Plasmodium falciparum: induction, selection, and characterization of pyrimethamine-resistant mutants. ( Banyal, HS; Inselburg, J, 1986) |
| "Six imported cases of chloroquine-resistant Falciparum malaria have been studied since October 1984." | 3.67 | Imported cases of chloroquine-resistant falciparum malaria in Iran. ( Afshar, A; Edrissian, GH; Emadi, AM; Ghorbani, M; Hajseyed-Javadi, J; Khaleghian, B; Pishva, E; Saghari, H; Shahabi, S, 1986) |
| "A case of concurrent chloroquine- and Fransidar-resistant Plasmodium falciparum malaria imported into Zimbabwe by an adult male Zimbabwean from either Malawi or Mozambique is reported." | 3.67 | Concurrent chloroquine- and Fansidar-resistant Plasmodium falciparum: an imported case into Zimbabwe. ( Dallas, AB; Mutambu, SL; Okwanga, PN; Pfumojena, JW, 1986) |
| "Seven patients (one black African and six white Europeans) developed chloroquine-resistant falciparum malaria in East Africa." | 3.67 | Chloroquine-resistant falciparum malaria from East Africa. ( Bhattacharya, DN; Hall, AP, 1986) |
| "Sixty-eight cases of vivax and 30 cases of falciparum malaria patients were treated with a combination of sulfamonomethoxine-pyrimethamine (MP tablet with 500 mg of sulfamonomethoxine and 25 mg of pyrimethamine) and the results were compared with those with chloroquine, Fansidar and quinine." | 3.67 | A combination of sulfamonomethoxine and pyrimethamine versus other drugs for the treatment of malaria. ( Ebisawa, I; Ohara, H, 1986) |
| "The in vivo response of Plasmodium falciparum to standard treatment with sulphadoxine/pyrimethamine was studied in 19 hospital patients from Yekepa town with hypoendemic malaria and in 28 children, two to nine years old, living in a village with holoendemic malaria." | 3.67 | In vivo and in vitro susceptibility of Plasmodium falciparum to sulphadoxine/pyrimethamine in Liberia, West Africa. ( Björkman, A; Willcox, M, 1986) |
| "The protective effect of malaria chemoprophylaxis with either Fansidar (pyrimethamine-sulfadoxine) or chloroquine was estimated by determining the attack rates of Plasmodium falciparum infections acquired in Kenya and imported by U." | 3.67 | Efficacy of malaria prophylaxis in American and Swiss travelers to Kenya. ( Lobel, HO; Roberts, JM; Somaini, B; Steffen, R, 1987) |
| "Mefloquine-sulphadoxine-pyrimethamine (MSP) in combination has proved effective against multiple-drug-resistant falciparum malaria, but nothing is known about mefloquine absorption when it is given in this formulation." | 3.67 | Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine. ( Back, DJ; Karbwang, J; Looareesuwan, S; Molyneux, ME; Nagachinta, B; Phillips, RE; Warrell, DA; Wattanagoon, Y, 1987) |
| "A fatal case of Stevens-Johnson syndrome associated with Fansidar and chloroquine is reported in a 5-year-old boy." | 3.67 | Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine. ( Bamber, MG; Elder, AT; Gray, JA; Minns, RA, 1986) |
| "An American Peace Corps volunteer contracted chloroquine-resistant Plasmodium falciparum malaria while serving in Malawi and taking regular chloroquine prophylaxis." | 3.67 | Chloroquine-resistant falciparum malaria in northern Malawi. ( Ainsworth, B; Breman, JG; Patchen, LC; Teklehaimanot, A; Wolfe, MS, 1985) |
| " There was no significant difference between the mean values of plasma 4-aminobenzoic acid (PABA) in falciparum malaria patients and in healthy controls." | 3.67 | In vitro susceptibility of Plasmodium falciparum collected from pyrimethamine-sulfadoxine sensitive and resistant areas in Thailand. ( Attanath, P; Chongsuphajaisiddhi, T; Doberstyn, EB; Kanjanapipatkul, K; Sabchareon, A; Suebsaeng, L, 1985) |
| "We report a patient who developed agranulocytosis following exposure to three drugs: amodiaquine, pyrimethamine and dipyrone." | 3.67 | Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum. ( Douer, D; Ramot, B; Schwartz, E; Shaked, N, 1985) |
| "The efficacy of chloroquine and pyrimethamine as malaria chemoprophylactics was investigated in young Nigerian children." | 3.67 | A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children. ( Akintunde, A; Attai, ED; Bartlett, A; Bidwell, DE; Bradley, AK; Bradley-Moore, AM; Fleming, AF; Greenwood, BM; Kirkwood, BR; Voller, A, 1985) |
| " Many of the thioquinazolines (VIII) showed suppressive antimalarial activity comparable with or superior to chloroquine, cycloguanil, and pyrimethamine against drug-sensitive lines of Plasmodium berghei in mice and Plasmodium gallinaceum in chicks, and several displayed potent prophylactic activity with P." | 3.66 | Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects. ( Elslager, EF; Jacob, P; Johnson, J; Rane, L; Werbel, LM; Worth, DF, 1978) |
| "Since it was first introduced 'Fansidar' (pyrimethamine 25 mg, sulfadoxine 500 mg) has been the preferred treatment for uncomplicated chloroquine-resistant Plasmodium falciparum malaria in Thailand." | 3.66 | Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand. ( Campbell, CC; Hurwitz, ES; Johnson, D, 1981) |
| "The anti-malarial drug pyrimethamine suppresses in vitro mitogenic lectin-induced blast transformation by human peripheral blood mononuclear cells (MNC) when the drug is added to cells (1 X 10(-5) M/culture)." | 3.66 | Suppression of mitogenic lectin-induced blast transformation of human peripheral blood mononuclear cells by pyrimethamine. ( Gilbreath, MJ; Groves, J; Pavanand, K; Phisphumvithi, P, 1983) |
| "Two tourists from Kenya with falciparum malaria had an R1-resistance against chloroquine (WHO-extended field test, no in-vitro test)." | 3.66 | [Drug-resistant malaria in East Africa]. ( Diesfeld, HJ; Kroeger, A, 1983) |
| "The first two cases from East Africa of RII chloroquine- and Fansidar-resistant falciparum malaria are described." | 3.66 | Combined chloroquine/Fansidar-resistant falciparum malaria appears in East Africa. ( Hess, U; Jones, M; Timmermans, PM, 1983) |
| "Two different diets for the host and three drug dosage regimens were used to select lines resistant to sulfadoxine and pyrimethamine from the parent strain of the rodent malaria parasite Plasmodium berghei [the N (K173) strain]." | 3.66 | Plasmodium berghei: diet and drug dosage regimens influencing selection of drug-resistant parasites in mice. ( Merkli, B; Richle, R, 1983) |
| "Since 1978 several cases of chloroquine-resistant falciparum malaria have been reported from East Africa (Petterson et al." | 3.66 | Fansidar-resistant Plasmodium falciparum infection from Tanzania. ( Meuwissen, JH; Vleugels, MP; Wetsteyn, JC, 1982) |
| " falciparum malaria contracted in Thailand, the course of the disease under treatment suggested resistance to both chloroquine and pyrimethamine-sulfadoxine, as well as reduced sensitivity to quinine." | 3.66 | [Plasmodium falciparum malaria resistant to polychemotherapy. Usefulness of pathogen culture (author's transl)]. ( Bastin, R; Charmot, G; Dournon, E; Frottier, J; Le Bras, J, 1981) |
| "A case of Plasmodium falciparum malaria resistant to Fansidar (sulphadoxine plus pyrimethamine) at a level corresponding to R III and resistant to chloroquine is reported." | 3.66 | Fansidar resistant falciparum malaria acquired in South East Asia. ( Black, F; Bygbjerg, I; Effersøe, P; Gomme, G; Jensen, GA; Jepsen, S, 1981) |
| "A case of Plasmodium falciparum malaria resistant to chloroquine occurring in a patient taking Fansidar (a combination of pyrimethamine and sulphadoxine) regularly as prophylaxis is reported." | 3.66 | Drug-resistant malaria in Africa. A case report and review of the problem and treatment. ( Halkett, JA; Nieuwveld, RW; Spracklen, FH, 1982) |
| "A total of 49 semi-immune Laotians aged 3 to 49 years, with falciparum malaria were treated with a single dose of sulfadoxine pyrimethamine (1500 mg, 75 mg, adult dose), in Vientiane, Laos." | 3.66 | Clearance of falciparum parasitaemia with a single dose sulfadoxine-pyrimethamine in Vientiane, Laos. ( Tawil, NA, 1978) |
| "The effect of pyrimethamine and the combination of pyrimethamine-sulfadoxine (Fansidar) upon the termination of the acute attack of vivax malaria was studied in Thailand." | 3.66 | Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone. ( Andre, RG; Doberstyn, EB; Noeypatimanondh, S; Phintuyothin, P; Teerakiartkamjorn, C, 1979) |
| "A 42-year-old hospital worker had a recrudescence of falciparum malaria after chloroquine therapy." | 3.66 | Possible chloroquine-resistant Plasmodium falciparum in Nigeria. ( Eke, RA, 1979) |
| "A review of chloroquine and sulfa-antifol combination treated falciparum malaria patients revealed a high incidence of chloroquine-resistance, wither R1 or R2, in patients infected in Southeast Asia or Oceania." | 3.66 | Chemotherapy of falciparum malaria: regional differences in responsiveness to treatment. ( Ebisawa, I; Muto, T; Tanabe, S, 1979) |
| "As part of the search for new antimalarial drugs, a screening program was developed using sensitive and chlorguanide triazine (CGT, cycloguanil) resistant strains of the folate-requiring bacteria, Streptococcus faecium durans, Lactobacillus casei, and Pediococcus cerevisiae." | 3.65 | Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli. ( Genther, CS; Smith, CS, 1977) |
| "Chloroquine and amodiaquine are demonstrably still the most reliable drugs for the treatment of malaria, except in the south east Asia area, and in parts of south and central America where an altered sensitivity of falciparum plasmodia has been confirmed." | 3.65 | [Chemotherapy and chemoprophylaxis of malaria (author's transl)]. ( Bruce-Chwatt, LJ, 1976) |
| "Quinine (at least four doses given at intervals of eight to 12 hours) followed by a single dose of sulfadoxine-pyrimethamine (Fansidar) is the most effective treatment of chloroquine-resistant falciparum malaria." | 3.65 | Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine. ( Doberstyn, EB; Hall, AP; Mettaprakong, V; Sonkom, P, 1975) |
| "Evidence is presented of the chloroquine-resistance in Plasmodium falciparum in West Irian and East Kalimantan as shown by clinical observation and quantitative parasite counts in two patients hospitalized in Tokyo where no natural transmission of malaria occurs." | 3.65 | Chloroquine resistance of Plasmodium falciparum in West Irian and East Kalimantan. ( Ebisawa, I; Fukuyama, T, 1975) |
| "Serum was collected from six adults participating in a field trial of sulfadoxine and pyrimethamine in combination which was being administered once monthly for malaria suppression." | 3.65 | Pharmacokinetic rationale for a malarial suppressant administered once monthly. ( Joyce, BE; Lewis, AN; Peck, CC, 1975) |
| "Mass drug administration was introduced in Syria to supplement DDT spraying after the main malaria vector Anopheles sacharovi had developed considerable resistance to the insecticide." | 3.65 | Experience with mass drug administration as a supplementary attack measure in areas of vivax malaria. ( Onori, E, 1972) |
| "During the course of antimalarial screening, it was discovered that sulfamethoxydiazine, a long-acting sulfanilamide extensively used in genitourinary tract infections, not only was effective against Plasmodium berghei infections in mice when administered alone but also was active when used in combination with chloroquine, in effect making it possible to use half as much of the latter drug as normally required to achieve the same results." | 3.65 | Chemotherapeutic activity of combination doses of chloroquine, pyrimethamine, and sulfamethoxy-diazine, a long-acting sulfanilamide, against Plasmodium berghei infections in mice. ( Berberian, DA; Slighter, RG, 1973) |
| "Development of resistance to chloroquine in rodent malaria is inhibited by giving this compound together with a potentiating mixture of pyrimethamine and sulfadoxine but this does not prevent the development of resistance to the last two compounds." | 3.65 | Prevention of drug resistance in rodent malaria by the use of drug mixtures. ( Peters, W, 1974) |
| "Chlorproguanil is one of the antimalarial drugs developed in recent years which have shown promise for field use in malaria eradication campaigns." | 3.64 | Field trials with chlorproguanil in the prophylaxis of malaria in Ghana. ( CHARLES, LJ, 1961) |
| "During the preparatory phase of the Malaria Eradication Pilot Project in Ghana, a weekly pyrimethamine regimen was instituted at two hyperendemic villages, primarily to assess the reliability of self-administration techniques under local conditions." | 3.64 | The appearance of pyrimethamine resistance in Plasmodium falciparum following self-medication by a rural community in Ghana. ( BRADY, J; CHARLES, LJ; VAN DER KAAY, HJ; VINCKE, IH, 1962) |
| " Eleven volunteers received chloroquine in usually curative doses on a three-day schedule during acute clinical malaria attacks." | 3.64 | STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND. ( ALVING, AS; BREWER, GJ; MILLAR, JW; POWELL, RD, 1964) |
| "The authors describe a two-year investigation carried out on a group of Nigerian schoolchildren with the object of assessing the effect of suppressing malaria infection with pyrimethamine on the physical development of the African child." | 3.63 | Suppression of malaria with pyrimethamine in Nigerian schoolchildren. ( ARCHIBALD, HM; BRUCE-CHWATT, LJ, 1956) |
| "The authors present the results of a study carried out to determine the efficacy of chloroquine- and pyrimethamine-salt mixtures as a suppressive against sporozoite-induced vivax malaria (Chesson strain)." | 3.63 | Chloroquine or pyrimethamine in salt as a supressive against sporozoite-induced vivax malaria (Chesson strain). ( BURGESS, RW; COATNEY, GR; MICKELSEN, O; PIRKLE, CI; YOUNG, MD, 1958) |
| "We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth." | 3.30 | The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Fan, YM; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2023) |
| "Intermittent preventive treatment of malaria among schoolchildren (IPTsc) reduces clinical malaria, asymptomatic parasitemia, and anemia." | 3.11 | Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial. ( Bamadio, A; Chico, RM; Cohee, LM; Coumare, S; Dara, A; Diarra, M; Djimde, AA; Doumbo, OK; Kodio, A; Maiga, H; Opondo, C; Sagara, I; Sidibe, B; Tekete, M; Traore, OB; Traore, ZI, 2022) |
| "Children with sickle cell anemia (SCA) in areas of Africa with endemic malaria transmission are commonly prescribed malaria chemoprevention." | 3.11 | Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial. ( Clapp, S; Freedman, B; Green, CL; Kirui, JK; Korwa, S; Njuguna, FM; O'Meara, WP; Taylor, SM; Wu, A, 2022) |
| " RCTs comparing IPTp DP versus recommended standard treatment for IPTp with these outcome measures were analyzed; change in QTc interval, serious adverse events (SAE), grade 3 or 4 adverse events possibly related to study drug and vomiting within 30 min after study drug administration." | 3.01 | Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials. ( Abebe, A; Ahmedin, M; Atim, MG; Embaye, SM; Kahabuka, M; Kazembe, D; Manyazewal, T; Mesfin, T; Muthoka, EN; Namuganza, S; Usmael, K, 2023) |
| "In endemic areas, malaria and its adverse effects in schoolchildren may be prevented by intermittent preventive treatment (IPTsc)." | 2.84 | Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial. ( da Luz, RI; Doua, JY; Lutumba, P; Matangila, JR; Mitashi, P; Van Geertruyden, JP, 2017) |
| "Malaria is one of the most serious global problems." | 2.82 | The efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine vs artemisinin-based drugs for malaria: a systematic review and meta-analysis. ( Chen, N; Chu, X; Feng, L; Li, M; Liu, Y; Wang, Q; Wang, S; Yan, P; Yang, K; Zhang, N; Zhang, Z, 2022) |
| " Understanding the safety, pharmacokinetic and pharmacodynamic properties of antimalarial combination therapies is crucial in optimising dosing." | 2.82 | Pharmacokinetic considerations in seasonal malaria chemoprevention. ( Chotsiri, P; Tarning, J; White, NJ, 2022) |
| "Intermittent preventive treatment in pregnancy has not been evaluated outside of Africa." | 2.80 | Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial. ( Bardaji, A; Betuela, I; Hanieh, S; Kongs, C; Lufele, E; Menendez, C; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, SJ; Rosanas-Urgell, A; Samol, P; Schofield, L; Siba, P; Singirok, D; Suen, CS; Sui, D; Umbers, AJ; Unger, HW; Wangnapi, RA; Wapling, J, 2015) |
| "The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect." | 2.80 | Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. ( Baker, M; Marquart, L; McCarthy, JS; O'Rourke, P, 2015) |
| " CF fortified with highly bioavailable iron improved iron status but not Hb concentration, despite three-monthly IPT of malaria." | 2.80 | The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial. ( Adiossan, LG; Brittenham, GM; Diakité, VG; Glinz, D; Hurrell, RF; N'Goran, EK; Ouattara, M; Righetti, AA; Seifert, B; Utzinger, J; Wegmüller, R; Zimmermann, MB, 2015) |
| "Piperaquine (PQ) levels were used as a measure of compliance in the DP arm." | 2.79 | Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. ( Achan, J; Aweeka, FT; Bigira, V; Clark, TD; Dorsey, G; Havlir, DV; Huang, L; Kamya, MR; Kapisi, J; Kinara, S; Muhindo, MK; Mwangwa, F; Osterbauer, B; Rosenthal, PJ, 2014) |
| " We developed population pharmacokinetic (PK) models to describe the distribution of sulfadoxine (SDX) and pyrimethamine (PYM) in children with uncomplicated malaria in Malawi." | 2.76 | Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. ( Bell, DJ; Molyneux, ME; Mukaka, M; Nyirongo, SK; Ward, SA; Winstanley, PA, 2011) |
| " The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0." | 2.76 | A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. ( Bousema, T; Drakeley, C; Gosling, R; Hermsen, R; Masokoto, A; Mosha, F; Mwanziva, C; Okell, L; Sauerwein, R; Semvua, S; Shekalaghe, SA; Teelen, K; ter Braak, R; van den Bijllaardt, W; van den Bosch, S, 2011) |
| "Intermittent preventive treatment of malaria during pregnancy (IPTp) and insecticide-treated nets (ITN) are recommended malaria interventions during pregnancy; however, there is limited information on their efficacy in areas of low malaria transmission in sub-Saharan Africa." | 2.76 | Efficacy of malaria prevention during pregnancy in an area of low and unstable transmission: an individually-randomised placebo-controlled trial using intermittent preventive treatment and insecticide-treated nets in the Kabale Highlands, southwestern Uga ( Clarke, SE; Hansen, KS; Hutchison, CL; Magnussen, P; Ndyomugyenyi, R, 2011) |
| "Malaria in pregnancy may affect neonatal survival, though no strong evidence exists to support this association." | 2.75 | Malaria prevention with IPTp during pregnancy reduces neonatal mortality. ( Alonso, PL; Aponte, JJ; Bardají, A; Mabunda, S; Menéndez, C; Sanz, S; Sigauque, B, 2010) |
| "Intermittent preventive treatment for malaria in children (IPTc) involves the administration of a full course of an anti-malarial treatment to children under 5 years old at specified time points regardless of whether or not they are known to be infected, in areas where malaria transmission is seasonal." | 2.75 | Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children. ( Chandramohan, D; Conteh, L; Greenwood, B; Kweku, M; Legood, R; Patouillard, E, 2010) |
| "5% improvement in the accumulated proportion of patients (1) treated, (2) treated within 24h of illness onset, (3) treated with the recommended antimalarials, (4) treated at an adequate dosage and (5) treated for the correct duration." | 2.73 | Home-based management of fever and malaria treatment practices in Uganda. ( Nsungwa-Sabiiti, J; Ogwal-Okeng, J; Pariyo, G; Peterson, S; Petzold, MG; Tomson, G, 2007) |
| "Malaria was an important risk factor for any and moderate anaemia; use of an insecticide-treated net (ITN) was a protective factor for any anaemia." | 2.73 | Malaria and anaemia among pregnant women at first antenatal clinic visit in Kisumu, western Kenya. ( Ayisi, JG; Hamel, MJ; Kager, PA; Otieno, K; Ouma, P; Parise, M; Slutsker, L; van Eijk, AM, 2007) |
| " Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP." | 2.73 | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. ( Bâ, el H; Boulanger, D; Cissé, B; Gaye, O; Greenwood, B; Hallett, R; Lines, J; Milligan, P; Simondon, F; Simondon, K; Sokhna, C; Sutherland, C; Targett, G; Trape, JF, 2008) |
| "Intermittent preventive treatment for malaria in Infants (IPTi) has been shown to give effective and safe protection against malaria." | 2.73 | Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana. ( Awine, T; Cairns, M; Carneiro, I; Chandramohan, D; Gosling, R; Greenwood, B; Milligan, P; Owusu-Agyei, S, 2008) |
| "The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed." | 2.72 | Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. ( Al Khaja, KAJ; Sequeira, RP, 2021) |
| " Additionally, these models are able to identify patient characteristics that cause alterations in the expected PK/PD profiles and through simulations can recommend changes to dosing which compensate for the differences." | 2.72 | Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations. ( Hughes, E; Jagannathan, P; Mohamed Ali, A; Savic, RM; Wallender, E, 2021) |
| "Treatment with sulfalene (1500 mg) + Pyrimethamine (75 mg) has no advantage over the SLP (1000 + 50) mg." | 2.67 | Efficacy of sulfalene and pyrimethamine combination drugs alone and with quinine in treatment of P. falciparum cases in chloroquine resistant areas of north east India. ( Barkakaty, BN; Chakravorty, NK; Narasimham, MV, 1990) |
| "Intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine is contraindicated in the first trimester and provides imperfect chemoprevention because of inadequate dosing, poor (few and late) antenatal clinic attendance, increasing antimalarial drug resistance, and decreasing naturally acquired maternal immunity due to the decreased incidence of malaria." | 2.66 | Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs. ( Briand, V; McGready, R; Min, AM; Saito, M, 2020) |
| "In conclusion it seems possible to treat falciparum malaria in semi-immune adults, weighing less than 60 kg, with a single dose of 500 mg mefloquine base, 1000 mg sulfadoxine and 50 mg pyrimethamine (2 tablets), instead of the higher dose (3 tablets) currently recommended." | 2.66 | Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma. ( Lasserre, R; Lim, MA; Tin, F; Win, S, 1987) |
| "Pyrimethamine alone was ineffective." | 2.64 | Single-dose therapy of Falciparum malaria using pyrimethamine in combination with diformyldapsone or sulfadoxine. ( Doberstyn, EB; Hall, AP; Sonkon, P; Vetvutanapibul, K, 1976) |
| " Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP." | 2.55 | Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis. ( Dorsey, G; Gutman, J; Kovacs, S; Stergachis, A; Ter Kuile, FO, 2017) |
| "Pregnancy is also associated with the risk of neural tube defects (NTDs), especially in women with low folate status, and folic acid supplementation is recommended in pregnancy to lower the risk of NTDs." | 2.50 | Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate. ( Molloy, AM; Nzila, A; Okombo, J, 2014) |
| "Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its subsequent malaria-associated morbidity." | 2.50 | Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. ( Abellana, R; Cot, M; Moya-Alvarez, V, 2014) |
| "Malaria in pregnancy is a significant contributor to adverse pregnancy outcome, especially in Sub-Saharan Africa." | 2.49 | A systematic review of the impact of malaria prevention in pregnancy on low birth weight and maternal anemia. ( Dent, AE; Goldenberg, RL; McClure, EM; Meshnick, SR, 2013) |
| "Malaria in pregnancy has important consequences for mother and baby." | 2.49 | Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-Saharan Africa: a systematic review and meta-analysis. ( D'Mello-Guyett, L; Hill, J; Hoyt, J; Smith, H; Steketee, R; Ter Kuile, FO; van Eijk, AM; Webster, J, 2013) |
| "Intermittent preventive treatment for malaria during infancy (IPTi) is the administration of a full therapeutic course of antimalarial drugs to infants living in settings where malaria is endemic, at the time of routine vaccination in the first year of life." | 2.48 | Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. ( Crawley, J; Goodman, T; Milligan, P; Sismanidis, C, 2012) |
| " Identified articles were included in the review if the study had at least one group that reported at least one pharmacokinetic parameter of interest in pregnant women." | 2.47 | Pharmacokinetics of antimalarials in pregnancy: a systematic review. ( Ensom, MH; Wilby, KJ, 2011) |
| "Malaria in pregnancy is one of the major causes of maternal morbidity and adverse birth outcomes." | 2.44 | Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas. ( Briand, V; Cot, M; Cottrell, G; Massougbodji, A, 2007) |
| "Prophylaxis and intermittent treatment with antimalarial drugs reduce clinical malaria and severe anaemia in preschool children." | 2.43 | Chemoprophylaxis and intermittent treatment for preventing malaria in children. ( Garner, P; Meremikwu, MM; Omari, AA, 2005) |
| "Malaria is frequently a deadly disease, particularly in tropical countries of the world where this protozoan infection is endemic." | 2.41 | Malaria: a rising incidence in the United States. ( Broder, JS; Colletti, JE; Geroff, AJ; Grundmann, KA; Hanna, JR; Jerrard, DA; Mattu, A, 2002) |
| "Severe anaemia in pregnancy is an important contributor to maternal and perinatal morbidity and mortality." | 2.40 | Malaria in pregnancy: its relevance to safe-motherhood programmes. ( Shulman, CE, 1999) |
| " Similarly, evaluation of the pharmacokinetic properties of halofantrine has led to the demonstration that poor and erratic absorption could be just as likely to explain therapeutic failure as resistance of the parasite to effects of this drug." | 2.39 | Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations. ( Edwards, G; Ward, SA; Winstanley, PA, 1994) |
| "malariae are sensitive to the current antimalarial drugs." | 2.39 | [Malaria and drug resistance]. ( Kager, PA; Wetsteyn, JC, 1996) |
| "Malaria is the most important emergency in people returning from tropical countries." | 2.38 | [Malaria: the most important emergency in subjects returning from the tropics]. ( Schubarth, P, 1993) |
| " The dosage of mefloquine is 250 mg weekly (1 tablet Lariam) for 4 weeks, followed by 1 tablet every fortnight." | 2.37 | [Malaria in Switzerland]. ( Fernex, M, 1988) |
| " Safe and effective drugs, capable of being administered as a single-dose or short-course treatment, are urgently needed to control the adaptable malaria parasite." | 2.36 | Falciparum malaria: the urgent need for safe and effective drugs. ( Rieckmann, KH, 1983) |
| "Malaria is not a disease of the past." | 2.36 | [Current information on treatment and prophylaxis of malaria (author's transl)]. ( Cambournac, FJ, 1979) |
| "For the treatment of malaria, combinations of drugs with antifolic action have the great advantage, compared with other drug associations, of synergic action, which increases the effectiveness of the preparation, limits its toxicity, and reduces the risk of resistance." | 2.35 | Antifolic combinations in the treatment of malaria. ( Conno, L, 1974) |
| "Intermittent Preventive Treatment of malaria in infants (IPTi) is a malaria control strategy consisting of the administration of an anti-malarial drug alongside routine immunizations." | 1.91 | Coverage of intermittent preventive treatment of malaria in infants after four years of implementation in Sierra Leone. ( Berne, ML; Bertran-Cobo, C; Briand, V; Chen, H; Ekouevi, DK; Fombah, AE; Gonzalez, R; Jalloh, A; Kamara, ARY; Menendez, C; Owusu-Kyei, K; Quinto, L; Ramirez, M; Samai, M; Saute, F; Sesay, T; Sunders, JC; Wassenaar, M; Williams, J, 2023) |
| "Low birth weight is a public health problem in Africa with the cause attributable to malaria in pregnancy." | 1.72 | Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model. ( Afagbedzi, S; Guure, C, 2022) |
| "007) and dosage (p = 0." | 1.72 | Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi ( Achidi, EA; Amambua-Ngwa, A; Anchang-Kimbi, JK; Apinjoh, TO; Chi, HF; Dionne-Odom, J; Kwi, PN; Mayaba, JM; Moyeh, MN; Ntui, VN; Tangi, LN; Tita, ATN; Titanji, VPK; Toussi, CT, 2022) |
| "Malaria is a significant cause of morbidity and mortality." | 1.72 | Determinants of utilization of malaria preventive measures during pregnancy among women aged 15 to 49 years in Kenya: an analysis of the Malaria Indicator Survey 2020. ( Chirwa, T; Ibisomi, L; Kagura, J; Kinyanjui, S; Mkubwa, B, 2022) |
| "Intermittent preventive treatment during pregnancy using sulphadoxine-pyrimethamine is one way of reducing the effect of the disease on pregnancy outcomes." | 1.62 | Late ANC initiation and factors associated with sub-optimal uptake of sulphadoxine-pyrimethamine in pregnancy: a preliminary study in Cape Coast Metropolis, Ghana. ( Amoako, BK; Anto, F, 2021) |
| "Intermittent preventative treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) was documented and prompt treatment regardless of symptoms given upon malaria diagnosis." | 1.62 | Malaria Infection Is Common and Associated With Perinatal Mortality and Preterm Delivery Despite Widespread Use of Chemoprevention in Mali: An Observational Study 2010 to 2014. ( Andemel, N; Attaher, O; Barry, A; Dembele, AB; Diarra, BS; Dicko, A; Duffy, PE; Fried, M; Gaoussou, S; Keita, S; Mahamar, A; Sidibe, Y; Swihart, B; Traore, M, 2021) |
| "Malaria is one of the most widespread human infectious diseases worldwide and a cause of mortality." | 1.56 | Plasmodium infection cure cycles induce modulation of conventional dendritic cells. ( Adachi, R; Tamura, T, 2020) |
| "Malaria in pregnancy is of public health significance because of its associated maternal and fetal complications." | 1.56 | Health Workers' Awareness and Knowledge of Current Recommendation of Intermittent Preventive Treatment in Pregnancy in South-Western Nigeria. ( Bello, OO; Oni, O, 2020) |
| " Also, three or more dosing was associated (p < 0." | 1.56 | Coverage and effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) on adverse pregnancy outcomes in the Mount Cameroon area, South West Cameroon. ( Achidi, EA; Anchang-Kimbi, JK; Apinjoh, TO; Dionne-Odom, J; Kalaji, LN; Mbacham, HF; Ngole Sumbele, IU; Tita, ATN; Wepnje, GB, 2020) |
| "Malaria and curable sexually transmitted infections (STI) are the most common curable infections known to have a severe impact on pregnancy outcomes in sub-Saharan Africa." | 1.56 | Malaria and curable sexually transmitted infections in pregnant women: A two-years observational study in rural Burkina Faso. ( Bihoun, B; Derra, K; Donnen, P; Dramaix, M; Lingani, M; Robert, A; Rouamba, E; Rouamba, T; Samadoulougou, OS; Tinto, H; Valea, I; Zango, SH, 2020) |
| "Intermittent preventive treatment of malaria during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) is recommended as a chemoprevention therapy." | 1.48 | Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) among postpartum women in Zomba District, Malawi: a cross-sectional study. ( Azizi, SC; Chipukuma, H; Chongwe, G; Jacobs, C; Michelo, C; Zgambo, J, 2018) |
| " It was nongenotoxic in an Ames assay, an in vitro micronucleus assay, and an in vivo rat micronucleus assay when dosed orally up to 2000 mg/kg." | 1.46 | Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate. ( Berry, P; Campo, B; Cao, J; Ciaravino, V; Easom, EE; Erve, JCL; Freund, YR; Gamo, FJ; Guo, D; Jacobs, RT; Plattner, JJ; Rosenthal, PJ; Sanz, LM; Zhang, YK, 2017) |
| "Malaria is a leading cause of morbidity and mortality among HIV-infected pregnant women in sub-Saharan Africa: at least 1 million pregnancies among HIV-infected women are complicated by co-infection with malaria annually, leading to increased risk of premature delivery, severe anaemia, delivery of low birth weight infants, and maternal death." | 1.46 | Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa. ( Bendavid, E; Brandeau, ML; Choi, SE, 2017) |
| "Malaria is still one of the most serious diseases in tropical regions." | 1.46 | A novel prediction approach for antimalarial activities of Trimethoprim, Pyrimethamine, and Cycloguanil analogues using extremely randomized trees. ( Hannongbua, S; Khamsemanan, N; Lawtrakul, L; Nattee, C; Toochinda, P, 2017) |
| "Malaria in pregnancy is an immense public health problem with at least 50 million pregnant women living in malaria endemic areas." | 1.43 | Assessment of the usage and effectiveness of intermittent preventive treatment and insecticide-treated nets on the indicators of malaria among pregnant women attending antenatal care in the Buea Health District, Cameroon. ( Anchang-Kimbi, JK; Fokam, EB; Ngimuh, L; Wanji, S, 2016) |
| "Intermittent Preventive Treatment during pregnancy with sulphadoxine-pyrimethamine (IPTp-SP) and iron supplement to prevent anemia to all pregnant women receiving antenatal care (ANC) services is highly recommended." | 1.43 | Factors Influencing Anti-Malarial Prophylaxis and Iron Supplementation Non-Compliance among Pregnant Women in Simiyu Region, Tanzania. ( Ishunga, E; Kimambo, R; Matasha, E; Matumu, G; Ngilangwa, DP; Noronha, R; Peng, Y; Sambili, B, 2016) |
| "Prompt and effective treatment of malaria in pregnancy in accordance with recommended guidelines is essential to help prevent adverse events among pregnant mothers and the foetus." | 1.43 | Antimalarial treatment patterns among pregnant women attending antenatal care clinics in south east Nigeria and the future implications. ( Esimone, C; Ezenduka, C; Godman, BB; Massele, A; Nworgu, C, 2016) |
| "Overall, there is an over treatment of malaria, thus departing from the WHO guidelines of appropriate treatment." | 1.42 | Trends in malaria case management following changes in the treatment policy to artemisinin combination therapy at the Mbakong Health Centre, Cameroon 2006-2012: a retrospective study. ( Boakye, DA; Grobler, AF; Mbacham, WF; Ndong, IC; Reenen, Mv, 2015) |
| "Prevention and treatment of malaria during pregnancy is crucial for reduction of malaria in pregnancy and its adverse outcomes." | 1.42 | Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study. ( Chilongola, J; Juma, A; Mosha, D; Ndeserua, R, 2015) |
| "Malaria impacts cognitive development in a number of ways that may impact later educational participation." | 1.40 | Early childhood malaria prevention and children's patterns of school leaving in the Gambia. ( Jukes, MC; Zuilkowski, SS, 2014) |
| "Untreated and pyrimethamine-treated controls showed decreasing %Hct." | 1.40 | Protective effect of Thunbergia laurifolia extract on hemolysis during Plasmodium berghei infection. ( Jaihan, U; Khobjai, W; Somsak, V; Watcharasamphankul, W, 2014) |
| "Malaria has adverse effects on pregnancy outcomes for mothers, their foetuses and newborns." | 1.40 | Compliance with intermittent preventive treatment during pregnancy among postpartum women in Ibadan, Nigeria. ( Aluko, JO; Oluwatosin, OA, 2014) |
| " While SP was well known and attitudes towards IPTp were positive, health workers were often not informed of up-to-date dosing schedules, limiting coverage." | 1.39 | Systemic constraints continue to limit coverage of intermittent preventive treatment for malaria in pregnancy in southeast Tanzania. ( Ba-Break, MM; Graham, KJ, 2013) |
| "Intermittent preventive treatment of malaria in pregnancy (IPTp) is a strategy where pregnant women in malaria-endemic countries receive full doses of sulphadoxine-pyrimethamine (SP), whether or not they have malaria." | 1.39 | Perceptions of intermittent preventive treatment of malaria in pregnancy (IPTp) and barriers to adherence in Nasarawa and Cross River States in Nigeria. ( Belay, KA; Diala, CC; Marin, C; Pennas, T, 2013) |
| "Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against malaria but may also affect hematopoiesis and contribute to fetal anemia." | 1.38 | The effects of malaria and intermittent preventive treatment during pregnancy on fetal anemia in Malawi. ( Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Rogawski, ET; Rogerson, SJ, 2012) |
| "Malaria in pregnancy is a major health problem that can cause maternal anaemia, stillbirth, spontaneous abortion, low birth weight and intra-uterine stunting." | 1.38 | Validity of self-reported use of sulphadoxine-pyrimethamine intermittent presumptive treatment during pregnancy (IPTp): a cross-sectional study. ( Kironde, F; Mirembe, F; Namusoke, F; Ntale, M; Wahlgren, M, 2012) |
| "Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance." | 1.37 | Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. ( Bathurst, I; Buckner, FS; Burrows, J; Charman, SA; Charman, WN; Creason, S; Deng, X; El Mazouni, F; Floyd, DM; Gujjar, R; Matthews, D; Phillips, MA; Rathod, PK; Shackleford, DM; White, J; White, KL, 2011) |
| " The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity." | 1.37 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. ( Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011) |
| "Malaria is an important public health problem in Africa." | 1.37 | Field evaluation of the intermittent preventive treatment of malaria during pregnancy (IPTp) in Benin: evolution of the coverage rate since its implementation. ( Agboton-Zoumenou, MA; Briand, V; Cottrell, G; d'Almeida, TC; Garcia, A; Imorou, Y; Massougbodji, A, 2011) |
| "Intermittent preventive treatment (IPT) of malaria has recently been shown to be a highly effective way of reducing morbidity from malaria in children living in areas of seasonal malaria transmission, and it can be delivered efficiently by community volunteers." | 1.37 | Combining community case management and intermittent preventive treatment for malaria. ( Bojang, K; Greenwood, B; Pagnoni, F; Tagbor, H, 2011) |
| " The optimized spiroindolone NITD609 shows pharmacokinetic properties compatible with once-daily oral dosing and has single-dose efficacy in a rodent malaria model." | 1.36 | Spiroindolones, a potent compound class for the treatment of malaria. ( Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B, 2010) |
| "Maternal malaria is associated with serious adverse pregnancy outcomes." | 1.36 | Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda. ( Brentlinger, PE; Kiwuwa, MS; Richardson, BA; Sangaré, LR; Staedke, SG; Stergachis, A; Weiss, NS, 2010) |
| "The burden of malaria is greatest in sub-Saharan Africa where it contributes directly or indirectly to maternal and perinatal morbidity and mortality." | 1.35 | The challenges of diagnosis and treatment of malaria in pregnancy in low resource settings. ( Abe, E; Feyi-Waboso, P; Okonofua, FE; Omo-Aghoja, LO, 2008) |
| "Pyrimethamine was significantly more commonly prescribed in private health facilities compared with public health facilities (p < 0." | 1.35 | Perception and practice of malaria prophylaxis in pregnancy among primary health care providers in Ibadan, Nigeria. ( Fawole, AO; Onyeaso, NC, 2008) |
| ") was tested alone, or in a double and triple combination with a fixed oral dose of 1." | 1.35 | Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model. ( Ishih, A; Kano, S; Kino, H; Muregi, FW, 2009) |
| "malariae is correlated with increased P." | 1.35 | Increased Plasmodium falciparum gametocyte production in mixed infections with P. malariae. ( Arens, T; Bousema, JT; Drakeley, CJ; Gouagna, LC; Houben, R; Mens, PF; Omar, SA; Sauerwein, RW; Schallig, H, 2008) |
| "Chloroquine was prescribed by 42." | 1.34 | Perception and practice of malaria prophylaxis in pregnancy among health care providers in Ibadan. ( Fawole, AO; Onyeaso, NC, 2007) |
| "Intermittent preventive treatment of malaria during pregnancy (IPTp) is a key intervention in the national strategy for malaria control in Tanzania." | 1.33 | Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe District, North-Eastern Tanzania. ( Bloch, P; Ijumba, J; Kamugisha, M; Kitua, A; Mubyazi, G, 2005) |
| "Malaria is a leading cause of death in Sub-Saharan Africa." | 1.33 | How sulfadoxine-pyrimethamine (SP) was perceived in some rural communities after phasing out chloroquine (CQ) as a first-line drug for uncomplicated malaria in Tanzania: lessons to learn towards moving from monotherapy to fixed combination therapy. ( Nsimba, SE, 2006) |
| "Malaria is a huge public health problem in Africa that is responsible for more than one million deaths annually." | 1.33 | A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. ( Abdulmumini, U; Gebremeskel, T; Gebremichael, A; Ghebrat, Y; Gunawardena, D; Kosia, A; Mebrahtu, G; Mufunda, J; Nyarango, PM; Ogbamariam, A; Okbaldet, Y, 2006) |
| " The results indicate the suitability of this technique in antimalarial drug quality and bioavailability studies." | 1.33 | A simple technique for the detection of anti-malarial drug formulations and their presence in human urine. ( Akida, JA; Lemnge, MM; Lugimbana, L; Malebo, HM; Malle, LN; Segeja, MD, 2006) |
| "Malaria is a major cause of death in school-age (5-18 years) children in Malawi." | 1.32 | The effect of providing fansidar (sulfadoxine-pyrimethamine) in schools on mortality in school-age children in Malawi. ( Del Rosso, J; Marsh, D; Mukaka, M; Pasha, O, 2003) |
| "This work shows that an early treatment of a malaria infection produced by a non-lethal parasite drives the immune response towards a loss of cross-protection to further infections, in particular with more virulent parasites." | 1.32 | Early treatment during a primary malaria infection modifies the development of cross immunity. ( Hernández-Clemente, FF; Legorreta-Herrera, M; Licona-Chávez, RN; Soto-Cruz, I; Ventura-Ayala, ML, 2004) |
| "Pyrimethamine-sulfadoxine is an inhibitor of dihydrofolate reductase (DHFR) that has been widely used to treat chloroquine-resistant Plasmodium falciparum malaria." | 1.31 | Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. ( Hastings, MD; Sibley, CH, 2002) |
| "Oral treatment of pyrimethamine (10 mg/kg body weightx4 days) to P." | 1.31 | Studies on hepatic mitochondrial cytochrome P-450 during Plasmodium yoelii infection and pyrimethamine treatment in mice. ( Pandey, VC; Srivastava, P, 2000) |
| "Malaria is a major cause of death among children in many parts of the world, even though simple and effective treatments exist." | 1.31 | Patterns of care for childhood malaria in Zambia. ( Baume, C; Helitzer, D; Kachur, SP, 2000) |
| "Chloroquine plus Maloprim was used significantly more by general practitioners in older age groups, ie 45 years and over (p < 0." | 1.30 | Malaria prophylaxis prescribed for travellers from New Zealand. ( Heydon, JL; Leggat, PA; Menon, A, 1997) |
| "Pyrimethamine (oral) treatment (10 mg/kg body weight) to infected mice (5-10%) for four days brought back the altered levels of the above cellular constituents in different tissues to normal, a week after cessation of drug treatment." | 1.30 | Status of ammonia, glutamate, lactate and pyruvate during Plasmodium yoelii infection and pyrimethamine treatment in mice. ( Agarwal, A; Pandey, VC; Tripathi, LM, 1997) |
| "The urea level was found elevated in liver, brain and plasma during P." | 1.30 | Status of urea and related enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. ( Agrawal, A; Pandey, VC; Tripathi, LM, 1997) |
| " All sanctioned providers limited their first choices of antimalarial drug to those recommended by the national malaria control program and reported using correct dosing regimens." | 1.30 | Use of antimalarial drugs in Mali: policy versus reality. ( Dicko, A; Diop, S; Djimde, A; Doumbo, O; Plowe, CV; Wellems, TE, 1998) |
| "In The Gambia, insecticide impregnation of bed nets, used alone or combined with Maloprim, reduced morbidity and mortality from malaria amongst children between one and 4 years of age." | 1.29 | A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 8. Cost-effectiveness of bed net impregnation alone or combined with chemoprophylaxis in preventing mortality and morbidit ( Aikins, M; Alonso, PL; Armstrong Schellenberg, JR; Greenwood, BM; Mills, A; Picard, J, 1993) |
| "Despite the encouragement of early treatment, malaria was the major cause of death in children after the neonatal period in 1988." | 1.29 | Malaria treatment in Vanuatu: new national treatment guidelines. ( Reeve, PA, 1994) |
| "Sulfadoxine-pyrimethamine was effective treatment." | 1.29 | Malaria in east African refugees resettling to the United States: development of strategies to reduce the risk of imported malaria. ( Campbell, CC; Keane, V; McCance, C; Slutsker, L; Tipple, M, 1995) |
| "Oral pyrimethamine treatment (10 mg/kg for 4 days) in infected mice (5-10%) returned the altered levels of the above enzymes to almost normal 1 week after the cessation of drug treatment." | 1.29 | Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. ( Agrawal, A; Pandey, VC; Puri, SK; Tripathi, LM, 1996) |
| "001) serum concentrations of PYR were found in Papua New Guineans than in Caucasians at both sampling times, an observation which may reflect differences in the bioavailability of PYR between the two racial groups." | 1.27 | Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis. ( Cochrane, JP; Cook, IF; Edstein, MD, 1986) |
| " Reappraisal of quinine therapy has led to important modifications in dosage recommendations and recognition of a major complication of severe malaria associated with its use--hypoglycaemia." | 1.27 | Management of Plasmodium falciparum malaria. ( Phillips, RE, 1984) |
| "Pyrimethamine-sulfadoxine has been associated with severe and fatal cutaneous reactions as well as transient liver damage." | 1.27 | Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). ( Alexander, J; Howrie, DL; Kuritsky, JN; Miller, KD; Perez, TH; Taylor, S; Van Thiel, DH; Zitelli, BJ, 1987) |
| "Chloroquine resistance was confirmed by testing in vitro and in vivo." | 1.27 | Multiple drug resistant Plasmodium falciparum malaria in a pregnant indigenous Zambian woman. ( Rolfe, M, 1988) |
| "The actual situation of the treatment of malaria for the past 10 years in Japan was investigated and analyzed." | 1.27 | Clinical evaluation of antimalarial regimens in Japan. ( Hioki, A; Ishizaki, T; Nakabayashi, T; Ohtomo, H; Tanabe, K, 1987) |
| "Quinine was therapeutically more effective in the intact mice than in the deprived mice early after initiation of treatment and, while the normal mice suffered a transient recrudescence after quinine, the deprived mice retained a high parasitaemia during and after treatment." | 1.27 | Reduced efficacy of chemotherapy of Plasmodium chabaudi in T cell-deprived mice. ( Doenhoff, MJ; Targett, GA, 1987) |
| "A clinical case of Black Water Fever following Plasmodium falciparum infection is reported." | 1.27 | A case of black water fever treated with peritoneal dialysis and artemether (quinghaosu derivative). ( , 1987) |
| "Amodiaquine was associated with a 3." | 1.27 | Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis. ( Gyr, N; Schär, M; Stürchler, D, 1987) |
| "Malaria was studied in the province of Takeo, Cambodia." | 1.27 | Malaria in the province of Takeo, Cambodia. ( Giboda, M, 1985) |
| "A high-performance liquid chromatographic method was developed to enable dapsone, monoacetyl dapsone and pyrimethamine to be measured simultaneously in plasma samples from volunteers in England and Malaysia who had been dosed with Maloprim." | 1.26 | Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim. ( Jones, CR; Ovenell, SM, 1979) |
| "When sulfalene was administered during malaria, this difference was no longer apparent." | 1.26 | The influence of acetylator phenotype on the response to sulfalene in individuals with chloroquine-resistant falciparum malaria. ( Carson, PE; Frischer, H; Rieckmann, KH; Trenholme, GM; Williams, RL, 1978) |
| "Imported malaria has been increasing in the United States." | 1.26 | Malaria--a red alert. ( Amin, NM, 1979) |
| " The usefulness of high dosage heparin in the treatment of the subacute form of disseminated intravascualr coagulation is illustrated in the first admission." | 1.25 | A case of recurrent subacute disseminated intravascular coagulation associated with malarial prophylaxis. ( Gon, F; Reid, FP, 1975) |
| " In groups 1, 2, and 3 the dosages of chloroquine base administered alone were adjusted to body weight, surface area of subject, and age; in group 4 a combination of chloroquine diphosphate and pyrimethamine was given at a standard dosage related to age." | 1.25 | Effect of four different types of single-dose treatment with chloroquine and with chloroquine and pyrimethamine on Plasmodium falciparum infections in a semi-immune population in northern Nigeria. ( Kusnecov, R; Lietaert, P; Storey, J, 1972) |
| " Increasing the drug dosage does not overcome the resistance." | 1.24 | The development of pyrimethamine resistance by Plasmodium falciparum. ( BURGESS, RW; YOUNG, MD, 1959) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 719 (51.80) | 18.7374 |
| 1990's | 90 (6.48) | 18.2507 |
| 2000's | 196 (14.12) | 29.6817 |
| 2010's | 281 (20.24) | 24.3611 |
| 2020's | 102 (7.35) | 2.80 |
| Authors | Studies |
|---|---|
| Elslager, EF | 2 |
| Jacob, P | 2 |
| Johnson, J | 2 |
| Werbel, LM | 3 |
| Worth, DF | 3 |
| Rane, L | 2 |
| Hutt, MP | 1 |
| Temporelli, B | 1 |
| Genther, CS | 2 |
| Smith, CS | 1 |
| Ress, RW | 1 |
| Chai, SY | 1 |
| Winkley, MW | 1 |
| Russell, RB | 1 |
| McKie, JH | 1 |
| Douglas, KT | 1 |
| Chan, C | 2 |
| Roser, SA | 1 |
| Yates, R | 1 |
| Read, M | 1 |
| Hyde, JE | 1 |
| Dascombe, MJ | 1 |
| Yuthavong, Y | 3 |
| Sirawaraporn, W | 1 |
| Jensen, NP | 1 |
| Ager, AL | 1 |
| Bliss, RA | 1 |
| Canfield, CJ | 4 |
| Kotecka, BM | 1 |
| Rieckmann, KH | 9 |
| Terpinski, J | 1 |
| Jacobus, DP | 1 |
| Nallan, L | 1 |
| Bauer, KD | 1 |
| Bendale, P | 1 |
| Rivas, K | 1 |
| Yokoyama, K | 1 |
| Hornéy, CP | 1 |
| Pendyala, PR | 1 |
| Floyd, D | 1 |
| Lombardo, LJ | 1 |
| Williams, DK | 1 |
| Hamilton, A | 1 |
| Sebti, S | 1 |
| Windsor, WT | 1 |
| Weber, PC | 1 |
| Buckner, FS | 2 |
| Chakrabarti, D | 1 |
| Gelb, MH | 1 |
| Van Voorhis, WC | 1 |
| Tanomsing, N | 1 |
| Imwong, M | 2 |
| Pukrittayakamee, S | 2 |
| Chotivanich, K | 1 |
| Looareesuwan, S | 3 |
| Mayxay, M | 2 |
| Dolecek, C | 1 |
| Hien, TT | 3 |
| do Rosario, VE | 1 |
| Arez, AP | 1 |
| Michon, P | 1 |
| Snounou, G | 1 |
| White, NJ | 9 |
| Day, NP | 1 |
| Plouffe, D | 2 |
| Brinker, A | 1 |
| McNamara, C | 2 |
| Henson, K | 1 |
| Kato, N | 3 |
| Kuhen, K | 2 |
| Nagle, A | 3 |
| Adrián, F | 1 |
| Matzen, JT | 1 |
| Anderson, P | 1 |
| Nam, TG | 2 |
| Gray, NS | 1 |
| Chatterjee, A | 2 |
| Janes, J | 1 |
| Yan, SF | 1 |
| Trager, R | 1 |
| Caldwell, JS | 1 |
| Schultz, PG | 2 |
| Zhou, Y | 2 |
| Winzeler, EA | 4 |
| Park, WH | 1 |
| Lee, SJ | 2 |
| Moon, HI | 1 |
| Nzila, A | 3 |
| Rottmann, M | 4 |
| Chitnumsub, P | 1 |
| Kiara, SM | 1 |
| Kamchonwongpaisan, S | 3 |
| Maneeruttanarungroj, C | 1 |
| Taweechai, S | 1 |
| Yeung, BK | 2 |
| Goh, A | 3 |
| Lakshminarayana, SB | 3 |
| Zou, B | 2 |
| Wong, J | 1 |
| Ma, NL | 1 |
| Weaver, M | 1 |
| Keller, TH | 2 |
| Dartois, V | 3 |
| Wittlin, S | 5 |
| Brun, R | 4 |
| Diagana, TT | 3 |
| Lee, MC | 3 |
| Russell, B | 1 |
| Seitz, P | 1 |
| Plouffe, DM | 2 |
| Dharia, NV | 2 |
| Tan, J | 1 |
| Cohen, SB | 1 |
| Spencer, KR | 1 |
| González-Páez, GE | 1 |
| Suwanarusk, R | 1 |
| Jegla, T | 1 |
| Schmitt, EK | 1 |
| Beck, HP | 1 |
| Nosten, F | 7 |
| Renia, L | 2 |
| Fidock, DA | 4 |
| Gujjar, R | 1 |
| El Mazouni, F | 1 |
| White, KL | 2 |
| White, J | 1 |
| Creason, S | 1 |
| Shackleford, DM | 2 |
| Deng, X | 1 |
| Charman, WN | 1 |
| Bathurst, I | 1 |
| Burrows, J | 1 |
| Floyd, DM | 1 |
| Matthews, D | 1 |
| Charman, SA | 2 |
| Phillips, MA | 1 |
| Rathod, PK | 1 |
| Ndakala, AJ | 1 |
| Gessner, RK | 1 |
| Gitari, PW | 1 |
| October, N | 1 |
| Hudson, A | 1 |
| Fakorede, F | 1 |
| Kaiser, M | 1 |
| Yeates, C | 2 |
| Chibale, K | 3 |
| Wu, T | 2 |
| Gagaring, K | 2 |
| Borboa, R | 2 |
| Francek, C | 1 |
| Chen, Z | 1 |
| Wu, J | 1 |
| Ang, HQ | 1 |
| Zeng, P | 1 |
| Kang, ML | 1 |
| Tan, W | 1 |
| Tan, M | 1 |
| Ye, N | 1 |
| Lin, X | 1 |
| Caldwell, C | 1 |
| Ek, J | 1 |
| Skolnik, S | 1 |
| Liu, F | 1 |
| Wang, J | 1 |
| Chang, J | 1 |
| Li, C | 2 |
| Hollenbeck, T | 1 |
| Tuntland, T | 2 |
| Isbell, J | 1 |
| Fischli, C | 1 |
| Keller, T | 1 |
| Diagana, T | 1 |
| Winzeler, E | 1 |
| Glynne, R | 1 |
| Tully, DC | 1 |
| Chatterjee, AK | 1 |
| Meister, S | 2 |
| Kuhen, KL | 1 |
| Bonamy, GM | 1 |
| Barnes, SW | 1 |
| Bopp, SE | 1 |
| Bright, AT | 1 |
| Che, J | 1 |
| Cohen, S | 1 |
| Gettayacamin, M | 1 |
| Gordon, P | 1 |
| Groessl, T | 1 |
| McNamara, CW | 1 |
| Richmond, W | 1 |
| Roland, J | 1 |
| Zhou, B | 1 |
| Froissard, P | 1 |
| Glynne, RJ | 1 |
| Mazier, D | 3 |
| Sattabongkot, J | 1 |
| Walker, JR | 1 |
| Rodrigues, T | 1 |
| Prudêncio, M | 3 |
| Moreira, R | 1 |
| Mota, MM | 4 |
| Lopes, F | 1 |
| Huang, H | 1 |
| Lu, W | 1 |
| Li, X | 2 |
| Cong, X | 1 |
| Ma, H | 1 |
| Liu, X | 1 |
| Zhang, Y | 2 |
| Che, P | 1 |
| Ma, R | 1 |
| Li, H | 1 |
| Shen, X | 1 |
| Jiang, H | 2 |
| Huang, J | 5 |
| Zhu, J | 2 |
| Derbyshire, ER | 1 |
| Clardy, J | 1 |
| Biamonte, MA | 1 |
| Wanner, J | 1 |
| Le Roch, KG | 1 |
| Ramachandran, S | 1 |
| Hameed P, S | 1 |
| Srivastava, A | 1 |
| Shanbhag, G | 1 |
| Morayya, S | 1 |
| Rautela, N | 1 |
| Awasthy, D | 1 |
| Kavanagh, S | 1 |
| Bharath, S | 1 |
| Reddy, J | 1 |
| Panduga, V | 1 |
| Prabhakar, KR | 1 |
| Saralaya, R | 1 |
| Nanduri, R | 1 |
| Raichurkar, A | 1 |
| Menasinakai, S | 1 |
| Achar, V | 1 |
| Jiménez-Díaz, MB | 2 |
| Martínez, MS | 1 |
| Angulo-Barturen, I | 2 |
| Ferrer, S | 2 |
| Sanz, LM | 2 |
| Gamo, FJ | 2 |
| Duffy, S | 1 |
| Avery, VM | 1 |
| Waterson, D | 2 |
| Coburn-Flynn, O | 1 |
| Iyer, PS | 1 |
| Narayanan, S | 1 |
| Hosagrahara, V | 1 |
| Sambandamurthy, VK | 1 |
| Cohen, A | 1 |
| Suzanne, P | 1 |
| Lancelot, JC | 1 |
| Verhaeghe, P | 1 |
| Lesnard, A | 1 |
| Basmaciyan, L | 1 |
| Hutter, S | 1 |
| Laget, M | 1 |
| Dumètre, A | 1 |
| Paloque, L | 1 |
| Deharo, E | 2 |
| Crozet, MD | 1 |
| Rathelot, P | 1 |
| Dallemagne, P | 1 |
| Lorthiois, A | 1 |
| Sibley, CH | 2 |
| Vanelle, P | 1 |
| Valentin, A | 2 |
| Rault, S | 1 |
| Azas, N | 1 |
| Mendoza-Martínez, C | 1 |
| Correa-Basurto, J | 1 |
| Nieto-Meneses, R | 1 |
| Márquez-Navarro, A | 1 |
| Aguilar-Suárez, R | 1 |
| Montero-Cortes, MD | 1 |
| Nogueda-Torres, B | 1 |
| Suárez-Contreras, E | 1 |
| Galindo-Sevilla, N | 1 |
| Rojas-Rojas, Á | 1 |
| Rodriguez-Lezama, A | 1 |
| Hernández-Luis, F | 1 |
| Le Manach, C | 1 |
| Paquet, T | 1 |
| Brunschwig, C | 2 |
| Njoroge, M | 2 |
| Han, Z | 1 |
| Gonzàlez Cabrera, D | 1 |
| Bashyam, S | 1 |
| Dhinakaran, R | 1 |
| Taylor, D | 1 |
| Reader, J | 2 |
| Botha, M | 2 |
| Churchyard, A | 2 |
| Lauterbach, S | 2 |
| Coetzer, TL | 2 |
| Birkholtz, LM | 2 |
| Witty, MJ | 1 |
| Santos Martínez, M | 1 |
| Street, LJ | 1 |
| Promchai, T | 1 |
| Jaidee, A | 1 |
| Cheenpracha, S | 1 |
| Trisuwan, K | 1 |
| Rattanajak, R | 1 |
| Laphookhieo, S | 1 |
| Pyne, SG | 1 |
| Ritthiwigrom, T | 1 |
| Singh, K | 1 |
| Okombo, J | 2 |
| Ndubi, F | 1 |
| Barnard, L | 1 |
| Wilkinson, C | 1 |
| Njogu, PM | 1 |
| Laing, L | 1 |
| Machado, M | 1 |
| Nondaba, S | 1 |
| Burrows, JN | 1 |
| Denti, P | 3 |
| Wiesner, L | 1 |
| Egan, TJ | 1 |
| Zhang, YK | 1 |
| Plattner, JJ | 1 |
| Easom, EE | 1 |
| Jacobs, RT | 1 |
| Guo, D | 1 |
| Freund, YR | 1 |
| Berry, P | 1 |
| Ciaravino, V | 1 |
| Erve, JCL | 1 |
| Rosenthal, PJ | 7 |
| Campo, B | 1 |
| Cao, J | 2 |
| Chen, W | 1 |
| Huang, Z | 1 |
| Wang, W | 1 |
| Mao, F | 1 |
| Guan, L | 1 |
| Tang, Y | 1 |
| Li, J | 1 |
| Jiang, L | 1 |
| Tibon, NS | 1 |
| Ng, CH | 1 |
| Cheong, SL | 1 |
| Zuilkowski, SS | 1 |
| Jukes, MC | 2 |
| McLarty, DG | 2 |
| Webber, RH | 1 |
| Jaatinen, M | 2 |
| Kihamia, CH | 1 |
| Murru, M | 1 |
| Kumano, M | 1 |
| Aubert, B | 1 |
| Magnuson, LW | 1 |
| Ponnampalam, JT | 8 |
| Richards, PN | 1 |
| Spracklen, FH | 3 |
| Biddulph, J | 2 |
| Ikram, RB | 1 |
| Faoagali, JL | 1 |
| Paltridge, GP | 1 |
| Rée, GH | 1 |
| Friman, G | 1 |
| Nyström-Rosander, C | 1 |
| Jonsell, G | 1 |
| Björkman, A | 7 |
| Lekås, G | 1 |
| Svendsrup, B | 1 |
| Vergara, RV | 1 |
| Woodruff, AW | 1 |
| Fox, JS | 1 |
| Bradley, DJ | 2 |
| Warhurst, DC | 3 |
| Menendez, C | 17 |
| Todd, J | 1 |
| Alonso, PL | 7 |
| Lulat, S | 1 |
| Francis, N | 1 |
| Greenwood, BM | 14 |
| Lindsay, SW | 2 |
| Armstrong Schellenberg, JR | 3 |
| Keita, K | 1 |
| Gomez, P | 1 |
| Shenton, FC | 3 |
| Hill, AG | 2 |
| David, PH | 2 |
| Fegan, G | 2 |
| Cham, K | 1 |
| Picard, J | 1 |
| Aikins, M | 1 |
| Mills, A | 2 |
| Petersen, E | 2 |
| Marbiah, NT | 1 |
| Magbiti, E | 1 |
| Lines, JD | 1 |
| Maude, GH | 1 |
| Høgh, B | 1 |
| Curtis, C | 2 |
| Greenwood, B | 28 |
| Bradley, D | 1 |
| Leggat, PA | 1 |
| Heydon, JL | 1 |
| Menon, A | 3 |
| Thong, BY | 1 |
| Leong, KP | 1 |
| Chng, HH | 1 |
| Jones, CR | 1 |
| Ovenell, SM | 1 |
| Armstrong, JR | 1 |
| Conteh, M | 1 |
| de Francisco, A | 1 |
| Hall, AJ | 1 |
| Allen, SJ | 1 |
| Snow, RW | 8 |
| Marsh, K | 1 |
| Hayes, RH | 1 |
| Carson, DC | 1 |
| Otoo, L | 1 |
| Shenton, F | 1 |
| Byass, P | 3 |
| Zavala, F | 1 |
| Davis, DR | 1 |
| Hutton, DC | 1 |
| Watanasook, C | 2 |
| Singharaj, P | 1 |
| Suriyamongkol, V | 2 |
| Karwacki, JJ | 2 |
| Shanks, D | 1 |
| Phintuyothin, P | 6 |
| Pilungkasa, S | 1 |
| Wasuwat, P | 1 |
| Edstein, MD | 3 |
| Veenendaal, JR | 3 |
| O'Donoghue, M | 1 |
| Greenwood, AM | 2 |
| Bradley, AK | 4 |
| Hayes, RJ | 1 |
| N'Jie, AB | 1 |
| Otoo, LN | 1 |
| Heap, BJ | 1 |
| Lee, PS | 2 |
| Lau, EY | 1 |
| Cook, IF | 4 |
| Cochrane, JP | 1 |
| Ti, TY | 2 |
| Jacob, E | 1 |
| Wee, YJ | 1 |
| Chiodini, PL | 1 |
| Cook, GC | 1 |
| Newman, K | 1 |
| Hyslop, R | 1 |
| Monteagudo, FS | 1 |
| Lee, HS | 1 |
| Yap, CL | 1 |
| Panton, LJ | 1 |
| Tulloch, S | 1 |
| Danis, M | 5 |
| Gentilini, M | 3 |
| Kish, MY | 1 |
| Donovan, KD | 1 |
| Agu, AP | 2 |
| Umeokonkwo, CD | 1 |
| Eze, NC | 1 |
| Akpa, CO | 1 |
| Nnabu, RC | 1 |
| Akamike, IC | 2 |
| Okedo-Alex, IN | 2 |
| Alo, C | 1 |
| Uneke, JC | 1 |
| Aberese-Ako, M | 3 |
| Magnussen, P | 15 |
| Ampofo, GD | 3 |
| Gyapong, M | 3 |
| Ansah, E | 1 |
| Tagbor, H | 10 |
| Chu, X | 1 |
| Yan, P | 1 |
| Zhang, N | 1 |
| Chen, N | 1 |
| Liu, Y | 1 |
| Feng, L | 1 |
| Li, M | 1 |
| Zhang, Z | 1 |
| Wang, Q | 1 |
| Wang, S | 1 |
| Yang, K | 1 |
| Doumbia, I | 1 |
| Seydou, F | 1 |
| Diakalia, K | 1 |
| Bennis, I | 1 |
| Patson, N | 1 |
| Mukaka, M | 5 |
| Peterson, I | 2 |
| Divala, T | 1 |
| Kazembe, L | 1 |
| Mathanga, D | 3 |
| Laufer, MK | 10 |
| Chirwa, T | 2 |
| Mahamar, A | 2 |
| Sumner, KM | 1 |
| Levitt, B | 2 |
| Freedman, B | 2 |
| Traore, A | 3 |
| Barry, A | 4 |
| Issiaka, D | 1 |
| Dembele, AB | 2 |
| Kanoute, MB | 1 |
| Attaher, O | 2 |
| Diarra, BN | 1 |
| Sagara, I | 11 |
| Djimde, A | 3 |
| Duffy, PE | 4 |
| Fried, M | 4 |
| Taylor, SM | 4 |
| Dicko, A | 13 |
| Waltmann, A | 1 |
| McQuade, ETR | 1 |
| Chinkhumba, J | 4 |
| Operario, DJ | 1 |
| Mzembe, E | 1 |
| Itoh, M | 1 |
| Kayange, M | 2 |
| Puerto-Meredith, SM | 1 |
| Mathanga, DP | 6 |
| Juliano, JJ | 1 |
| Carroll, I | 1 |
| Bartelt, LA | 1 |
| Gutman, JR | 5 |
| Meshnick, SR | 7 |
| Musoke, D | 1 |
| Ndejjo, R | 1 |
| Wafula, ST | 1 |
| Kasasa, S | 1 |
| Nakiyingi-Miiro, J | 1 |
| Musoke, MB | 1 |
| Guure, C | 1 |
| Afagbedzi, S | 1 |
| Plowe, CV | 6 |
| Vincenz, C | 1 |
| Dolo, Z | 1 |
| Saye, S | 1 |
| Lovett, JL | 1 |
| Strassmann, BI | 1 |
| Kumah, E | 1 |
| Duvor, F | 1 |
| Otchere, G | 1 |
| Ankomah, SE | 1 |
| Fusheini, A | 1 |
| Kokuro, C | 1 |
| Karikari, AK | 1 |
| Adom, J | 1 |
| Chotsiri, P | 1 |
| Tarning, J | 5 |
| Rubenstein, BL | 1 |
| Chilima, E | 1 |
| Kwizombe, C | 1 |
| Malpass, A | 2 |
| Cash, S | 1 |
| Wright, K | 1 |
| Troell, P | 1 |
| Nsona, H | 1 |
| Kachale, F | 1 |
| Ali, D | 3 |
| Kaunda, E | 1 |
| Lankhulani, S | 1 |
| Munthali, J | 1 |
| Kamau, A | 1 |
| Musau, M | 1 |
| Mwakio, S | 1 |
| Amadi, D | 1 |
| Nyaguara, A | 1 |
| Bejon, P | 1 |
| Seale, AC | 1 |
| Berkley, JA | 1 |
| Ahadzie-Soglie, A | 1 |
| Addai-Mensah, O | 1 |
| Abaka-Yawson, A | 1 |
| Setroame, AM | 1 |
| Kwadzokpui, PK | 1 |
| Orji, BC | 2 |
| Bryce, E | 1 |
| Odio, B | 1 |
| Onuoha, HE | 1 |
| Njoku, E | 1 |
| Anoke, C | 1 |
| Ugwa, E | 2 |
| Enne, J | 1 |
| Oniyire, A | 1 |
| Otolorin, E | 1 |
| Afolabi, K | 1 |
| Ogbulafor, NC | 1 |
| Oliveras, E | 1 |
| Flegg, JA | 1 |
| Humphreys, GS | 1 |
| Montanez, B | 1 |
| Strickland, T | 1 |
| Jacome-Meza, ZJ | 1 |
| Barnes, KI | 6 |
| Raman, J | 1 |
| Guerin, PJ | 1 |
| Hopkins Sibley, C | 1 |
| Dahlström Otienoburu, S | 1 |
| Akinnawo, A | 1 |
| Seyram, K | 1 |
| Kaali, EB | 1 |
| Harrison, S | 1 |
| Dosoo, D | 2 |
| Cairns, M | 18 |
| Asante, KP | 3 |
| Maiga, H | 5 |
| Opondo, C | 2 |
| Chico, RM | 7 |
| Cohee, LM | 3 |
| Traore, OB | 1 |
| Tekete, M | 1 |
| Dara, A | 2 |
| Traore, ZI | 2 |
| Diarra, M | 3 |
| Coumare, S | 3 |
| Kodio, A | 1 |
| Bamadio, A | 2 |
| Sidibe, B | 2 |
| Doumbo, OK | 12 |
| Djimde, AA | 5 |
| Joste, V | 1 |
| Guillochon, E | 1 |
| Clain, J | 1 |
| Coppée, R | 1 |
| Houzé, S | 1 |
| Mohammed, AG | 1 |
| Duah, D | 1 |
| Kenu, E | 1 |
| Nonvignon, J | 1 |
| Manu, A | 2 |
| Bonful, HA | 1 |
| Nana, RRD | 1 |
| Hawadak, J | 1 |
| Foko, LPK | 1 |
| Kumar, A | 2 |
| Chaudhry, S | 1 |
| Arya, A | 1 |
| Singh, V | 1 |
| Apinjoh, TO | 2 |
| Ntui, VN | 1 |
| Chi, HF | 1 |
| Moyeh, MN | 1 |
| Toussi, CT | 1 |
| Mayaba, JM | 1 |
| Tangi, LN | 1 |
| Kwi, PN | 1 |
| Anchang-Kimbi, JK | 3 |
| Dionne-Odom, J | 2 |
| Tita, ATN | 2 |
| Achidi, EA | 3 |
| Amambua-Ngwa, A | 1 |
| Titanji, VPK | 1 |
| Ameyaw, EK | 1 |
| Korwa, S | 1 |
| Wu, A | 1 |
| Green, CL | 1 |
| Clapp, S | 1 |
| Kirui, JK | 1 |
| O'Meara, WP | 3 |
| Njuguna, FM | 1 |
| Bangirana, P | 1 |
| Conroy, AL | 1 |
| Opoka, RO | 1 |
| Semrud-Clikeman, M | 1 |
| Jang, JH | 1 |
| Apayi, C | 1 |
| Kakuru, A | 6 |
| Muhindo, MK | 4 |
| Georgieff, MK | 1 |
| Dorsey, GM | 1 |
| Kamya, MR | 12 |
| Havlir, D | 1 |
| John, CC | 1 |
| Zhang, K | 1 |
| Liang, D | 1 |
| Zhang, D | 1 |
| Osarfo, J | 1 |
| Asem, L | 1 |
| Komey, MN | 1 |
| Mohammed, W | 1 |
| Ofosu, AA | 1 |
| Barry, I | 1 |
| Toure, AA | 1 |
| Sangho, O | 2 |
| Beavogui, AH | 2 |
| Cisse, D | 1 |
| Diallo, A | 2 |
| Magassouba, AS | 1 |
| Sylla, Y | 1 |
| Doumbia, L | 1 |
| Cherif, MS | 1 |
| Camara, AY | 1 |
| Diawara, F | 2 |
| Tounkara, M | 2 |
| Delamou, A | 1 |
| Doumbia, S | 3 |
| Beshir, KB | 2 |
| Muwanguzi, J | 1 |
| Nader, J | 1 |
| Mansukhani, R | 1 |
| Gamougam, K | 1 |
| Ceesay, S | 2 |
| Bazie, T | 1 |
| Kolie, F | 1 |
| Lamine, MM | 1 |
| Snell, P | 1 |
| Scott, S | 1 |
| Merle, CS | 1 |
| NDiaye, JL | 7 |
| Razafindralambo, L | 1 |
| Moroso, D | 1 |
| Ouedraogo, JB | 4 |
| Zongo, I | 4 |
| Kessely, H | 1 |
| Doumagoum, D | 1 |
| Bojang, K | 4 |
| Loua, K | 1 |
| Laminou, IM | 1 |
| Ogboi, SJ | 1 |
| Eloike, T | 1 |
| Milligan, P | 14 |
| Sutherland, CJ | 3 |
| Biteghe-Bi-Essone, JC | 1 |
| Imboumy-Limoukou, RK | 1 |
| Ekogha-Ovono, JJ | 1 |
| Maghendji-Nzondo, S | 1 |
| Sir-Ondo-Enguier, PN | 1 |
| Oyegue, LS | 1 |
| Lekana-Douki, JB | 1 |
| Peters, GO | 3 |
| Naidoo, M | 3 |
| Mkubwa, B | 1 |
| Kagura, J | 1 |
| Ibisomi, L | 1 |
| Kinyanjui, S | 1 |
| Olukosi, AY | 1 |
| Ajibaye, O | 1 |
| Omoniwa, O | 1 |
| Oresanya, O | 1 |
| Oluwagbemiga, AO | 1 |
| Ujuju, C | 1 |
| Ekholuenetale, M | 1 |
| Maxwell, K | 1 |
| Tibenderana, JK | 1 |
| Hallamaa, L | 3 |
| Ashorn, P | 5 |
| Cheung, YB | 5 |
| Luntamo, M | 5 |
| Ashorn, U | 3 |
| Kulmala, T | 4 |
| Maleta, K | 3 |
| Mangani, C | 3 |
| Fan, YM | 1 |
| Hansen, N | 1 |
| Dentinger, CM | 1 |
| Youll, S | 2 |
| Cotte, A | 1 |
| Mattern, C | 1 |
| Ravaoarinosy, A | 1 |
| Okek, EJ | 1 |
| Ocan, M | 1 |
| Obondo, SJ | 1 |
| Kiyimba, A | 1 |
| Arinaitwe, E | 4 |
| Nankabirwa, J | 1 |
| Ssewanyana, I | 1 |
| Akinola, O | 1 |
| Ategbero, E | 1 |
| Amusan, AI | 1 |
| Gbotosho, GO | 1 |
| Uwimana, A | 2 |
| Sethi, R | 2 |
| Murindahabi, M | 2 |
| Ntirandeka, C | 1 |
| Piercefield, E | 2 |
| Umulisa, N | 2 |
| Abram, A | 2 |
| Eckert, E | 5 |
| Munguti, K | 2 |
| Sullivan, D | 1 |
| Uyizeye, D | 1 |
| Mbituyumuremyi, A | 2 |
| González, R | 10 |
| Manun'Ebo, MF | 2 |
| Meremikwu, M | 4 |
| Rabeza, VR | 2 |
| Sacoor, C | 3 |
| Figueroa-Romero, A | 2 |
| Arikpo, I | 3 |
| Macete, E | 8 |
| Mbombo Ndombe, D | 2 |
| Ramananjato, R | 2 |
| LIach, M | 1 |
| Pons-Duran, C | 5 |
| Sanz, S | 6 |
| Ramírez, M | 3 |
| Cirera, L | 1 |
| Maly, C | 2 |
| Roman, E | 5 |
| Pagnoni, F | 4 |
| Lingani, M | 2 |
| Zango, SH | 2 |
| Valéa, I | 2 |
| Samadoulougou, S | 2 |
| Somé, G | 1 |
| Sanou, M | 1 |
| Kaboré, B | 1 |
| Rouamba, T | 3 |
| Sorgho, H | 1 |
| Tahita, MC | 1 |
| Derra, K | 2 |
| Dramaix, M | 2 |
| Tinto, H | 6 |
| Donnen, P | 2 |
| Robert, A | 2 |
| Moss, S | 1 |
| Mańko, E | 1 |
| Vasileva, H | 1 |
| Da Silva, ET | 1 |
| Goncalves, A | 1 |
| Osborne, A | 2 |
| Phelan, J | 1 |
| Rodrigues, A | 1 |
| Djata, P | 1 |
| D'Alessandro, U | 10 |
| Mabey, D | 1 |
| Krishna, S | 1 |
| Last, A | 1 |
| Clark, TG | 2 |
| Campino, S | 2 |
| Koné, S | 1 |
| Probst-Hensch, N | 1 |
| Dao, D | 1 |
| Utzinger, J | 2 |
| Fink, G | 1 |
| Chang, MA | 1 |
| Fouché, B | 1 |
| LaFortune, W | 1 |
| Holmes, K | 1 |
| Rigodon, J | 1 |
| Juin, S | 1 |
| Marseille, S | 1 |
| Rogier, E | 1 |
| Green, M | 2 |
| Kheradmand, T | 1 |
| Moore, SG | 1 |
| Gaul, DA | 1 |
| Boncy, J | 1 |
| Telfort, MA | 1 |
| Fombah, AE | 1 |
| Chen, H | 1 |
| Owusu-Kyei, K | 1 |
| Quinto, L | 1 |
| Williams, J | 3 |
| Berne, ML | 1 |
| Wassenaar, M | 1 |
| Jalloh, A | 1 |
| Sunders, JC | 1 |
| Bertran-Cobo, C | 1 |
| Saute, F | 2 |
| Ekouevi, DK | 2 |
| Briand, V | 12 |
| Kamara, ARY | 1 |
| Sesay, T | 1 |
| Samai, M | 1 |
| Solanke, BL | 1 |
| Yinusa, RA | 1 |
| Oyeleye, OJ | 1 |
| Oluwatope, OB | 1 |
| Ilesanmi, BB | 1 |
| Oni, TO | 1 |
| Sinyange, D | 1 |
| Mukumbuta, N | 1 |
| Mutale, LS | 1 |
| Mumbole, H | 1 |
| Hamainza, B | 1 |
| Sialubanje, C | 1 |
| Anabire, NG | 1 |
| Aculley, B | 1 |
| Pobee, A | 1 |
| Kyei-Baafour, E | 1 |
| Awandare, GA | 1 |
| Del Pilar Quintana, M | 1 |
| Hviid, L | 1 |
| Ofori, MF | 2 |
| L'Episcopia, M | 1 |
| Doderer-Lang, C | 2 |
| Perrotti, E | 1 |
| Priuli, GB | 1 |
| Cavallari, S | 1 |
| Guidetti, C | 1 |
| Bernieri, F | 1 |
| Menard, D | 5 |
| Severini, C | 1 |
| Phelan, JE | 1 |
| Kaneko, A | 3 |
| Kagaya, W | 1 |
| Ngara, M | 1 |
| Kongere, J | 1 |
| Kita, K | 1 |
| Gitaka, J | 1 |
| Tarama, CW | 1 |
| Soré, H | 1 |
| Siribié, M | 1 |
| Débé, S | 1 |
| Kinda, R | 1 |
| Ganou, A | 1 |
| Nonkani, WG | 1 |
| Tiendrebeogo, F | 1 |
| Bantango, W | 1 |
| Yira, K | 1 |
| Sagnon, A | 1 |
| Ilboudo, S | 1 |
| Hien, EY | 1 |
| Guelbéogo, MW | 1 |
| Sagnon, N | 1 |
| Traoré, Y | 1 |
| Gansané, A | 3 |
| Alruwaili, M | 1 |
| Sullivan, DJ | 1 |
| Bissombolo, D | 1 |
| Ratsimbasoa, A | 2 |
| Lemba, E | 1 |
| Nhama, A | 1 |
| Rakotosaona, R | 1 |
| Llach, M | 2 |
| Ma, L | 1 |
| Mayor, A | 2 |
| Muthoka, EN | 1 |
| Usmael, K | 1 |
| Embaye, SM | 1 |
| Abebe, A | 1 |
| Mesfin, T | 1 |
| Kazembe, D | 1 |
| Ahmedin, M | 1 |
| Namuganza, S | 1 |
| Kahabuka, M | 1 |
| Atim, MG | 1 |
| Manyazewal, T | 1 |
| Flueckiger, RM | 1 |
| Thierno, DM | 1 |
| Colaço, R | 1 |
| Guilavogui, T | 1 |
| Bangoura, L | 1 |
| Reithinger, R | 1 |
| Fitch, ER | 1 |
| Taton, JL | 1 |
| Fofana, A | 1 |
| Pestehchian, N | 1 |
| Vafaei, MR | 1 |
| Nematolahy, P | 1 |
| Varshosaz, J | 1 |
| Yousefi, HA | 1 |
| Bide, VZ | 1 |
| Kalani, H | 1 |
| Adewole, AO | 1 |
| Fawole, O | 1 |
| Ajayi, I | 2 |
| Yusuf, B | 1 |
| Oladimeji, A | 1 |
| Waziri, E | 1 |
| Nguku, P | 1 |
| Ajumobi, O | 2 |
| Searle, AR | 1 |
| Hurley, EA | 2 |
| Doumbia, SO | 2 |
| Winch, PJ | 2 |
| Yaya, S | 1 |
| Kota, K | 1 |
| Buh, A | 1 |
| Bishwajit, G | 1 |
| Song, TQ | 1 |
| Wang, CC | 1 |
| Tian, BP | 1 |
| Vandy, AO | 1 |
| Peprah, NY | 1 |
| Jerela, JY | 1 |
| Titiati, P | 1 |
| Akamah, J | 1 |
| Maya, ET | 2 |
| Torpey, K | 1 |
| Umemmuo, MU | 1 |
| Agboghoroma, CO | 1 |
| Iregbu, KC | 1 |
| Quakyi, I | 1 |
| Tornyigah, B | 1 |
| Houze, P | 1 |
| Kusi, KA | 1 |
| Coleman, N | 1 |
| Escriou, G | 1 |
| Laar, A | 1 |
| Cot, M | 12 |
| Fobil, J | 1 |
| Asare, GQ | 1 |
| Deloron, P | 5 |
| Anang, AK | 1 |
| Cottrell, G | 4 |
| Ndam, NT | 1 |
| van Lenthe, M | 1 |
| van der Meulen, R | 1 |
| Lassovski, M | 1 |
| Ouabo, A | 1 |
| Bakula, E | 1 |
| Badio, C | 1 |
| Cibenda, D | 1 |
| Okell, L | 3 |
| Piriou, E | 1 |
| Grignard, L | 1 |
| Lanke, K | 1 |
| Rao, B | 1 |
| Bousema, T | 3 |
| Roper, C | 5 |
| Mandoko, PN | 1 |
| Mbongi, DM | 1 |
| Mumba, DN | 1 |
| Bi Shamamba, SK | 1 |
| Tshilolo, LM | 1 |
| Muyembe, JJ | 1 |
| Parzy, D | 1 |
| Sinou, V | 1 |
| Noguchi, L | 1 |
| Grenier, L | 1 |
| Kabue, M | 1 |
| Oyetunji, J | 1 |
| Suhowatsky, S | 1 |
| Onguti, B | 1 |
| Orji, B | 1 |
| Whiting-Collins, L | 1 |
| Adetiloye, O | 1 |
| Adachi, R | 1 |
| Tamura, T | 1 |
| Bello, OO | 1 |
| Oni, O | 1 |
| Kalaji, LN | 1 |
| Mbacham, HF | 1 |
| Wepnje, GB | 1 |
| Ngole Sumbele, IU | 1 |
| Biaou, COA | 1 |
| Kpozehouen, A | 1 |
| Glèlè-Ahanhanzo, Y | 1 |
| Ayivi-Vinz, G | 1 |
| Ouro-Koura, AR | 1 |
| Azandjèmé, C | 1 |
| Otuli Noël, L | 1 |
| Nguma Jean-Didier, B | 1 |
| Alongo Mike-Antoine, M | 1 |
| Bosunga Gedeon, K | 1 |
| Mukonkole Jean-Paulin, M | 1 |
| Likwela Joris, L | 1 |
| Okenge Jean-Pascal, M | 1 |
| Azizi, SC | 2 |
| Ategeka, J | 2 |
| Kajubi, R | 3 |
| Wasswa, R | 1 |
| Ochokoru, H | 2 |
| Yeka, A | 2 |
| Jagannathan, P | 5 |
| Muehlenbachs, A | 4 |
| Dorsey, G | 11 |
| Martin, MK | 1 |
| Venantius, KB | 1 |
| Patricia, N | 1 |
| Bernard, K | 1 |
| Keith, B | 1 |
| Allen, K | 1 |
| Godfrey, A | 1 |
| Rogers, T | 1 |
| Damazo, KT | 1 |
| Dathan, BM | 1 |
| Mikomangwa, WP | 3 |
| Minzi, O | 1 |
| Mutagonda, R | 1 |
| Baraka, V | 2 |
| Mlugu, EM | 1 |
| Aklillu, E | 2 |
| Kamuhabwa, AAR | 2 |
| Alegana, VA | 2 |
| Kirakoya-Samadoulougou, F | 1 |
| Diengou, NH | 1 |
| Cumber, SN | 1 |
| Nkfusai, CN | 1 |
| Mbinyui, MS | 1 |
| Viyoff, VZ | 1 |
| Bede, F | 1 |
| Akwah, L | 1 |
| Tsoka-Gwegweni, JM | 1 |
| Judith, AK | 1 |
| Hema-Ouangraoua, S | 1 |
| Kabore, NF | 1 |
| Frédéric, N | 1 |
| Yerbanga, RS | 1 |
| Compaore, YD | 2 |
| Kuepfer, I | 2 |
| Chandramohan, D | 24 |
| Salman, S | 3 |
| Davis, TME | 3 |
| Moore, B | 1 |
| Roh, ME | 1 |
| Kuile, FOT | 1 |
| Rerolle, F | 1 |
| Glymour, MM | 1 |
| Shiboski, S | 1 |
| Gosling, R | 8 |
| Gutman, J | 6 |
| Desai, M | 5 |
| L'Ianziva, A | 1 |
| Ndu, A | 1 |
| Mbachu, C | 1 |
| Anitube, O | 1 |
| Ezeoke, U | 1 |
| Ochieng, T | 1 |
| Nakalembe, M | 2 |
| Clark, TD | 6 |
| Ruel, T | 1 |
| Staedke, SG | 5 |
| Havlir, DV | 4 |
| Djontu, JC | 1 |
| Lloyd, YM | 1 |
| Megnekou, R | 1 |
| Seumko'o, RMN | 1 |
| Salanti, A | 1 |
| Taylor, DW | 2 |
| Leke, RGF | 1 |
| Hussien, M | 1 |
| Abdel Hamid, MM | 1 |
| Elamin, EA | 1 |
| Hassan, AO | 1 |
| Elaagip, AH | 1 |
| Salama, AHA | 1 |
| Abdelraheem, MH | 1 |
| Mohamed, AO | 1 |
| Gaudart, J | 2 |
| Djimde, M | 3 |
| Sangare, B | 1 |
| Dicko, Y | 1 |
| Tembely, A | 1 |
| Traore, D | 2 |
| Lasry, E | 1 |
| Doumbo, O | 7 |
| Saito, M | 1 |
| Min, AM | 1 |
| McGready, R | 2 |
| Alo, CN | 1 |
| Nzeh, CB | 1 |
| Ndukwe, CD | 1 |
| Okoro, OO | 1 |
| Abateneh, DD | 1 |
| Uneke, CJ | 1 |
| Samadoulougou, OS | 1 |
| Bihoun, B | 1 |
| Rouamba, E | 1 |
| Nkoka, O | 1 |
| Chuang, TW | 1 |
| Chen, YH | 1 |
| Myers-Hansen, JL | 1 |
| Abuaku, B | 1 |
| Oyebola, MK | 1 |
| Mensah, BA | 1 |
| Ahorlu, C | 1 |
| Wilson, MD | 1 |
| Awandare, G | 1 |
| Koram, KA | 1 |
| Ngwa, AA | 1 |
| Ghansah, A | 1 |
| Méndez, S | 1 |
| Tholandi, M | 1 |
| Al Khaja, KAJ | 1 |
| Sequeira, RP | 1 |
| Amoako, BK | 1 |
| Anto, F | 3 |
| Diawara, H | 1 |
| Walker, P | 2 |
| Steinhardt, LC | 1 |
| Kamate, B | 1 |
| Duval, L | 1 |
| Sicuri, E | 4 |
| Sadou, A | 1 |
| Mihigo, J | 1 |
| Conteh, L | 6 |
| Hughes, E | 1 |
| Wallender, E | 1 |
| Mohamed Ali, A | 1 |
| Savic, RM | 1 |
| Andemel, N | 1 |
| Swihart, B | 1 |
| Sidibe, Y | 1 |
| Gaoussou, S | 1 |
| Traore, M | 4 |
| Diarra, BS | 1 |
| Keita, S | 1 |
| Das, S | 3 |
| Kar, A | 1 |
| Manna, S | 1 |
| Mandal, S | 2 |
| Saha, B | 1 |
| Hati, AK | 1 |
| Muhammad, FM | 1 |
| Nedjat, S | 1 |
| Sajadi, HS | 1 |
| Parsaeian, M | 1 |
| Assan, A | 1 |
| Majdzadeh, R | 1 |
| Whiting-Collins, LJ | 1 |
| Beebe, M | 1 |
| Andronescu, LR | 1 |
| Sharma, A | 1 |
| Kachingwe, M | 1 |
| Kachepa, W | 1 |
| Liang, Y | 1 |
| Okoli, CI | 1 |
| Hajizadeh, M | 1 |
| Rahman, MM | 1 |
| Khanam, R | 1 |
| Esu, EB | 1 |
| Oringanje, C | 1 |
| Meremikwu, MM | 2 |
| Toukam, LL | 1 |
| Tatsinkou Fossi, B | 1 |
| Taiwe, GS | 1 |
| Bila, RB | 1 |
| Feugaing Sofeu, DD | 1 |
| Ivo, EP | 1 |
| Mutanyi, JA | 1 |
| Onguru, DO | 1 |
| Ogolla, SO | 1 |
| Adipo, LB | 1 |
| Manirakiza, A | 2 |
| Tondeur, L | 1 |
| Ketta, MYB | 1 |
| Sepou, A | 1 |
| Serdouma, E | 1 |
| Gondje, S | 1 |
| Bata, GGB | 1 |
| Boulay, A | 1 |
| Moyen, JM | 1 |
| Sakanga, O | 1 |
| Le-Fouler, L | 1 |
| Kazanji, M | 1 |
| Lombart, JP | 1 |
| Vray, M | 1 |
| Chaponda, EB | 1 |
| Ariti, C | 1 |
| Salomão, C | 1 |
| Sacarlal, J | 2 |
| Gudo, ES | 1 |
| York, A | 1 |
| de Kock, M | 2 |
| Workman, L | 1 |
| Nyunt, MM | 2 |
| Adam, I | 1 |
| Mbaye, A | 1 |
| Gaye, A | 1 |
| Dieye, B | 1 |
| Ndiaye, YD | 1 |
| Bei, AK | 1 |
| Affara, M | 1 |
| Deme, AB | 1 |
| Yade, MS | 1 |
| Diongue, K | 1 |
| Ndiaye, IM | 1 |
| Ndiaye, T | 2 |
| Sy, M | 1 |
| Sy, N | 1 |
| Koita, O | 1 |
| Krogstad, DJ | 2 |
| Volkman, S | 1 |
| Nwakanma, D | 1 |
| Ndiaye, D | 1 |
| Clark, RL | 1 |
| Aprioku, JS | 1 |
| Mankwe, AC | 1 |
| Owusu-Boateng, I | 1 |
| van Schalkwyk, DA | 1 |
| Moon, RW | 1 |
| Blasco, B | 1 |
| Pitt, C | 2 |
| Ndiaye, M | 5 |
| Sy, O | 2 |
| Hadj Ba, E | 1 |
| Cissé, B | 8 |
| Gomis, JF | 3 |
| Gaye, O | 7 |
| Milligan, PJ | 6 |
| Choi, SE | 1 |
| Brandeau, ML | 1 |
| Bendavid, E | 1 |
| Coldiron, ME | 1 |
| Von Seidlein, L | 2 |
| Grais, RF | 1 |
| Berry, I | 1 |
| Coulibaly, SO | 7 |
| Kayentao, K | 11 |
| Oduro, A | 2 |
| Cates, JE | 1 |
| Westreich, D | 1 |
| Unger, HW | 4 |
| Bauserman, M | 1 |
| Adair, L | 1 |
| Cole, SR | 1 |
| Meshnick, S | 4 |
| Rogerson, SJ | 9 |
| Talundzic, E | 1 |
| Ravishankar, S | 1 |
| Kelley, J | 1 |
| Patel, D | 1 |
| Plucinski, M | 1 |
| Schmedes, S | 1 |
| Ljolje, D | 1 |
| Clemons, B | 1 |
| Madison-Antenucci, S | 1 |
| Arguin, PM | 2 |
| Lucchi, NW | 2 |
| Vannberg, F | 1 |
| Udhayakumar, V | 1 |
| Gladstone, M | 1 |
| Ibrahim, H | 1 |
| Issah, K | 1 |
| Apanga, PA | 1 |
| Bachan, EG | 1 |
| Noora, CL | 1 |
| Ruh, E | 1 |
| Bateko, JP | 1 |
| Imir, T | 1 |
| Taylan-Ozkan, A | 1 |
| Piqueras, M | 2 |
| Aponte, JJ | 9 |
| Ter Kuile, FO | 29 |
| Chongwe, G | 1 |
| Chipukuma, H | 1 |
| Jacobs, C | 1 |
| Zgambo, J | 1 |
| Michelo, C | 1 |
| Moya-Alvarez, V | 2 |
| Ouédraogo, S | 2 |
| Accrombessi, M | 2 |
| Akinyotu, O | 2 |
| Bello, F | 2 |
| Abdus-Salam, R | 2 |
| Arowojolu, A | 2 |
| Rassi, C | 2 |
| Gore-Langton, GR | 1 |
| Gidudu Walimbwa, B | 1 |
| Strachan, CE | 1 |
| King, R | 2 |
| Basharat, S | 1 |
| Christiansen-Jucht, C | 1 |
| Graham, K | 2 |
| Gudoi, SS | 2 |
| Divala, TH | 2 |
| Mungwira, RG | 1 |
| Mawindo, PM | 1 |
| Nyirenda, OM | 2 |
| Kanjala, M | 1 |
| Ndaferankhande, M | 1 |
| Tsirizani, LE | 1 |
| Masonga, R | 1 |
| Muwalo, F | 1 |
| Boudová, S | 2 |
| Potter, GE | 1 |
| Kennedy, J | 1 |
| Goswami, J | 1 |
| Wylie, BJ | 1 |
| Ndovie, L | 1 |
| Mvula, P | 1 |
| Mbilizi, Y | 1 |
| Tomoka, T | 1 |
| Marealle, AI | 1 |
| Mbwambo, DP | 1 |
| Kilonzi, M | 1 |
| Mlyuka, HJ | 1 |
| Mutagonda, RF | 1 |
| Ramharter, M | 4 |
| Schwab, M | 1 |
| Mombo-Ngoma, G | 3 |
| Zoleko Manego, R | 1 |
| Akerey-Diop, D | 2 |
| Basra, A | 2 |
| Mackanga, JR | 2 |
| Würbel, H | 2 |
| Wojtyniak, JG | 1 |
| Hofmann, U | 1 |
| Geditz, M | 1 |
| Matsiegui, PB | 2 |
| Kremsner, PG | 6 |
| Kerb, R | 1 |
| Lehr, T | 1 |
| Arnaldo, P | 1 |
| Cambe, MI | 1 |
| Magaço, A | 1 |
| Chicumbe, S | 1 |
| Rovira-Vallbona, E | 1 |
| Rosanas-Urgell, A | 3 |
| Enosse, SM | 2 |
| Ward, A | 1 |
| Guillot, A | 1 |
| Nepomnyashchiy, LE | 1 |
| Graves, JC | 1 |
| Maloney, K | 1 |
| Omoniwa, OF | 1 |
| Emegbuonye, L | 1 |
| Kerac, M | 1 |
| Omoluabi, E | 1 |
| Bhattacharya, A | 1 |
| Milch Hariharan, K | 1 |
| Wiwa, O | 1 |
| Cohen, JM | 2 |
| Le Menach, A | 1 |
| Tapily, A | 1 |
| Nikiema, F | 1 |
| Yerbanga, S | 1 |
| Thera, I | 1 |
| Sottas, O | 1 |
| Guidi, M | 1 |
| Thieffry, B | 1 |
| Schneider, M | 1 |
| Décosterd, L | 1 |
| Mueller, I | 7 |
| Genton, B | 2 |
| Csajka, C | 1 |
| Senn, N | 2 |
| Hansa, AP | 1 |
| Buffet, C | 1 |
| Hasang, W | 1 |
| Teo, A | 1 |
| Randall, L | 1 |
| Ome-Kaius, M | 3 |
| Karl, S | 1 |
| Anuan, AA | 1 |
| Beeson, JG | 3 |
| Stock, SJ | 1 |
| Yavo, JC | 1 |
| Amari, ASG | 1 |
| Assi, SB | 1 |
| Assemian, A | 1 |
| Kouamé, R | 1 |
| Balayssac, E | 1 |
| Kamagaté, M | 1 |
| Olugbade, OT | 1 |
| Ilesanmi, OS | 1 |
| Gubio, AB | 1 |
| Nguku, PM | 1 |
| Diarra, SS | 1 |
| Konaté, D | 1 |
| Diawara, SI | 2 |
| Tall, M | 1 |
| Diakité, M | 2 |
| Adeoye, IA | 1 |
| Fagbamigbe, AF | 1 |
| Olaleye, A | 1 |
| Okusanya, BO | 1 |
| Oduwole, O | 1 |
| Esu, E | 1 |
| Oppong, FB | 1 |
| Gyaase, S | 1 |
| Zandoh, C | 1 |
| Nettey, OEA | 1 |
| Amenga-Etego, S | 1 |
| Anane, EA | 1 |
| Adda, R | 1 |
| Dosoo, DK | 1 |
| Owusu-Agyei, S | 5 |
| Oms, M | 1 |
| Okethwangu, D | 1 |
| Opigo, J | 1 |
| Atugonza, S | 1 |
| Kizza, CT | 1 |
| Nabatanzi, M | 1 |
| Biribawa, C | 1 |
| Kyabayinze, D | 1 |
| Ario, AR | 1 |
| Garner, P | 4 |
| van Eijk, AM | 12 |
| Naidoo, I | 2 |
| Mulokozi, A | 1 |
| MacArthur, JR | 3 |
| Bouyou-Akotet, MK | 1 |
| Mawili-Mboumba, DP | 1 |
| Kombila, M | 2 |
| Bisoffi, Z | 1 |
| Sirima, BS | 2 |
| Gobbi, F | 1 |
| Angheben, A | 1 |
| Buonfrate, D | 1 |
| Van den Ende, J | 1 |
| McClure, EM | 1 |
| Goldenberg, RL | 1 |
| Dent, AE | 1 |
| Rajan, A | 1 |
| Bagai, U | 1 |
| Opare, DA | 1 |
| Bamba, S | 1 |
| Séré, A | 1 |
| Nikiéma, R | 1 |
| Halidou, T | 1 |
| Thiéba, B | 1 |
| Dao, B | 1 |
| Guiguemdé, RT | 1 |
| Obala, A | 1 |
| Thirumurthy, H | 1 |
| Khwa-Otsyula, B | 1 |
| Hill, J | 8 |
| Dellicour, S | 1 |
| Bruce, J | 5 |
| Ouma, P | 4 |
| Smedley, J | 3 |
| Otieno, P | 3 |
| Ombock, M | 1 |
| Kariuki, S | 4 |
| Hamel, MJ | 6 |
| Webster, J | 7 |
| Abathina, A | 1 |
| Haiballa, AA | 1 |
| Kikueta, CM | 1 |
| Kambu, OK | 1 |
| Mbenza, AP | 1 |
| Mavinga, ST | 1 |
| Mbamu, BM | 1 |
| Cos, P | 1 |
| Maes, L | 1 |
| Apers, S | 1 |
| Pieters, L | 1 |
| Cimanga, RK | 1 |
| Haile, ZT | 1 |
| Gurka, KK | 1 |
| Chertok, IR | 1 |
| Sambamoorthi, U | 1 |
| Kang, H | 1 |
| Kreuels, B | 1 |
| Adjei, O | 1 |
| Krumkamp, R | 1 |
| May, J | 3 |
| Small, DS | 1 |
| Hoyt, J | 1 |
| D'Mello-Guyett, L | 1 |
| Steketee, R | 3 |
| Smith, H | 1 |
| Faiz, MA | 1 |
| Mokuolu, OA | 2 |
| Dondorp, AM | 1 |
| Sharma, L | 1 |
| Shukla, G | 1 |
| Ades, V | 2 |
| Walakira, A | 1 |
| Ninsiima, B | 1 |
| Mugagga, O | 1 |
| Patil, TS | 1 |
| Schwartz, A | 1 |
| Nasr, S | 1 |
| Chang, M | 1 |
| Filler, S | 1 |
| Graham, KJ | 1 |
| Ba-Break, MM | 1 |
| Onyeneho, NG | 1 |
| Okeibunor, JC | 1 |
| Brieger, WR | 1 |
| Mbonye, AK | 7 |
| Yanow, S | 1 |
| Birungi, J | 1 |
| Larsen, DA | 1 |
| Steketee, RW | 7 |
| Eisele, TP | 1 |
| Diala, CC | 1 |
| Pennas, T | 1 |
| Marin, C | 1 |
| Belay, KA | 1 |
| Doua, JY | 2 |
| Matangila, J | 1 |
| Lutumba, P | 2 |
| Van Geertruyden, JP | 2 |
| Huijben, S | 3 |
| Bell, AS | 4 |
| Sim, DG | 4 |
| Tomasello, D | 1 |
| Mideo, N | 1 |
| Day, T | 1 |
| Read, AF | 5 |
| Mubyazi, GM | 2 |
| Byskov, J | 2 |
| Bloch, P | 3 |
| Molloy, AM | 1 |
| Bisong, CE | 1 |
| Dongmo, CM | 1 |
| Exavery, A | 1 |
| Mbaruku, G | 1 |
| Mbuyita, S | 1 |
| Makemba, A | 1 |
| Kinyonge, IP | 1 |
| Kweka, H | 1 |
| Bygbjerg, IC | 8 |
| Ijumba, JN | 1 |
| Marero, M | 1 |
| Mboera, LE | 1 |
| Molteni, F | 1 |
| Taylor, S | 3 |
| Guirou, EA | 1 |
| Khairallah, C | 3 |
| Guindo, N | 1 |
| Bationo, R | 2 |
| Soulama, A | 2 |
| Dabira, E | 2 |
| Barry, B | 1 |
| Niangaly, M | 1 |
| Diakite, H | 1 |
| Konate, S | 1 |
| Keita, M | 1 |
| Traore, B | 3 |
| Mishra, N | 2 |
| Gupta, R | 1 |
| Singh, S | 1 |
| Rana, R | 1 |
| Shahi, B | 1 |
| Das, MK | 4 |
| Anvikar, AR | 2 |
| Valecha, N | 3 |
| Khobjai, W | 1 |
| Jaihan, U | 1 |
| Watcharasamphankul, W | 1 |
| Somsak, V | 1 |
| Touré, M | 1 |
| Diarwara, S | 1 |
| Mbu, RE | 1 |
| Takang, WA | 1 |
| Fouedjio, HJ | 1 |
| Fouelifack, FY | 1 |
| Tumasang, FN | 1 |
| Tonye, R | 1 |
| Gomez, PP | 1 |
| Dickerson, A | 2 |
| Andre, ZH | 1 |
| Savargaonkar, D | 1 |
| Shah, N | 1 |
| Srivastava, B | 1 |
| Mosha, D | 2 |
| Chilongola, J | 2 |
| Ndeserua, R | 2 |
| Mwingira, F | 1 |
| Abellana, R | 1 |
| Kalilani-Phiri, L | 1 |
| Joshi, S | 2 |
| Mukadam, R | 1 |
| Seydel, KB | 1 |
| Mawindo, P | 1 |
| Thesing, P | 1 |
| Kamiza, S | 1 |
| Makwakwa, K | 1 |
| Taylor, TE | 4 |
| Mbeye, NM | 1 |
| Davies, MA | 1 |
| Phiri, KS | 1 |
| Egger, M | 1 |
| Wandeler, G | 1 |
| Bigira, V | 2 |
| Kapisi, J | 2 |
| Kinara, S | 2 |
| Mwangwa, F | 2 |
| Osterbauer, B | 1 |
| Aweeka, FT | 2 |
| Huang, L | 2 |
| Achan, J | 2 |
| Coleman, M | 2 |
| Al-Zahrani, MH | 1 |
| Hemingway, J | 1 |
| Omar, A | 1 |
| Stanton, MC | 1 |
| Thomsen, EK | 1 |
| Alsheikh, AA | 1 |
| Alhakeem, RF | 1 |
| McCall, PJ | 1 |
| Al Rabeeah, AA | 1 |
| Memish, ZA | 1 |
| Rabiu, KA | 1 |
| Davies, NO | 1 |
| Nzeribe-Abangwu, UO | 1 |
| Adewunmi, AA | 1 |
| Akinlusi, FM | 1 |
| Akinola, OI | 1 |
| Ogundele, SO | 1 |
| Wallon, M | 1 |
| Brieger, W | 1 |
| Rawlins, B | 1 |
| Agarwal, K | 1 |
| Odongo, CO | 1 |
| Bisaso, RK | 1 |
| Byamugisha, J | 1 |
| Obua, C | 1 |
| Gresty, KJ | 1 |
| Gray, KA | 1 |
| Bobogare, A | 1 |
| Wini, L | 1 |
| Taleo, G | 1 |
| Hii, J | 1 |
| Cheng, Q | 3 |
| Waters, NC | 2 |
| Oluwatosin, OA | 1 |
| Aluko, JO | 1 |
| Mpogoro, FJ | 1 |
| Matovelo, D | 1 |
| Dosani, A | 1 |
| Ngallaba, S | 1 |
| Mugono, M | 1 |
| Mazigo, HD | 1 |
| Wangnapi, RA | 2 |
| Umbers, AJ | 2 |
| Hanieh, S | 2 |
| Suen, CS | 1 |
| Robinson, LJ | 1 |
| Wapling, J | 1 |
| Lufele, E | 1 |
| Kongs, C | 1 |
| Samol, P | 1 |
| Sui, D | 1 |
| Singirok, D | 1 |
| Bardaji, A | 3 |
| Schofield, L | 2 |
| Betuela, I | 1 |
| Siba, P | 3 |
| Aho, C | 1 |
| Jack, W | 1 |
| Lafana, A | 1 |
| Michael, A | 1 |
| Greenhill, AR | 1 |
| Walker, PG | 2 |
| Fernandes, S | 2 |
| Were, V | 2 |
| Akazili, J | 1 |
| Madanitsa, M | 2 |
| Hanson, K | 3 |
| Capan-Melser, M | 1 |
| Mombo Ngoma, G | 1 |
| Groger, M | 1 |
| Zoleko-Manego, R | 1 |
| Schipulle, U | 1 |
| Schwing, J | 1 |
| Lötsch, F | 1 |
| Rehman, K | 1 |
| Agnandji, ST | 1 |
| Adegnika, AA | 2 |
| Bélard, S | 1 |
| Takala-Harrison, S | 2 |
| Massougbodgi, A | 1 |
| Abdulla, S | 4 |
| Kuwawenaruwa, A | 1 |
| Katana, A | 2 |
| Kremsner, P | 2 |
| Slustker, L | 1 |
| Aponte, J | 1 |
| Some, AF | 1 |
| Sutherland, C | 3 |
| Maïga-Ascofaré, O | 1 |
| Rakotozandrindrainy, R | 1 |
| Girmann, M | 1 |
| Hahn, A | 1 |
| Randriamampionona, N | 1 |
| Poppert, S | 1 |
| Schwarz, NG | 2 |
| Marquart, L | 1 |
| Baker, M | 1 |
| O'Rourke, P | 1 |
| McCarthy, JS | 1 |
| Kibusi, SM | 1 |
| Kimunai, E | 1 |
| Hines, CS | 1 |
| Escolano, S | 1 |
| Journot, V | 1 |
| Massougbodji, A | 9 |
| Tubert-Bitter, P | 1 |
| Ndong, IC | 1 |
| Reenen, Mv | 1 |
| Boakye, DA | 1 |
| Mbacham, WF | 1 |
| Grobler, AF | 1 |
| Abubakar, I | 1 |
| Akor, F | 2 |
| Mohammed, K | 1 |
| Guirou, E | 1 |
| Awine, T | 4 |
| Quaye, S | 1 |
| Njie, F | 2 |
| Ordi, J | 2 |
| Hodgson, A | 3 |
| ter Kuile, F | 3 |
| Woukeu, A | 1 |
| Yoder, PS | 1 |
| Nsabagasani, X | 2 |
| Moran, A | 1 |
| Yé, Y | 1 |
| Owusu, R | 1 |
| Mahama, E | 1 |
| Awini, E | 1 |
| Anyorigiya, T | 1 |
| Amu, A | 1 |
| Jakpa, G | 1 |
| Ofei, E | 1 |
| Segbaya, S | 1 |
| Oduro, AR | 2 |
| Bart-Plange, C | 1 |
| Glinz, D | 1 |
| Hurrell, RF | 1 |
| Ouattara, M | 1 |
| Zimmermann, MB | 1 |
| Brittenham, GM | 1 |
| Adiossan, LG | 1 |
| Righetti, AA | 1 |
| Seifert, B | 1 |
| Diakité, VG | 1 |
| N'Goran, EK | 1 |
| Wegmüller, R | 1 |
| Moss, WJ | 2 |
| L'lanziva, A | 1 |
| Otieno, K | 4 |
| Juma, E | 1 |
| Laserson, K | 1 |
| Williamson, J | 3 |
| Artimovich, E | 1 |
| Kapito-Tembo, A | 2 |
| Pensulo, P | 1 |
| Nyirenda, O | 1 |
| Brown, S | 1 |
| Escalante, AA | 1 |
| Wiegand, RE | 1 |
| Kalilani, L | 2 |
| Mace, KE | 2 |
| Edgar, D | 1 |
| Chaluluka, E | 3 |
| Kamuliwo, M | 1 |
| Skarbinski, J | 2 |
| Shi, YP | 4 |
| Nuralitha, S | 1 |
| Siregar, JE | 1 |
| Syafruddin, D | 1 |
| Roelands, J | 1 |
| Verhoef, J | 1 |
| Hoepelman, AI | 1 |
| Marzuki, S | 1 |
| Antwi, GD | 1 |
| Acheampong, PR | 1 |
| Bart Plange, C | 1 |
| Poirot, E | 1 |
| Vittinghoff, E | 1 |
| Ishengoma, D | 1 |
| Alifrangis, M | 2 |
| Carneiro, I | 6 |
| Hashim, R | 2 |
| Mosha, J | 2 |
| Gesase, S | 3 |
| Kupka, R | 1 |
| Belko, MM | 1 |
| Oyakhirome, S | 1 |
| Williams, JE | 1 |
| Rupérez, M | 1 |
| Kabanywanyi, AM | 2 |
| Sevene, E | 1 |
| Kakolwa, MA | 1 |
| Vala, A | 1 |
| Manego Zoleko, R | 1 |
| Grigg, MJ | 1 |
| Barber, BE | 1 |
| Marfurt, J | 1 |
| William, T | 1 |
| Bird, E | 1 |
| Piera, KA | 1 |
| Aziz, A | 1 |
| Boonyuen, U | 1 |
| Drakeley, CJ | 2 |
| Cox, J | 1 |
| Yeo, TW | 1 |
| Auburn, S | 1 |
| Anstey, NM | 1 |
| Songsungthong, W | 1 |
| Koonyosying, P | 1 |
| Uthaipibull, C | 1 |
| Juma, A | 1 |
| Orish, VN | 1 |
| Onyeabor, OS | 1 |
| Boampong, JN | 1 |
| Afoakwah, R | 1 |
| Nwaefuna, E | 1 |
| Acquah, S | 1 |
| Sanyaolu, AO | 1 |
| Iriemenam, NC | 1 |
| Natureeba, P | 1 |
| Awori, P | 1 |
| Opira, B | 1 |
| Olwoch, P | 1 |
| Nayebare, P | 1 |
| Feeney, ME | 1 |
| Charlebois, ED | 1 |
| Rizzuto, G | 1 |
| Fokam, EB | 1 |
| Ngimuh, L | 1 |
| Wanji, S | 1 |
| Ameh, S | 1 |
| Owoaje, E | 1 |
| Oyo-Ita, A | 1 |
| Kabiru, CW | 1 |
| Akpet, OEO | 1 |
| Etokidem, A | 1 |
| Enembe, O | 1 |
| Ekpenyong, N | 1 |
| Mwendera, C | 1 |
| de Jager, C | 1 |
| Longwe, H | 1 |
| Phiri, K | 2 |
| Hongoro, C | 1 |
| Mutero, CM | 1 |
| Essiben, F | 1 |
| Foumane, P | 1 |
| de Nguefack, MA | 1 |
| Eko, FE | 1 |
| Njotang, PN | 1 |
| Enow, RM | 1 |
| Mboudou, ET | 1 |
| Sambili, B | 1 |
| Kimambo, R | 1 |
| Peng, Y | 1 |
| Ishunga, E | 1 |
| Matasha, E | 1 |
| Matumu, G | 1 |
| Noronha, R | 1 |
| Ngilangwa, DP | 1 |
| Mwangi, VI | 1 |
| Mumo, RM | 1 |
| Kiboi, DM | 1 |
| Omar, SA | 2 |
| Ng'ang'a, ZW | 1 |
| Ozwara, HS | 1 |
| Mufubenga, P | 2 |
| Meier, J | 1 |
| Harvey, SA | 1 |
| Rao, N | 1 |
| Diarra, NH | 1 |
| Klein, MC | 1 |
| Diop, SI | 1 |
| Wanzira, H | 1 |
| Katamba, H | 1 |
| Okullo, AE | 1 |
| Rubahika, D | 1 |
| Mwapasa, V | 2 |
| Pace, C | 1 |
| Thwai, KL | 1 |
| Wang, D | 1 |
| Kang'ombe, A | 1 |
| Faragher, B | 1 |
| Kateera, F | 1 |
| Nsobya, SL | 2 |
| Tukwasibwe, S | 1 |
| Hakizimana, E | 1 |
| Mutesa, L | 1 |
| Mens, PF | 2 |
| Grobusch, MP | 4 |
| van Vugt, M | 1 |
| Kumar, N | 1 |
| Ba, EH | 3 |
| Ndour, CT | 1 |
| Molez, JF | 1 |
| Fall, FB | 2 |
| Sokhna, C | 7 |
| Faye, B | 3 |
| Kouevijdin, E | 2 |
| Niane, FK | 1 |
| Trape, JF | 8 |
| Rogier, C | 4 |
| Stoner, MC | 1 |
| Vwalika, B | 1 |
| Smid, M | 1 |
| Kumwenda, A | 1 |
| Stringer, E | 1 |
| Chi, BH | 1 |
| Stringer, JS | 1 |
| Orobaton, N | 1 |
| Austin, AM | 1 |
| Abegunde, D | 1 |
| Ibrahim, M | 1 |
| Mohammed, Z | 1 |
| Abdul-Azeez, J | 1 |
| Ganiyu, H | 1 |
| Nanbol, Z | 1 |
| Fapohunda, B | 1 |
| Beal, K | 1 |
| Nattee, C | 1 |
| Khamsemanan, N | 1 |
| Lawtrakul, L | 1 |
| Toochinda, P | 1 |
| Hannongbua, S | 1 |
| Kovacs, S | 1 |
| Stergachis, A | 2 |
| Dial, Y | 1 |
| Faye, E | 2 |
| Lo, A | 1 |
| Tine, R | 1 |
| Faye, S | 1 |
| Konate, L | 2 |
| Flach, C | 1 |
| Faye, O | 3 |
| Thior, PM | 1 |
| Faye, OK | 1 |
| Slutsker, L | 7 |
| Ezenduka, C | 1 |
| Nworgu, C | 1 |
| Godman, BB | 1 |
| Massele, A | 1 |
| Esimone, C | 1 |
| Matangila, JR | 1 |
| Mitashi, P | 1 |
| da Luz, RI | 1 |
| Stephen, AA | 1 |
| Wurapa, F | 1 |
| Afari, EA | 1 |
| Sackey, SO | 1 |
| Malm, KL | 1 |
| Nyarko, KM | 1 |
| Price, RN | 1 |
| Luxemburger, C | 2 |
| Baiwog, F | 1 |
| Page-Sharp, M | 1 |
| Griffin, S | 1 |
| Karunajeewa, HA | 1 |
| Siba, PM | 1 |
| Ilett, KF | 1 |
| Floyd, J | 1 |
| Hansen, KS | 2 |
| Omo-Aghoja, LO | 1 |
| Abe, E | 1 |
| Feyi-Waboso, P | 1 |
| Okonofua, FE | 1 |
| Sissoko, MS | 2 |
| Guindo, O | 2 |
| Diallo, AI | 2 |
| Kone, M | 2 |
| Toure, OB | 2 |
| Sacko, M | 1 |
| Ross, A | 1 |
| Penny, M | 1 |
| Maire, N | 1 |
| Studer, A | 1 |
| Schellenberg, D | 9 |
| Tanner, M | 9 |
| Smith, T | 1 |
| Stolk, WA | 1 |
| Habbema, JD | 1 |
| Mshinda, H | 8 |
| Bloland, PB | 4 |
| Kachur, SP | 6 |
| Pérez, MA | 1 |
| Cortés, LJ | 1 |
| Guerra, AP | 1 |
| Knudson, A | 1 |
| Usta, C | 1 |
| Nicholls, RS | 1 |
| Manzi, F | 5 |
| Hutton, G | 3 |
| Schellenberg, J | 5 |
| Alonso, P | 7 |
| Mathew, JL | 1 |
| Buffet, PA | 1 |
| Thellier, M | 1 |
| Lepère, JF | 1 |
| Gies, S | 5 |
| Ouattara, FT | 2 |
| Ky, C | 3 |
| Brabin, BJ | 4 |
| Mushi, AK | 2 |
| Mrisho, M | 1 |
| Mbuya, C | 1 |
| Mponda, H | 2 |
| Pool, R | 1 |
| Hamis, Y | 1 |
| Shirima, K | 3 |
| Mwita, A | 2 |
| Simba, A | 1 |
| Rusibamayila, N | 1 |
| Kitambi, M | 1 |
| Temperley, M | 1 |
| Mueller, DH | 1 |
| Njagi, JK | 1 |
| Akhwale, W | 1 |
| Clarke, SE | 2 |
| Estambale, BB | 1 |
| Brooker, S | 1 |
| Ouma, PO | 1 |
| Parise, M | 4 |
| Ayisi, JG | 6 |
| Kager, PA | 10 |
| Okokon, JE | 1 |
| Nwafor, PA | 1 |
| Minzi, OM | 1 |
| Haule, AF | 1 |
| Fawole, AO | 2 |
| Onyeaso, NC | 2 |
| Warsame, M | 2 |
| Atta, H | 1 |
| Klena, JD | 1 |
| Waqar, BA | 1 |
| Elmi, HH | 1 |
| Jibril, AM | 1 |
| Hassan, HM | 1 |
| Hassan, AM | 1 |
| Marchant, T | 1 |
| Nathan, R | 1 |
| Jones, C | 2 |
| Sedekia, Y | 1 |
| Kweku, M | 2 |
| Liu, D | 1 |
| Adjuik, M | 1 |
| Binka, F | 2 |
| Seidu, M | 1 |
| Billal, DS | 1 |
| Hotomi, M | 1 |
| Yamanaka, N | 1 |
| Greenhouse, B | 2 |
| Slater, M | 2 |
| Njama-Meya, D | 2 |
| Nzarubara, B | 2 |
| Maiteki-Sebuguzi, C | 2 |
| Hubbard, A | 1 |
| Msyamboza, KP | 1 |
| Savage, EJ | 1 |
| Kazembe, PN | 2 |
| Kalanda, G | 2 |
| Brabin, L | 1 |
| Stokes, E | 1 |
| Dumbaya, I | 1 |
| Owens, S | 1 |
| Danquah, I | 3 |
| Dietz, E | 2 |
| Zanger, P | 3 |
| Reither, K | 3 |
| Ziniel, P | 3 |
| Bienzle, U | 3 |
| Mockenhaupt, FP | 3 |
| Muregi, FW | 1 |
| Kano, S | 2 |
| Kino, H | 1 |
| Ishih, A | 1 |
| Tediosi, F | 2 |
| Kahigwa, E | 3 |
| Sigauque, B | 3 |
| Mas, X | 1 |
| Trapero, M | 1 |
| Trilla, A | 1 |
| Kar, PK | 1 |
| Bhatt, RM | 1 |
| Anvikar, A | 1 |
| Dua, VK | 2 |
| Nébié, I | 2 |
| Soulama, I | 2 |
| Tiono, A | 1 |
| Diarra, A | 4 |
| Konaté, AT | 3 |
| Ouédraogo, A | 4 |
| Mutabingwa, TK | 4 |
| Muze, K | 1 |
| Ord, R | 2 |
| Briceño, M | 1 |
| Drakeley, C | 3 |
| Whitty, CJ | 2 |
| Yatich, NJ | 1 |
| Yi, J | 1 |
| Agbenyega, T | 1 |
| Turpin, A | 1 |
| Rayner, JC | 1 |
| Stiles, JK | 2 |
| Ellis, WO | 1 |
| Funkhouser, E | 1 |
| Ehiri, JE | 1 |
| Williams, JH | 1 |
| Jolly, PE | 1 |
| Souares, A | 3 |
| Lalou, R | 4 |
| Sene, I | 1 |
| Sow, D | 3 |
| Le Hesran, JY | 5 |
| Irungu, B | 1 |
| Kiboi, D | 1 |
| Langat, B | 1 |
| Rukunga, G | 1 |
| Sinclair, D | 1 |
| Zani, B | 1 |
| Donegan, S | 1 |
| Olliaro, P | 3 |
| Knight, SE | 1 |
| Anyachebelu, EJ | 1 |
| Geddes, R | 1 |
| Maharaj, R | 1 |
| Sayang, C | 1 |
| Gausseres, M | 1 |
| Vernazza-Licht, N | 1 |
| Malvy, D | 2 |
| Bley, D | 1 |
| Millet, P | 2 |
| Bottero, J | 1 |
| Noël, H | 1 |
| Masse, V | 1 |
| Cordel, H | 1 |
| Guerra, J | 2 |
| Kossou, H | 1 |
| Fayomi, B | 2 |
| Ayemonna, P | 1 |
| Fievet, N | 2 |
| Bell, DJ | 3 |
| Wootton, D | 1 |
| Montgomery, J | 2 |
| Kayange, N | 1 |
| Chimpeni, P | 1 |
| Hughes, DA | 1 |
| Molyneux, ME | 7 |
| Ward, SA | 4 |
| Winstanley, PA | 4 |
| Lalloo, DG | 1 |
| Senghor, P | 1 |
| Sabot, OJ | 1 |
| Ipuge, Y | 1 |
| Gordon, M | 1 |
| Bishop, D | 1 |
| Odhiambo, M | 1 |
| Ward, L | 1 |
| Goodman, C | 2 |
| NDiaye, O | 1 |
| Cames, C | 3 |
| Cheng, Y | 1 |
| Lô, AC | 1 |
| Simondon, K | 3 |
| Gabor, JJ | 1 |
| Poetschke, M | 1 |
| Doernemann, J | 1 |
| Schuster, K | 1 |
| Koester, KB | 1 |
| Profanter, K | 1 |
| Borchert, LB | 1 |
| Kurth, F | 1 |
| Pongratz, P | 1 |
| Issifou, S | 1 |
| Lell, B | 1 |
| Nakibuuka, V | 1 |
| Ndeezi, G | 1 |
| Nakiboneka, D | 1 |
| Ndugwa, CM | 1 |
| Tumwine, JK | 1 |
| Eastman, RT | 1 |
| Dembele, B | 1 |
| Friedman, A | 1 |
| Yakubu, AA | 1 |
| Moulin, P | 1 |
| Sarrassat, S | 2 |
| Carlotti, MP | 1 |
| Touré, SO | 2 |
| Dama, S | 1 |
| Dicko, M | 1 |
| Coulibaly, OM | 1 |
| de Sousa, A | 4 |
| Fillol, F | 2 |
| Cournil, A | 1 |
| Simondon, KB | 1 |
| Legorreta-Herrera, M | 3 |
| Retana-Ugalde, R | 1 |
| Ventura-Gallegos, JL | 2 |
| Narváez, V | 2 |
| Mabunda, S | 2 |
| Mosha, JF | 1 |
| Kaur, H | 2 |
| Lemnge, M | 1 |
| Mosha, FW | 1 |
| Ndyomugyenyi, R | 2 |
| Katamanywa, J | 1 |
| Odhiambo, FO | 2 |
| Lindblade, K | 1 |
| Peterson, E | 1 |
| Vulule, J | 1 |
| Newman, RD | 6 |
| Oyibo, WA | 1 |
| Agomo, CO | 1 |
| Gosling, RD | 4 |
| Cairns, ME | 1 |
| Msyamboza, K | 1 |
| Savage, E | 1 |
| Kazembe, P | 2 |
| Obonyo, B | 1 |
| Biao, P | 1 |
| Masika, P | 1 |
| Matovu, F | 1 |
| Hamel, M | 1 |
| Egan, A | 1 |
| Bojang, KA | 3 |
| Conway, DJ | 2 |
| Sisay-Joof, F | 1 |
| Jallow, M | 1 |
| Nwakanma, DC | 1 |
| Abubakr, I | 1 |
| Diop, S | 2 |
| Soudré, F | 1 |
| Seck, M | 1 |
| Guèye, YB | 1 |
| Diéye, TN | 1 |
| Fall, AO | 1 |
| Sall, A | 1 |
| Thiam, D | 1 |
| Diakhaté, L | 1 |
| Feng, G | 2 |
| Simpson, JA | 1 |
| Grietens, KP | 1 |
| Somda, J | 1 |
| Toomer, E | 1 |
| Muela Ribera, J | 1 |
| Buchholz, U | 1 |
| Kobbe, R | 1 |
| Abruquah, HH | 1 |
| Orostegui, L | 1 |
| Balu, L | 1 |
| Chevret, L | 1 |
| Habes, D | 1 |
| Pussard, E | 1 |
| Patouillard, E | 1 |
| Legood, R | 1 |
| Hunt, P | 3 |
| Martinelli, A | 2 |
| Modrzynska, K | 1 |
| Borges, S | 1 |
| Creasey, A | 1 |
| Rodrigues, L | 1 |
| Beraldi, D | 1 |
| Loewe, L | 1 |
| Fawcett, R | 1 |
| Kumar, S | 1 |
| Thomson, M | 1 |
| Trivedi, U | 1 |
| Otto, TD | 1 |
| Pain, A | 1 |
| Blaxter, M | 1 |
| Cravo, P | 1 |
| Wang, H | 1 |
| Bei, ZC | 1 |
| Wang, JY | 1 |
| Cao, WC | 1 |
| Gara, SN | 1 |
| Madaki, AJ | 1 |
| Thacher, TD | 2 |
| Bertin, G | 1 |
| Spalding, MD | 1 |
| Eyase, FL | 1 |
| Akala, HM | 1 |
| Bedno, SA | 1 |
| Prigge, ST | 1 |
| Coldren, RL | 1 |
| Sangaré, LR | 1 |
| Brentlinger, PE | 2 |
| Richardson, BA | 1 |
| Kiwuwa, MS | 2 |
| Weiss, NS | 1 |
| Boulanger, D | 3 |
| Sarr, JB | 1 |
| Schacht, AM | 1 |
| Riveau, G | 1 |
| Simondon, F | 3 |
| Remoué, F | 2 |
| Nyirongo, SK | 2 |
| Agbo, M | 1 |
| Sesay, S | 1 |
| Touray, E | 1 |
| Sowe, M | 1 |
| Webb, EL | 1 |
| van Hensbroek, MB | 1 |
| Fitzgerald, M | 1 |
| Thwing, JI | 1 |
| Njau, JD | 1 |
| Munkondya, J | 1 |
| Mkikima, S | 1 |
| Kirui, V | 1 |
| Gething, PW | 1 |
| Le Port, A | 1 |
| Dechavanne, C | 1 |
| Bouraima, A | 1 |
| Choudat, I | 1 |
| Migot-Nabias, F | 1 |
| Garcia, A | 2 |
| Richards, JS | 1 |
| Fowkes, FJ | 1 |
| Webb, E | 1 |
| Bittaye, O | 1 |
| Jasseh, M | 1 |
| Wiseman, V | 3 |
| Yaro, JB | 1 |
| Ouédraogo, AZ | 1 |
| Kangoyé, DT | 1 |
| Kaboré, Y | 1 |
| Ouédraogo, E | 1 |
| Tiono, AB | 2 |
| Ouédraogo, IN | 1 |
| Cousens, S | 2 |
| Sirima, SB | 3 |
| Diallo, DA | 1 |
| Willey, BA | 1 |
| Maokola, W | 1 |
| Chemba, M | 1 |
| Maiga, AS | 1 |
| Diawara, A | 1 |
| Sango, HA | 1 |
| Coulibaly, CO | 1 |
| Jansen, FH | 2 |
| Friesen, J | 1 |
| Borrmann, S | 1 |
| Matuschewski, K | 1 |
| Prajapati, SK | 1 |
| Joshi, H | 1 |
| Dev, V | 2 |
| Vanga-Bosson, HA | 1 |
| Coffie, PA | 1 |
| Kanhon, S | 1 |
| Sloan, C | 1 |
| Kouakou, F | 1 |
| Eholie, SP | 1 |
| Dabis, F | 1 |
| Menan, H | 1 |
| Ghani, A | 1 |
| Asoala, V | 1 |
| Akinleye, SO | 1 |
| Ajayi, IO | 1 |
| d'Almeida, TC | 1 |
| Agboton-Zoumenou, MA | 1 |
| Imorou, Y | 1 |
| Wilson, NO | 1 |
| Ceesay, FK | 1 |
| Obed, SA | 1 |
| Adjei, AA | 1 |
| Gyasi, RK | 1 |
| Rodney, P | 1 |
| Ndjakani, Y | 1 |
| Anderson, WA | 1 |
| Diakite, OS | 1 |
| Maiga, OM | 1 |
| Traoré, BT | 1 |
| Diallo, M | 1 |
| Ongoiba, A | 2 |
| Doumtabé, D | 2 |
| Doumbo, S | 1 |
| Traoré, MS | 1 |
| Karim, DM | 1 |
| Coulibaly, S | 1 |
| Bougoudogo, F | 1 |
| Harrington, WE | 1 |
| Kabyemela, E | 1 |
| Leke, RG | 1 |
| Diallo, AT | 1 |
| Salomon, R | 1 |
| Randriambelomanana, JA | 1 |
| Rakotoarisoa, H | 1 |
| Herinirina, SA | 1 |
| Zafindravola, BA | 1 |
| Andrianampanalinarivo, HR | 1 |
| Tongo, OO | 1 |
| Orimadegun, AE | 1 |
| Akinyinka, OO | 1 |
| Shekalaghe, SA | 1 |
| van den Bosch, S | 1 |
| ter Braak, R | 1 |
| van den Bijllaardt, W | 1 |
| Mwanziva, C | 1 |
| Semvua, S | 1 |
| Masokoto, A | 1 |
| Mosha, F | 2 |
| Teelen, K | 1 |
| Hermsen, R | 1 |
| Sauerwein, R | 2 |
| Nelson, WA | 2 |
| Lagarde, M | 1 |
| Smith Paintain, L | 1 |
| Antwi, G | 1 |
| Mwandama, D | 1 |
| Jafali, J | 1 |
| Luka, M | 1 |
| Filler, SJ | 2 |
| Sande, J | 1 |
| Tekete, MM | 1 |
| Toure, S | 2 |
| Fredericks, A | 1 |
| Sangare, CP | 1 |
| Evans, A | 1 |
| Smith, P | 1 |
| Cissé, M | 1 |
| Hutchison, CL | 1 |
| Wilby, KJ | 1 |
| Ensom, MH | 1 |
| Uthman, OA | 1 |
| Phares, CR | 1 |
| Kapella, BK | 1 |
| Doney, AC | 1 |
| Mekonnen, L | 1 |
| Galev, A | 1 |
| Weinberg, M | 1 |
| Stauffer, WM | 1 |
| Fehintola, FA | 1 |
| Balogun, ST | 1 |
| Adeoye, SB | 1 |
| Khim, N | 1 |
| Kim, S | 1 |
| Bouchier, C | 1 |
| Tichit, M | 1 |
| Ariey, F | 2 |
| Fandeur, T | 1 |
| Chim, P | 1 |
| Ke, S | 1 |
| Sum, S | 1 |
| Man, S | 1 |
| Durand, R | 1 |
| Rabarijaona, LP | 2 |
| Ndyiae, M | 1 |
| Hassan, J | 2 |
| Lambo, N | 1 |
| Adovohekpe, P | 1 |
| Guidetti, F | 1 |
| Recht, J | 2 |
| Affo, A | 1 |
| Shah, NK | 1 |
| Kamal, VK | 1 |
| Sharma, SK | 1 |
| Srivastava, HC | 1 |
| Pradhan, K | 1 |
| Kumar, H | 1 |
| Gupta, YK | 1 |
| Gupta, P | 1 |
| Dash, AP | 2 |
| Kinde-Gazard, D | 1 |
| Vignon Makong, J | 1 |
| Kossou, HD | 1 |
| Sossa, CJ | 1 |
| Likwela, JL | 1 |
| Lokwa, BL | 1 |
| Meuris, S | 1 |
| Dramaix, MW | 1 |
| Tenkorang, O | 1 |
| Inkoom, E | 1 |
| Ravelomanantena, HV | 1 |
| Njarasoa, S | 1 |
| Whang, JN | 1 |
| Ndiaye, Y | 1 |
| Akadiri, G | 1 |
| Kubalalika, P | 1 |
| Bizuneh, K | 1 |
| Randriasamimanana, JR | 1 |
| Bjelic, I | 1 |
| Dodoo, A | 1 |
| Umeh, UA | 1 |
| Obi, SN | 1 |
| Onah, HE | 1 |
| Ugwu, EO | 1 |
| Ajah, LO | 1 |
| Umeh, CR | 1 |
| Okafor, II | 1 |
| Collins, WE | 8 |
| Sullivan, JS | 1 |
| Jeffery, GM | 4 |
| Nace, D | 1 |
| Williams, T | 1 |
| Galland, GG | 1 |
| Williams, A | 1 |
| Barnwell, JW | 1 |
| Konare, M | 1 |
| Testa, J | 2 |
| Salamon, R | 1 |
| Iwanaga, S | 1 |
| Kaneko, I | 1 |
| Yuda, M | 1 |
| Rarau, P | 1 |
| Stanisic, DI | 1 |
| Robinson, L | 1 |
| Barnadas, C | 1 |
| Manong, D | 1 |
| Salib, M | 1 |
| Iga, J | 1 |
| Tarongka, N | 1 |
| Ley, S | 1 |
| Zimmerman, PA | 1 |
| Reeder, JC | 1 |
| Huynh, BT | 1 |
| Borgella, S | 1 |
| Onwujekwe, OC | 1 |
| Soremekun, RO | 1 |
| Uzochukwu, B | 1 |
| Shu, E | 1 |
| Onwujekwe, O | 1 |
| Rutta, AS | 1 |
| Francis, F | 1 |
| Mmbando, BP | 1 |
| Ishengoma, DS | 1 |
| Sembuche, SH | 1 |
| Malecela, EK | 1 |
| Sadi, JY | 1 |
| Kamugisha, ML | 1 |
| Lemnge, MM | 2 |
| Paaijmans, KP | 2 |
| Chan, BH | 1 |
| Shaukat, AM | 1 |
| Gilliams, EA | 1 |
| Kenefic, LJ | 1 |
| Laurens, MB | 1 |
| Dzinjalamala, FK | 2 |
| Thesing, PC | 2 |
| Jacob, CG | 1 |
| Xu, Y | 1 |
| Lam, KF | 1 |
| Fofana, B | 1 |
| Togo, A | 1 |
| Sanogo, K | 1 |
| Dembele, D | 1 |
| Giorgi, R | 1 |
| Rogawski, ET | 1 |
| Rantala, AM | 1 |
| Crawley, J | 1 |
| Sismanidis, C | 1 |
| Goodman, T | 1 |
| Namusoke, F | 1 |
| Ntale, M | 1 |
| Wahlgren, M | 1 |
| Kironde, F | 2 |
| Mirembe, F | 1 |
| Garavito, G | 1 |
| Bertani, S | 1 |
| Quiliano, M | 1 |
| Aldana, I | 1 |
| Anaba, FC | 1 |
| Ahiante, BO | 1 |
| Pepple, DJ | 1 |
| Schneider, P | 1 |
| O'Donnell, AJ | 1 |
| Blanford, S | 1 |
| Reece, SE | 1 |
| Urassa, DP | 1 |
| Nystrom, L | 1 |
| Carlsted, A | 1 |
| Pearce, RJ | 1 |
| Lupala, C | 1 |
| Hastings, MD | 1 |
| Jerrard, DA | 1 |
| Broder, JS | 1 |
| Hanna, JR | 1 |
| Colletti, JE | 1 |
| Grundmann, KA | 1 |
| Geroff, AJ | 1 |
| Mattu, A | 1 |
| Rodríguez, MC | 1 |
| Margos, G | 1 |
| Compton, H | 1 |
| Ku, M | 1 |
| Lanz, H | 1 |
| Rodríguez, MH | 1 |
| Sinden, RE | 2 |
| Verhoef, H | 2 |
| West, CE | 2 |
| Nzyuko, SM | 1 |
| de Vogel, S | 1 |
| van der Valk, R | 1 |
| Wanga, MA | 1 |
| Kuijsten, A | 1 |
| Veenemans, J | 1 |
| Kok, FJ | 1 |
| Ramsay, S | 1 |
| Terlouw, DJ | 3 |
| Courval, JM | 2 |
| Kolczak, MS | 2 |
| Rosenberg, OS | 2 |
| Oloo, AJ | 4 |
| Lal, AA | 2 |
| Nahlen, BL | 8 |
| Deng, S | 1 |
| Hu, Y | 1 |
| Pasha, O | 1 |
| Del Rosso, J | 1 |
| Marsh, D | 1 |
| Desai, MR | 3 |
| Mei, JV | 1 |
| Kariuki, SK | 4 |
| Wannemuehler, KA | 2 |
| Phillips-Howard, PA | 3 |
| Vulule, JM | 1 |
| Raharimalala, LA | 1 |
| Rabarijaona, L | 1 |
| Randrianarivelojosia, M | 1 |
| Razanavololo, F | 1 |
| Rason, MA | 1 |
| Andrianantenaina, HB | 1 |
| Andrianaivolambo, L | 1 |
| Rakotoniaina, JC | 1 |
| Leong Pock Tsi, JM | 1 |
| Rajaonarivelo, E | 1 |
| Léon, T | 1 |
| Duchemin, JB | 1 |
| González, IJ | 1 |
| Padilla, JO | 1 |
| Giraldo, LE | 1 |
| Saravia, NG | 1 |
| Strauss, R | 1 |
| Pfeifer, C | 1 |
| Tavrow, P | 1 |
| Shabahang, J | 1 |
| Makama, S | 1 |
| Nair, S | 1 |
| Williams, JT | 1 |
| Brockman, A | 1 |
| Paiphun, L | 1 |
| Newton, PN | 1 |
| Guthmann, JP | 2 |
| Smithuis, FM | 1 |
| Anderson, TJ | 1 |
| Chippaux, JP | 1 |
| Isah, AB | 1 |
| Ibrahim, YK | 1 |
| Iwalewa, EO | 1 |
| Hawley, WA | 1 |
| Kuile, FO | 1 |
| MISRA, BG | 7 |
| RAY, AP | 10 |
| BASU, PC | 5 |
| BAMI, HL | 1 |
| ROLLO, IM | 4 |
| GOODWIN, LG | 3 |
| JONES, SA | 3 |
| WILSON, T | 1 |
| EDESON, JF | 1 |
| CHAKRAVARTY, NK | 2 |
| CHAUDHURI, RN | 3 |
| SCHMIDT, LH | 12 |
| COVELL, G | 2 |
| SHUTE, PG | 2 |
| MARYON, M | 2 |
| SINGH, J | 6 |
| KRISHNASWAMI, AK | 1 |
| RAMAKRISHNAN, SP | 2 |
| VINCKE, I | 1 |
| LIPS, M | 1 |
| PIRES, M | 1 |
| ROTTEGLIA, E | 1 |
| GREENBERG, J | 4 |
| COATNEY, GR | 10 |
| TREMBLEY, HL | 4 |
| MYATT, AV | 3 |
| HERNANDEZ, T | 3 |
| JEFFEREY, GM | 1 |
| COOPER, WC | 1 |
| JELLIFFE, DB | 1 |
| SRIVASTAVA, RS | 1 |
| CHAKRABARTI, AK | 1 |
| MUKHERJEE, SK | 1 |
| TREVINO, A | 1 |
| REYES, LA | 1 |
| MENDOZA, F | 1 |
| BROU, M | 1 |
| MASSEGUIN, A | 1 |
| PALINACCI, A | 1 |
| CLYDE, DF | 16 |
| GROUNDS, JG | 1 |
| MILLER, MJ | 2 |
| HOUEL, G | 2 |
| PAL, R | 1 |
| NAIR, CP | 3 |
| SHARMA, MI | 1 |
| KRISHNAMURTHY, BS | 1 |
| CHANDRASEKHAR, GR | 1 |
| KHATRI, LD | 1 |
| SAMUELS, RD | 1 |
| LAHA, PN | 1 |
| SINGHAL, RN | 1 |
| NAVANI, H | 1 |
| SRIVASTAVA, JR | 1 |
| CLARK, HC | 1 |
| HOEKENGA, MT | 1 |
| DELANNOY, A | 1 |
| HUGON, J | 1 |
| ANNECKE, DH | 1 |
| JACOBS, AJ | 1 |
| SINGH, I | 1 |
| ALICATA, JE | 1 |
| DAJANI, SW | 1 |
| CAMBOURNAC, FJ | 2 |
| GANDARA, AF | 1 |
| PENA, AJ | 1 |
| BISHOP, A | 1 |
| PRESS, J | 2 |
| SHUTE, GT | 4 |
| ARCHIBALD, HM | 1 |
| BRUCE-CHWATT, LJ | 6 |
| DA MOURAO, MC | 1 |
| YOUNG, MD | 7 |
| LEPES, T | 1 |
| SOBERON Y PARRA, G | 1 |
| PEREZ REYES, R | 1 |
| WEBBE, G | 1 |
| MICKELSEN, O | 1 |
| BURGESS, RW | 4 |
| PIRKLE, CI | 1 |
| GABALDON, A | 1 |
| GUERRERO, L | 1 |
| ARCHER, TC | 1 |
| CHARLES, LJ | 2 |
| GUTIERREZ BALLESTEROS, E | 1 |
| GOMEZ, R | 1 |
| LAHON, H | 1 |
| DE SMET, M | 1 |
| BOETS, L | 1 |
| MAURANGES, P | 1 |
| BRAY, RS | 3 |
| FOX, RM | 1 |
| VAN DER KAAY, HJ | 3 |
| VINCKE, IH | 3 |
| BRADY, J | 1 |
| GILLES, HM | 4 |
| HENDRICKSE, RG | 2 |
| SINGH, H | 1 |
| SINGH, N | 5 |
| MCGREGOR, IA | 4 |
| WILLIAMS, K | 3 |
| MOLENAAR, JC | 1 |
| VOORS, AW | 1 |
| DORDEVIC, D | 1 |
| STEFANOVSKI, S | 1 |
| MEEUWISSEN, JH | 1 |
| CONTACOS, PG | 7 |
| LUNN, JS | 2 |
| MORLEY, D | 2 |
| WOODLAND, M | 1 |
| CUTHBERTSON, WF | 1 |
| SKINNER, JC | 2 |
| POWELL, RD | 7 |
| BREWER, GJ | 3 |
| ALVING, AS | 2 |
| MILLAR, JW | 1 |
| ZULUETA, J | 1 |
| KAFUKO, GW | 1 |
| MCCRAE, AW | 1 |
| CULLEN, JR | 1 |
| PEDRSEN, CK | 1 |
| WASSWA, DF | 1 |
| SANDOSHAM, AA | 1 |
| EYLES, DE | 1 |
| MONTGOMERY, R | 1 |
| VOLLER, A | 3 |
| WILSON, H | 1 |
| MEUWISSEN, JH | 5 |
| ROBERTS, JM | 7 |
| JACOBS, RL | 3 |
| LAING, AB | 9 |
| LEGTERS, LJ | 1 |
| WALLACE, DK | 1 |
| POLLACK, S | 1 |
| DEGOWIN, RL | 2 |
| SINGH, NN | 1 |
| SANDHINAND, U | 1 |
| PINSWASDI, K | 1 |
| NEELY, JM | 1 |
| COLLIS, WR | 1 |
| AUDU, IS | 1 |
| DAVID, HL | 1 |
| BASS, BH | 1 |
| MACFARLANE, RG | 1 |
| HAINE, J | 1 |
| HURLY, MG | 2 |
| Molta, NB | 1 |
| Watila, IM | 1 |
| Akpede, GO | 1 |
| Ekanem, OJ | 2 |
| Stauffer, W | 1 |
| Fischer, PR | 2 |
| Holtz, TH | 1 |
| Marum, LH | 1 |
| Mkandala, C | 3 |
| Chizani, N | 3 |
| Macheso, A | 1 |
| Parise, ME | 5 |
| Attaran, A | 1 |
| Fanello, CI | 1 |
| Galinski, MR | 1 |
| Kokwaro, G | 1 |
| Makanga, M | 1 |
| Talisuna, A | 2 |
| Watkins, WM | 6 |
| SMITH, DA | 1 |
| Pfeiffer, CM | 1 |
| Otieno, JA | 2 |
| Misore, AO | 1 |
| Odondi, JO | 1 |
| Rosen, DH | 3 |
| Hoshen, M | 1 |
| Hayton, K | 1 |
| Su, XZ | 1 |
| Guyatt, HL | 1 |
| Noor, AM | 1 |
| Ochola, SA | 1 |
| Dhar, R | 1 |
| Ventura-Ayala, ML | 1 |
| Licona-Chávez, RN | 1 |
| Soto-Cruz, I | 1 |
| Hernández-Clemente, FF | 1 |
| Majori, G | 1 |
| Omari, A | 1 |
| de Roode, JC | 1 |
| Culleton, R | 2 |
| Challis, K | 1 |
| Osman, NB | 1 |
| Cotiro, M | 1 |
| Nordahl, G | 1 |
| Dgedge, M | 3 |
| Bergström, S | 1 |
| Kodio, M | 2 |
| Coulibaly, D | 2 |
| Keita, AS | 2 |
| Maiga, B | 2 |
| Mungai, M | 2 |
| Carter, R | 3 |
| Pitmang, SL | 1 |
| Madaki, JK | 1 |
| Egah, DZ | 1 |
| Baird, JK | 3 |
| Walliker, D | 5 |
| Babiker, H | 1 |
| Madji, N | 1 |
| Djalle, D | 1 |
| Koula, MR | 1 |
| Talarmin, A | 1 |
| Ibeh, CC | 1 |
| Ekejindu, IM | 1 |
| Ibeh, NC | 1 |
| Shu, EN | 1 |
| Chukwuka, JO | 1 |
| Banek, K | 1 |
| Bakyaita, N | 1 |
| Kilian, A | 1 |
| Reingold, A | 1 |
| Wabwire-Mangen, F | 1 |
| Mubyazi, G | 1 |
| Kamugisha, M | 1 |
| Kitua, A | 1 |
| Ijumba, J | 1 |
| Smego, RA | 1 |
| Neema, S | 1 |
| Carmona, J | 1 |
| Pabón, A | 1 |
| Márquez, D | 1 |
| López, C | 1 |
| Morales, G | 1 |
| Blair, S | 1 |
| Holtz, T | 1 |
| Kaimila, N | 1 |
| Bloland, P | 1 |
| Kublin, J | 1 |
| Amponsa-Achiano, K | 1 |
| Mensah, N | 1 |
| Jaffar, S | 1 |
| Baiden, R | 1 |
| Zurovac, D | 1 |
| Ndhlovu, M | 1 |
| Rowe, AK | 1 |
| Hamer, DH | 3 |
| Thea, DM | 3 |
| McIntosh, HM | 3 |
| Jones, KL | 1 |
| Omari, AA | 1 |
| Breman, JG | 3 |
| Alker, AP | 1 |
| Vogel, G | 2 |
| Nsimba, SE | 1 |
| Foote, SJ | 1 |
| Iraqi, F | 1 |
| Kemp, SJ | 1 |
| Jongco, AM | 1 |
| Ting, LM | 1 |
| Thathy, V | 2 |
| Kim, K | 1 |
| Nyarango, PM | 1 |
| Gebremeskel, T | 1 |
| Mebrahtu, G | 1 |
| Mufunda, J | 1 |
| Abdulmumini, U | 1 |
| Ogbamariam, A | 1 |
| Kosia, A | 1 |
| Gebremichael, A | 1 |
| Gunawardena, D | 1 |
| Ghebrat, Y | 1 |
| Okbaldet, Y | 1 |
| Schellenberg, DM | 1 |
| Boctor, F | 1 |
| Gimnig, JE | 1 |
| M'bang'ombe, M | 1 |
| Kramer, MH | 1 |
| Stern, RS | 1 |
| Campbell, CH | 2 |
| Kolaczinski, JH | 1 |
| Ojok, N | 1 |
| Opwonya, J | 1 |
| Meek, S | 2 |
| Collins, A | 1 |
| Sabarinath, S | 1 |
| Singh, RP | 1 |
| Gupta, RC | 1 |
| Dieng, Y | 2 |
| Capuano, F | 1 |
| Dieme, JL | 1 |
| Semrau, K | 1 |
| Kuhn, L | 1 |
| Kasonde, P | 1 |
| Sinkala, M | 1 |
| Kankasa, C | 1 |
| Shutes, E | 1 |
| Vwalika, C | 1 |
| Ghosh, M | 1 |
| Aldrovandi, G | 1 |
| Cotte, AH | 1 |
| Konaté, A | 1 |
| Moran, AC | 1 |
| Asamoa, K | 1 |
| Bougouma, EC | 2 |
| Pinoges, L | 1 |
| Checchi, F | 1 |
| Balkan, S | 1 |
| van Herp, M | 1 |
| Legros, D | 1 |
| Swarthout, TD | 1 |
| van den Broek, IV | 1 |
| Kayembe, G | 1 |
| Pota, H | 1 |
| Kim, M | 1 |
| Ono, T | 1 |
| Tadakuma, T | 1 |
| Rodriguez, A | 1 |
| Snyder, C | 1 |
| Chollet, J | 1 |
| Santo-Tomas, J | 1 |
| Scheurer, C | 1 |
| Nakazibwe, C | 1 |
| Alam, MT | 1 |
| Bora, H | 1 |
| Bharti, PK | 1 |
| Saifi, MA | 1 |
| Das, B | 1 |
| Sharma, YD | 1 |
| Ramos-Avila, A | 1 |
| Zentella-Dehesa, A | 1 |
| Machuca-Rodríguez, C | 1 |
| Moreno-Altamirano, MM | 1 |
| Källander, K | 1 |
| Peterson, S | 2 |
| Pariyo, G | 2 |
| Tomson, G | 2 |
| Stevens, W | 1 |
| Bygbjerg, IB | 1 |
| Falade, CO | 1 |
| Yusuf, BO | 1 |
| Fadero, FF | 1 |
| Salako, LA | 4 |
| Kindermans, JM | 1 |
| Vandenbergh, D | 1 |
| Vreeke, E | 1 |
| D'Altilia, JP | 1 |
| Mukhtar, EA | 1 |
| Gadalla, NB | 1 |
| El-Zaki, SE | 1 |
| Mukhtar, I | 1 |
| Mansour, FA | 1 |
| Babiker, A | 1 |
| El-Sayed, BB | 1 |
| Roepcke, F | 1 |
| Saad, E | 1 |
| Dzisi, SY | 1 |
| Frempong, M | 1 |
| Agana-Nsiire, P | 1 |
| Amoo-Sakyi, F | 1 |
| Otchwemah, R | 1 |
| Cramer, JP | 1 |
| Anemana, SD | 1 |
| Launiala, A | 1 |
| Honkasalo, ML | 1 |
| Sharma, VP | 4 |
| Mehta, U | 1 |
| Durrheim, D | 1 |
| Mabuza, A | 1 |
| Blumberg, L | 1 |
| Allen, E | 1 |
| Aide, P | 1 |
| Tarimo, DS | 2 |
| Malekela, DA | 1 |
| Green, MD | 1 |
| van Ter Kuile, FO | 1 |
| Nettey, H | 1 |
| Shekalaghe, S | 1 |
| Ndaro, A | 1 |
| van Meegeren, M | 1 |
| Enevold, A | 1 |
| Nsungwa-Sabiiti, J | 1 |
| Ogwal-Okeng, J | 1 |
| Petzold, MG | 1 |
| van Oosterhout, JJ | 1 |
| Hsi, T | 1 |
| Beraho, L | 1 |
| Graham, SM | 1 |
| Gill, CJ | 1 |
| Macleod, WB | 1 |
| Mwanakasale, V | 1 |
| Chalwe, V | 1 |
| Mwananyanda, L | 1 |
| Champo, D | 1 |
| Mukwamataba, D | 1 |
| Chilengi, R | 1 |
| Correia, MA | 1 |
| Rojas, AJ | 1 |
| Gimbel-Sherr, KH | 1 |
| Stubbs, BA | 1 |
| Mercer, MA | 1 |
| Gloyd, S | 1 |
| Nzayirambaho, M | 1 |
| Freund, RJ | 1 |
| Lombrail, P | 1 |
| Potel, G | 1 |
| Tarimo, SD | 1 |
| Lesaffre, E | 1 |
| Penali, LK | 1 |
| Zattera, MJ | 1 |
| Die-Kakou, H | 1 |
| Bissagnene, E | 1 |
| Bâ, el H | 1 |
| Hallett, R | 1 |
| Targett, G | 1 |
| Lines, J | 1 |
| Lugimbana, L | 1 |
| Malebo, HM | 1 |
| Segeja, MD | 1 |
| Akida, JA | 1 |
| Malle, LN | 1 |
| Zijlstra, EE | 1 |
| Asa, OO | 1 |
| Onayade, AA | 1 |
| Fatusi, AO | 1 |
| Ijadunola, KT | 1 |
| Abiona, TC | 1 |
| Stepniewska, K | 1 |
| Bousema, JT | 1 |
| Arens, T | 1 |
| Houben, R | 1 |
| Gouagna, LC | 1 |
| Schallig, H | 1 |
| Sauerwein, RW | 1 |
| Schultz Hansen, K | 1 |
| Ghani, AC | 1 |
| Deen, JL | 1 |
| Romagosa, C | 1 |
| Serra-Casas, E | 1 |
| Berenguera, A | 1 |
| David, C | 1 |
| Dobaño, C | 1 |
| Naniche, D | 1 |
| Mandomando, I | 1 |
| Ajuonuma, BC | 1 |
| Ajuonuma, MU | 1 |
| Uzo-Ngerem, A | 1 |
| Ajuonuma, MK | 1 |
| Ajuonuma, FO | 1 |
| Chukwu, CL | 1 |
| Ajonuma, LC | 1 |
| Sheehy, TW | 3 |
| Reba, RC | 2 |
| Peters, W | 19 |
| Most, H | 3 |
| Herman, R | 1 |
| Schoenfeld, C | 2 |
| Bartelloni, PJ | 2 |
| Tigertt, WD | 2 |
| Stürchler, D | 4 |
| Holzer, B | 1 |
| Bonmarchand, M | 1 |
| Darlow, B | 6 |
| Vrbova, H | 5 |
| Stace, J | 5 |
| Heywood, P | 1 |
| Aalpers, M | 1 |
| Hurwitz, ES | 1 |
| Johnson, D | 1 |
| Campbell, CC | 8 |
| Reacher, M | 1 |
| Freeman, J | 1 |
| Doberstyn, EB | 11 |
| Brandling-Bennett, AD | 3 |
| Nguyen-Dinh, P | 6 |
| Spencer, HC | 5 |
| Chemangey-Masaba, S | 1 |
| Churchill, FC | 2 |
| Lelijveld, J | 1 |
| Olsen, VV | 2 |
| Loft, S | 1 |
| Christensen, KD | 1 |
| Eichenlaub, D | 4 |
| Rogler, G | 4 |
| Hoffmann, HG | 2 |
| Weise, HJ | 3 |
| Whitfield, D | 1 |
| Roth, B | 1 |
| Cheng, CC | 1 |
| Harpey, JP | 2 |
| Darbois, Y | 1 |
| Lefèbvre, G | 1 |
| Sixsmith, DG | 3 |
| Boriga, DA | 1 |
| Kariuki, DM | 1 |
| Kipingor, T | 1 |
| Koech, DK | 4 |
| Li, GQ | 2 |
| Arnold, K | 3 |
| Guo, XB | 2 |
| Jian, HX | 1 |
| Fu, LC | 2 |
| Stemberger, H | 3 |
| Leimer, R | 6 |
| Wiedermann, G | 4 |
| Knowles, G | 1 |
| Gilbreath, MJ | 1 |
| Groves, J | 1 |
| Pavanand, K | 1 |
| Phisphumvithi, P | 1 |
| Steinkampf, RW | 1 |
| Tin, F | 5 |
| Kroeger, A | 1 |
| Diesfeld, HJ | 1 |
| Hess, U | 1 |
| Timmermans, PM | 1 |
| Jones, M | 1 |
| Merkli, B | 1 |
| Richle, R | 1 |
| Main, EK | 1 |
| Main, DM | 1 |
| Vestergaard Olsen, V | 1 |
| Ponnampalan, JT | 1 |
| Frank, HA | 1 |
| Oostburg, BF | 1 |
| Jozefzoon, LM | 1 |
| de Souza, JM | 5 |
| von Sonnenburg, F | 1 |
| Prüfer, L | 1 |
| Ferraroni, JJ | 6 |
| Chongsuphajaisiddhi, T | 7 |
| Sabchareon, A | 3 |
| Attanath, P | 2 |
| Overbosch, D | 2 |
| van den Wall Bake, AW | 1 |
| Stuiver, PC | 2 |
| Tan-ariya, P | 1 |
| Brockelman, C | 1 |
| Kroll, MH | 1 |
| Burger, W | 1 |
| Weber, B | 1 |
| Blumenfeld, AM | 1 |
| Sieling, WL | 1 |
| Davidson, A | 1 |
| Isaäcson, M | 1 |
| Schapira, A | 5 |
| Juma, FD | 1 |
| Genaro, O | 1 |
| Turner, GD | 1 |
| Chulay, JD | 1 |
| Zevallos-Ipenza, A | 2 |
| Magloire, R | 1 |
| Tan, HS | 1 |
| Tan, PE | 1 |
| Corachán, M | 1 |
| Cerralbo, M | 1 |
| Rossan, RN | 4 |
| Ittiravivongs, A | 1 |
| Vasuvat, C | 1 |
| Kongrod, S | 1 |
| Robinson, BL | 2 |
| Wismans, PJ | 1 |
| Charmot, G | 4 |
| Herzog, C | 1 |
| Kibbler, CC | 1 |
| Ellis, CJ | 1 |
| Mtawali, CV | 1 |
| Kihamia, CM | 2 |
| Eyre, SJ | 1 |
| Svanbom, M | 1 |
| Rombo, L | 6 |
| Gustafsson, L | 1 |
| Kofoed, PE | 1 |
| Phillips, RE | 2 |
| Pradhan, VR | 1 |
| Renapurkar, DM | 1 |
| Chaicumpa, W | 1 |
| Roca, RV | 1 |
| Atthasishtha, N | 1 |
| Gelfand, M | 1 |
| Froese, EH | 1 |
| Speer, CA | 2 |
| Johnson, DE | 1 |
| Roendej, P | 1 |
| Williams, RG | 2 |
| Melo, JE | 2 |
| Dixon, KE | 1 |
| Pongsupat, T | 1 |
| Pitaktong, U | 1 |
| De Geus, A | 1 |
| van Rijn, A | 1 |
| Vleugels, MP | 1 |
| Wetsteyn, JC | 2 |
| Lambros, C | 1 |
| Childs, GE | 1 |
| Notsch, JD | 1 |
| Scovill, JP | 1 |
| Klayman, DL | 1 |
| Davidson, DE | 2 |
| Lamont, G | 3 |
| Alencar, FH | 1 |
| Shrimpton, R | 1 |
| LaBraico, JM | 1 |
| Thomson, NP | 1 |
| Bell, D | 1 |
| Pohle, HD | 2 |
| Brohult, J | 3 |
| Sirleaf, V | 1 |
| Willcox, M | 3 |
| Bengtsson, E | 3 |
| Pearlman, EJ | 7 |
| Sudsok, S | 1 |
| Thiemanun, W | 4 |
| Kennedy, RS | 2 |
| Wolff, JA | 1 |
| Smith, RP | 1 |
| Payne, D | 2 |
| Cooke, RA | 1 |
| Shannon, J | 1 |
| Chen, P | 1 |
| Elliott, T | 1 |
| Kidson, C | 1 |
| Brown, G | 1 |
| Mitchell, G | 1 |
| Alpers, M | 3 |
| Youngchaiyudha, S | 1 |
| Rungpitarangsri, V | 1 |
| Trishnananda, M | 1 |
| Ruksakul, T | 1 |
| Charnond, L | 1 |
| Boonamrung, S | 1 |
| Barkakaty, BN | 3 |
| Rao, CV | 1 |
| Ghosh, RB | 1 |
| Kapoor, AL | 1 |
| Roy, RG | 3 |
| Pattanayak, S | 3 |
| Wery, M | 2 |
| Coosemans, M | 1 |
| Pribadi, W | 1 |
| Dakung, LS | 1 |
| Gandahusada, S | 1 |
| Rubis, C | 1 |
| Wilson, M | 1 |
| Cooke, R | 1 |
| Puri, SK | 3 |
| Dutta, GP | 1 |
| Beale, GH | 2 |
| Dournon, E | 1 |
| Le Bras, J | 4 |
| Frottier, J | 1 |
| Bastin, R | 1 |
| Howells, RE | 4 |
| Judge, BM | 2 |
| Graham, NB | 1 |
| McNeill, ME | 1 |
| Naparstek, Y | 1 |
| Weiler-Ravell, D | 1 |
| Shemer, J | 1 |
| Englehard, D | 1 |
| Sack, J | 2 |
| Spira, DT | 1 |
| Adler, J | 1 |
| Black, F | 1 |
| Bygbjerg, I | 1 |
| Effersøe, P | 1 |
| Gomme, G | 1 |
| Jepsen, S | 3 |
| Jensen, GA | 1 |
| Olatunde, A | 1 |
| Walker, O | 1 |
| Gibney, S | 2 |
| Jolley, D | 2 |
| Gordon-Smith, EC | 1 |
| Thommen-Scott, K | 1 |
| Sinclair, N | 1 |
| Sharp, P | 1 |
| Davis, S | 1 |
| Knight, DJ | 1 |
| Williamson, P | 1 |
| Nieuwveld, RW | 1 |
| Halkett, JA | 1 |
| Markwalder, KA | 1 |
| Meyer, HE | 1 |
| Sweeney, TR | 1 |
| Smalley, ME | 1 |
| Brown, J | 1 |
| Schwartz, IK | 1 |
| Feberwee, JD | 1 |
| Lang, W | 1 |
| Padelt, H | 1 |
| Hölzer, E | 1 |
| Boreham, PF | 1 |
| Lenahan, JK | 1 |
| Port, GR | 1 |
| Wickramasinghe, SN | 1 |
| Litwinczuk, RA | 1 |
| Khoo, KK | 1 |
| Cai, XZ | 6 |
| Ibeziako, PA | 2 |
| Williams, AI | 2 |
| Reeve, PA | 1 |
| Caillard, V | 1 |
| Beauté-Lafitte, A | 1 |
| Chabaud, A | 1 |
| Ginsburg, H | 1 |
| Landau, I | 2 |
| Mnyika, KS | 1 |
| Killewo, JZ | 1 |
| Kabalimu, TK | 1 |
| Ngou-Milama, E | 1 |
| Duong, TH | 1 |
| Ozouaki, P | 1 |
| Igwangou, P | 1 |
| Oyediran, AB | 1 |
| Topley, E | 2 |
| Osunkoya, BO | 1 |
| Bamgboye, A | 1 |
| Ogunba, EO | 1 |
| Asuzu, MC | 1 |
| Tipple, M | 1 |
| Keane, V | 1 |
| McCance, C | 1 |
| Edwards, G | 1 |
| Saul, A | 1 |
| Shinondo, CJ | 1 |
| Lanners, HN | 1 |
| Lowrie, RC | 1 |
| Wiser, MF | 1 |
| Bálint, GS | 1 |
| Pridgeon, JM | 1 |
| Mittelholzer, ML | 2 |
| Kerr, L | 2 |
| Schubarth, P | 1 |
| Berger, BJ | 1 |
| Paciorkowski, A | 1 |
| Suskin, M | 1 |
| Dai, WW | 1 |
| Cerami, A | 1 |
| Ulrich, P | 1 |
| Agrawal, A | 2 |
| Tripathi, LM | 3 |
| Pandey, VC | 4 |
| Gunasekera, DP | 1 |
| Perera, DP | 1 |
| Ménard, R | 1 |
| Janse, C | 1 |
| Langhorne, J | 1 |
| Cross, C | 1 |
| Seixas, E | 1 |
| von der Weid, T | 1 |
| Agarwal, A | 1 |
| Hogh, B | 2 |
| Gamage-Mendis, A | 1 |
| Butcher, GA | 1 |
| Thompson, R | 1 |
| Begtrup, K | 1 |
| Mendis, C | 1 |
| Barreto, J | 1 |
| Eling, W | 1 |
| Uche-Nwachi, EO | 1 |
| Warren, M | 2 |
| de Górgolas Hernández-Mora, M | 1 |
| Blanco García, A | 1 |
| Martín Torres, MP | 1 |
| Fernández Guerrero, ML | 1 |
| Wellems, TE | 3 |
| Steffen, R | 4 |
| Vanhauwere, B | 1 |
| Schildknecht, J | 1 |
| Fuchs, E | 1 |
| Edwards, R | 1 |
| Davis, TM | 1 |
| Mar, M | 1 |
| Diop, M | 1 |
| Bah, IB | 1 |
| Dieng, T | 1 |
| N'Dir, O | 1 |
| Diallo, S | 2 |
| Schultz, LJ | 1 |
| Misore, A | 1 |
| Muga, R | 1 |
| Bourgeade, A | 1 |
| Delmont, J | 2 |
| Griffin, JP | 1 |
| Buckling, A | 1 |
| Crooks, L | 1 |
| Read, A | 1 |
| Kocken, CH | 1 |
| van der Wel, A | 1 |
| Thomas, AW | 1 |
| Williams, HA | 1 |
| Nalwamba, NC | 1 |
| Hightower, A | 1 |
| Simoonga, C | 1 |
| Mphande, PC | 1 |
| Shulman, CE | 1 |
| Mengesha, T | 1 |
| Makonnen, E | 1 |
| Feikin, DR | 1 |
| Dowell, SF | 1 |
| Nwanyanwu, OC | 1 |
| Klugman, KP | 1 |
| Barat, LM | 1 |
| Graf, C | 1 |
| Ziba, C | 1 |
| Huebner, RE | 1 |
| Schwartz, B | 1 |
| Srivastava, P | 1 |
| Baume, C | 1 |
| Helitzer, D | 1 |
| Ettling, M | 1 |
| Nahlen, B | 1 |
| Nussenzweig, RS | 1 |
| Nussenzweig, V | 1 |
| Santos-Filho, OA | 1 |
| de Alencastro, RB | 1 |
| Figueroa-Villar, JD | 1 |
| Otoguro, K | 1 |
| Kohana, A | 1 |
| Manabe, C | 1 |
| Ishiyama, A | 1 |
| Ui, H | 1 |
| Shiomi, K | 1 |
| Yamada, H | 1 |
| Omura, S | 1 |
| Nicolas, X | 1 |
| Granier, H | 1 |
| Laborde, JP | 1 |
| Martin, J | 1 |
| Talarmin, F | 1 |
| Okafor, HU | 1 |
| Nwaiwu, O | 1 |
| Minjas, JN | 1 |
| Goodman, CA | 1 |
| Coleman, PG | 1 |
| Mills, AJ | 1 |
| Wendo, C | 1 |
| Ogunbode, O | 2 |
| Oluboyede, O | 1 |
| Ayeni, O | 1 |
| Esan, GJ | 1 |
| Golenser, J | 2 |
| Verhave, JP | 1 |
| Kan, SC | 1 |
| Siddiqui, WA | 1 |
| Ansdell, VE | 1 |
| Wright, SG | 1 |
| Hutchinson, DB | 1 |
| Rosario, VE | 1 |
| Hall, R | 1 |
| Rumans, LW | 1 |
| Dennis, DT | 1 |
| Atmosoedjono, S | 1 |
| Crosby, R | 2 |
| Rasco, J | 1 |
| Vaughan, D | 2 |
| Ebizawa, I | 1 |
| Everett, WD | 1 |
| Htun Nyun, R | 1 |
| Hlaing, N | 3 |
| U, T | 1 |
| Myint, T | 1 |
| Kyi, KK | 1 |
| Hall, AP | 12 |
| Karnchanachetanee, C | 1 |
| Samransamruajkit, S | 1 |
| Laixuthai, B | 2 |
| Lampe, RM | 2 |
| Miller, CF | 1 |
| Duursma, SA | 1 |
| Ugarte, G | 1 |
| Apt, W | 1 |
| Faiguenbaum, J | 1 |
| Portus, J | 1 |
| Williams, RL | 3 |
| Trenholme, GM | 3 |
| Carson, PE | 5 |
| Frischer, H | 5 |
| Maier, W | 1 |
| Piekarski, G | 1 |
| Black, RH | 1 |
| Cowie, RL | 1 |
| Tawil, NA | 1 |
| Noeypatimanondh, S | 2 |
| Teerakiartkamjorn, C | 2 |
| Andre, RG | 1 |
| Bentley, SJ | 1 |
| Kingston, D | 1 |
| Subchareon, A | 1 |
| Puangpartk, S | 1 |
| Harinasuta, T | 5 |
| Hayes, J | 1 |
| Eke, RA | 1 |
| Copper, JR | 1 |
| Ebisawa, I | 8 |
| Muto, T | 6 |
| Tanabe, S | 1 |
| Phukan, D | 1 |
| Barkakuty, BN | 1 |
| Sen, N | 1 |
| Harrison, J | 3 |
| Fernex, M | 4 |
| Amin, NM | 1 |
| Várnai, F | 2 |
| Ecker, A | 1 |
| Vetvutanapibul, K | 1 |
| Sonkon, P | 1 |
| McCarthy, VC | 9 |
| Miller, RM | 6 |
| Hornick, RB | 3 |
| Jadin, J | 1 |
| Timperman, G | 1 |
| De Ruysser, F | 1 |
| Seow, CL | 1 |
| Roy, OS | 1 |
| Baerg, DC | 1 |
| Johnsen, DO | 1 |
| Tanticharoenyos, P | 1 |
| Hickman, RL | 1 |
| Kinnamon, KE | 1 |
| Yoeli, M | 4 |
| Bergson, V | 1 |
| Ferenc, V | 1 |
| Agnes, E | 1 |
| Coulibaly, A | 1 |
| Lewis, AN | 2 |
| Mettaprakong, V | 1 |
| Sonkom, P | 1 |
| Ryan, BP | 1 |
| Segal, HE | 2 |
| Chinvanthananond, P | 1 |
| Na-Nakorn, A | 1 |
| Castaneda, BF | 3 |
| Fukuyama, T | 1 |
| du Preez, O | 1 |
| Cockcroft, CR | 1 |
| Harland, PS | 1 |
| Frood, JD | 1 |
| Parkin, JM | 1 |
| Shafei, AZ | 1 |
| Gon, F | 1 |
| Reid, FP | 1 |
| Peck, CC | 1 |
| Joyce, BE | 1 |
| Weber, MC | 1 |
| de Clarke, V | 1 |
| Harwin, RM | 2 |
| Shiff, CJ | 1 |
| Niang, I | 1 |
| Senghor, AS | 1 |
| Sanokho, A | 1 |
| Sanderson, A | 1 |
| Hargreaves, BJ | 1 |
| Weinke, T | 3 |
| Held, T | 1 |
| Trautmann, M | 2 |
| Mravak, S | 2 |
| Alexander, M | 1 |
| Okuonghae, HO | 1 |
| Nwankwo, MU | 1 |
| Offor, E | 1 |
| Webster, HK | 1 |
| Edstein, M | 1 |
| Phaipun, L | 1 |
| Thew, KL | 1 |
| Watt, G | 2 |
| Shanks, GD | 2 |
| Msuya, FH | 1 |
| Curtis, CF | 1 |
| Hioki, A | 2 |
| Ohtomo, H | 2 |
| Freese, JA | 1 |
| Markus, MB | 1 |
| Carme, B | 2 |
| Basri, H | 1 |
| Jones, TR | 2 |
| Bangs, MJ | 1 |
| Ritonga, A | 1 |
| Botella de Maglia, J | 1 |
| Valls Ferrer, JM | 1 |
| Martínez Paz, ML | 1 |
| Espacio Casanovas, A | 1 |
| Shao, BR | 4 |
| Huang, ZS | 3 |
| Shi, XH | 4 |
| Meng, F | 3 |
| Boudreau, EF | 1 |
| Pang, LW | 1 |
| Chaikummao, S | 1 |
| Witayarut, C | 1 |
| Nevill, CG | 2 |
| Gozal, D | 1 |
| Hengy, C | 2 |
| Holdener, F | 1 |
| Wyss, R | 1 |
| Nurminen, L | 1 |
| Masbar, S | 1 |
| Ratiwayanto, S | 1 |
| Leksana, B | 1 |
| Gardner, A | 1 |
| Ezedinachi, EN | 2 |
| Ejezie, GC | 1 |
| Emeribe, AO | 1 |
| Prasad, RN | 1 |
| Prasad, H | 1 |
| Virk, KJ | 1 |
| Thimasarn, K | 1 |
| Pinichpongse, S | 1 |
| Malikul, S | 1 |
| Rooney, W | 2 |
| Tansophalaks, S | 1 |
| Hanson, AP | 1 |
| Flacks, H | 1 |
| Fujioka, H | 1 |
| Fujita, M | 1 |
| Fujimura, K | 1 |
| Nishiyama, Y | 1 |
| Sánchez-Porto, A | 1 |
| Regordan, C | 1 |
| Domínguez-Corrales, MV | 1 |
| Chakravorty, NK | 2 |
| Narasimham, MV | 1 |
| Weber, G | 1 |
| Schultes, U | 1 |
| Hopfenmüller, W | 1 |
| Janitschke, K | 1 |
| Peterson, DS | 1 |
| Milhous, WK | 2 |
| Malin, AS | 1 |
| Eberlé, F | 1 |
| Gazin, P | 1 |
| Kouka-Bemba, D | 1 |
| Gelas, H | 1 |
| Jambou, R | 1 |
| Mjönes, S | 1 |
| Usanga, EA | 1 |
| Gemade, EI | 1 |
| Ikpatt, NW | 1 |
| Alaribe, AA | 1 |
| Wernsdorfer, WH | 5 |
| Ericsson, O | 1 |
| Ye, XY | 3 |
| Keuter, M | 1 |
| van Eijk, A | 1 |
| Hoogstrate, M | 1 |
| Raasveld, M | 1 |
| van de Ree, M | 1 |
| Ngwawe, WA | 1 |
| Were, JB | 1 |
| Moudzeo, H | 1 |
| Mbitsi, A | 1 |
| Sathounkazi, C | 1 |
| Ndounga, M | 1 |
| Brandicourt, O | 2 |
| Gay, F | 1 |
| Karbwang, J | 3 |
| Cowman, AF | 1 |
| Lew, AM | 1 |
| Takada, S | 1 |
| Dinis, DV | 1 |
| Back, DJ | 2 |
| Bunnag, D | 3 |
| Breckenridge, AM | 1 |
| Franklin, RM | 1 |
| Grieder, A | 1 |
| Obana, M | 1 |
| Yamakawa, H | 1 |
| Matsuoka, Y | 1 |
| Waki, S | 1 |
| Suzuki, M | 1 |
| Behrens, RH | 1 |
| Dunlop, J | 1 |
| Akintunde, A | 2 |
| Alakija, T | 1 |
| Edungbola, LD | 1 |
| Adetoro, O | 1 |
| Zain, RB | 1 |
| Doi, H | 1 |
| Panjaitan, W | 2 |
| Ishii, A | 3 |
| Kiatfuengfoo, R | 1 |
| Suthiphongchai, T | 1 |
| Prapunwattana, P | 1 |
| Hüther, AM | 1 |
| Sauer, A | 1 |
| Parnham, MJ | 1 |
| Mbudi, PK | 1 |
| Pela, NN | 1 |
| Kalonji, MW | 1 |
| Disu, MM | 1 |
| Zumla, A | 1 |
| Laurenson, I | 1 |
| Randriamanjaka, JR | 1 |
| Coulaud, JP | 2 |
| Prociv, P | 1 |
| Shukla, MM | 1 |
| Saxena, BN | 1 |
| Rastogi, M | 1 |
| Pal, NL | 1 |
| Sen, AB | 1 |
| Hansford, CF | 1 |
| Zhan, CQ | 1 |
| Ha, SH | 1 |
| Belec, L | 1 |
| Bouree, P | 1 |
| Quenum, B | 1 |
| Georges, AJ | 1 |
| Kamei, K | 1 |
| Suzuki, T | 1 |
| Siagian, R | 1 |
| Daniel, PT | 1 |
| Holzschuh, J | 1 |
| Berg, PA | 1 |
| Ndumbe, PM | 1 |
| Fadeke Aderounmu, A | 1 |
| Laoye, AJ | 1 |
| Modupe Makinde, J | 1 |
| Aina Adio, R | 1 |
| Peto, TE | 1 |
| Newbold, CI | 1 |
| Pasvol, G | 1 |
| Lasserre, R | 3 |
| Vinijanont, S | 1 |
| Tjokrosonto, S | 1 |
| Win, K | 2 |
| Thwe, Y | 1 |
| Lwin, TT | 1 |
| Hoffman, SL | 2 |
| Rustama, D | 2 |
| Dimpudus, AJ | 2 |
| Punjabi, NH | 1 |
| Campbell, JR | 1 |
| Oetomo, HS | 1 |
| Marwoto, HA | 1 |
| Harun, S | 1 |
| Sukri, N | 1 |
| Heizmann, P | 2 |
| Stenbeck, J | 2 |
| Lobel, HO | 4 |
| Papaioanou, M | 1 |
| Miller, KD | 4 |
| Reber-Liske, R | 1 |
| Stohler, H | 1 |
| Taylor, P | 1 |
| Mutambu, SL | 2 |
| Sarikabhuti, B | 2 |
| Keschamrus, N | 2 |
| Noeypatimanond, S | 2 |
| Weidekamm, E | 1 |
| Wernsdorfer, W | 1 |
| Kölle, EU | 1 |
| Kollaritsch, H | 1 |
| Mailer, H | 1 |
| Kollaritsch, R | 1 |
| Ortel, B | 1 |
| Sivayathorn, A | 1 |
| Hönigsmann, H | 1 |
| Tun, T | 1 |
| Win, S | 2 |
| Langtry, JA | 1 |
| Harper, JI | 1 |
| Staughton, RC | 1 |
| Barrington, P | 1 |
| Heusser, R | 1 |
| Satriale, RF | 1 |
| Kuritsky, JN | 2 |
| Stern, R | 1 |
| Zitelli, BJ | 1 |
| Alexander, J | 1 |
| Howrie, DL | 1 |
| Perez, TH | 1 |
| Van Thiel, DH | 1 |
| Hellgren, U | 1 |
| Berg, B | 1 |
| Carlson, J | 1 |
| Wiholm, BE | 1 |
| Huang, OL | 1 |
| Ouyang, WC | 1 |
| Zhou, JX | 2 |
| Wu, Z | 2 |
| Zhang, KY | 2 |
| Huang, JK | 2 |
| Pang, XJ | 2 |
| Fu, SG | 3 |
| Wang, XF | 1 |
| Draper, CC | 1 |
| Hills, M | 1 |
| Kilimali, VA | 2 |
| Brubaker, G | 1 |
| Raeber, PA | 1 |
| Ruedi, B | 1 |
| Golinski, M | 1 |
| Birk, O | 1 |
| Zotter, GM | 1 |
| Feldmeier, H | 1 |
| Graninger, W | 1 |
| Rocha, RM | 1 |
| Giboda, M | 2 |
| Vanista, J | 1 |
| Dastych, P | 1 |
| Kupferschmidt, HG | 2 |
| Schröder, K | 1 |
| Beltzner, B | 1 |
| Ellis-Pegler, RB | 2 |
| Beeching, NJ | 1 |
| Eales, M | 1 |
| Fraser, AG | 1 |
| Wells, AU | 1 |
| Viravan, C | 1 |
| Buranasin, P | 1 |
| Aderounmu, AF | 1 |
| Laoye, JO | 1 |
| Makinde, JM | 1 |
| Adio, RA | 1 |
| Zeng, LH | 1 |
| Guo, RN | 1 |
| Xing, QF | 1 |
| Liu, QJ | 1 |
| Chen, QY | 1 |
| Lin, KH | 1 |
| Ou, FZ | 1 |
| Liu, YP | 1 |
| Liu, XM | 1 |
| Liu, HH | 1 |
| Huang, QL | 1 |
| Quyang, WC | 1 |
| Pan, XJ | 1 |
| Huang, XF | 1 |
| Chen, PQ | 1 |
| Rolfe, M | 1 |
| Sharma, GK | 1 |
| Reyes, S | 1 |
| Osanai, CH | 1 |
| Passos, AD | 1 |
| Asthana, OP | 1 |
| Tangri, AN | 1 |
| Nityanand, S | 1 |
| Davis, RE | 1 |
| Kumagai, Y | 1 |
| Kushimoto, K | 1 |
| Sawae, Y | 1 |
| Aoki, T | 1 |
| Moriyasu, M | 1 |
| Goya, N | 1 |
| Kofi Ekue, JM | 1 |
| Phiri, DE | 2 |
| Mukunyandela, M | 2 |
| Sheth, UK | 7 |
| Gubler, J | 1 |
| Fogh, S | 1 |
| Mordhorst, CH | 1 |
| Kuijlen, K | 1 |
| Ravn, P | 1 |
| Rønn, A | 1 |
| Gøtzsche, PC | 1 |
| Selby, CD | 1 |
| Ladusans, EJ | 1 |
| Smith, PG | 1 |
| Robinson, MJ | 1 |
| Jiang, JB | 1 |
| Krotoski, WA | 3 |
| Canning, EU | 1 |
| Liang, DS | 1 |
| Huang, JC | 1 |
| Liao, JY | 1 |
| Li, DS | 1 |
| Lun, ZR | 1 |
| Krotowski, WA | 1 |
| Sexton, JD | 2 |
| Bugilimfura, L | 2 |
| Ntilivamunda, A | 1 |
| Neill, M | 1 |
| Sezibera, C | 1 |
| Onrumpun, P | 1 |
| Burchard, GD | 1 |
| Winkler, E | 1 |
| Schwalbach, JF | 1 |
| Quakyi, IA | 1 |
| McCutchan, TF | 1 |
| Szarfman, A | 1 |
| London, WT | 1 |
| Corcoran, LM | 1 |
| Burkot, TR | 1 |
| Isaacs, RD | 1 |
| Campbell, J | 1 |
| Surumpaet, B | 1 |
| Rusch, J | 1 |
| Marwoto, H | 1 |
| Mihaly, GW | 1 |
| Date, NM | 1 |
| Newman, KT | 1 |
| Smallwood, RA | 1 |
| Tanabe, K | 1 |
| Nakabayashi, T | 1 |
| Ishizaki, T | 1 |
| Rieckmann, K | 1 |
| Suebsaeng, L | 2 |
| Greenberg, AE | 1 |
| Kabote, N | 1 |
| Davachi, F | 1 |
| Goussard, B | 1 |
| Embonga, B | 1 |
| Trigg, PI | 2 |
| Vanijanond, S | 1 |
| Charoenlarp, P | 1 |
| Suntharasmai, P | 1 |
| Chitamas, S | 1 |
| Ekue, JM | 2 |
| Assefa, T | 1 |
| Myint, PT | 1 |
| Shwe, T | 1 |
| Padre, LP | 1 |
| Tuazon, LR | 1 |
| Laughlin, LW | 1 |
| Simon, F | 1 |
| Rosenheim, M | 2 |
| Druilhe, P | 1 |
| Datry, A | 1 |
| Brasseur, P | 1 |
| Brucker, G | 1 |
| Duflo, B | 1 |
| Delacollette, C | 1 |
| Cibanguka, J | 1 |
| Buregea, H | 1 |
| Nkera, J | 1 |
| Imvithaya, S | 1 |
| Vincenti, M | 1 |
| Delmas, G | 1 |
| Lebihan, G | 1 |
| Hausler, B | 1 |
| White, N | 1 |
| Choudhury, DS | 1 |
| Sinha, S | 1 |
| Ghosh, SK | 1 |
| Devi, CU | 1 |
| Coosemans, MH | 1 |
| Barutwanayo, M | 1 |
| Onori, E | 2 |
| Otoul, C | 1 |
| Gryseels, B | 1 |
| Heymann, DL | 1 |
| Khoromana, CO | 1 |
| Wirima, JJ | 1 |
| Lim, MA | 1 |
| Smith, AW | 1 |
| Eggelte, TA | 1 |
| Huikeshoven, H | 1 |
| de Wit, M | 1 |
| Targett, GA | 1 |
| Doenhoff, MJ | 1 |
| Strickland, GT | 4 |
| Khaliq, AA | 2 |
| Sarwar, M | 2 |
| Hassan, H | 1 |
| Pervez, M | 1 |
| Fox, E | 2 |
| Flachs, H | 1 |
| Bentzon, MW | 1 |
| Meek, SR | 1 |
| Gaüzère, BA | 1 |
| Thanapanich, C | 1 |
| Nordlander, E | 1 |
| Phuphaisan, S | 1 |
| Macdonald, M | 1 |
| Armstead, A | 1 |
| Banyal, HS | 1 |
| Inselburg, J | 1 |
| Brown, GV | 1 |
| Hedman, P | 2 |
| Potter, J | 1 |
| Edrissian, GH | 1 |
| Shahabi, S | 1 |
| Pishva, E | 1 |
| Hajseyed-Javadi, J | 1 |
| Khaleghian, B | 1 |
| Ghorbani, M | 1 |
| Emadi, AM | 1 |
| Afshar, A | 1 |
| Saghari, H | 1 |
| Verdrager, J | 4 |
| Pappaioanou, M | 1 |
| Patchen, LC | 2 |
| Pehrson, PO | 1 |
| Kollie, E | 1 |
| Alestig, K | 1 |
| Hanson, A | 1 |
| Watkins, WW | 1 |
| Dallas, AB | 1 |
| Okwanga, PN | 1 |
| Pfumojena, JW | 1 |
| Bhattacharya, DN | 1 |
| Ohara, H | 1 |
| Pearson, RD | 1 |
| Hewlett, EL | 1 |
| Somaini, B | 1 |
| McMeeking, AA | 1 |
| Chen, GX | 1 |
| Mueller, C | 1 |
| Wendlinger, M | 1 |
| Zolg, JW | 1 |
| Wattanagoon, Y | 1 |
| Nagachinta, B | 1 |
| Warrell, DA | 2 |
| Schär, M | 1 |
| Gyr, N | 1 |
| Bamber, MG | 1 |
| Elder, AT | 1 |
| Gray, JA | 1 |
| Minns, RA | 1 |
| Bánhegyi, D | 1 |
| Lindberg, A | 1 |
| Bergqvist, Y | 1 |
| Félix, H | 1 |
| Niklewski, G | 1 |
| Landscheidt, H | 1 |
| Glasner, H | 1 |
| Simooya, OO | 1 |
| Njelesani, EK | 1 |
| Espinal, CA | 1 |
| Cortes, GT | 1 |
| Guerra, P | 1 |
| Arias, AE | 1 |
| Wolfe, MS | 1 |
| Ainsworth, B | 1 |
| Teklehaimanot, A | 2 |
| Day, MM | 1 |
| Duverseau, YT | 1 |
| Kanjanapipatkul, K | 1 |
| de Oliveira, RM | 2 |
| Roulet, H | 1 |
| de Souza, SD | 1 |
| Gomes, AT | 1 |
| Cavalcante, EQ | 1 |
| Kissane, D | 1 |
| Yang, XP | 1 |
| He, XZ | 1 |
| Zhan, WC | 1 |
| Zhan, X | 1 |
| Ye, BS | 1 |
| Mkufya, AR | 1 |
| Botero, D | 1 |
| Restrepo, M | 1 |
| Montoya, A | 1 |
| Ahlqvist, J | 1 |
| Warhurst, D | 1 |
| Adams, SJ | 1 |
| Broadbent, J | 1 |
| Clayden, LM | 1 |
| Ridley, CM | 1 |
| Douer, D | 1 |
| Schwartz, E | 1 |
| Shaked, N | 1 |
| Ramot, B | 1 |
| Bent, NS | 1 |
| Hemmer, R | 1 |
| Bradley-Moore, AM | 1 |
| Attai, ED | 1 |
| Fleming, AF | 3 |
| Bartlett, A | 1 |
| Bidwell, DE | 1 |
| Kirkwood, BR | 1 |
| Schubert, S | 1 |
| Granz, W | 1 |
| Dickmeiss, H | 1 |
| Cowan, GO | 1 |
| Parry, ES | 1 |
| Matthews, JI | 1 |
| Molitor, JT | 1 |
| Hunt, KK | 1 |
| Rebert, CC | 1 |
| Wilson, RJ | 1 |
| Miller, MB | 1 |
| Bratton, JL | 1 |
| Hanson, JP | 1 |
| Cohen, M | 1 |
| Reynolds, RD | 1 |
| Lohr, DC | 1 |
| Hunt, J | 1 |
| Jilek, D | 1 |
| Glew, RH | 2 |
| Miller, LH | 2 |
| Howard, WA | 2 |
| Wyler, DJ | 1 |
| Chaves-Carballo, E | 1 |
| Neva, FA | 2 |
| Willerson, D | 1 |
| Kass, L | 1 |
| Richard, L | 1 |
| Bowman, JE | 1 |
| Diop Mar, I | 1 |
| Sow, A | 1 |
| Adner, MM | 1 |
| Altstatt, LB | 2 |
| Conrad, ME | 1 |
| Comer, RD | 1 |
| Johnson, CM | 2 |
| Babione, RW | 1 |
| Bolton, JM | 1 |
| DuPont, HL | 2 |
| Macmillan, AL | 1 |
| O'Holohan, DR | 2 |
| Dondero, TJ | 1 |
| Terzian, LA | 2 |
| Stahler, N | 2 |
| Dawkins, AT | 3 |
| Omar, MS | 1 |
| Nethercott, AS | 1 |
| Kamel, ZA | 1 |
| Payet, M | 1 |
| Pasticier, A | 1 |
| Saimot, G | 1 |
| Olatunde, IA | 1 |
| Kusnecov, R | 1 |
| Storey, J | 2 |
| Lietaert, P | 2 |
| Molina, JJ | 1 |
| Simpson, B | 1 |
| Jamieson, WS | 1 |
| Dimond, AH | 1 |
| Wolfensberger, HR | 2 |
| Colwell, EJ | 2 |
| Osnes, M | 1 |
| Chin, W | 5 |
| Bear, DM | 1 |
| Kosakal, S | 1 |
| MacLennan, R | 1 |
| Walsh, RJ | 1 |
| Rozman, RS | 1 |
| Oxbrow, AI | 1 |
| Gilman, RH | 1 |
| Ashton, WT | 1 |
| Hynes, JB | 1 |
| Intraprasert, R | 1 |
| Ames, CW | 1 |
| Holiday, J | 1 |
| Biggs, JC | 1 |
| Backhouse, TC | 1 |
| Rattanarithikul, M | 1 |
| Imperato, PJ | 1 |
| Shookhoff, HB | 1 |
| Harvey, RP | 1 |
| Woodward, WE | 1 |
| Briesch, PE | 1 |
| Morgan, S | 1 |
| Berberian, DA | 1 |
| Slighter, RG | 1 |
| Arnold, JD | 5 |
| Martin, DC | 5 |
| Komoriya, T | 1 |
| Kimura, M | 1 |
| Botelho, A | 1 |
| Rossi-Espagnet, A | 1 |
| Mandel, SP | 1 |
| Matsushima, T | 1 |
| Thomas, D | 1 |
| Brogger, S | 1 |
| Duby, C | 1 |
| Gramiccia, G | 1 |
| Entner, N | 1 |
| Botha, D | 1 |
| Gyr, K | 1 |
| Speck, B | 1 |
| Ritz, R | 1 |
| Cornu, P | 1 |
| Buckner, CD | 1 |
| Conno, L | 1 |
| Benazet, F | 1 |
| Godard, C | 1 |
| Jaroonvesama, N | 1 |
| Munangmanee, L | 1 |
| Harrison, KA | 1 |
| Heischkeil, R | 2 |
| Platzer, EG | 1 |
| Lamy, L | 1 |
| Riche, A | 2 |
| Chheang, CM | 1 |
| Hunter, GW | 1 |
| Batey, RL | 1 |
| Meleney, HE | 1 |
| Sanders, E | 1 |
| Reed, WP | 1 |
| Feinstein, M | 1 |
| Steiger, BW | 1 |
| Eichler, P | 1 |
| Barry, KG | 3 |
| Berman, SJ | 1 |
| Fredericks, HJ | 1 |
| Blount, RE | 4 |
| Walker, AJ | 1 |
| Lopez-Antunano, FJ | 1 |
| Donno, L | 4 |
| Ricciardi, ML | 2 |
| Soldati, M | 2 |
| Parks, GR | 1 |
| Sanguineti, V | 2 |
| Swisher, CN | 1 |
| Hunsicker, LG | 1 |
| Lucas, AO | 1 |
| Okubadejo, OA | 1 |
| Richards, WH | 2 |
| Neal, RA | 1 |
| Kofie, BA | 1 |
| Brooks, MH | 2 |
| Cirksena, WJ | 2 |
| Malloy, JP | 1 |
| Bruton, J | 1 |
| Gilliland, PF | 1 |
| Deaton, JG | 1 |
| Kameko, S | 2 |
| Mitsui, G | 3 |
| Tong, MJ | 1 |
| Votteri, BA | 1 |
| Gunning, JJ | 1 |
| Kostinas, JE | 1 |
| Huehne, WH | 2 |
| Sangalang, RP | 1 |
| Music, SI | 1 |
| Chow, EA | 1 |
| Catarinella, G | 1 |
| Fung, WP | 1 |
| Hugoe-Matthews, J | 1 |
| McNamara, JV | 2 |
| Stockert, TA | 1 |
| Pinder, RM | 1 |
| Ellison, R | 2 |
| Worcester, P | 2 |
| Hawkey, CM | 1 |
| Ridley, DS | 1 |
| Heiner, GG | 1 |
| Fink, E | 2 |
| Kretschmar, W | 1 |
| Rosowsky, A | 1 |
| Modest, EJ | 1 |
| Hitchings, GH | 1 |
| Keller, HI | 1 |
| Sasa, M | 1 |
| Chinzei, H | 1 |
| Oshima, S | 1 |
| Tanaka, H | 1 |
| Nogueira, RA | 2 |
| de Jesús, SP | 2 |
| Leitão, JM | 2 |
| McFarlane, H | 1 |
| Ojo, OA | 1 |
| Houba, JE | 1 |
| Akene, JS | 1 |
| Yang, TH | 1 |
| K'an, SN | 1 |
| Yang, SA | 1 |
| Chang, L | 1 |
| Huang, PP | 1 |
| King, HK | 1 |
| Brossi, A | 1 |
| Powers, KG | 1 |
| Good, WC | 1 |
| Koontz, LC | 1 |
| Diggens, SM | 4 |
| Ferone, R | 1 |
| O'Shea, M | 1 |
| Gutteridge, WE | 1 |
| Gregory, KG | 2 |
| Bennike, T | 1 |
| Scheepers-Biva, M | 1 |
| Bafort, J | 1 |
| Hendrickse, JP | 1 |
| Allan, NC | 1 |
| Reback, H | 1 |
| Moore, WL | 1 |
| Hedberg, CL | 1 |
| Sanford, J | 1 |
| Taylor, J | 1 |
| Schneider, MD | 1 |
| Beesley, WN | 1 |
| Drew, R | 1 |
| Upmanis, RS | 1 |
| Sullivan, LW | 1 |
| Gregory, K | 1 |
| Herbert, V | 1 |
| Waxman, S | 1 |
| Harling, DS | 1 |
| Jerusalem, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health[NCT00167843] | Phase 4 | 1,189 participants | Interventional | 2002-12-31 | Completed | ||
| Comparison of Two Strategies for Control of Malaria Within A Primary Health Care Programme in the Gambia[NCT00294580] | Phase 4 | 2,253 participants | Interventional | 1982-04-30 | Completed | ||
| A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi[NCT01443130] | Phase 3 | 900 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi[NCT03376217] | 1,447 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)[NCT03178643] | Phase 4 | 246 participants (Actual) | Interventional | 2018-01-23 | Completed | ||
| Prevention of Malaria in HIV-uninfected Pregnant Women and Infants[NCT02793622] | Phase 3 | 782 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia[NCT06166498] | Phase 3 | 600 participants (Anticipated) | Interventional | 2024-02-15 | Not yet recruiting | ||
| Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali[NCT01168271] | 15,000 participants (Anticipated) | Observational | 2010-08-30 | Recruiting | |||
| A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi[NCT03009526] | Phase 3 | 602 participants (Actual) | Interventional | 2017-01-17 | Completed | ||
| An Open-label Individually Randomised Controlled Trial to Assess the Efficacy of Artemether-lumefantrine Prophylaxis for Malaria Among Forest Goers in Cambodia[NCT04041973] | 1,480 participants (Actual) | Interventional | 2020-03-11 | Completed | |||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| A Trial of Intermittent Preventive Treatment With Sulfadoxine-pyrimethamine Versus Intermittent Screening and Treatment of Malaria in Pregnancy[NCT01084213] | Phase 4 | 5,354 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin[NCT00131235] | Phase 3 | 1,320 participants (Actual) | Interventional | 2003-12-31 | Active, not recruiting | ||
| Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy[NCT00811421] | 5,820 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients[NCT02524444] | Phase 1 | 142 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Community-based Scheduled Screening and Treatment of Malaria in Pregnancy for Improved Maternal and Infant Health: a Cluster-randomized Trial in The Gambia, Burkina Faso and Benin[NCT01941264] | 4,265 participants (Actual) | Interventional | 2013-10-31 | Completed | |||
| Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight[NCT04147546] | Phase 3 | 340 participants (Actual) | Interventional | 2020-08-31 | Completed | ||
| A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children[NCT02211729] | Phase 3 | 22,090 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Scaling up the Use of Sulphadoxine-Pyrimethamine for the Preventive Treatment of Malaria in Pregnancy: Results and Lessons on Scalability, Costs and Program From Three Local Government Areas in Sokoto State, Nigeria[NCT02758353] | 31,493 participants (Actual) | Interventional | 2015-04-30 | Completed | |||
| Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care[NCT01976325] | 100 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | |||
| Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections[NCT05086887] | 715 participants (Anticipated) | Observational [Patient Registry] | 2019-04-15 | Recruiting | |||
| Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes[NCT02325180] | Phase 4 | 338 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas[NCT04783051] | Phase 3 | 250 participants (Actual) | Interventional | 2021-05-06 | Completed | ||
| Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial[NCT01722539] | Phase 3 | 616 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria[NCT00948896] | Phase 3 | 600 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099] | Phase 3 | 723 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Effectiveness of Seasonal Malaria Chemoprevention in Koulikoro, Mali[NCT04149106] | Phase 3 | 4,556 participants (Anticipated) | Interventional | 2019-07-01 | Active, not recruiting | ||
| Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years[NCT00941785] | Phase 2/Phase 3 | 1,500 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects[NCT02223871] | Phase 1 | 8 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Aetiology, Prevention and Control of Anaemia in Sub-Saharan Africa - Work Package 2: Efficacy Study: Efficacy of 2 Iron Fortified Porridges and IPT for the Prevention of Anemia in Young Children in Côte d'Ivoire.[NCT01634945] | 629 participants (Actual) | Interventional | 2012-04-30 | Completed | |||
| Intermittent Screening and Treatment (IST) or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya: a Randomized Controlled Trial[NCT01669941] | Phase 4 | 1,546 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)[NCT02163447] | Phase 3 | 300 participants (Actual) | Interventional | 2014-06-23 | Completed | ||
| Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal[NCT00712374] | Phase 4 | 100,000 participants (Anticipated) | Interventional | 2008-09-30 | Enrolling by invitation | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04301531] | 5,861 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| Exploring the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04167566] | 5,000 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Evaluation of a Malaria Transmission Target Strategy Based on the Periodic Treatment With Sulfadoxine-Pyrimethamine vs. Early Case Management[NCT00623155] | 262 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| The Effect of Folic Acid Supplementation on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya[NCT00130065] | Phase 4 | 600 participants | Interventional | 2003-11-30 | Completed | ||
| A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana[NCT00119132] | Phase 2/Phase 3 | 2,602 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552] | Phase 3 | 601 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania[NCT00146731] | Phase 3 | 310 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine[NCT00274235] | Phase 3 | 1,600 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
| Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal[NCT00529620] | Phase 3 | 1,833 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial[NCT00124267] | Phase 3 | 108 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744] | Phase 4 | 200 participants (Anticipated) | Interventional | 2022-05-10 | Not yet recruiting | ||
| Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781] | 1,028 participants | Interventional | 2003-08-31 | Active, not recruiting | |||
| Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs[NCT00158574] | Phase 2/Phase 3 | 2,419 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya[NCT00111163] | 1,516 participants | Interventional | 2004-03-31 | Completed | |||
| Chemoprophylaxis With Sulfadoxine-pyrimethamine to Prevent Recurrence of Severe Anaemia in Gambian Children Aged 3 Months to 9 Years[NCT00131716] | Phase 3 | 1,200 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| The Effectiveness, Cost and Cost Effectiveness of Intermittent Preventive Treatment or Screening and Treatment of Malaria in Pregnancy Among Women Using Long Lasting Insecticide Treated Bed Net: a Randomised Controlled Trial.[NCT00432367] | Phase 3 | 3,333 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia[NCT00944840] | Phase 3 | 1,312 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission[NCT00376155] | Phase 4 | 14,000 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946] | 6,000 participants (Anticipated) | Interventional | 2008-08-31 | Completed | |||
| [NCT00766662] | 0 participants | Interventional | 2006-10-31 | Completed | |||
| Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial[NCT01878357] | Phase 4 | 1,488 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine[NCT00509015] | 6,000 participants (Anticipated) | Interventional | 2008-02-29 | Completed | |||
| The Efficacy and Cost-effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-treated Nets.[NCT00142207] | Phase 3 | 4,775 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants[NCT00285662] | 1,100 participants (Anticipated) | Interventional | 2006-06-30 | Completed | |||
| Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial[NCT00206739] | Phase 4 | 1,070 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation[NCT00857077] | 2,485 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation[NCT00819390] | Phase 2 | 70 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598] | Phase 3 | 468 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children[NCT00132548] | Phase 3 | 2,200 participants | Interventional | 2004-06-30 | Completed | ||
| Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly - Malawi[NCT00126906] | 700 participants | Interventional | 2002-10-31 | Completed | |||
| Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria[NCT00167739] | Phase 4 | 50 participants | Interventional | 2003-04-30 | Completed | ||
| Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment[NCT00126971] | Phase 1 | 132 participants | Interventional | 2005-07-31 | Suspended | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of placental malaria infections in maternal subjects diagnosed by the presence of parasites and/or pigment on histological section or molecular evidence of infection (PCR). (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 3.09 |
| Maternal Chloroquine IPT | 3.16 |
| Maternal SP IPT | 4.74 |
Maternal participants were followed to outcome of the pregnancy. Clinical malaria is defined as malaria infection at any parasite density with associated symptoms including at least one of the following: objective fever measured at the clinic, history of fever in the past 48 hours or other symptoms in the last 48 hours including: headache, myalgia, vomiting, or weakness. (NCT01443130)
Timeframe: Enrollment to delivery (approximately 12-36 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.67 |
| Maternal Chloroquine IPT | 1.33 |
| Maternal SP IPT | 3.00 |
Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of positive for malaria cord blood smear and cord PCR results in maternal subjects based on the results of the thick smear and PCR from the cord blood sample. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 1.95 |
| Maternal Chloroquine IPT | 2.78 |
| Maternal SP IPT | 0.80 |
Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants with IUGR at delivery. IUGR is defined as weight below the 10th percentile for gestational age based on the World Health Organization (WHO) fetal growth curve. This classification is supported by literature resulting from the INTERGROWTH-21st Project; José Villar. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of participants (Number) |
|---|---|
| Infant Chloroquine Prophylaxis | 16.54 |
| Infant Chloroquine IPT | 18.01 |
| Infant SP IPT | 20.80 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of infants whose birthweight was less than 2500 grams. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of infants (Number) |
|---|---|
| Infant Chloroquine Prophylaxis | 15.59 |
| Infant Chloroquine IPT | 10.98 |
| Infant SP IPT | 12.11 |
Maternal participants were followed to outcome of the pregnancy. This outcome measure provides the number of malaria infection episodes measured by positive parasitemia in maternal subjects. (NCT01443130)
Timeframe: Enrollment to delivery (approximately 12-36 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.67 |
| Maternal Chloroquine IPT | 1.67 |
| Maternal SP IPT | 3.00 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of anemia among maternal participants during pregnancy . Anemia is defined as having a hemoglobin value less than 10 grams/deciliter (gm/dL). (NCT01443130)
Timeframe: From enrollment until delivery, approximately 12-36 weeks
| Intervention | percentage of maternal participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 18.3 |
| Maternal Chloroquine IPT | 23.7 |
| Maternal SP IPT | 22.0 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of severe anemia among maternal participants during pregnancy. Severe anemia is defined as having a hemoglobin value less than 7 gm/dl. (NCT01443130)
Timeframe: From enrollment until delivery, approximately 12-36 weeks
| Intervention | percentage of maternal participants (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.0 |
| Maternal Chloroquine IPT | 0.3 |
| Maternal SP IPT | 0.3 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was miscarriage, defined as an infant delivered without any signs of life at less than 28 weeks of gestation. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of pregnancies (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0.33 |
| Maternal Chloroquine IPT | 0.67 |
| Maternal SP IPT | 1.00 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of malaria infection in the placenta based on diagnosis by positive placental impression smear results. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of placentas (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 0 |
| Maternal Chloroquine IPT | 0 |
| Maternal SP IPT | 0.40 |
The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of pregnancies (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 11.58 |
| Maternal Chloroquine IPT | 15.42 |
| Maternal SP IPT | 15.42 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was preterm delivery, defined as delivery less than 37 weeks of gestation. The outcome of the delivery was not considered, and could have been live birth, stillbirth, or miscarriage. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of deliveries (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 8.46 |
| Maternal Chloroquine IPT | 9.89 |
| Maternal SP IPT | 6.84 |
Maternal participants were followed to outcome of the pregnancy. The outcome measure provides the incidence of participants' deliveries whose outcome was stillbirth, defined as an infant born without any signs of life at 28 weeks or greater of gestation. (NCT01443130)
Timeframe: At delivery: Approximately 12-36 weeks after enrollment
| Intervention | percentage of deliveries (Number) |
|---|---|
| Maternal Chloroquine Prophylaxis | 1.10 |
| Maternal Chloroquine IPT | 0.37 |
| Maternal SP IPT | 1.90 |
Infants were followed from the time of delivery until 14 weeks of age. This outcome measure provides the incidence of infants who died within 14 weeks of delivery. (NCT01443130)
Timeframe: For 14 weeks after delivery.
| Intervention | percentage of infants (Number) |
|---|---|
| Infant Chloroquine Prophylaxis | 2.22 |
| Infant Chloroquine IPT | 3.65 |
| Infant SP IPT | 3.09 |
Complicated malaria defined as an episode of malaria with danger signs (any of the following: less than 3 convulsions over 24 h, inability to sit or stand, vomiting everything, unable to breastfeed or drink) or the meeting standardized criteria for severe malaria. (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 44 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 24 |
Admission to the pediatric ward for any cause (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 19 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
episodes per person year (NCT02793622)
Timeframe: Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination
| Intervention | episodes per person year (Number) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 1.98 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1.71 |
Any deaths occurring after birth (NCT02793622)
Timeframe: Birth up to 12 months of age
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 9 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 |
Gestational age in weeks determined by ultrasound dating (gold standard) and by the metabolic profiling outcome from biological specimens including placental tissue and placental blood. (NCT02793622)
Timeframe: At the time of delivery
| Intervention | weeks (Mean) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 39.4 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 39.6 |
Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference) (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 60 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 54 |
All grade 3 and 4 adverse events (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 54 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 43 |
"Defined as the proportion with hemoglobin < 10 g/dL measure routinely at 12, 28, and 52 weeks of age. Number of cases per person year (PPY).~This is a prevalence measure but are repeated measures during infancy. In other words we measured this outcome up to 3 times for each participant during infancy (at 12, 28 and 52 weeks of age)." (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | routine hemoglobin measurement (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 222 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 216 |
hemoglobin < 11 g/dL (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 8 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Birth up to 12 months of age or early termination
| Intervention | blood smears (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 344 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 357 |
Proportion of routine monthly samples positive for parasites by microscopy and LAMP (NCT02793622)
Timeframe: Starting at the time of their first study drug administration, approximately gestational age between 12-20 weeks, up to one month post-delivery
| Intervention | blood smears (Count of Units) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 519 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 9 |
Maternal blood positive for malaria parasites by microscopy. (NCT02793622)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 28 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 1 |
Any evidence of placental infection (parasites or pigment). Number of participants with placental tissue positive for malaria parasites or pigment. (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 197 |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 94 |
Proportion of placental blood samples positive for parasites by Loop-mediated isothermal amplification (LAMP) or microscopy (NCT02793622)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| LAMP | Microscopy | |
| Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy | 7 | 1 |
| Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy | 71 | 29 |
NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004 (NCT00948896)
Timeframe: Time from randomization until 24 months of age
| Intervention | incidence per person-year at risk (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All grade 3-4 adverse events | Grade 3-4 AEs possibly related to study drugs | All serious adverse events | Elevated Temperature | Anemia | Thrombocytopenia | Elevated aspartate aminotransferase | Elevated alanine aminotransferase | Neutropenia | Malnutrition | |
| HIV-exposed & Daily TS | 0.659 | 0.062 | 0.330 | 0.206 | 0.206 | 0 | 0.041 | 0 | 0 | 0.021 |
| HIV-exposed & Monthly DP | 0.678 | 0.097 | 0.194 | 0.174 | 0.291 | 0.058 | 0.039 | 0 | 0 | 0.039 |
| HIV-exposed & Monthly SP | 1.478 | 0 | 0.453 | 0.532 | 0.631 | 0.118 | 0.020 | 0 | 0 | 0.020 |
| HIV-exposed & no Chemoprevention | 1.214 | NA | 0.411 | 0.431 | 0.705 | 0 | 0.039 | 0 | 0 | 0.020 |
| HIV-unexposed & Daily TS | 0.914 | 0.054 | 0.196 | 0.393 | 0.318 | 0.061 | 0.041 | 0.027 | 0.014 | 0 |
| HIV-unexposed & Monthly DP | 0.611 | 0.021 | 0.091 | 0.323 | 0.168 | 0.035 | 0.021 | 0.021 | 0.007 | 0 |
| HIV-unexposed & Monthly SP | 1.415 | 0.056 | 0.364 | 0.546 | 0.602 | 0.119 | 0.056 | 0.028 | 0.042 | 0 |
| HIV-unexposed & no Chemoprevention | 1.159 | NA | 0.178 | 0.542 | 0.384 | 0.123 | 0.048 | 0.027 | 0.021 | 0 |
The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria. (NCT00948896)
Timeframe: Randomization to 24 months of age
| Intervention | Episodes per person year at risk (Number) | ||
|---|---|---|---|
| Randomization - 24 mo. of Age | Randomization -16 mo. of Age | 17-24 mo. of Age | |
| HIV-exposed & Daily TS | 2.86 | 1.70 | 3.79 |
| HIV-exposed & Monthly DP | 1.83 | 0.90 | 2.67 |
| HIV-exposed & Monthly SP | 4.50 | 3.72 | 5.22 |
| HIV-exposed & no Chemoprevention | 6.28 | 5.42 | 7.04 |
The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6-24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria. (NCT00948896)
Timeframe: 6 to 24 months of age
| Intervention | Episode per person year at risk (Number) | ||
|---|---|---|---|
| 6-24 mo. of Age | 6-11 mo. of Age | 12-24 mo. of Age | |
| HIV-unexposed & Daily TS | 5.21 | 3.27 | 6.32 |
| HIV-unexposed & Monthly DP | 3.02 | 1.49 | 3.88 |
| HIV-unexposed & Monthly SP | 6.73 | 5.51 | 7.41 |
| HIV-unexposed & no Chemoprevention | 6.95 | 6.41 | 7.24 |
(NCT00948896)
Timeframe: 24 months to 36 months of age
| Intervention | Incidence per person year at risk (Number) | ||
|---|---|---|---|
| All incident episodes of malaria | Complicated malaria | All-cause hospital admissions | |
| HIV-exposed & Daily TS | 8.13 | 0.116 | 0.186 |
| HIV-exposed & Monthly DP | 6.78 | 0.044 | 0.089 |
| HIV-exposed & Monthly SP | 6.75 | 0.147 | 0.318 |
| HIV-exposed & no Chemoprevention | 9.08 | 0.161 | 0.459 |
| HIV-unexposed & Daily TS | 10.90 | 0.046 | 0.091 |
| HIV-unexposed & Monthly DP | 10.77 | 0 | 0.023 |
| HIV-unexposed & Monthly SP | 11.98 | 0.132 | 0.452 |
| HIV-unexposed & no Chemoprevention | 10.85 | 0.046 | 0.046 |
"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.~The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated following the data-driven method by Marquart et al. (2015), removing potential lag and tail phases prior to log-linear regression modeling." (NCT02223871)
Timeframe: 48 hours after study drug administration
| Intervention | Ratio (Mean) |
|---|---|
| ACT-451840 500 mg | 73.6 |
"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.~The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated using an objective standardized approach (observed data over 48 h)" (NCT02223871)
Timeframe: 48 hours after study drug administration
| Intervention | Ratio (Mean) |
|---|---|
| ACT-451840 500 mg | 234.5 |
Cmax was directly derived from the plasma concentrations-time curves of ACT-451840. Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose. (NCT02223871)
Timeframe: From pre-dose to 144 hours after study drug adminsitration
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ACT-451840 500 mg | 121.7 |
Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug adminsitration
| Intervention | Hours (Geometric Mean) |
|---|---|
| ACT-451840 500 mg | 36.4 |
tmax was directly derived from the plasma concentration-time curves of ACT-451840. Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose. (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug administration
| Intervention | Hours (Median) |
|---|---|
| ACT-451840 500 mg | 4.0 |
"Two AUCs were calculated using non-compartmental analysis: AUC(0-t) from pre-dose to last time-point of measure and AUC(0-inf) from pre-dose and extrapolated to infinity.~Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose" (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug administration
| Intervention | ng*h/mL (Geometric Mean) | |
|---|---|---|
| AUC(0-t) | AUC(0-inf) | |
| ACT-451840 500 mg | 1254.8 | 1284.4 |
Vital signs, including diastolic and systolic blood pressure (DBP/SBP), were measured at each outpatient visit up to 7 days after ACT-451840 administration, every day during confinement or when malaria symptoms were presented and at the end of study visit (EOS). Other measures were performed if required. (NCT02223871)
Timeframe: Day 28 (EOS)
| Intervention | mmHg (Median) | |||||
|---|---|---|---|---|---|---|
| SBP at baseline (Day 0) | SBP at EOS (Day 28) | Change from Day 0 to Day 28 in SBP | DBP at baseline (Day 0) | DBP at EOS (Day 28) | Change from Day 0 to Day 28 in DBP | |
| ACT-451840 500 mg | 121.0 | 125.5 | 2.5 | 66.0 | 70.5 | 0.5 |
Body temperature was measured orally (NCT02223871)
Timeframe: Day 28 (EOS)
| Intervention | Degree Celsius (Median) | ||
|---|---|---|---|
| Temperature at baseline (Day 0) | Temperature at EOS (Day 28) | Change from Day 0 to Day 28 in temperature | |
| ACT-451840 500 mg | 36.3 | 35.9 | -0.2 |
(NCT02223871)
Timeframe: Day 28 (EOS)
| Intervention | Breaths/min (Median) | ||
|---|---|---|---|
| Respiratory rate at baseline (Day 0) | Respiratory rate at EOS (Day 28) | Change from Day 0 to Day 28 in respiratory rate | |
| ACT-451840 500 mg | 14 | 16 | 1.5 |
Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.022 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.024 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.000 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.035 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.000 |
Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.043 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.036 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.089 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.082 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.043 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.87 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.88 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.83 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 1.24 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.64 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.26 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.30 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.00 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.43 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.03 |
Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination
| Intervention | events per person years (Number) |
|---|---|
| Mothers - 3 Dose SP | 0.95 |
| Mothers - 3 Dose DP | 0.31 |
| Mothers - Monthly DP | 0 |
Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 19 |
| Mothers - 3 Dose DP | 19 |
| Mothers - Monthly DP | 9 |
Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination
| Intervention | hemoglobin measurements taken every 12wk (Number) |
|---|---|
| Mothers - 3 Dose SP | 94 |
| Mothers - 3 Dose DP | 72 |
| Mothers - Monthly DP | 61 |
Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 7 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 1 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 4 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0 |
Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Positive blood smears (Number) |
|---|---|
| Mothers - 3 Dose SP | 4 |
| Mothers - 3 Dose DP | 1 |
| Mothers - Monthly DP | 3 |
Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination
| Intervention | Positive specimens (Number) |
|---|---|
| Mothers - 3 Dose SP | 206 |
| Mothers - 3 Dose DP | 74 |
| Mothers - Monthly DP | 26 |
Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 59 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 25 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 7 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 52 |
| Monthly DP Pregnancy / Monthly DP Infancy | 4 |
Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 49 |
| Mothers - 3 Dose DP | 30 |
| Mothers - Monthly DP | 26 |
Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Micropscopic assessment of placental blood | LAMP assessment of placental blood | |
| Mothers - 3 Dose DP | 3 | 3 |
| Mothers - 3 Dose SP | 5 | 19 |
| Mothers - Monthly DP | 0 | 2 |
Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery
| Intervention | participants (Number) | |
|---|---|---|
| Microscopy | LAMP | |
| Mothers - 3 Dose DP | 1 | 3 |
| Mothers - 3 Dose SP | 5 | 25 |
| Mothers - Monthly DP | 0 | 1 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -2.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | -0.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -3.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -1.2 |
The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Pre-entry, entry, Weeks 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 10.8 |
| C: Chloroquine Then Placebo for On-ART Participants | -2.4 |
For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+. (NCT00819390)
Timeframe: For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -2.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -3.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -2.9 |
The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+ (NCT00819390)
Timeframe: At Weeks 10, 12, 22 and 24
| Intervention | percent of CD8 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 5.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.5 |
| C: Chloroquine Then Placebo for On-ART Participants | -0.1 |
| D: Placebo Then Chloroquine for On-ART Participants | -2.9 |
Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count (NCT00819390)
Timeframe: At pre-entry, entry, weeks 10 and 12
| Intervention | cells/mm^3 (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | -27 |
| B: Placebo Then Chloroquine for Off-ART Participants | -11 |
| C: Chloroquine Then Placebo for On-ART Participants | -6 |
| D: Placebo Then Chloroquine for On-ART Participants | 7 |
Results reported are for entry fasting LPS. (NCT00819390)
Timeframe: At entry
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 13.68 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.64 |
| C: Chloroquine Then Placebo for On-ART Participants | 8.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 7.00 |
Results reported are the week 12 fasting LPS. (NCT00819390)
Timeframe: At week 12
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 14.37 |
| B: Placebo Then Chloroquine for Off-ART Participants | 13.06 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 7.00 |
Results reported are the week 24 fasting LPS. (NCT00819390)
Timeframe: At week 24
| Intervention | pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 20.54 |
| B: Placebo Then Chloroquine for Off-ART Participants | 2.83 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.00 |
| D: Placebo Then Chloroquine for On-ART Participants | 8.00 |
Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants. (NCT00819390)
Timeframe: At Entry
| Intervention | log10 copies/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 4.48 |
| B: Placebo Then Chloroquine for Off-ART Participants | 4.42 |
Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment. (NCT00819390)
Timeframe: From start of study treatment to study completion at week 28
| Intervention | participants (Number) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1 |
| C: Chloroquine Then Placebo for On-ART Participants | 1 |
| D: Placebo Then Chloroquine for On-ART Participants | 0 |
Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 8.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 9.8 |
| C: Chloroquine Then Placebo for On-ART Participants | 8.7 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.9 |
Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 12
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 6.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 10.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.7 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.0 |
Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+. (NCT00819390)
Timeframe: At Week 24
| Intervention | percent of CD4 expressing HLA-DR+/CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 11.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 12.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 7.3 |
| D: Placebo Then Chloroquine for On-ART Participants | 9.2 |
Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 71.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 77.0 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.8 |
| D: Placebo Then Chloroquine for On-ART Participants | 49.9 |
Results reported are the week 12 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 12
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 71.5 |
| B: Placebo Then Chloroquine for Off-ART Participants | 79.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.9 |
| D: Placebo Then Chloroquine for On-ART Participants | 51.9 |
Results reported are the week 24 percentage of CD8 expressing CD38+. (NCT00819390)
Timeframe: At Week 24
| Intervention | percent of CD8 expressing CD38+ (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 78.0 |
| B: Placebo Then Chloroquine for Off-ART Participants | 79.5 |
| C: Chloroquine Then Placebo for On-ART Participants | 50.6 |
| D: Placebo Then Chloroquine for On-ART Participants | 48.7 |
Baseline sCD14 was computed as the mean of pre-entry and entry sCD14. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.43 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.97 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.80 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.58 |
Results reported are the week 12 sCD14. (NCT00819390)
Timeframe: At week 12
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.88 |
| C: Chloroquine Then Placebo for On-ART Participants | 2.04 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.63 |
Results reported are the week 24 sCD14. (NCT00819390)
Timeframe: At week 24
| Intervention | million pg/mL (Median) |
|---|---|
| A: Chloroquine Then Placebo for Off-ART Participants | 1.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 2.19 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.77 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.72 |
Results reported are for HIV-1 RNA at study entry for on-ART participants. (NCT00819390)
Timeframe: At Entry
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 16 | 2 |
| D: Placebo Then Chloroquine for On-ART Participants | 17 | 2 |
Results reported are for HIV-1 RNA at week 12 for on-ART participants. (NCT00819390)
Timeframe: At week 12
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 16 | 1 |
| D: Placebo Then Chloroquine for On-ART Participants | 18 | 1 |
Results reported are for HIV-1 RNA at week 24 for on-ART participants. (NCT00819390)
Timeframe: At week 24
| Intervention | participants (Number) | |
|---|---|---|
| at or below lower limit of quantitation | above lower limit of quantitation | |
| C: Chloroquine Then Placebo for On-ART Participants | 14 | 2 |
| D: Placebo Then Chloroquine for On-ART Participants | 18 | 1 |
Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants. (NCT00819390)
Timeframe: At weeks 12 and 24
| Intervention | log10 copies/mL (Median) | |
|---|---|---|
| Week 12 | Week 24 | |
| A: Chloroquine Then Placebo for Off-ART Participants | 4.68 | 4.69 |
| B: Placebo Then Chloroquine for Off-ART Participants | 4.28 | 4.61 |
Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.65 | 1228.66 | 286390 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.62 | 1377.81 | 328460 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.01 | 1316.63 | 107890 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.51 | 1250.85 | 103530 |
Results reported are the week 12 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 12
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.68 | 1209.50 | 251320 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.28 | 1347.06 | 319770 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.15 | 1441.35 | 126540 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.30 | 1304.77 | 117890 |
Results reported are the week 24 IL-6, sTNF-rI and D-dimer. (NCT00819390)
Timeframe: At week 24
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IL-6 | sTNF-rI | D-dimer | |
| A: Chloroquine Then Placebo for Off-ART Participants | 1.34 | 1327.21 | 264240 |
| B: Placebo Then Chloroquine for Off-ART Participants | 1.18 | 1420.30 | 294780 |
| C: Chloroquine Then Placebo for On-ART Participants | 1.02 | 1230.21 | 100860 |
| D: Placebo Then Chloroquine for On-ART Participants | 1.27 | 1176.20 | 124920 |
Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC. (NCT00819390)
Timeframe: At pre-entry and entry
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.03 | 45.48 | 9.12 | 2.52 | 1.04 | 38.60 | 96.29 | 9.82 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.03 | 36.15 | 9.35 | 6.13 | 0.83 | 39.94 | 97.52 | 16.37 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.13 | 19.91 | 10.96 | 4.48 | 1.31 | 48.17 | 96.11 | 4.58 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.07 | 23.65 | 12.66 | 6.49 | 1.17 | 26.08 | 95.38 | 8.28 |
Results reported are the week 12 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 12
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.00 | 51.90 | 7.66 | 3.74 | 0.84 | 43.51 | 97.90 | 15.03 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.05 | 40.49 | 8.48 | 8.43 | 1.03 | 36.47 | 97.18 | 16.32 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.10 | 14.70 | 13.93 | 7.24 | 1.47 | 47.83 | 95.40 | 7.10 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.14 | 18.20 | 13.64 | 5.16 | 1.01 | 26.75 | 95.15 | 6.09 |
Results reported are the week 24 percent activation levels of pDC and mDC. (NCT00819390)
Timeframe: At week 24
| Intervention | percentage of cells (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| %pDC expressing CD80+ | %pDC expressing CD83+ | %pDC expressing CD86+ | %pDC expressing PDL-1+ | %mDC expressing CD80+ | %mDC expressing CD83+ | %mDC expressing CD86+ | %mDC expressing PDL-1+ | |
| A: Chloroquine Then Placebo for Off-ART Participants | 0.05 | 44.50 | 10.13 | 4.34 | 0.94 | 41.21 | 97.70 | 9.53 |
| B: Placebo Then Chloroquine for Off-ART Participants | 0.00 | 38.96 | 7.89 | 7.45 | 1.12 | 33.19 | 97.05 | 14.84 |
| C: Chloroquine Then Placebo for On-ART Participants | 0.08 | 14.80 | 11.79 | 5.63 | 0.76 | 36.65 | 96.69 | 4.13 |
| D: Placebo Then Chloroquine for On-ART Participants | 0.16 | 17.65 | 12.88 | 6.52 | 1.39 | 24.14 | 92.41 | 7.49 |
100 reviews available for pyrimethamine and Malaria
| Article | Year |
|---|---|
Targeting the liver stage of malaria parasites: a yet unmet goal.
Topics: Animals; Antimalarials; Humans; Life Cycle Stages; Liver; Malaria; Plasmodium; Structure-Activity Re | 2012 |
Recent advances in malaria drug discovery.
Topics: Animals; Antimalarials; Drug Discovery; Humans; Liver; Liver Transplantation; Malaria; Molecular Str | 2013 |
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular St | 2020 |
Falciparum malaria: the urgent need for safe and effective drugs.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Dapsone; Drug Combinations; Humans; Malaria; Plas | 1983 |
Malaria 1984. Part I. Malaria prophylaxis.
Topics: Antimalarials; Chloroquine; Dapsone; Drug Combinations; Drug Resistance, Microbial; Female; Humans; | 1984 |
Recent work concerning anemia in the tropics.
Topics: Adolescent; Adult; Anemia; Anemia, Hypochromic; Anemia, Megaloblastic; Animals; Child; Child, Presch | 1982 |
Malaria chemoprophylaxis: an update.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child, Preschool; Dapsone; Drug Combinations; Female; | 1987 |
The chemoprophylaxis of malaria.
Topics: Amodiaquine; Animals; Chloroquine; Dapsone; Drug Combinations; Drug Resistance; Malaria; Plasmodium | 1987 |
The efficacy and safety of intermittent preventive treatment with sulphadoxine-pyrimethamine vs artemisinin-based drugs for malaria: a systematic review and meta-analysis.
Topics: Antimalarials; Artemisinins; Drug Combinations; Humans; Infant, Newborn; Malaria; Malaria, Falciparu | 2022 |
Malaria chemoprevention and drug resistance: a review of the literature and policy implications.
Topics: Chemoprevention; Drug Combinations; Drug Resistance; Female; Humans; Infant; Malaria; Policy; Pregna | 2022 |
Pharmacokinetic considerations in seasonal malaria chemoprevention.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2022 |
Intermittent preventive treatment with Sulfadoxine pyrimethamine for malaria: a global overview and challenges affecting optimal drug uptake in pregnant women.
Topics: Antimalarials; COVID-19; Drug Combinations; Female; Humans; Malaria; Pharmaceutical Preparations; Pr | 2023 |
Malaria in pregnancy control and pregnancy outcomes: a decade's overview using Ghana's DHIMS II data.
Topics: Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Ghana; Humans; Malaria; Pregnancy; P | 2022 |
Status of malaria in pregnancy services in Madagascar 2010-2021: a scoping review.
Topics: Antimalarials; Drug Combinations; Female; Humans; Madagascar; Malaria; Patient Acceptance of Health | 2023 |
Safety and tolerability of repeated doses of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a systematic review and an aggregated data meta-analysis of randomized controlled trials.
Topics: Antimalarials; Drug Combinations; Female; Humans; Infant; Malaria; Pregnancy; Pregnancy Complication | 2023 |
Deleterious effects of malaria in pregnancy on the developing fetus: a review on prevention and treatment with antimalarial drugs.
Topics: Abnormalities, Drug-Induced; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; | 2020 |
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine | 2021 |
Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations.
Topics: Amodiaquine; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins | 2021 |
Intermittent preventive treatment for malaria in infants.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemisinins; Bias; Confidence Intervals; Di | 2021 |
Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Malaria; Malar | 2017 |
Mefloquine for preventing malaria in pregnant women.
Topics: Abortion, Spontaneous; Africa South of the Sahara; Antimalarials; Dizziness; Drug Combinations; Drug | 2018 |
Mefloquine for preventing malaria in pregnant women.
Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum | 2018 |
A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy.
Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female; Humans; Ma | 2019 |
Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis.
Topics: Africa; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Infant, Low | 2013 |
A systematic review of the impact of malaria prevention in pregnancy on low birth weight and maternal anemia.
Topics: Africa South of the Sahara; Anemia; Antimalarials; Drug Combinations; Female; Humans; Infant, Low Bi | 2013 |
Factors affecting the delivery, access, and use of interventions to prevent malaria in pregnancy in sub-Saharan Africa: a systematic review and meta-analysis.
Topics: Africa South of the Sahara; Antimalarials; Delivery of Health Care; Drug Combinations; Female; Human | 2013 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Malaria.
Topics: Africa South of the Sahara; Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Artesunate | 2014 |
Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11.
Topics: Adult; Africa South of the Sahara; Antimalarials; Drug Combinations; Family Characteristics; Female; | 2013 |
Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11.
Topics: Adult; Africa South of the Sahara; Antimalarials; Drug Combinations; Family Characteristics; Female; | 2013 |
Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11.
Topics: Adult; Africa South of the Sahara; Antimalarials; Drug Combinations; Family Characteristics; Female; | 2013 |
Coverage of intermittent preventive treatment and insecticide-treated nets for the control of malaria during pregnancy in sub-Saharan Africa: a synthesis and meta-analysis of national survey data, 2009-11.
Topics: Adult; Africa South of the Sahara; Antimalarials; Drug Combinations; Family Characteristics; Female; | 2013 |
Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.
Topics: Anencephaly; Animals; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; Folic Aci | 2014 |
Pregnancy-associated malaria and malaria in infants: an old problem with present consequences.
Topics: Adult; Africa South of the Sahara; Antimalarials; Comorbidity; Complement Activation; Developmental | 2014 |
Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis.
Topics: Africa South of the Sahara; Antimalarials; Child; Drug Combinations; Drug Resistance; HIV Infections | 2014 |
A country on the verge of malaria elimination--the Kingdom of Saudi Arabia.
Topics: Antimalarials; Artemisinins; Drug Combinations; Geography; Humans; Incidence; Malaria; Outcome Asses | 2014 |
Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Topics: Africa South of the Sahara; Anemia; Antimalarials; Cost-Benefit Analysis; Drug Combinations; Female; | 2015 |
Antimalarial drug resistance in Africa: key lessons for the future.
Topics: Africa; Animals; Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Resistance; Drug | 2015 |
The role of folate in malaria - implications for home fortification programmes among children aged 6-59 months.
Topics: Africa South of the Sahara; Antimalarials; Child, Preschool; Dietary Supplements; Dose-Response Rela | 2015 |
Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis.
Topics: Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Pyrimeth | 2017 |
Malaria during Pregnancy.
Topics: Africa; Antimalarials; Artemisinins; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Ma | 2017 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Combinations; Drug Design; Drug Interactions; Drug Sy | 2009 |
Intermittent preventive treatment against malaria: an update.
Topics: Africa South of the Sahara; Animals; Antimalarials; Child; Child, Preschool; Clinical Trials as Topi | 2010 |
Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy.
Topics: Adult; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antimalar | 2011 |
Drug resistance maps to guide intermittent preventive treatment of malaria in African infants.
Topics: Africa; Antimalarials; Dihydropteroate Synthase; Drug Combinations; Drug Resistance; Humans; Infant; | 2011 |
Pharmacokinetics of antimalarials in pregnancy: a systematic review.
Topics: Anti-Bacterial Agents; Antimalarials; Artemisinins; Atovaquone; Chloroquine; Drug Therapy, Combinati | 2011 |
Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women.
Topics: Antimalarials; Drug Combinations; Female; HIV Seropositivity; Humans; Malaria; Pregnancy; Pregnancy | 2011 |
Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials.
Topics: Antibodies, Bacterial; Antibodies, Viral; Antimalarials; Diphtheria-Tetanus-Pertussis Vaccine; Drug | 2012 |
Malaria: a rising incidence in the United States.
Topics: Antimalarials; Chemoprevention; Chloroquine; Drug Combinations; Drug Resistance; Female; Global Heal | 2002 |
WHO, the Global Fund, and medical malpractice in malaria treatment.
Topics: Africa; Antimalarials; Artemisinins; Child; Chloroquine; Drug Combinations; Drug Costs; Drug Resista | 2004 |
Genetic and biochemical aspects of drug resistance in malaria parasites.
Topics: Animals; Antimalarials; Chloroquine; Dihydropteroate Synthase; Drug Resistance; Drug Resistance, Mul | 2004 |
[Combined antimalarial therapy using artemisinin].
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Doxycycline; | 2004 |
Malaria in endemic areas.
Topics: Antimalarials; Artemether; Artemisinins; Blood Transfusion; Chloroquine; Deferoxamine; Drug Combinat | 2003 |
Effectiveness of antimalarial drugs.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combination; | 2005 |
Fitness of drug-resistant malaria parasites.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance, Multiple; Humans; Malaria; Mutation; Plasmodiu | 2005 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2005 |
Chemoprophylaxis and intermittent treatment for preventing malaria in children.
Topics: Antimalarials; Child, Preschool; Chloroquine; Dapsone; Humans; Infant; Malaria; Pyrimethamine; Rando | 2005 |
Controlling malaria and African trypanosomiasis: the role of the mouse.
Topics: Animals; Disease Models, Animal; Disease Progression; Drug Resistance; Genetic Linkage; Genetic Pred | 2005 |
Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic review.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Pregnancy; Pregnancy Com | 2007 |
Intermittent preventive treatment for the prevention of malaria during pregnancy in high transmission areas.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Pregnancy; Pregnancy Com | 2007 |
Assessment of the relative advantage of various artesunate-based combination therapies by a multi-treatment Bayesian random-effects meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Bayes Theorem; C | 2007 |
Recent progress in the medicinal chemistry of 2,4-diaminopyrimidines.
Topics: Amino Acid Sequence; Animals; Folic Acid Antagonists; Glutamates; Glutamic Acid; Malaria; Mathematic | 1982 |
Resistance of Plasmodium falciparum.
Topics: Africa; Animals; Antimalarials; Asia; Chloroquine; DNA; Drug Resistance; Drug Synergism; Hemin; Mala | 1984 |
[Progress in immunodiagnosis and chemotherapy of protozoan infections].
Topics: Amebiasis; Animals; Antibodies; Babesiosis; Chloroquine; Drug Resistance, Microbial; Giardiasis; Hum | 1983 |
Practical therapeutics malaria chemoprophylaxis.
Topics: Adult; Africa, Eastern; Aminoquinolines; Antimalarials; Child; Chloroquine; Drug Combinations; Drug | 1984 |
Chemoprophylaxis of malaria in Africa: the spent "magic bullet".
Topics: Africa; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Ma | 1982 |
[Drug resistance in malaria].
Topics: Africa; Amodiaquine; Animals; Asia; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Plasmo | 1980 |
The genetics of drug resistance in malaria parasites.
Topics: Animals; Chloroquine; Drug Resistance, Microbial; Malaria; Plasmodium; Pyrimethamine; Rodentia | 1980 |
The present status of malaria chemotherapy: mefloquine, a novel antimalarial.
Topics: Amodiaquine; Animals; Antimalarials; Aotus trivirgatus; Chemical Phenomena; Chemistry; Chloroquine; | 1981 |
Clinical pharmacokinetics in the treatment of tropical diseases. Some applications and limitations.
Topics: Chloroquine; Diethylcarbamazine; Drug Resistance; Echinococcosis; Filariasis; Humans; Malaria; Meflo | 1994 |
[Malaria: the most important emergency in subjects returning from the tropics].
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Emergencies; Humans; Malaria; Malaria, Falci | 1993 |
[Malaria and drug resistance].
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Microbial Sensitivity Tests; | 1996 |
Drug interactions with antimalarial agents.
Topics: Antimalarials; Dapsone; Drug Interactions; Humans; Malaria; Proguanil; Pyrimethamine; Quinolines; Su | 1999 |
Malaria in pregnancy: its relevance to safe-motherhood programmes.
Topics: Anemia; Antimalarials; Female; Health Policy; Humans; Kenya; Malaria; Pregnancy; Pregnancy Complicat | 1999 |
Comparative efficacy and safety of chloroquine and alternative antimalarial drugs: a meta-analysis from six African countries.
Topics: Africa, Eastern; Africa, Western; Amodiaquine; Antimalarials; Chloroquine; Drug Combinations; Drug C | 1999 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2000 |
Combination therapy for malaria in Africa: hype or hope?
Topics: Africa; Antimalarials; Artemisinins; Artesunate; Asia, Southeastern; Chloroquine; Cross-Cultural Com | 2000 |
Chloroquine or amodiaquine combined with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Topics: Adult; Amodiaquine; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Mala | 2001 |
[Present condition and problems of malaria].
Topics: Chloroquine; Drug Combinations; Drug Synergism; Humans; Malaria; Pyrimethamine; Sulfanilamides | 1978 |
[Current information on treatment and prophylaxis of malaria (author's transl)].
Topics: Adolescent; Adult; Amodiaquine; Child; Child, Preschool; Chloroquine; Dose-Response Relationship, Dr | 1979 |
Clinical pharmacokinetics of mefloquine.
Topics: Animals; Antimalarials; Drug Combinations; Drug Interactions; Humans; Malaria; Mefloquine; Plasmodiu | 1990 |
Extension of multiple drug resistant Plasmodium falciparum malaria in Africa: report of a Central African case.
Topics: Adult; Animals; Chloroquine; Drug Resistance; Humans; Malaria; Male; Plasmodium falciparum; Pyrimeth | 1989 |
[Malaria in Switzerland].
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria; Mefloquine; Plasmodium | 1988 |
Clinical chemistry of folic acid.
Topics: Absorption; Aged; Alcoholism; Anemia, Sickle Cell; Anticonvulsants; Arthritis, Rheumatoid; Biologica | 1986 |
Chemoprophylaxis of malaria.
Topics: Adolescent; Adult; Africa; Anemia, Hemolytic; Asia; Australia; Child; Child, Preschool; Chloroquine; | 1986 |
Use of pyrimethamine-sulfadoxine (Fansidar) in prophylaxis against chloroquine-resistant Plasmodium falciparum and Pneumocystis carinii.
Topics: Acquired Immunodeficiency Syndrome; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria | 1987 |
The problem of drug resistance in malaria.
Topics: Africa; Animals; Antimalarials; Artemisinins; Chemical Phenomena; Chemistry; Chloroquine; Clinical T | 1985 |
New drugs and their potential use against drug-resistant malaria.
Topics: Aminoquinolines; Animals; Antimalarials; Artemisinins; Drug Resistance, Microbial; Drug Therapy, Com | 1985 |
Recent advances in antimalarial chemotherapy and drug resistance.
Topics: Agglutination; Amodiaquine; Animals; Anti-Bacterial Agents; Antimalarials; Chloroquine; Cross Reacti | 1974 |
The present status of chloroquine in the drug treatment of malaria.
Topics: Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Plasmodium; Primaquine; Proguanil; Pyrimet | 1972 |
Development of new antimalarial drugs.
Topics: Amodiaquine; Antimalarials; Chloroquine; Drug Resistance, Microbial; Folic Acid Antagonists; Humans; | 1972 |
Advances in malariology relating to control and eradication.
Topics: Aedes; Animals; Anopheles; Antimalarials; Asia, Southeastern; Carbamates; Culex; DDT; Dieldrin; Drug | 1972 |
A review of the drug sensitivity of Plasmodium falciparum in Thailand.
Topics: Chloroquine; Drug Resistance; Geography; Humans; Malaria; Methylamines; Naphthacenes; Plasmodium fal | 1972 |
Chemotherapy of malaria.
Topics: Animals; Antimalarials; Drug Resistance, Microbial; Folic Acid Antagonists; Humans; Malaria; Phenant | 1973 |
[Importation of malaria into the Federal Republic of Germany including Berlin (West) in the last ten years (1963-1972)].
Topics: Africa; Age Factors; Aircraft; Amodiaquine; Antimalarials; Asia; Berlin; Chloroquine; Disease Outbre | 1974 |
Antifolic combinations in the treatment of malaria.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Resistance; Drug Synergism; Drug Therapy, Combinati | 1974 |
The pharmacology of the antimalarials. A rational approach to the therapy of resistant falciparum malaria.
Topics: Amodiaquine; Antimalarials; Chemical Phenomena; Chemistry; Chloroquine; Dapsone; Drug Resistance, Mi | 1969 |
Drug resistance in malaria--a perspective.
Topics: Adult; Africa; Animals; Antimalarials; Asia, Southeastern; Child; Chloroquine; Drug Resistance, Micr | 1969 |
Chemotherapy of the drug-resistant malarias.
Topics: Chloroquine; Cinchona; Drug Resistance, Microbial; Malaria; Mutation; Phytotherapy; Plants, Medicina | 1969 |
Malaria. Chemoprophylaxis and chemotherapy.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dapsone; Drug Resistance, Microbial; Drug Synergism; Humans | 1971 |
Recent advances in the chemotherapy of malaria.
Topics: Acridines; Animals; Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Cinchona; Culture M | 1971 |
Synthesis and biological activity of tricyclic antifolate compounds with fixed geometry.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chickens; Enterococcus faecali | 1971 |
Folate antagonists as antibacterial and antiprotozoal agents.
Topics: Anti-Bacterial Agents; Antimalarials; Antiprotozoal Agents; Escherichia coli; Folic Acid Antagonists | 1971 |
220 trials available for pyrimethamine and Malaria
| Article | Year |
|---|---|
Malaria chemoprophylaxis, infection of the placenta and birth weight in Gambian primigravidae.
Topics: Acute Disease; Antimalarials; Birth Weight; Chronic Disease; Dapsone; Double-Blind Method; Drug Comb | 1994 |
Controlled trial of lambda-cyhalothrin impregnated bed nets and Maloprim chemosuppression to control malaria in children living in a holoendemic area of Sierra Leone, west Africa. Study design and preliminary results.
Topics: Animals; Anopheles; Bedding and Linens; Child; Child, Preschool; Dapsone; Double-Blind Method; Drug | 1993 |
The effect of insecticide-treated bed nets on mortality of Gambian children.
Topics: Antimalarials; Bedding and Linens; Child, Preschool; Community Health Workers; Dapsone; Drug Adminis | 1991 |
Compliance with malaria chemoprophylaxis over a five-year period among children in a rural area of The Gambia.
Topics: Antimalarials; Attitude of Health Personnel; Attitude to Health; Child, Preschool; Community Health | 1990 |
Malaria prophylaxis with doxycycline in soldiers deployed to the Thai-Kampuchean border.
Topics: Antimalarials; Dapsone; Dose-Response Relationship, Drug; Doxycycline; Drug Combinations; Drug Evalu | 1989 |
Comparison of two strategies for control of malaria within a primary health care programme in the Gambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Community Health Workers; Dapsone; Drug Combina | 1988 |
Comparison of two strategies for control of malaria within a primary health care programme in the Gambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Community Health Workers; Dapsone; Drug Combina | 1988 |
Comparison of two strategies for control of malaria within a primary health care programme in the Gambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Community Health Workers; Dapsone; Drug Combina | 1988 |
Comparison of two strategies for control of malaria within a primary health care programme in the Gambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Community Health Workers; Dapsone; Drug Combina | 1988 |
Immunity to malaria in young Gambian children after a two-year period of chemoprophylaxis.
Topics: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Child, Preschool; Cohort Studies | 1988 |
The positive effect of malaria IPTp-SP on birthweight is mediated by gestational weight gain but modifiable by maternal carriage of enteric pathogens.
Topics: Antimalarials; Birth Weight; Cryptosporidiosis; Cryptosporidium; Drug Combinations; Escherichia coli | 2022 |
A cluster randomized trial of delivery of intermittent preventive treatment of malaria in pregnancy at the community level in Malawi.
Topics: Antimalarials; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Malawi; Pregnancy; Pregn | 2022 |
Overall and Gender-Specific Effects of Intermittent Preventive Treatment of Malaria with Artemisinin-Based Combination Therapies among Schoolchildren in Mali: A Three-Group Open Label Randomized Controlled Trial.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy | 2022 |
Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
Topics: Amodiaquine; Anemia, Sickle Cell; Antimalarials; Artemisinins; Chemoprevention; Child; Child, Presch | 2022 |
Effect of Malaria and Malaria Chemoprevention Regimens in Pregnancy and Childhood on Neurodevelopmental and Behavioral Outcomes in Children at 12, 24, and 36 Months: A Randomized Clinical Trial.
Topics: Antimalarials; Artemisinins; Chemoprevention; Child; Drug Combinations; Female; Humans; Malaria; Pre | 2023 |
The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial.
Topics: Antimalarials; Azithromycin; Drug Combinations; Female; Fetal Development; Humans; Malaria; Parasite | 2023 |
Effects of anti-malarial prophylaxes on maternal transfer of Immunoglobulin-G (IgG) and association to immunity against Plasmodium falciparum infections among children in a Ugandan birth cohort.
Topics: Antimalarials; Birth Cohort; Child; Drug Combinations; Female; Humans; Immunoglobulin G; Malaria; Ma | 2023 |
Effectiveness of Intermittent Screening and Treatment of Malaria in Pregnancy on Maternal and Birth Outcomes in Selected Districts in Rwanda: A Cluster Randomized Controlled Trial.
Topics: Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Pl | 2023 |
Effects of maternal antenatal treatment with two doses of azithromycin added to monthly sulfadoxine-pyrimethamine for the prevention of low birth weight in Burkina Faso: an open-label randomized controlled trial.
Topics: Abortion, Spontaneous; Antimalarials; Azithromycin; Birth Weight; Burkina Faso; Drug Combinations; F | 2023 |
Improving coverage of antenatal iron and folic acid supplementation and malaria prophylaxis through targeted information and home deliveries in Côte d'Ivoire: a cluster randomised controlled trial.
Topics: Adolescent; Anemia; Cote d'Ivoire; Dietary Supplements; Drug Combinations; Female; Folic Acid; Human | 2023 |
Effect of group versus individual antenatal care on uptake of intermittent prophylactic treatment of malaria in pregnancy and related malaria outcomes in Nigeria and Kenya: analysis of data from a pragmatic cluster randomized trial.
Topics: Adolescent; Adult; Antimalarials; Cluster Analysis; Cohort Studies; Drug Combinations; Female; Human | 2020 |
Overall, anti-malarial, and non-malarial effect of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine on birthweight: a mediation analysis.
Topics: Adult; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Newborn; Kenya; Malar | 2020 |
Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial.
Topics: Adult; Antimalarials; Artesunate; Double-Blind Method; Drug Combinations; Female; Humans; Incidence; | 2020 |
The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria.
Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Infant; Malaria; Malawi; Para | 2022 |
Cotrimoxazole versus sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria in HIV-infected pregnant women in Bangui, Central African Republic: A pragmatic randomised controlled trial.
Topics: Adult; Antimalarials; Central African Republic; Drug Combinations; Female; HIV Infections; Humans; M | 2021 |
Pharmacokinetics of Sulfadoxine and Pyrimethamine for Intermittent Preventive Treatment of Malaria During Pregnancy and After Delivery.
Topics: Adult; Africa; Antimalarials; Drug Combinations; Female; Humans; Malaria; Models, Biological; Postpa | 2017 |
Child Health Outcomes After Presumptive Infection Treatment in Pregnant Women: A Randomized Trial.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Child Development; Child Health; Child Mo | 2018 |
Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Malaria; Mefloquine; Nigeri | 2018 |
Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Benin; Burkina Faso; Drug Combinati | 2019 |
Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Benin; Burkina Faso; Drug Combinati | 2019 |
Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Benin; Burkina Faso; Drug Combinati | 2019 |
Community-based Malaria Screening and Treatment for Pregnant Women Receiving Standard Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: A Multicenter (The Gambia, Burkina Faso, and Benin) Cluster-randomized Controlled Trial.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Benin; Burkina Faso; Drug Combinati | 2019 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Preg | 2018 |
Seasonal malaria chemoprevention packaged with malnutrition prevention in northern Nigeria: A pragmatic trial (SMAMP study) with nested case-control.
Topics: Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Female; Humans; Infant; Malaria; M | 2019 |
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Topics: Antimalarials; Cross-Sectional Studies; Drug Combinations; Feasibility Studies; Female; Humans; Infa | 2019 |
Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection.
Topics: Azithromycin; Biomarkers; Drug Combinations; Female; Humans; Infant, Newborn; Live Birth; Malaria; N | 2019 |
The impact of maternal antenatal treatment with two doses of azithromycin and monthly sulphadoxine-pyrimethamine on child weight, mid-upper arm circumference and head circumference: A randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Arm; Azithromycin; Birth Weight; Child; Child, Preschoo | 2019 |
A randomized controlled trial of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy among human immunodeficiency virus-positive women.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Drug Combinations; Drug Therapy, Combinat | 2019 |
Intermittent preventive treatment: efficacy and safety of sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine plus piperaquine regimens in schoolchildren of the Democratic Republic of Congo: a study protocol for a randomized controlled trial.
Topics: Antimalarials; Child; Clinical Protocols; Congo; Drug Combinations; Drug Therapy, Combination; Ethic | 2013 |
Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Cohort Studies; Drug Combinations; Female; Humans; Incidence; Infant; M | 2014 |
Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Cohort Studies; Drug Combinations; Female; Humans; Incidence; Infant; M | 2014 |
Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Cohort Studies; Drug Combinations; Female; Humans; Incidence; Infant; M | 2014 |
Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Cohort Studies; Drug Combinations; Female; Humans; Incidence; Infant; M | 2014 |
Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Cohort Studies; Drug Combinations; F | 2014 |
Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Cohort Studies; Drug Combinations; F | 2014 |
Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Cohort Studies; Drug Combinations; F | 2014 |
Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.
Topics: Antimalarials; Artemisinins; Chemoprevention; Child, Preschool; Cohort Studies; Drug Combinations; F | 2014 |
Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Low Birt | 2015 |
Impact of intermittent preventive treatment in pregnancy with azithromycin-containing regimens on maternal nasopharyngeal carriage and antibiotic sensitivity of Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus: a cross-sectional
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antimalarials; Azithromycin; Bacterial Infections; Carrie | 2015 |
Economic evaluation of an alternative drug to sulfadoxine-pyrimethamine as intermittent preventive treatment of malaria in pregnancy.
Topics: Antimalarials; Cost-Benefit Analysis; Drug Combinations; Female; HIV Infections; Humans; Kenya; Mala | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemisinins; Burkina Faso; Case-Control Studies; Chemoprevention; Child | 2015 |
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.
Topics: Adolescent; Adult; Algorithms; Antimalarials; Area Under Curve; Drug Combinations; Female; Half-Life | 2015 |
Mefloquine Versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment in Pregnancy: A Joint Analysis on Efficacy and Tolerability.
Topics: Anemia; Antimalarials; Benin; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Malaria; | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
A Non-Inferiority, Individually Randomized Trial of Intermittent Screening and Treatment versus Intermittent Preventive Treatment in the Control of Malaria in Pregnancy.
Topics: Adolescent; Adult; Africa; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Gam | 2015 |
The effect of iron-fortified complementary food and intermittent preventive treatment of malaria on anaemia in 12- to 36-month-old children: a cluster-randomised controlled trial.
Topics: Amodiaquine; Anemia; Antimalarials; Child, Preschool; Cote d'Ivoire; Diphosphates; Drug Combinations | 2015 |
Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-lab
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female | 2015 |
Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-lab
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female | 2015 |
Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-lab
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female | 2015 |
Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-lab
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female | 2015 |
Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Chemoprevention; Child, Preschool; Drug Combin | 2016 |
Risks of Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficient Infants Exposed to Chlorproguanil-Dapsone, Mefloquine and Sulfadoxine-Pyrimethamine as Part of Intermittent Presumptive Treatment of Malaria in Infants.
Topics: Antimalarials; Cohort Studies; Dapsone; Double-Blind Method; Drug Combinations; Female; Genotype; Gl | 2015 |
Mortality, Morbidity, and Developmental Outcomes in Infants Born to Women Who Received Either Mefloquine or Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment of Malaria in Pregnancy: A Cohort Study.
Topics: Adult; Africa, Southern; Antimalarials; Child; Child Development; Drug Combinations; Female; Humans; | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Tr
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Diagnostic Tests, Routine; Drug Combinations; Female | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Safety of Seasonal Malaria Chemoprevention (SMC) with Sulfadoxine-Pyrimethamine plus Amodiaquine when Delivered to Children under 10 Years of Age by District Health Services in Senegal: Results from a Stepped-Wedge Cluster Randomized Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Drug Therap | 2016 |
Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Drug Combinations; Humans; Inf | 2016 |
Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.
Topics: Adolescent; Anemia; Antimalarials; Chemoprevention; Child; Child, Preschool; Democratic Republic of | 2017 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Incidence; Infant; Malaria; Mali; | 2008 |
[Efficacy of the amodiaquine+sulfadoxine-pyrimethamine combination and of chloroquine for the treatment of malaria in Córdoba, Colombia, 2006].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Colombia; Drug Combinati | 2008 |
From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control.
Topics: Antimalarials; Community Health Services; Drug Combinations; Health Care Costs; Health Plan Implemen | 2008 |
A community effectiveness trial of strategies promoting intermittent preventive treatment with sulphadoxine-pyrimethamine in pregnant women in rural Burkina Faso.
Topics: Adolescent; Adult; Antimalarials; Burkina Faso; Chloroquine; Drug Combinations; Female; Health Promo | 2008 |
Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria.
Topics: Adult; Animals; Antimalarials; Dietary Supplements; Drug Combinations; Female; Folic Acid; Humans; K | 2008 |
Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Combinations; G | 2008 |
Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Dr | 2009 |
Reduced efficacy of intermittent preventive treatment of malaria in malnourished children.
Topics: Antimalarials; Double-Blind Method; Drug Combinations; Ghana; Humans; Infant; Infection Control; Mal | 2009 |
Community-based promotional campaign to improve uptake of intermittent preventive antimalarial treatment in pregnancy in Burkina Faso.
Topics: Adolescent; Adult; Antimalarials; Burkina Faso; Community Health Services; Drug Combinations; Female | 2009 |
Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania.
Topics: Adult; Amodiaquine; Artemisinins; Artesunate; Dapsone; Drug Combinations; Drug Therapy, Combination; | 2009 |
Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Antimalarials; Drug Combinations; Female; | 2009 |
Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ch | 2009 |
Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cluster Analysis; Drug Combinations; Female; Humans; | 2009 |
Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cluster Analysis; Drug Combinations; Female; Humans; | 2009 |
Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cluster Analysis; Drug Combinations; Female; Humans; | 2009 |
Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cluster Analysis; Drug Combinations; Female; Humans; | 2009 |
No rebound of morbidity following intermittent preventive sulfadoxine-pyrimethamine treatment of malaria in infants in Gabon.
Topics: Anemia; Antimalarials; Child, Preschool; Cohort Studies; Double-Blind Method; Drug Administration Sc | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children.
Topics: Age Factors; Amodiaquine; Antimalarials; Body Weight; Child; Child, Preschool; Dose-Response Relatio | 2010 |
Active malaria morbidity management has limited impact on height status of preschool Senegalese children.
Topics: Antimalarials; Body Height; Child, Preschool; Chloroquine; Drug Combinations; Female; Growth Disorde | 2010 |
Malaria prevention with IPTp during pregnancy reduces neonatal mortality.
Topics: Adolescent; Adult; Antimalarials; Child; Drug Combinations; Female; Follow-Up Studies; Humans; Infan | 2010 |
Duration of protection against clinical malaria provided by three regimens of intermittent preventive treatment in Tanzanian infants.
Topics: Antimalarials; Dapsone; Drug Administration Schedule; Drug Combinations; Drug Resistance; Humans; Im | 2010 |
Intermittent preventive treatment in infants for the prevention of malaria in rural Western kenya: a randomized, double-blind placebo-controlled trial.
Topics: Anemia; Antimalarials; Artemisinins; Artesunate; Dapsone; Double-Blind Method; Drug Combinations; Hu | 2010 |
Prevention of the recurrence of anaemia in Gambian children following discharge from hospital.
Topics: Anemia; Animals; Antimalarials; Drug Combinations; Drug Resistance; Drug-Related Side Effects and Ad | 2010 |
Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Child, Preschool; Drug Comb | 2010 |
Sickle-cell disease and malaria: evaluation of seasonal intermittent preventive treatment with sulfadoxine-pyrimethamine in Senegalese patients-a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antimalarials; Double-Blind Method; Drug Combinations; Femal | 2011 |
Multiplicity of Plasmodium falciparum infection following intermittent preventive treatment in infants.
Topics: Antigens, Protozoan; Antimalarials; Chemoprevention; Drug Combinations; Female; Ghana; Humans; Infan | 2010 |
Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children.
Topics: Amodiaquine; Anemia; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Cost-Benefit Analysi | 2010 |
A comparison of iron and folate with folate alone in hematologic recovery of children treated for acute malaria.
Topics: Anemia; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Therapy, Combination; | 2010 |
Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria.
Topics: Age Factors; Antimalarials; Child, Preschool; Drug Combinations; Female; Humans; Infant; Malaria; Ma | 2011 |
Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Drug Resistance; Female; Geography; Ghana; Huma | 2010 |
Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Drug Resistance; Female; Geography; Ghana; Huma | 2010 |
Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Drug Resistance; Female; Geography; Ghana; Huma | 2010 |
Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Drug Resistance; Female; Geography; Ghana; Huma | 2010 |
A trial of intermittent preventive treatment and home-based management of malaria in a rural area of The Gambia.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Double-Blind Method; Drug Combinations; Female; Gambia | 2011 |
Prevention of malaria during pregnancy: assessing the effect of the distribution of IPTp through the national policy in Benin.
Topics: Adult; Antimalarials; Benin; Chloroquine; Drug Combinations; Female; Health Policy; HIV Infections; | 2011 |
Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Infant; Inse | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial.
Topics: Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Double-Blind Method; Drug Combinations; | 2011 |
Evaluating the effectiveness of IPTi on malaria using routine health information from sentinel health centres in southern Tanzania.
Topics: Anemia; Antimalarials; Comorbidity; Drug Administration Schedule; Drug Combinations; Female; Humans; | 2011 |
[Pharmacovigilance and impact of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women in Sélingué, Mali].
Topics: Adolescent; Adult; Anemia; Antimalarials; Drug Administration Schedule; Drug Combinations; Endemic D | 2010 |
Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trial.
Topics: Adolescent; Adult; Anemia; Antimalarials; Chemoprevention; Drug Combinations; Female; Humans; Infant | 2011 |
Increase in EPI vaccines coverage after implementation of intermittent preventive treatment of malaria in infant with Sulfadoxine -pyrimethamine in the district of Kolokani, Mali: results from a cluster randomized control trial.
Topics: Antimalarials; Cluster Analysis; Cross-Sectional Studies; Drug Combinations; Female; Humans; Immuniz | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
Effects of amodiaquine and artesunate on sulphadoxine-pyrimethamine pharmacokinetic parameters in children under five in Mali.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Blood Chemical Analysis; Child, Preschool; Dru | 2011 |
Efficacy of malaria prevention during pregnancy in an area of low and unstable transmission: an individually-randomised placebo-controlled trial using intermittent preventive treatment and insecticide-treated nets in the Kabale Highlands, southwestern Uga
Topics: Adolescent; Adult; Analysis of Variance; Antimalarials; Drug Combinations; Female; House Calls; Huma | 2011 |
The implementation of malaria intermittent preventive trialtreatment with sulphadoxine-pyrimethamine in infants reduced all-cause mortality in the district of Kolokani, Mali: results from a cluster randomized control.
Topics: Antimalarials; Drug Combinations; Female; Humans; Incidence; Infant; Malaria; Male; Mali; Pyrimetham | 2012 |
Intermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trial.
Topics: Amodiaquine; Antimalarials; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Malaria; Mal | 2012 |
Consequences of gestational malaria on birth weight: finding the best timeframe for intermittent preventive treatment administration.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Newborn; | 2012 |
Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2012 |
The effect of monthly sulfadoxine-pyrimethamine, alone or with azithromycin, on PCR-diagnosed malaria at delivery: a randomized controlled trial.
Topics: Adolescent; Adult; Antimalarials; Azithromycin; Drug Administration Schedule; Drug Combinations; Fem | 2012 |
Effectiveness of routine antihelminthic treatment on anaemia in pregnancy in Rufiji District, Tanzania: a cluster randomised controlled trial.
Topics: Adult; Albendazole; Anemia; Anemia, Iron-Deficiency; Anthelmintics; Antimalarials; Cluster Analysis; | 2011 |
A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Drug Resistance; Female; Humans; Inf | 2013 |
Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial.
Topics: Anemia; Anthropometry; Antimalarials; Double-Blind Method; Drug Combinations; Female; Hemoglobins; H | 2002 |
Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine for the treatment of mild childhood anemia in western Kenya.
Topics: Anemia; Child, Preschool; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; | 2003 |
[Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002].
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Colombia; Drug Combinations; | 2003 |
Sulfadoxine-pyrimethamine in treatment of malaria in Western Kenya: increasing resistance and underdosing.
Topics: Anti-Infective Agents; Antimalarials; Body Weight; Drug Combinations; Drug Resistance; Female; Human | 2003 |
Relation between the response to iron supplementation and sickle cell hemoglobin phenotype in preschool children in western Kenya.
Topics: Anemia; Antimalarials; Child, Preschool; Dietary Supplements; Disease Susceptibility; Double-Blind M | 2004 |
Daily iron supplementation is more efficacious than twice weekly iron supplementation for the treatment of childhood anemia in western Kenya.
Topics: Anemia; Antimalarials; Child, Preschool; Dietary Supplements; Drug Administration Schedule; Drug Com | 2004 |
Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Double-Blind Method; Drug Administration Schedule; D | 2004 |
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anemia; Birth Weight; Chemoprevention; Chloroquine; Drug A | 2005 |
Comparison of sulfadoxine-pyrimethamine with and without chloroquine for uncomplicated malaria in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Body Weight; Child; Chloroquine; Drug Therapy, Combination; Female | 2005 |
Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Chloroquine; Drug Combinations; Drug The | 2005 |
Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia.
Topics: Anti-Infective Agents; Child, Preschool; Drug Combinations; Erythromycin; Humans; Infant; Malaria; M | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks.
Topics: Amodiaquine; Animals; Anthelmintics; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschoo | 2007 |
Artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamine-resistant haplotypes.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; Democratic Republic | 2006 |
Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Dizziness; Drug Combinations; Female; Humans; Malari | 2007 |
A comparative study on the efficacy of artesunate plus sulphadoxine/pyrimethamine versus artemether-lumefantrine in eastern Sudan.
Topics: Adolescent; Adult; Animals; Antigens, Protozoan; Antimalarials; Artemether, Lumefantrine Drug Combin | 2007 |
Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana.
Topics: Anemia; Antimalarials; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Fem | 2007 |
Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana.
Topics: Anemia; Antimalarials; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Fem | 2007 |
Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana.
Topics: Anemia; Antimalarials; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Fem | 2007 |
Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana.
Topics: Anemia; Antimalarials; Data Interpretation, Statistical; Double-Blind Method; Drug Combinations; Fem | 2007 |
Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya.
Topics: Adolescent; Adult; Antimalarials; Area Under Curve; Drug Combinations; Female; Half-Life; HIV Infect | 2007 |
Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinat | 2007 |
Home-based management of fever and malaria treatment practices in Uganda.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Community Health Services; Drug Combinations; D | 2007 |
Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Malaria and anaemia among pregnant women at first antenatal clinic visit in Kisumu, western Kenya.
Topics: Adolescent; Adult; Anemia; Antimalarials; Bedding and Linens; Drug Combinations; Female; Humans; Ins | 2007 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
Topics: Amodiaquine; Antimalarials; Arsenites; Child; Drug Combinations; Drug Resistance; Drug Therapy, Comb | 2008 |
[Comparative impact of three malaria preventive regimens during pregnancy on maternal anemia due to malaria in Burkina Faso].
Topics: Adult; Anemia; Antimalarials; Burkina Faso; Chloroquine; Drug Therapy, Combination; Female; Humans; | 2008 |
Sulfadoxine-pyrimethamine-based combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi.
Topics: Child, Preschool; Double-Blind Method; Drug Combinations; Drug Resistance; Drug Therapy, Combination | 2008 |
Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian women.
Topics: Adolescent; Adult; Anemia; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria; N | 2008 |
Intermittent preventive treatment of malaria in pregnancy: a new delivery system and its effect on maternal health and pregnancy outcomes in Uganda.
Topics: Adolescent; Adult; Antimalarials; Child; Drug Combinations; Female; Humans; Infant, Low Birth Weight | 2008 |
A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinic.
Topics: Adolescent; Adult; Africa; Bedding and Linens; Double-Blind Method; Female; Humans; Insecticides; Ma | 2008 |
Duration of protection against malaria and anaemia provided by intermittent preventive treatment in infants in Navrongo, Ghana.
Topics: Anemia; Drug Administration Schedule; Drug Combinations; Ghana; Humans; Infant; Malaria; Placebos; P | 2008 |
Combined therapy for chloroquine-resistant, Plasmodium falciparum infection. Concurrent use of long-acting sulphormethoxine and pyrimethamine.
Topics: Adult; Drug Resistance, Microbial; Drug Synergism; Humans; Malaria; Male; Pyrimethamine; Sulfonamide | 1967 |
Drug therapy for Plasmodium falciparum malaria resistant to pyrimethamine-sulfadoxine (Fansidar). A study of alternate regimens in Eastern Thailand, 1980.
Topics: Child; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Plasmodium falciparum; Pyrimet | 1981 |
Susceptibility of Plasmodium falciparum to pyrimethamine and sulfadoxine/pyrimethamine in Kisumu, Kenya.
Topics: Child; Drug Resistance; Drug Therapy, Combination; Female; Humans; Kenya; Malaria; Male; Plasmodium | 1982 |
Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya.
Topics: Adolescent; Amodiaquine; Blood; Child; Chloroquine; Drug Combinations; Drug Resistance, Microbial; F | 1984 |
Randomised comparative study of mefloquine, qinghaosu, and pyrimethamine-sulfadoxine in patients with falciparum malaria.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; China; Clinical Trials as Topic; Drug Combina | 1984 |
Tolerability of long-term prophylaxis with fansidar: a randomized double-blind study in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Blood Cell Count; Chloroquine; Clinical Trials as Topic; Double-Bl | 1984 |
A phase I clinical trial of mefloquine in Brazilian male subjects.
Topics: Adult; Antimalarials; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Humans; Malar | 1983 |
A phase II clinical trial of mefloquine in Brazilian male subjects.
Topics: Adult; Antimalarials; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Humans; Malar | 1983 |
Treatment of quinine resistant falciparum malaria in Thai children.
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, | 1983 |
Falciparum malaria acquired in the area of the Thai-Khmer border resistant to treatment with Fansidar.
Topics: Antimalarials; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Male; Military Medici | 1982 |
A comparative trial of Mefloquine and Fansidar in the treatment of falciparum malaria: failure of Fansidar.
Topics: Antimalarials; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Mefloquine; Plasmodiu | 1982 |
Chemosuppressive field trials in Thailand. IV. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by mefloquine (WR 142,490, A 4-quinolinemethanol).
Topics: Adolescent; Adult; Antimalarials; Child; Drug Therapy, Combination; Female; Humans; Malaria; Male; M | 1980 |
Quinine alone versus quinine plus a pyrimethamine-sulfadoxine combination in the treatment of Plasmodium faliciparum cerebral malaria.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; | 1981 |
The in vivo sensitivity of Plasmodium falciparum to chloroquine and to sulphadoxine-pyrimethamine combination in Ibadan, Nigeria.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, Microbial; | 1981 |
Sulfadoxine-pyrimethamine for the treatment of acute malaria in children in Papua New Guinea. I. Plasmodium falciparum.
Topics: Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; | 1982 |
Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. Plasmodium vivax.
Topics: Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; | 1982 |
Sulfadoxine-pyrimethamine resistant falciparum malaria in Thai children.
Topics: Child; Child, Preschool; Drug Resistance, Microbial; Female; Humans; Infant; Malaria; Male; Plasmodi | 1981 |
The present status of malaria chemotherapy: mefloquine, a novel antimalarial.
Topics: Amodiaquine; Animals; Antimalarials; Aotus trivirgatus; Chemical Phenomena; Chemistry; Chloroquine; | 1981 |
The treatment of malaria in glucose-6-phosphate dehydrogenase deficient patients in Sabah.
Topics: Adolescent; Adult; Anemia, Hemolytic; Antimalarials; Child; Chloroquine; Drug Combinations; Female; | 1981 |
Severe morbidity among children in a trial malaria chemoprophylaxis with pyrimethamine or chloroquine in Ibarapa, Nigeria.
Topics: Age Factors; Child, Preschool; Chloroquine; Female; Follow-Up Studies; Humans; Incidence; Infant; Ma | 1993 |
The differing impact of chloroquine and pyrimethamine/sulfadoxine upon the infectivity of malaria species to the mosquito vector.
Topics: Animals; Anopheles; Antimalarials; Carrier State; Chloroquine; Drug Combinations; Drug Resistance; F | 1998 |
A community perspective on the efficacy of malaria treatment options for children in Lundazi district, Zambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Community Health Services; Drug Combinations; F | 1999 |
Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine.
Topics: Anti-Bacterial Agents; Antimalarials; Carrier State; Child; Disease Susceptibility; Drug Resistance, | 2000 |
Anemia of persistent malarial parasitemia in Nigerian children.
Topics: Anemia; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu | 2001 |
Chloroquine-resistant malaria in Burma.
Topics: Chloroquine; Clinical Trials as Topic; Dapsone; Drug Resistance, Microbial; Humans; Malaria; Myanmar | 1975 |
Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria.
Topics: Adolescent; Adult; Aged; Antimalarials; Drug Combinations; Drug Therapy, Combination; Humans; Malari | 1977 |
Chemosuppressive field trials in Thailand. III. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by a sulfadoxine-pyrimethamine combination.
Topics: Blood; Clinical Trials as Topic; Dapsone; Drug Combinations; Female; Humans; Malaria; Male; Plasmodi | 1977 |
Single-dose therapy of falciparum malaria with mefloquine or pyrimethamine-sulfadoxine.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Humans; Malaria; Piperi | 1979 |
Single-dose therapy of Falciparum malaria using pyrimethamine in combination with diformyldapsone or sulfadoxine.
Topics: Adolescent; Adult; Clinical Trials as Topic; Dapsone; Drug Combinations; Drug Evaluation; Humans; Ma | 1976 |
Suppression of malaria with monthly administration of combined sulphadoxine and pyrimethamine.
Topics: Adolescent; Adult; Blood; Child; Child, Preschool; Chloroquine; Clinical Trials as Topic; Drug Combi | 1975 |
Comparison of diaminodiphenylsulphonepyrimethamine and sulfadoxine-pyrimethamine combinations in the treatment of falciparum malaria in Thailand.
Topics: Adolescent; Adult; Dapsone; Drug Evaluation; Drug Synergism; Female; Humans; Malaria; Male; Middle A | 1975 |
Malaria prophylaxis.
Topics: Chloroquine; Dapsone; Drug Combinations; Humans; Malaria; Military Medicine; Plasmodium falciparum; | 1975 |
Chemosuppressive field trials in Thailand. II. The suppression of Plasmodium falciparum and Plasmodium vivax parasitemias by a diformyldapsone-pyrimethamine combination.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Dapsone; Drug Administration Schedule; Drug Evaluatio | 1975 |
Comparative efficiency of pyrimethamine-sulphormethoxine in malaria suppression given as single weekly, fortnightly and monthly doses.
Topics: Administration, Oral; Adolescent; Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female | 1975 |
Mefloquine-resistant falciparum malaria on the Thai-Burmese border.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Drug Combinations; Drug Evaluation; Drug Resist | 1991 |
Proguanil/sulfamethoxazole malaria chemoprophy-laxis on the Thai-Cambodian border.
Topics: Adult; Animals; Cambodia; Dapsone; Drug Resistance; Drug Therapy, Combination; Humans; Malaria; Male | 1991 |
Comparison of mefloquine, chloroquine plus pyrimethamine-sulfadoxine (Fansidar), and chloroquine as malarial prophylaxis in eastern Thailand.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Animals; Antimalarials; Cambodia; Chloroquine; Confid | 1991 |
Efficacy of pyrimethamine/sulfadoxine in uncomplicated severe falciparum malaria in Kenya.
Topics: Animals; Antimalarials; Drug Combinations; Humans; Kenya; Malaria; Plasmodium falciparum; Prospectiv | 1990 |
Phase III double-blind comparative study of Fansimef and Lariam for the curative treatment of Plasmodium falciparum infections in Thailand.
Topics: Adult; Animals; Antimalarials; Double-Blind Method; Drug Combinations; Drug Resistance; Female; Foll | 1990 |
Efficacy of sulfalene and pyrimethamine combination drugs alone and with quinine in treatment of P. falciparum cases in chloroquine resistant areas of north east India.
Topics: Adolescent; Animals; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; | 1990 |
Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Dapsone; Drug Therapy, Combination; Female; | 1990 |
[Comparative study of sulfadoxine-pyrimethamine and amodiaquine + sulfadoxine-pyrimethamine for the treatment of malaria caused by chloroquine-resistant Plasmodium falciparum in Maputo, Mozambique].
Topics: Adult; Amodiaquine; Animals; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combinat | 1990 |
Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women.
Topics: Adolescent; Adult; Animals; Chloroquine; Drug Evaluation; Drug Resistance; Female; Follow-Up Studies | 1989 |
Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria.
Topics: Animals; Antimalarials; Child; Chloroquine; Clinical Trials as Topic; Drug Administration Schedule; | 1988 |
Trials of mefloquine in vivax and of mefloquine plus 'fansidar' in falciparum malaria.
Topics: Adolescent; Adult; Chloroquine; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Dr | 1985 |
Combination of mefloquine with sulfadoxine-pyrimethamine compared with two sulfadoxine-pyrimethamine combinations in malaria chemoprophylaxis.
Topics: Adolescent; Adult; Antimalarials; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Micr | 1985 |
RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia.
Topics: Adolescent; Adult; Antimalarials; Child; Clinical Trials as Topic; Drug Combinations; Drug Resistanc | 1985 |
Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya.
Topics: Adolescent; Child; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; | 1987 |
Tolerability of long-term malaria prophylaxis with the combination mefloquine + sulfadoxine + pyrimethamine (Fansimef): results of a double blind field trial versus chloroquine in Nigeria.
Topics: Adolescent; Adult; Animals; Antimalarials; Aspartate Aminotransferases; Blood Cell Count; Child; Chl | 1988 |
Effectiveness of amodiaquine, sulfadoxine-pyrimethamine, and combinations of these drugs for treating chloroquine-resistant falciparum malaria in Hainan Island, China.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, | 1988 |
A comparative trial of three regimens for treating uncomplicated falciparum malaria in Acre, Brazil.
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Brazil; Clindamycin; Clinical Trials as Topi | 1988 |
Parenteral Fansidar in falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Clinical Trials as Topic; Drug Combinations; Humans; Inje | 1988 |
Sensitivity of Plasmodium falciparum to mefloquine-sulphadoxine-pyrimethamine (Fansimef) in vivo and to mefloquine alone in vitro in Nigeria.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Evaluation; Drug Resistance; Fem | 1988 |
[Effects of combined dose of pyronaridine/sulfadoxine/pyrimethamine on falciparum malaria].
Topics: Adolescent; Adult; Animals; Antimalarials; Drug Therapy, Combination; Female; Humans; Malaria; Male; | 1988 |
[Efficacy of amodiaquine, Fansidar and their combination in the treatment of chloroquine-resistant falciparum malaria].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Double-Blind Method; Drug Combi | 1988 |
Double-blind dose finding study of mefloquine-sulfadoxine-pyrimethamine in children with acute falciparum malaria.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Clinical Trials as Topic; Double-Blind | 1988 |
[In vivo resistance of Plasmodium falciparum to 4-aminoquinolines and to a sulfadoxine-pyrimethamine combination. II. Study of Manaus, Amazonas 1983-1984].
Topics: Adolescent; Adult; Amodiaquine; Animals; Brazil; Chloroquine; Clinical Trials as Topic; Drug Resista | 1986 |
Clinical trial of fansimef in Indian patients of P. falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Clinical Trials as Topic; Drug Combinations; Humans; Mala | 1988 |
Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine.
Topics: Adult; Animals; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Malaria; Ma | 1988 |
Parasitologic and clinical efficacy of 25 and 50 mg/kg of chloroquine for treatment of Plasmodium falciparum malaria in Rwandan children.
Topics: Animals; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Infant; Malaria; Male; Mefl | 1988 |
Amodiaquine and sulfadoxine-pyrimethamine as treatment for chloroquine-resistant Plasmodium falciparum in Rwanda.
Topics: Amodiaquine; Animals; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Hum | 1988 |
Evaluation of four therapeutic regimens for falciparum malaria in Mozambique, 1986.
Topics: Amodiaquine; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Drug Therapy, Combination; | 1988 |
A phase II/III double-blind, dose-finding clinical trial of a combination of mefloquine, sulfadoxine, and pyrimethamine (Fansimef) in falciparum malaria.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Brazil; Double-Blind Method; Drug C | 1987 |
Mefloquine, sulfadoxine, and pyrimethamine in the treatment of symptomatic falciparum malaria: a double-blind trial for determining the most effective dose.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Double-Blind Method; Drug Combinati | 1987 |
A double-blind trial of a fixed combination of mefloquine plus sulfadoxine-pyrimethamine compared with sulfadoxine-pyrimethamine alone in symptomatic falciparum malaria.
Topics: Administration, Oral; Adolescent; Adult; Animals; Antimalarials; Child; Double-Blind Method; Drug Co | 1987 |
The effect of mefloquine-sulfadoxine-pyrimethamine vs quinine on patients with complicated falciparum malaria.
Topics: Adult; Animals; Antimalarials; Drug Combinations; Female; Humans; Malaria; Male; Mefloquine; Plasmod | 1987 |
Double-blind study to assess the efficacy of chlorproguanil given alone or in combination with chloroquine for malaria chemoprophylaxis in an area with Plasmodium falciparum resistance to chloroquine, pyrimethamine and cycloguanil.
Topics: Adolescent; Animals; Antimalarials; Child; Chloroquine; Clinical Trials as Topic; Double-Blind Metho | 1987 |
The use of immunofluorescence to evaluate the efficacy of malarial chemoprophylaxis.
Topics: Adolescent; Adult; Animals; Antibodies, Protozoan; Drug Therapy, Combination; Fluorescent Antibody T | 1987 |
Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Double-Blind Method; Drug Therapy, Combination; Fem | 1987 |
Treatment of falciparum malaria with quinne and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border.
Topics: Cambodia; Drug Therapy, Combination; Humans; Malaria; Mefloquine; Plasmodium falciparum; Plasmodium | 1986 |
Effects of chloroquine, amodiaquine and pyrimethamine-sulfadoxine on Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinatio | 1986 |
Monthly antimalarial chemotherapy to children in a holoendemic area of Liberia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Hematocrit; Humans; Immunoglobulin G; Liberia; | 1986 |
The problem of drug resistance in malaria.
Topics: Africa; Animals; Antimalarials; Artemisinins; Chemical Phenomena; Chemistry; Chloroquine; Clinical T | 1985 |
A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria.
Topics: Adolescent; Adult; Child; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; | 1985 |
An open, randomized, phase III clinical trial of mefloquine and of quinine plus sulfadoxine-pyrimethamine in the treatment of symptomatic falciparum malaria in Brazil.
Topics: Adolescent; Adult; Brazil; Clinical Trials as Topic; Drug Combinations; Humans; Malaria; Male; Meflo | 1985 |
A phase I clinical trial of Fansimef (mefloquine plus sulfadoxine-pyrimethamine) in Brazilian male subjects.
Topics: Adult; Brazil; Double-Blind Method; Drug Combinations; Drug Evaluation; Humans; Malaria; Male; Meflo | 1985 |
Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria.
Topics: Adolescent; Adult; Antimalarials; Clinical Trials as Topic; Colombia; Double-Blind Method; Drug Comb | 1985 |
Suppressive and curative trials in Plasmodium malariae infection with Fansidar.
Topics: Child; Chloroquine; Clinical Trials as Topic; Drug Combinations; Humans; Malaria; Nephrosis; Plasmod | 1972 |
A field trial of pyrimethamine combined with dapsone in the chemoprophylaxis of malaria.
Topics: Clinical Trials as Topic; Dapsone; Drug Therapy, Combination; Humans; Malaria; Plasmodium falciparum | 1972 |
Sulfalene with pyrimethamine and chloroquine with pyrimethamine in single-dose treatment of Plasmodium falciparum infections. A trial in a rural population in northern Nigeria.
Topics: Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Humans; Infant; Malar | 1973 |
Combinations of 4-aminobenzoic acid competitors and dihydrofolate dehydrogenase inhibitors in the chemotherapy of malaria. A commentary.
Topics: Africa; Antimalarials; Asia; Chloroquine; Clinical Trials as Topic; Dapsone; Drug Evaluation; Drug R | 1974 |
The effect of parasite populations on the curative action of pyrimethamine.
Topics: Adult; Child; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Humans; Malaria; | 1968 |
[New trends in malaria therapy with folic acid antagonists].
Topics: Chloroquine; Clinical Trials as Topic; Folic Acid Antagonists; Humans; Malaria; Nigeria; Pyrimethami | 1968 |
The drug response of a normal and a multi-resistant strain of P. falciparum to sulphalene.
Topics: Chloroquine; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Folic Acid Antago | 1968 |
The suppression of malarial parasitaemia by pyrimethamine in combination with dapsone or sulphormethoxine.
Topics: Adolescent; Antimalarials; Blood; Child; Clinical Trials as Topic; Dapsone; Escherichia coli; Feces; | 1969 |
Studies on the chemotherapy of malaria. I. The treatment of overt falciparum malaria with potentiating combinations of pyrimethamine and sulphormethoxine or dapsone in The Gambia.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Clinical Trials as Topic; Dapsone; Drug Resistan | 1970 |
Supplemental folates in the therapy of Plasmodium falciparum malaria.
Topics: Administration, Oral; Anemia; Antimalarials; Blood Platelets; Chloroquine; Clinical Trials as Topic; | 1970 |
Prophylactic and sporontocidal treatment of chloroquine resistant Plasmodium falciparum from Malaya.
Topics: Adult; Amodiaquine; Anopheles; Antimalarials; Blood; Chloroquine; Clinical Trials as Topic; Dapsone; | 1970 |
Characterization of a drug resistant strain of Plasmodium falciparum from the Philippines.
Topics: Adult; Anopheles; Chloroquine; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; Malaria | 1971 |
Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Vietnam.
Topics: Adult; Antimalarials; Chloroquine; Clinical Trials as Topic; Dapsone; Humans; Malaria; Male; Methemo | 1971 |
Treatment of Plasmodium falciparum malaria in Cameroon with a single dose of antifolic drugs. 1. Combination of sulfametopyrazine and pyrimethamine.
Topics: Adolescent; Adult; Aged; Cameroon; Child; Child, Preschool; Chloroquine; Clinical Trials as Topic; D | 1971 |
Characteristics of four new drug-resistant strains of Plasmodium falciparum from South-East Asia.
Topics: Adult; Antimalarials; Asia, Southeastern; Chloroquine; Clinical Trials as Topic; Drug Resistance, Mi | 1969 |
Erythrokinetics during treatment of acute falciparum malaria.
Topics: Adult; Anemia; Clinical Trials as Topic; Erythropoiesis; Humans; Leucovorin; Malaria; Male; Military | 1971 |
1070 other studies available for pyrimethamine and Malaria
| Article | Year |
|---|---|
Folate antagonists. 13. 2,4-Diamino-6-](alpha,alpha,alpha-trifluoro-m-tolyl)thio]quinazoline and related 2,4-diamino-6-[(phenyl- and naphthyl)thio]quinazolines, a unique class of antimetabolites with extraordinary antimalarial and antibacterial effects.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Aotus trivirgatus; Bacteria; Chickens; Folic Acid Ant | 1978 |
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
Topics: Animals; Antimalarials; Bacteria; Chemical Phenomena; Chemistry; Chickens; Drug Resistance; Folic Ac | 1979 |
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
Topics: Animals; Antimalarials; Bacteria; Drug Resistance, Microbial; Escherichia coli; Folic Acid; Folic Ac | 1977 |
Antimalarial activity of some novel derivatives of 2,4-diamino-5(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine).
Topics: Animals; Antimalarials; Chickens; Malaria; Malaria, Avian; Mice; Plasmodium berghei; Pyrimethamine; | 1976 |
Rational drug design approach for overcoming drug resistance: application to pyrimethamine resistance in malaria.
Topics: Animals; Antimalarials; Drug Design; Drug Resistance; Folic Acid Antagonists; Malaria; Male; Mice; M | 1998 |
Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials.
Topics: Animals; Antimalarials; Drug Evaluation, Preclinical; Female; Folic Acid Antagonists; Guanidines; Ma | 2001 |
Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.
Topics: Alkyl and Aryl Transferases; Animals; Antimalarials; Cells, Cultured; Electrophoresis, Polyacrylamid | 2005 |
Genetic analysis of the dihydrofolate reductase-thymidylate synthase gene from geographically diverse isolates of Plasmodium malariae.
Topics: Amino Acid Sequence; Animals; Antimalarials; Asia; Cloning, Molecular; DNA Primers; DNA, Protozoan; | 2007 |
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
Topics: Animals; Antimalarials; Cluster Analysis; Computational Biology; Drug Evaluation, Preclinical; Drug | 2008 |
Antimalarial activity of a new stilbene glycoside from Parthenocissus tricuspidata in mice.
Topics: Animals; Antimalarials; Chloroquine; Glycosides; Malaria; Male; Mice; Mice, Inbred ICR; Plant Extrac | 2008 |
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
Topics: Administration, Oral; Animals; Antimalarials; Biological Availability; Drug Resistance; Female; Foli | 2010 |
Spiroindolones, a potent compound class for the treatment of malaria.
Topics: Adenosine Triphosphatases; Animals; Antimalarials; Cell Line; Drug Discovery; Drug Resistance; Eryth | 2010 |
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
Topics: Animals; Antimalarials; Dihydroorotate Dehydrogenase; Disease Models, Animal; Drug Design; Drug Disc | 2011 |
Antimalarial pyrido[1,2-a]benzimidazoles.
Topics: Administration, Oral; Animals; Antimalarials; Benzimidazoles; Drug Resistance, Multiple; Humans; In | 2011 |
Imidazolopiperazines: hit to lead optimization of new antimalarial agents.
Topics: Amino Acids; Aniline Compounds; Animals; Antimalarials; Benzene Derivatives; Cell Line; Drug Resista | 2011 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Topics: Animals; Antimalarials; Cell Line, Tumor; Drug Discovery; Drug Evaluation, Preclinical; Drug Resista | 2011 |
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
Topics: Animals; Antimalarials; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Enzyme Inhibitors | 2012 |
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
Topics: Animals; Anopheles; Antimalarials; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Inhibitory Co | 2012 |
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds.
Topics: Aminopyridines; Animals; Antimalarials; Benzimidazoles; Hepatocytes; Humans; Malaria; Mice, SCID; Mi | 2014 |
Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
Topics: Animals; Antimalarials; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Eryth | 2015 |
Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
Topics: Administration, Oral; Animals; Antimalarials; Antiprotozoal Agents; Chlorocebus aethiops; Disease Mo | 2015 |
A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines.
Topics: Animals; Antimalarials; Ether-A-Go-Go Potassium Channels; Humans; Liver; Malaria; Malaria, Falciparu | 2015 |
Antimalarial Oxoprotoberberine Alkaloids from the Leaves of Miliusa cuneata.
Topics: Alkaloids; Animals; Annonaceae; Antimalarials; Chlorocebus aethiops; Dose-Response Relationship, Dru | 2016 |
Antimalarial Pyrido[1,2-a]benzimidazoles: Lead Optimization, Parasite Life Cycle Stage Profile, Mechanistic Evaluation, Killing Kinetics, and in Vivo Oral Efficacy in a Mouse Model.
Topics: Animals; Antimalarials; Benzimidazoles; Life Cycle Stages; Malaria; Male; Mice; Plasmodium berghei; | 2017 |
Benzoxaborole Antimalarial Agents. Part 5. Lead Optimization of Novel Amide Pyrazinyloxy Benzoxaboroles and Identification of a Preclinical Candidate.
Topics: Amides; Animals; Antimalarials; Boron Compounds; Dogs; Female; Humans; Malaria; Malaria, Falciparum; | 2017 |
Discovery of new antimalarial agents: Second-generation dual inhibitors against FP-2 and PfDHFR via fragments assembely.
Topics: Animals; Antimalarials; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dose-Response Relat | 2017 |
Early childhood malaria prevention and children's patterns of school leaving in the Gambia.
Topics: Adolescent; Antimalarials; Child; Dapsone; Drug Combinations; Early Medical Intervention; Female; Fo | 2014 |
Reactions to dapsone.
Topics: Agranulocytosis; Dapsone; Drug Combinations; Humans; Malaria; Medication Errors; Pyrimethamine | 1981 |
Chemoprophylaxis of malaria in non-immune residents in Dar es Salaam, Tanzania.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Dapsone; Drug Administ | 1984 |
Treatment of falciparum malaria with a single dose combination of dapsone and pyrimethamine (Maloprim).
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Dapsone; Drug Combinations; Female; Human | 1983 |
Malaria chemoprophylaxis--which drug?
Topics: Adult; Antimalarials; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Drug Resistance, Mi | 1983 |
Malaria in Christchurch.
Topics: Chloroquine; Dapsone; Drug Combinations; Humans; Malaria; New Zealand; Plasmodium falciparum; Plasmo | 1984 |
Chemoprophylaxis of malaria in Africa.
Topics: Agranulocytosis; Antimalarials; Dapsone; Drug Combinations; Humans; Malaria; Male; Middle Aged; Pyri | 1983 |
Agranulocytosis associated with malaria prophylaxis with Maloprim.
Topics: Adult; Aged; Agranulocytosis; Antimalarials; Dapsone; Drug Combinations; Female; Humans; Malaria; Ma | 1983 |
Agranulocytosis associated with Maloprim.
Topics: Aged; Agranulocytosis; Dapsone; Drug Combinations; Female; Humans; Malaria; Middle Aged; Pyrimethami | 1983 |
Malaria prophylaxis for long term visitors.
Topics: Antimalarials; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; | 1983 |
Maloprim--general toxicity or idiosyncrasy?
Topics: Adult; Agranulocytosis; Dapsone; Drug Combinations; Female; Humans; Malaria; Pyrimethamine | 1984 |
Drug prevention of malaria.
Topics: Dapsone; Drug Combinations; Humans; Malaria; Pyrimethamine | 1981 |
Malaria prophylaxis.
Topics: Antimalarials; Dapsone; Drug Combinations; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Tr | 1981 |
Malaria prophylaxis: guidelines for travellers from Britain. Malaria Reference Laboratory of the Public Health Laboratory Service, London.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Culicidae; Dapsone; Doxycycline; | 1995 |
A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 6. The impact of the interventions on mortality and morbidity from malaria.
Topics: Antimalarials; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Gambia; Humans; Hygiene; I | 1993 |
A malaria control trial using insecticide-treated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 8. Cost-effectiveness of bed net impregnation alone or combined with chemoprophylaxis in preventing mortality and morbidit
Topics: Antimalarials; Bedding and Linens; Child, Preschool; Cost-Benefit Analysis; Dapsone; Drug Combinatio | 1993 |
Malaria prophylaxis prescribed for travellers from New Zealand.
Topics: Antimalarials; Chloroquine; Dapsone; Drug Combinations; Drug Utilization; Humans; Malaria; New Zeala | 1997 |
Hypersensitivity syndrome associated with dapsone/pyrimethamine (Maloprim) antimalaria chemoprophylaxis.
Topics: Adult; Antimalarials; Dapsone; Drug Combinations; Drug Hypersensitivity; Glucocorticoids; Humans; Ma | 2002 |
Determination of plasma concentrations of dapsone, monoacetyl dapsone and pyrimethamine in human subjects dosed with maloprim.
Topics: Adult; Chromatography, High Pressure Liquid; Dapsone; Drug Combinations; Half-Life; Humans; Malaria; | 1979 |
Anti-sporozoite antibodies and immunity to malaria in a rural Gambian population.
Topics: Age Factors; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Preschool; Dapsone; Drug C | 1988 |
Malaria in travelers returning from Kenya: failure of self-treatment with pyrimethamine/sulfadoxine.
Topics: Animals; Antimalarials; Dapsone; Drug Combinations; Humans; Kenya; Malaria; Plasmodium falciparum; P | 1989 |
Plasmodium vivax resistance to chloroquine?
Topics: Acute Disease; Animals; Antimalarials; Blood Specimen Collection; Chloroquine; Dapsone; Drug Adminis | 1989 |
Failure of dapsone/pyrimethamine plus chloroquine against falciparum malaria in Papua New Guinea.
Topics: Adult; Animals; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; | 1988 |
Malaria chemoprophylaxis with a proguanil-chloroquine-maloprim combination in Papua New Guinea.
Topics: Animals; Antimalarials; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; | 1988 |
Risk of acute non-specific upper respiratory tract infections in healthy men taking dapsone-pyrimethamine for prophylaxis against malaria.
Topics: Acute Disease; Adolescent; Antimalarials; Dapsone; Drug Combinations; Humans; Immunosuppression Ther | 1988 |
Race-linked differences in serum concentrations of dapsone, monoacetyldapsone and pyrimethamine during malaria prophylaxis.
Topics: Adolescent; Adult; Biological Availability; Black People; Dapsone; Drug Combinations; Female; Humans | 1986 |
The effect of dapsone-pyrimethamine on immunoglobulin concentrations in malaria chemoprophylaxis.
Topics: Adolescent; Adult; Antimalarials; Dapsone; Depression, Chemical; Drug Combinations; Humans; Immunogl | 1987 |
Serious problems with antimalarial drugs.
Topics: Antimalarials; Chloroquine; Dapsone; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Co | 1986 |
Excretion of chloroquine, dapsone and pyrimethamine in human milk.
Topics: Adult; Chloroquine; Dapsone; Drug Combinations; Female; Humans; Malaria; Milk, Human; Pregnancy; Pyr | 1986 |
Malaria prophylaxis.
Topics: Antimalarials; Child; Chloroquine; Dapsone; Drug Combinations; Female; Humans; Malaria; Pregnancy; P | 1986 |
Inadequate prophylaxis of malaria with dapsone-pyrimethamine.
Topics: Adolescent; Adult; Antimalarials; Biological Availability; Child; Dapsone; Drug Combinations; Drug R | 1985 |
Malaria prophylaxis for travellers.
Topics: Dapsone; Drug Combinations; Humans; Malaria; Plasmodium falciparum; Plasmodium vivax; Pyrimethamine; | 1985 |
Malaria prophylaxis for Canadian travellers.
Topics: Amodiaquine; Canada; Chloroquine; Dapsone; Doxycycline; Drug Combinations; Drug Resistance, Microbia | 1985 |
Simultaneous estimation of serum concentrations of dapsone, monoacetyldapsone, and pyrimethamine in Chinese men on maloprim for malaria prophylaxis using reversed-phase high performance liquid chromatography.
Topics: Acetylation; Adolescent; Adult; China; Chromatography, High Pressure Liquid; Dapsone; Drug Administr | 1985 |
Susceptibility of Plasmodium falciparum in The Gambia to pyrimethamine, Maloprim and chloroquine.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Dapsone; Dose-Response Relationship, Drug; Drug | 1985 |
[Malaria chemoprophylaxis. Resistance problems].
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Drug Resistance, Mi | 1985 |
Haematological safety of long-term malarial prophylaxis with dapsone-pyrimethamine.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Child; Child, Preschool; Dapsone; Drug Combinations; | 1985 |
Maloprim for malaria prophylaxis.
Topics: Antimalarials; Dapsone; Drug Combinations; Humans; Malaria; Pyrimethamine | 1985 |
Knowledge of malaria control and attitudes towards community involvement among female community volunteers: effect of capacity building in a rural community, Southeast Nigeria.
Topics: Adult; Antimalarials; Capacity Building; Child, Preschool; Community Health Workers; Community Parti | 2021 |
An ethnographic study of how health system, socio-cultural and individual factors influence uptake of intermittent preventive treatment of malaria in pregnancy with sulfadoxine-pyrimethamine in a Ghanaian context.
Topics: Adult; Anthropology, Cultural; Antimalarials; Community Health Planning; Drug Combinations; Female; | 2021 |
The provider's checklist to improve pregnant women coverage by intermittent preventive malaria treatment in Mali: a pilot implementation study.
Topics: Antimalarials; Drug Combinations; Feasibility Studies; Female; Humans; Knowledge; Malaria; Mali; Pil | 2021 |
Effect of adverse events on non-adherence and study non-completion in malaria chemoprevention during pregnancy trial: A nested case control study.
Topics: Antimalarials; Case-Control Studies; Chemoprevention; Chloroquine; Data Analysis; Drug Combinations; | 2022 |
Effect of three years' seasonal malaria chemoprevention on molecular markers of resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine and amodiaquine in Ouelessebougou, Mali.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Cross-Sectional Studies; Drug | 2022 |
Malaria health seeking practices for children, and intermittent preventive treatment in pregnancy in Wakiso District, Uganda.
Topics: Adult; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Malaria; Pregnancy | 2021 |
Predicting the effect of sulfadoxine-pyrimethamine uptake by pregnant women on birth weight using a generalized ordered partial proportional odds model.
Topics: Adult; Antimalarials; Birth Weight; Demography; Drug Combinations; Female; Fetal Macrosomia; Ghana; | 2022 |
Risk factors for placental malaria, sulfadoxine-pyrimethamine doses, and birth outcomes in a rural to urban prospective cohort study on the Bandiagara Escarpment and Bamako, Mali.
Topics: Cohort Studies; Drug Combinations; Female; Gravidity; Humans; Malaria; Mali; Placenta; Pregnancy; Pr | 2022 |
Intermittent Preventive Treatment of Malaria in Pregnancy with Sulphadoxine-Pyrimethamine and its Associated Factors in the Atwima Kwanwoma District, Ghana.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Humans; Malaria; Pr | 2022 |
Impact of Intermittent Presumptive Treatment for Malaria in Pregnancy on Hospital Birth Outcomes on the Kenyan Coast.
Topics: Antimalarials; Drug Combinations; Female; Humans; Kenya; Malaria; Pregnancy; Pregnancy Complications | 2023 |
Prevalence and risk factors of malaria and anaemia and the impact of preventive methods among pregnant women: A case study at the Akatsi South District in Ghana.
Topics: Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Humans; Malaria; P | 2022 |
Retrospective evaluation of referral by community health workers on the uptake of intermittent preventive treatment of Malaria in pregnancy in Ohaukwu, Ebonyi State, Nigeria.
Topics: Antimalarials; Community Health Workers; Drug Combinations; Female; Humans; Malaria; Nigeria; Pregna | 2022 |
Spatiotemporal spread of Plasmodium falciparum mutations for resistance to sulfadoxine-pyrimethamine across Africa, 1990-2020.
Topics: Antimalarials; Bayes Theorem; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Malaria, | 2022 |
Assessing the relationship between gravidity and placental malaria among pregnant women in a high transmission area in Ghana.
Topics: Antimalarials; Female; Ghana; Gravidity; Humans; Infant, Newborn; Malaria; Placenta; Pregnancy; Preg | 2022 |
Development and Optimization of a Selective Whole-Genome Amplification To Study Plasmodium ovale Spp.
Topics: Amino Acids; Endonucleases; Humans; Malaria; Parasitemia; Plasmodium ovale; Pyrimethamine; Recurrenc | 2022 |
Factors influencing health workers' compliance with the WHO intermittent preventive treatment for malaria in pregnancy recommendations in the Northern Region, Ghana.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Humans; Malaria; Pr | 2022 |
Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi
Topics: Antimalarials; Birth Weight; Cameroon; Drug Combinations; Female; Humans; Infant, Newborn; Insectici | 2022 |
Uptake of intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) in Uganda: a national survey.
Topics: Antimalarials; Bayes Theorem; Drug Combinations; Female; Humans; Malaria; Patient Acceptance of Heal | 2022 |
Were Women Staying on Track with Intermittent Preventive Treatment for Malaria in Antenatal Care Settings? A Cross-Sectional Study in Senegal.
Topics: Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Malaria; Male; Pregnancy; | 2022 |
Variations in the use of malaria preventive measures among pregnant women in Guinea: a secondary analysis of the 2012 and 2018 demographic and health surveys.
Topics: Antimalarials; Drug Combinations; Family Characteristics; Female; Guinea; Humans; Malaria; Male; Pre | 2022 |
Prevalence of Plasmodium falciparum haplotypes associated with resistance to sulfadoxine-pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: a genomic surveillance study.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Drug Combinations; Drug Resistance; Genomics; Ha | 2023 |
Intermittent preventive treatment and malaria amongst pregnant women who give birth at the Centre Hospitalier Régional Paul Moukambi de Koula-Moutou in southeastern Gabon.
Topics: Adult; Antimalarials; Drug Combinations; Female; Gabon; Humans; Infant, Newborn; Malaria; Pregnancy; | 2022 |
Factors influencing intermittent preventive treatment for malaria prevention among pregnant women accessing antenatal care in selected primary health care facilities of Bwari Area Council, Abuja Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; Humans; Malaria; Nigeria; Parity; Pregnancy; Pregna | 2022 |
Factors influencing intermittent preventive treatment for malaria prevention among pregnant women accessing antenatal care in selected primary health care facilities of Bwari Area Council, Abuja Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; Humans; Malaria; Nigeria; Parity; Pregnancy; Pregna | 2022 |
Factors influencing intermittent preventive treatment for malaria prevention among pregnant women accessing antenatal care in selected primary health care facilities of Bwari Area Council, Abuja Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; Humans; Malaria; Nigeria; Parity; Pregnancy; Pregna | 2022 |
Factors influencing intermittent preventive treatment for malaria prevention among pregnant women accessing antenatal care in selected primary health care facilities of Bwari Area Council, Abuja Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; Humans; Malaria; Nigeria; Parity; Pregnancy; Pregna | 2022 |
Determinants of utilization of malaria preventive measures during pregnancy among women aged 15 to 49 years in Kenya: an analysis of the Malaria Indicator Survey 2020.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Humans; Insecticides; Kenya; Malaria; M | 2022 |
Baseline prevalence of molecular marker of sulfadoxine/pyrimethamine resistance in Ebonyi and Osun states, Nigeria: amplicon deep sequencing of dhps-540.
Topics: Antimalarials; Biomarkers; Child; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Dru | 2023 |
Comparative efficacy of sulphadoxine-pyrimethamine and dihydroartemisinin-piperaquine against malaria infection during late-stage pregnancy in mice.
Topics: Animals; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; Malaria; Malaria, Falc | 2023 |
The impact of community delivery of intermittent preventive treatment of malaria in pregnancy on its coverage in four sub-Saharan African countries (Democratic Republic of the Congo, Madagascar, Mozambique, and Nigeria): a quasi-experimental multicentre e
Topics: Adolescent; Adult; Antimalarials; Democratic Republic of the Congo; Drug Combinations; Female; Human | 2023 |
Population dynamics and drug resistance mutations in Plasmodium falciparum on the Bijagós Archipelago, Guinea-Bissau.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Folic Acid Antagonists; Guinea-Bissau; Humans; Ma | 2023 |
Investigation of Four Cases of Stevens-Johnson Syndrome among Participants in a Mass Drug Administration Campaign with Sulfadoxine-Pyrimethamine and Primaquine in Haiti, 2020.
Topics: Antimalarials; COVID-19; Drug Combinations; Haiti; Humans; Malaria; Mass Drug Administration; Pandem | 2023 |
Coverage of intermittent preventive treatment of malaria in infants after four years of implementation in Sierra Leone.
Topics: Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Humans; Infant; Malaria; Pyrime | 2023 |
Using Andersen's behavioral model of health care use for intermittent preventive treatment of malaria in pregnancy in Nigeria.
Topics: Animals; Antimalarials; Cross-Sectional Studies; Delivery of Health Care; Drug Combinations; Female; | 2023 |
Uptake of four or more doses of sulfadoxine pyrimethamine for intermittent preventive treatment of malaria during pregnancy in Zambia: findings from the 2018 malaria in pregnancy survey.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Malari | 2023 |
High burden of asymptomatic malaria and anaemia despite high adherence to malaria control measures: a cross-sectional study among pregnant women across two seasons in a malaria-endemic setting in Ghana.
Topics: Anemia; Antimalarials; Cross-Sectional Studies; Female; Ghana; Humans; Infant, Newborn; Malaria; Mal | 2023 |
Polymorphism analysis of drug resistance markers in Plasmodium falciparum isolates from Benin.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Benin; Drug Combinations; Drug | 2023 |
Drug resistance profiling of asymptomatic and low-density Plasmodium falciparum malaria infections on Ngodhe island, Kenya, using custom dual-indexing next-generation sequencing.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Female; High-Throughput Nucleotide Sequencing; Hu | 2023 |
Plasmodium falciparum drug resistance-associated mutations in isolates from children living in endemic areas of Burkina Faso.
Topics: Antimalarials; Burkina Faso; Child; Codon; Drug Combinations; Drug Resistance; Female; Humans; Malar | 2023 |
Peripheral and Placental Prevalence of Sulfadoxine-Pyrimethamine Resistance Markers in Plasmodium falciparum among Pregnant Women in Southern Province, Rwanda.
Topics: Antimalarials; Birth Weight; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Malaria, F | 2023 |
Prevalence of molecular markers of resistance to sulfadoxine-pyrimethamine before and after community delivery of intermittent preventive treatment of malaria in pregnancy in sub-Saharan Africa: a multi-country evaluation.
Topics: Antimalarials; Biomarkers; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Drug | 2023 |
Using Short Message Service Alerts to Increase Antenatal Care and Malaria Prevention: Findings from Implementation Research Pilot in Guinea.
Topics: Antimalarials; Drug Combinations; Female; Guinea; Health Facilities; Humans; Malaria; Patient Accept | 2019 |
A new effective antiplasmodial compound: Nanoformulated pyrimethamine.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Compounding; Liver; Malaria; Male; Mice; Micell | 2020 |
Determinants of intermittent preventive treatment of malaria among women attending antenatal clinics in primary health care centers in Ogbomoso, Oyo State, Nigeria.
Topics: Adult; Antimalarials; Directly Observed Therapy; Drug Combinations; Female; Focus Groups; Health Kno | 2019 |
"They Merely Prescribe and I Merely Swallow": Perceptions of Antenatal Pharmaceuticals and Nutritional Supplements Among Pregnant Women in Bamako, Mali.
Topics: Adult; Antimalarials; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; Health Knowl | 2020 |
Antenatal visits are positively associated with uptake of tetanus toxoid and intermittent preventive treatment in pregnancy in Ivory Coast.
Topics: Adolescent; Adult; Antimalarials; Cote d'Ivoire; Drug Combinations; Female; Humans; Infant, Newborn; | 2019 |
Mathematical models for within-host competition of malaria parasites.
Topics: Algorithms; Animals; Antimalarials; Chloroquine; Computer Simulation; Drug Resistance; Host-Parasite | 2019 |
Factors influencing adherence to the new intermittent preventive treatment of malaria in pregnancy policy in Keta District of the Volta region, Ghana.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Humans; | 2019 |
The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Cross-Sectional Studies; Drug Combinations; Female; | 2020 |
High uptake of Intermittent Preventive Treatment of malaria in pregnancy is associated with improved birth weight among pregnant women in Ghana.
Topics: Adolescent; Adult; Birth Weight; Cohort Studies; Drug Combinations; Female; Ghana; Humans; Linear Mo | 2019 |
Markers of sulfadoxine-pyrimethamine resistance in Eastern Democratic Republic of Congo; implications for malaria chemoprevention.
Topics: Adolescent; Antimalarials; Biomarkers; Chemoprevention; Child; Child, Preschool; Democratic Republic | 2019 |
Dare we dream of the end of malaria?
Topics: Antimalarials; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Insecti | 2020 |
Evaluation of the application of national malaria treatment guidelines in private pharmacies in a rural area in the Democratic Republic of Congo.
Topics: Adult; Aged; Antimalarials; Artemether, Lumefantrine Drug Combination; Case Management; Cross-Sectio | 2019 |
Plasmodium infection cure cycles induce modulation of conventional dendritic cells.
Topics: Animals; Antiprotozoal Agents; Cytokines; Dendritic Cells; Female; Immunologic Memory; Malaria; Mice | 2020 |
Health Workers' Awareness and Knowledge of Current Recommendation of Intermittent Preventive Treatment in Pregnancy in South-Western Nigeria.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Health Knowledge, Attitude | 2020 |
Coverage and effectiveness of intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP) on adverse pregnancy outcomes in the Mount Cameroon area, South West Cameroon.
Topics: Adolescent; Adult; Antimalarials; Cameroon; Drug Combinations; Female; Humans; Malaria; Pregnancy; P | 2020 |
[Sulfadoxine-pyrimethamine-based intermittent preventive treatment in pregnant women and its effect on birth weight: application of 3-dosing regimen in the urban area of South Benin in 2017].
Topics: Adult; Antimalarials; Benin; Birth Weight; Cross-Sectional Studies; Drug Combinations; Female; Human | 2019 |
Prevalence of Congenital Malaria in Kisangani, A Stable Malaria Transmission Area in Democratic Republic of the Congo.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Democratic Republic of the Congo; Drug Co | 2020 |
Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine in Malawi after adoption of updated World Health Organization policy: an analysis of demographic and health survey 2015-2016.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Care Surveys; Health Policy; Hum | 2020 |
Relationships Between Measures of Malaria at Delivery and Adverse Birth Outcomes in a High-Transmission Area of Uganda.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infan | 2020 |
Correlates of uptake of optimal doses of sulfadoxine-pyrimethamine for prevention of malaria during pregnancy in East-Central Uganda.
Topics: Adolescent; Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Combinations; Female; Human | 2020 |
Effect of sulfadoxine-pyrimethamine doses for prevention of malaria during pregnancy in hypoendemic area in Tanzania.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Endemic Diseases; Female; Humans; | 2020 |
Factors influencing the use of intermittent preventive treatment of pregnant women seeking care at primary healthcare facilities in the Bwari Area Council, Abuja, Nigeria.
Topics: Adult; Antimalarials; Clinical Competence; Drug Combinations; Female; Health Services Accessibility; | 2020 |
Severe-malaria infection and its outcomes among pregnant women in Burkina Faso health-districts: Hierarchical Bayesian space-time models applied to routinely-collected data from 2013 to 2018.
Topics: Adult; Antimalarials; Bayes Theorem; Burkina Faso; Drug Combinations; Female; Humans; Incidence; Mal | 2020 |
Factors associated with the uptake of intermittent preventive treatment of malaria in pregnancy in the Bamenda health districts, Cameroon.
Topics: Adolescent; Adult; Cameroon; Cross-Sectional Studies; Directly Observed Therapy; Drug Administration | 2020 |
Serotype Profile of Nasopharyngeal Isolates of
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Azithromycin; Burkina Faso; Carrier State; Chemop | 2020 |
Defining the combined benefit of intermittent preventive malaria treatment in pregnancy.
Topics: Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pyrimethamine; S | 2020 |
Inequities in the use of sulphadoxine-pyrimethamine for malaria prophylaxis during pregnancy in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Care Surveys; Health Services Ac | 2020 |
Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon.
Topics: Adult; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Cameroon; Drug Combinations; Femal | 2020 |
Antimalarial drug resistance molecular makers of Plasmodium falciparum isolates from Sudan during 2015-2017.
Topics: Adolescent; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Malaria; Male; Membr | 2020 |
Two-Year Scale-Up of Seasonal Malaria Chemoprevention Reduced Malaria Morbidity among Children in the Health District of Koutiala, Mali.
Topics: Antimalarials; Chemoprevention; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; | 2020 |
Managing intermittent preventive treatment of malaria in pregnancy challenges: an ethnographic study of two Ghanaian administrative regions.
Topics: Adolescent; Adult; Anthropology, Cultural; Antimalarials; Communicable Disease Control; Drug Combina | 2020 |
Reaching the unreached: effectiveness and satisfaction with community-directed distribution of sulfadoxine-pyrimethamine for preventing malaria in pregnancy in rural South-East, Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; Humans; Malaria; Nigeria; Personal Satisfaction; Pr | 2020 |
Malaria and curable sexually transmitted infections in pregnant women: A two-years observational study in rural Burkina Faso.
Topics: Adult; Antimalarials; Burkina Faso; Coinfection; Female; Humans; Malaria; Middle Aged; Pregnancy; Pr | 2020 |
Effects of Malaria Interventions During Pregnancy on Low Birth Weight in Malawi.
Topics: Antimalarials; Child; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study.
Topics: Adolescent; Adult; Africa, Central; Africa, Western; Amodiaquine; Antimalarials; Case-Control Studie | 2020 |
Assessment of antimalarial drug resistant markers in asymptomatic Plasmodium falciparum infections after 4 years of indoor residual spraying in Northern Ghana.
Topics: Amodiaquine; Antimalarials; Biomarkers, Pharmacological; Carrier State; Child, Preschool; Chloroquin | 2020 |
Coverage of intermittent preventive treatment of malaria in pregnancy in four sub-Saharan countries: findings from household surveys.
Topics: Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Infant; Madagascar; Malar | 2021 |
Late ANC initiation and factors associated with sub-optimal uptake of sulphadoxine-pyrimethamine in pregnancy: a preliminary study in Cape Coast Metropolis, Ghana.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Humans; | 2021 |
Cost-effectiveness of district-wide seasonal malaria chemoprevention when implemented through routine malaria control programme in Kita, Mali using fixed point distribution.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Communicable Disease Control; Cost-Be | 2021 |
Malaria Infection Is Common and Associated With Perinatal Mortality and Preterm Delivery Despite Widespread Use of Chemoprevention in Mali: An Observational Study 2010 to 2014.
Topics: Antimalarials; Chemoprevention; Drug Combinations; Female; Humans; Infant, Newborn; Longitudinal Stu | 2021 |
Artemisinin combination therapy fails even in the absence of Plasmodium falciparum kelch13 gene polymorphism in Central India.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; Female; | 2021 |
Malaria intermittent preventive treatment in Nigeria: a qualitative study to explore barriers.
Topics: Adolescent; Adult; Antimalarials; Delivery of Health Care; Drug Combinations; Female; Focus Groups; | 2021 |
Determinants of intermittent preventive treatment with sulfadoxine-pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey.
Topics: Adolescent; Adult; Antimalarials; Communicable Disease Control; Cross-Sectional Studies; Drug Combin | 2021 |
Decomposition of socioeconomic inequalities in the uptake of intermittent preventive treatment of malaria in pregnancy in Nigeria: evidence from Demographic Health Survey.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Healthcare Disparities; Humans; Malaria | 2021 |
In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA.
Topics: Animals; Antimalarials; Cameroon; Chloroquine; Disease Models, Animal; Drug Combinations; Fermented | 2021 |
Determinants of the uptake of intermittent preventive treatment of malaria in pregnancy with sulphadoxine pyrimethamine in Sabatia Sub County, Western Kenya.
Topics: Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Kenya; Malaria; Pregnancy | 2021 |
Sulfadoxine-Pyrimethamine Exhibits Dose-Response Protection Against Adverse Birth Outcomes Related to Malaria and Sexually Transmitted and Reproductive Tract Infections.
Topics: Adult; Anti-Infective Agents; Chemoprevention; Drug Combinations; Female; Humans; Malaria; Pregnancy | 2017 |
Assessment of coverage of preventive treatment and insecticide-treated mosquito nets in pregnant women attending antenatal care services in 11 districts in Mozambique in 2011: the critical role of supply chain.
Topics: Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Insecticide-Treated Bedne | 2017 |
Seasonal malaria chemoprevention in the Sahel.
Topics: Africa; Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Drug Combinations; Female; Hu | 2017 |
Ex vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, Senegal.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; DNA, Pro | 2017 |
Study on testicular response to prolong artemisinin-based combination therapy treatments in guinea pigs.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug C | 2018 |
Intermittent preventive treatment of malaria in pregnancy: a cross-sectional survey to assess uptake of the new sulfadoxine-pyrimethamine five dose policy in Ghana.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Health | 2017 |
Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents.
Topics: Antimalarials; Benzothiazoles; Colorimetry; Diamines; Dihydroorotate Dehydrogenase; Erythrocytes; Fl | 2017 |
Large-scale delivery of seasonal malaria chemoprevention to children under 10 in Senegal: an economic analysis.
Topics: Amodiaquine; Antimalarials; Chemoprevention; Child; Child, Preschool; Community Health Workers; Cost | 2017 |
Cost-effectiveness of malaria preventive treatment for HIV-infected pregnant women in sub-Saharan Africa.
Topics: Africa South of the Sahara; Antimalarials; Coinfection; Cost-Benefit Analysis; Drug Combinations; Fe | 2017 |
Response to "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".
Topics: Antimalarials; Female; Humans; Lactation; Malaria; Pregnancy; Pyrimethamine; Sulfadoxine | 2017 |
Regarding "Lactation Status and Studies of Pyrimethamine Pharmacokinetics in Pregnancy".
Topics: Antimalarials; Female; Humans; Lactation; Malaria; Pregnancy; Pyrimethamine; Sulfadoxine | 2017 |
Seasonal malaria chemoprevention: successes and missed opportunities.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Chemoprevention; Child, Preschool; Drug Comb | 2017 |
Seasonal Dynamics of Malaria in Pregnancy in West Africa: Evidence for Carriage of Infections Acquired Before Pregnancy Until First Contact with Antenatal Care.
Topics: Adolescent; Adult; Africa, Western; Antimalarials; Female; Humans; Infectious Disease Transmission, | 2018 |
Intermittent Preventive Therapy in Pregnancy and Incidence of Low Birth Weight in Malaria-Endemic Countries.
Topics: Africa; Antimalarials; Birth Weight; Female; Humans; Malaria; Malnutrition; Pregnancy; Pyrimethamine | 2018 |
Next-Generation Sequencing and Bioinformatics Protocol for Malaria Drug Resistance Marker Surveillance.
Topics: Antimalarials; Computational Biology; Drug Resistance; Genotype; High-Throughput Nucleotide Sequenci | 2018 |
Factors influencing uptake of intermittent preventive treatment of malaria in pregnancy using sulphadoxine pyrimethamine in Sunyani Municipality, Ghana.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Ghana; Health | 2017 |
Investigation of pregnancy-associated malaria by microscopy, rapid diagnostic test and PCR in Bandundu, the Democratic Republic of Congo.
Topics: Adolescent; Adult; Antimalarials; Democratic Republic of the Congo; Diagnostic Tests, Routine; Dose- | 2018 |
Uptake of intermittent preventive treatment for malaria during pregnancy with Sulphadoxine-Pyrimethamine (IPTp-SP) among postpartum women in Zomba District, Malawi: a cross-sectional study.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans; Logist | 2018 |
High folate levels are not associated with increased malaria risk but with reduced anaemia rates in the context of high-dosed folate supplements and intermittent preventive treatment against malaria in pregnancy with sulphadoxine-pyrimethamine in Benin.
Topics: Anemia; Benin; Cohort Studies; Dietary Supplements; Drug Combinations; Female; Folic Acid; Humans; M | 2018 |
Improving health worker performance through text messaging: A mixed-methods evaluation of a pilot intervention designed to increase coverage of intermittent preventive treatment of malaria in pregnancy in West Nile, Uganda.
Topics: Antimalarials; Female; Guideline Adherence; Health Facilities; Health Personnel; Humans; Malaria; Pa | 2018 |
A decade since sulfonamide-based anti-malarial medicines were limited for intermittent preventive treatment of malaria among pregnant women in Tanzania.
Topics: Antimalarials; Clinical Competence; Cross-Sectional Studies; Drug Combinations; Female; Humans; Mala | 2018 |
Population Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Humans; Malaria; Mefloquine; Pharmacoki | 2019 |
Access to and use of preventive intermittent treatment for Malaria during pregnancy: A qualitative study in the Chókwè district, Southern Mozambique.
Topics: Adult; Antimalarials; Communication; Drug Combinations; Female; Health Knowledge, Attitudes, Practic | 2019 |
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Azithromycin; Burkina Faso; Child Mortality; Chil | 2019 |
[Evaluation of the knowledge of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine in Ivory Coast].
Topics: Adult; Antimalarials; Clinical Competence; Cote d'Ivoire; Cross-Sectional Studies; Drug Administrati | 2019 |
Beyond birthweight: benefits and risks of preventing malaria in pregnancy.
Topics: Artemisinins; Double-Blind Method; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pyrimetham | 2019 |
The remarkable tenacity of sulfadoxine-pyrimethamine.
Topics: Africa; Drug Combinations; Humans; Malaria; Plasmodium falciparum; Pregnancy; Pyrimethamine; Sulfado | 2019 |
Socio-demographic and regional disparities in utilization of intermittent preventive treatment for malaria in pregnancy - Nigeria demographic health survey 2013.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Drug Combinations; Female; Health Surveys; Humans; Lo | 2019 |
Factors Associated with Intermittent Preventive Treatment of Malaria During Pregnancy in Mali.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Drug Combinations; Economic Status; Educational Statu | 2019 |
What is the Link between Malaria Prevention in Pregnancy and Neonatal Survival in Nigeria?
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combinations; Femal | 2019 |
Intermittent preventive treatment of pregnant women in Kintampo area of Ghana with sulphadoxine-pyrimethamine (SP): trends spanning 2011 and 2015.
Topics: Adolescent; Adult; Antimalarials; Child; Drug Administration Schedule; Drug Combinations; Educationa | 2019 |
Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region.
Topics: Adolescent; Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans | 2019 |
Factors associated with uptake of optimal doses of intermittent preventive treatment for malaria among pregnant women in Uganda: analysis of data from the Uganda Demographic and Health Survey, 2016.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Surveys; Humans; Malaria; Middle | 2019 |
Bigger babies for women given extra prophylaxis against malaria.
Topics: Africa South of the Sahara; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, | 2013 |
Antenatal care visit attendance, intermittent preventive treatment and bed net use during pregnancy in Gabon.
Topics: Adult; Analysis of Variance; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Gabo | 2013 |
Should malaria treatment be guided by a point of care rapid test? A threshold approach to malaria management in rural Burkina Faso.
Topics: Adult; Amodiaquine; Antimalarials; Burkina Faso; Child, Preschool; Decision Making; Drug Combination | 2013 |
Antimalarial potential of China 30 and Chelidonium 30 in combination therapy against lethal rodent malaria parasite: Plasmodium berghei.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Chelidonium; Chloroquine; Cinchona; Female; Homeop | 2013 |
Congenital malaria in newborn twins.
Topics: Adult; Diseases in Twins; Drug Combinations; Female; Humans; Infant, Newborn; Malaria; Male; Mosquit | 2012 |
[Intermittent preventive treatment with sulfadoxine--pyrimethamine for malaria in pregnant women: efficacy and compliance in two urban hospitals in Burkina Faso].
Topics: Adolescent; Adult; Antimalarials; Burkina Faso; Cross-Sectional Studies; Drug Combinations; Female; | 2013 |
The association between price, competition, and demand factors on private sector anti-malarial stocking and sales in western Kenya: considerations for the AMFm subsidy.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Commerce; Drug Combinations; | 2013 |
Effectiveness of antenatal clinics to deliver intermittent preventive treatment and insecticide treated nets for the control of malaria in pregnancy in Kenya.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antimalarials; Drug Combinations; Female; Humans; Inf | 2013 |
Prevention of malaria in pregnancy with intermittent preventive treatment and insecticide treated nets in Mali: a quantitative health systems effectiveness analysis.
Topics: Adult; Cross-Sectional Studies; Delivery of Health Care; Female; Humans; Insecticide-Treated Bednets | 2013 |
In vitro and in vivo antimalarial activity and cytotoxicity of extracts and fractions from the leaves, root-bark and stem-bark of Triclisia gilletii.
Topics: Animals; Antimalarials; Cell Line; Cell Survival; Chloroquine; Drug Resistance, Multiple; Humans; Ma | 2013 |
Factors associated with utilization of sulphadoxine-pyrimethamine during pregnancy among women in Kenya: a cross-sectional study.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Gravidity; Guideline Adherence; Humans; | 2014 |
The causal effect of malaria on stunting: a Mendelian randomization and matching approach.
Topics: Antimalarials; Case-Control Studies; Causality; Child Development; Child, Preschool; Cohort Studies; | 2013 |
Treatment of pregnant BALB/c mice with sulphadoxine pyrimethamine or chloroquine abrogates Plasmodium berghei induced placental pathology.
Topics: Animals; Antimalarials; Antioxidants; Chloroquine; DNA Fragmentation; Drug Combinations; Female; Lip | 2014 |
Intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, Uganda.
Topics: Adult; Cross-Sectional Studies; Dihydropteroate Synthase; Documentation; Drug Combinations; Drug Res | 2013 |
Systemic constraints continue to limit coverage of intermittent preventive treatment for malaria in pregnancy in southeast Tanzania.
Topics: Adult; Antimalarials; Attitude of Health Personnel; Clinical Competence; Delivery of Health Care; Dr | 2013 |
Characteristics of Nigerian women taking sulfadoxine/pyrimethamine twice during pregnancy for the prevention of malaria.
Topics: Adolescent; Adult; Antimalarials; Child; Child Mortality; Cross-Sectional Studies; Drug Combinations | 2013 |
A new strategy and its effect on adherence to intermittent preventive treatment of malaria in pregnancy in Uganda.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Promotion; Humans; Malaria; Medi | 2013 |
Perceptions of intermittent preventive treatment of malaria in pregnancy (IPTp) and barriers to adherence in Nasarawa and Cross River States in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combinations; Femal | 2013 |
Aggressive chemotherapy and the selection of drug resistant pathogens.
Topics: Animals; Antimalarials; Clone Cells; Dose-Response Relationship, Drug; Drug Resistance; Erythrocytes | 2013 |
Feasibility and coverage of implementing intermittent preventive treatment of malaria in pregnant women contacting private or public clinics in Tanzania: experience-based viewpoints of health managers in Mkuranga and Mufindi districts.
Topics: Antimalarials; Attitude of Health Personnel; Drug Administration Schedule; Drug Combinations; Female | 2013 |
Utilization of malaria prevention methods by pregnant women in Yaounde.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antimalarials; Cameroon; Cross-Sectional Studies; Dru | 2013 |
Factors affecting uptake of optimal doses of sulphadoxine-pyrimethamine for intermittent preventive treatment of malaria in pregnancy in six districts of Tanzania.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Co | 2014 |
Health facility-based data on women receiving sulphadoxine-pyrimethamine during pregnancy in Tanzania: lessons to learn from a cross-sectional survey in Mkuranga and Mufindi districts and other national survey reports.
Topics: Adult; Cross-Sectional Studies; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pregnancy Com | 2014 |
Parasite clearance following treatment with sulphadoxine-pyrimethamine for intermittent preventive treatment in Burkina-Faso and Mali: 42-day in vivo follow-up study.
Topics: Adolescent; Adult; Antimalarials; Asymptomatic Infections; Biomarkers; Burkina Faso; Dried Blood Spo | 2014 |
Insights following change in drug policy: a descriptive study for antimalarial prescription practices in children of public sector health facilities in Jharkhand state of India.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Cross-Sec | 2013 |
Protective effect of Thunbergia laurifolia extract on hemolysis during Plasmodium berghei infection.
Topics: Acanthaceae; Animals; Erythrocytes; Hemolysis; Malaria; Mice; Mice, Inbred ICR; Plant Extracts; Plan | 2014 |
Effectiveness of antenatal clinics to deliver intermittent preventive treatment and insecticide treated nets for the control of malaria in pregnancy in Mali: a household survey.
Topics: Adult; Demography; Drug Combinations; Family Characteristics; Female; Health Care Surveys; Humans; I | 2014 |
Clinical malaria among pregnant women on combined insecticide treated nets (ITNs) and intermittent preventive treatment (IPTp) with sulphadoxine-pyrimethamine in Yaounde, Cameroon.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Cameroon; Case-Control Studies; Chemoprevention; Coho | 2014 |
Assessment of the consistency of national-level policies and guidelines for malaria in pregnancy in five African countries.
Topics: Africa; Antimalarials; Chemoprevention; Drug Combinations; Female; Health Policy; Health Services Re | 2014 |
Plasmodium malariae infection: a case of missed diagnosis.
Topics: Artemisinins; Artesunate; Azure Stains; Child; Chromatography, Affinity; Diagnostic Errors; Drug Com | 2014 |
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia and birthweight in areas with high and low malaria transmission intensity in Tanzania.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Low Birth Wei | 2014 |
Submicroscopic malaria infection during pregnancy and the impact of intermittent preventive treatment.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Asymptomatic Diseases | 2014 |
Malaria prevention and treatment in pregnancy: survey of current practice among private medical practitioners in Lagos, Nigeria.
Topics: Adult; Antimalarials; Chloroquine; Female; Humans; Malaria; Male; Middle Aged; Nigeria; Practice Pat | 2015 |
Moving malaria in pregnancy programs from neglect to priority: experience from Malawi, Senegal, and Zambia.
Topics: Antimalarials; Capacity Building; Drug Combinations; Female; Health Policy; Health Priorities; Healt | 2014 |
Intermittent use of sulphadoxine-pyrimethamine for malaria prevention: a cross-sectional study of knowledge and practices among Ugandan women attending an urban antenatal clinic.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Health Knowled | 2014 |
Genetic mutations in Plasmodium falciparum and Plasmodium vivax dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) in Vanuatu and Solomon Islands prior to the introduction of artemisinin combination therapy.
Topics: Antimalarials; Artemisinins; Cross-Sectional Studies; Dihydropteroate Synthase; Dried Blood Spot Tes | 2014 |
Compliance with intermittent preventive treatment during pregnancy among postpartum women in Ibadan, Nigeria.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Educational Status; Female; Health Knowledge, A | 2014 |
Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geita district, North-Western Tanzania.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combinat | 2014 |
Value of additional chemotherapy for malaria in pregnancy.
Topics: Antimalarials; Cost-Benefit Analysis; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, P | 2015 |
Evaluation of intermittent preventive treatment of malaria against group B Streptococcus colonization in pregnant women: a nested analysis of a randomized controlled clinical trial of sulfadoxine/pyrimethamine versus mefloquine.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antimalarials; Drug Combinations; Female; Gabon; Humans; M | 2015 |
Molecular epidemiology and seroprevalence in asymptomatic Plasmodium falciparum infections of Malagasy pregnant women in the highlands.
Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Asymptomatic Infections; Chloroquine; Drug | 2015 |
Predictors for uptake of intermittent preventive treatment of malaria in pregnancy (IPTp) in Tanzania.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Care Surveys; Humans; Malaria; M | 2015 |
Intermittent presumptive treatment in pregnancy with sulfadoxine-pyrimethamine: a counter perspective.
Topics: Antimalarials; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, Paras | 2015 |
Trends in malaria case management following changes in the treatment policy to artemisinin combination therapy at the Mbakong Health Centre, Cameroon 2006-2012: a retrospective study.
Topics: Adolescent; Adult; Aged; Antimalarials; Cameroon; Child; Child, Preschool; Community Health Centers; | 2015 |
Perspectives of health care providers on the provision of intermittent preventive treatment in pregnancy in health facilities in Malawi.
Topics: Adult; Ambulatory Care Facilities; Antimalarials; Drug Combinations; Female; Health Personnel; Human | 2015 |
Glucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana - A Cohort Study.
Topics: Adult; Antimalarials; Cohort Studies; Drug Combinations; Female; Ghana; Glucosephosphate Dehydrogena | 2015 |
Prevention of malaria in pregnancy: a fork in the road?
Topics: Antimalarials; Artemisinins; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, Parasitic; | 2015 |
The effect of local variation in malaria transmission on the prevalence of sulfadoxine-pyrimethamine resistant haplotypes and selective sweep characteristics in Malawi.
Topics: Antimalarials; Disease Transmission, Infectious; DNA, Protozoan; Drug Combinations; Drug Resistance; | 2015 |
Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight.
Topics: Adult; Africa South of the Sahara; Amino Acid Substitution; Antimalarials; Dihydropteroate Synthase; | 2016 |
Within-Host Selection of Drug Resistance in a Mouse Model of Repeated Incomplete Malaria Treatment: Comparison between Atovaquone and Pyrimethamine.
Topics: Amino Acid Substitution; Animals; Antimalarials; Atovaquone; Cell Nucleus; Cytochromes b; Drug Resis | 2016 |
The risk of malaria in Ghanaian infants born to women managed in pregnancy with intermittent screening and treatment for malaria or intermittent preventive treatment with sulfadoxine/pyrimethamine.
Topics: Antimalarials; Drug Combinations; Female; Ghana; Humans; Infant; Infant, Newborn; Malaria; Male; Par | 2016 |
Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Drug Resistance; | 2016 |
Inhibition of Glutathione Biosynthesis Sensitizes Plasmodium berghei to Antifolates.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Resistance; Female; Glutamate-Cy | 2016 |
Risk factors for placental malaria and associated adverse pregnancy outcomes in Rufiji, Tanzania: a hospital based cross sectional study.
Topics: Adult; Antimalarials; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Combinations; | 2015 |
Prevalence of intermittent preventive treatment with sulphadoxine-pyrimethamine (IPTp-SP) use during pregnancy and other associated factors in Sekondi-Takoradi, Ghana.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Co | 2015 |
Treatment of Malaria in Pregnancy.
Topics: Antimalarials; Artemisinins; Female; Humans; Malaria; Malaria, Falciparum; Pregnancy; Pregnancy Comp | 2016 |
Assessment of the usage and effectiveness of intermittent preventive treatment and insecticide-treated nets on the indicators of malaria among pregnant women attending antenatal care in the Buea Health District, Cameroon.
Topics: Adolescent; Adult; Anemia; Antimalarials; Blood; Cameroon; Chemoprevention; Cross-Sectional Studies; | 2016 |
Barriers to and determinants of the use of intermittent preventive treatment of malaria in pregnancy in Cross River State, Nigeria: a cross-sectional study.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Family Characteristics | 2016 |
Malaria research and its influence on anti-malarial drug policy in Malawi: a case study.
Topics: Antimalarials; Artemether; Artemisinins; Biomedical Research; Chloroquine; Drug Combinations; Drug R | 2016 |
[Factors associated with the failure of Intermittent Preventive Treatment for malaria among pregnant women in Yaounde].
Topics: Adult; Antimalarials; Cameroon; Case-Control Studies; Drug Combinations; Female; Hospitalization; Hu | 2016 |
Factors Influencing Anti-Malarial Prophylaxis and Iron Supplementation Non-Compliance among Pregnant Women in Simiyu Region, Tanzania.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Dietary Supplements; Drug Combinations; F | 2016 |
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Drug-Related Side Effects and Adver | 2016 |
Assessing supply-side barriers to uptake of intermittent preventive treatment for malaria in pregnancy: a qualitative study and document and record review in two regions of Uganda.
Topics: Antimalarials; Drug Combinations; Female; Health Services Accessibility; Humans; Interviews as Topic | 2016 |
Underreporting and Missed Opportunities for Uptake of Intermittent Preventative Treatment of Malaria in Pregnancy (IPTp) in Mali.
Topics: Adult; Antimalarials; Drug Combinations; Female; Focus Groups; Health Surveys; Humans; Interviews as | 2016 |
The challenge of using intermittent preventive therapy with sulfadoxine/pyrimethamine among pregnant women in Uganda.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Knowledge, Attitudes, Practice; | 2016 |
Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda.
Topics: Adolescent; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Dru | 2016 |
Dosage of Sulfadoxine-Pyrimethamine and Risk of Low Birth Weight in a Cohort of Zambian Pregnant Women in a Low Malaria Prevalence Region.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Female; HIV In | 2017 |
Scaling-up the use of sulfadoxine-pyrimethamine for the preventive treatment of malaria in pregnancy: results and lessons on scalability, costs and programme impact from three local government areas in Sokoto State, Nigeria.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; Health Care Costs; Humans; Infant, Newb | 2016 |
A novel prediction approach for antimalarial activities of Trimethoprim, Pyrimethamine, and Cycloguanil analogues using extremely randomized trees.
Topics: Antimalarials; Humans; Hydrophobic and Hydrophilic Interactions; Malaria; Models, Molecular; Plasmod | 2017 |
Intermittent Preventive Treatment with Sulfadoxine-Pyrimethamine: More Than Just an Antimalarial?
Topics: Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Malaria; Pregnancy; Pregnancy Comp | 2017 |
Antimalarial treatment patterns among pregnant women attending antenatal care clinics in south east Nigeria and the future implications.
Topics: Adult; Ambulatory Care Facilities; Antimalarials; Drug Combinations; Female; Humans; Malaria; Nigeri | 2016 |
Factors influencing utilization of intermittent preventive treatment for pregnancy in the Gushegu district, Ghana, 2013.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Directly Observed Therapy; Drug Combinati | 2016 |
Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.
Topics: Adolescent; Adult; Anorexia; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dizzi | 2017 |
Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling.
Topics: Adult; Antimalarials; Azithromycin; Drug Combinations; Female; Humans; Inactivation, Metabolic; Mala | 2017 |
Estimated impact on birth weight of scaling up intermittent preventive treatment of malaria in pregnancy given sulphadoxine-pyrimethamine resistance in Africa: A mathematical model.
Topics: Africa South of the Sahara; Antimalarials; Birth Weight; Child; Child, Preschool; Drug Combinations; | 2017 |
Intermittent preventive treatment of malaria in pregnancy: the incremental cost-effectiveness of a new delivery system in Uganda.
Topics: Adolescent; Anemia; Animals; Antimalarials; Community Health Services; Cost-Benefit Analysis; Drug C | 2008 |
The challenges of diagnosis and treatment of malaria in pregnancy in low resource settings.
Topics: Antimalarials; Developing Countries; Drug Combinations; Female; Health Resources; Humans; Malaria; P | 2008 |
Modelling the epidemiological impact of intermittent preventive treatment against malaria in infants.
Topics: Antimalarials; Child; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Drug Resistance | 2008 |
Malaria in pregnant women in an area with sustained high coverage of insecticide-treated bed nets.
Topics: Adolescent; Adult; Antimalarials; Bedding and Linens; Cross-Sectional Studies; Drug Combinations; Fe | 2008 |
Preventing malaria in infants: a strategy that works.
Topics: Africa South of the Sahara; Antimalarials; Developing Countries; Drug Combinations; Humans; Immuniza | 2008 |
Anti malarial drugs for prevention of malaria.
Topics: Africa; Animals; Antimalarials; Drug Combinations; Humans; India; Malaria; Plasmodium falciparum; Py | 2008 |
Intermittent preventive antimalarial treatment to children (IPTc): firebreak or fire trap?
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Decision Making; Drug Administration Sch | 2008 |
[Is the antimalarial fight effective in Mayotte?].
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Comoros; Drug Combinations; Female; Humans; | 2008 |
Development of behaviour change communication strategy for a vaccination-linked malaria control tool in southern Tanzania.
Topics: Chemoprevention; Communicable Disease Control; Drug Combinations; Education; Health Knowledge, Attit | 2008 |
Intermittent preventive treatment for malaria and anaemia control in Tanzanian infants; the development and implementation of a public health strategy.
Topics: Anemia; Antimalarials; Child, Preschool; Delivery of Health Care; Female; Health Knowledge, Attitude | 2009 |
Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya.
Topics: Anemia; Antimalarials; Chemoprevention; Communicable Disease Control; Cost-Benefit Analysis; Drug Co | 2008 |
Intermittent preventive antimalarial treatment in infancy.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Humans; Infant; Malaria; Pyrimethami | 2008 |
Antiplasmodial activity of root extract and fractions of Croton zambesicus.
Topics: Animals; Antimalarials; Chloroquine; Croton; Female; Lethal Dose 50; Malaria; Male; Mice; Parasitemi | 2009 |
Poor knowledge on new malaria treatment guidelines among drug dispensers in private pharmacies in Tanzania: the need for involving the private sector in policy preparations and implementation.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Cross-Sectional | 2008 |
Perception and practice of malaria prophylaxis in pregnancy among primary health care providers in Ibadan, Nigeria.
Topics: Adolescent; Adult; Antimalarials; Awareness; Chloroquine; Cross-Sectional Studies; Female; Health Kn | 2008 |
Efficacy of monotherapies and artesunate-based combination therapies in children with uncomplicated malaria in Somalia.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com | 2009 |
Individual, facility and policy level influences on national coverage estimates for intermittent preventive treatment of malaria in pregnancy in Tanzania.
Topics: Animals; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Guideline Adherence | 2008 |
Intermittent preventive treatment with antimalarial drugs.
Topics: Amodiaquine; Anemia; Antimalarials; Drug Administration Schedule; Drug Combinations; Humans; Infant; | 2009 |
Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi.
Topics: Adolescent; Adult; Anemia; Antimalarials; Birth Weight; Community Health Services; Drug Combinations | 2009 |
Rural Gambian women's reliance on health workers to deliver sulphadoxine-pyrimethamine as recommended intermittent preventive treatment for malaria in pregnancy.
Topics: Adolescent; Adult; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Gambia; G | 2009 |
Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Dapsone; Drug Synergism; Drug Therapy, Combination | 2009 |
Cost-effectiveness of malaria intermittent preventive treatment in infants (IPTi) in Mozambique and the United Republic of Tanzania.
Topics: Antimalarials; Cost-Benefit Analysis; Drug Combinations; Female; Humans; Infant; Malaria; Male; Moza | 2009 |
Malaria - change in therapeutic policy.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Drug Resistance; Humans; Ma | 2009 |
[Change of antimalarial first-line treatment in Burkina Faso in 2005].
Topics: Animals; Antimalarials; Burkina Faso; Child, Preschool; Chloroquine; Female; Health Policy; Hemoglob | 2009 |
Malaria and intestinal helminth co-infection among pregnant women in Ghana: prevalence and risk factors.
Topics: Adolescent; Adult; Anthelmintics; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; | 2009 |
Factors related to compliance to anti-malarial drug combination: example of amodiaquine/sulphadoxine-pyrimethamine among children in rural Senegal.
Topics: Amodiaquine; Animals; Antimalarials; Caregivers; Child; Child, Preschool; Drug Administration Schedu | 2009 |
Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species.
Topics: Administration, Oral; Aminopterin; Animals; Biological Availability; Enzyme Inhibitors; Female; Foli | 2009 |
Impact of delayed introduction of sulfadoxine-pyrimethamine and arthemeter-lumefantrine on malaria epidemiology in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Ch | 2009 |
Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon.
Topics: Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool; Drug Combinations | 2009 |
Child age or weight: difficulties related to the prescription of the right dosage of antimalarial combinations to treat children in Senegal.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Body Weight; Child; Child, Preschool; Drug Combinatio | 2010 |
Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Commerce; Drug Combinations; | 2009 |
Mode of action and choice of antimalarial drugs for intermittent preventive treatment in infants.
Topics: Amodiaquine; Antimalarials; Clinical Trials as Topic; Drug Combinations; Drug Resistance; Female; Hu | 2009 |
Mathematical model for optimal use of sulfadoxine-pyrimethamine as a temporary malaria vaccine.
Topics: Animals; Antimalarials; Drug Combinations; Humans; Malaria; Malaria Vaccines; Mali; Models, Immunolo | 2010 |
Self-reported data: a major tool to assess compliance with anti-malarial combination therapy among children in Senegal.
Topics: Amodiaquine; Antimalarials; Caregivers; Child; Child, Preschool; Drug Administration Schedule; Drug | 2009 |
Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali.
Topics: Antimalarials; Child, Preschool; Cross-Sectional Studies; DNA Mutational Analysis; DNA, Protozoan; D | 2010 |
Pyrimethamine induces oxidative stress in Plasmodium yoelii 17XL-infected mice: a novel immunomodulatory mechanism of action for an old antimalarial drug?
Topics: Animals; Antimalarials; Catalase; Erythrocytes; Female; Gene Expression Regulation, Enzymologic; Glu | 2010 |
Intermittent preventive treatment of malaria in pregnancy (IPTp): do frequent antenatal care visits ensure access and compliance to IPTp in Ugandan rural communities?
Topics: Adolescent; Adult; Antimalarials; Child; Drug Combinations; Female; Health Services Accessibility; H | 2010 |
Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.
Topics: Africa; Antimalarials; Comorbidity; Drug Combinations; Drug Resistance; Female; HIV Infections; Huma | 2011 |
Trends in pregnancy outcomes in Malawian adolescents receiving antimalarial and hematinic supplements.
Topics: Adolescent; Adult; Anemia; Antimalarials; Cross-Sectional Studies; Delivery, Obstetric; Drug Combina | 2010 |
The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Antimalarials; Cost-Benefit Analysis; Drug Combinations; Humans; Infant; | 2010 |
Perception and practice of malaria prophylaxis in pregnancy among health care providers in Ibadan.
Topics: Antimalarials; Chloroquine; Community Health Services; Drug Combinations; Female; Guideline Adherenc | 2007 |
Decreasing burden of malaria in pregnancy in Malawian women and its relationship to use of intermittent preventive therapy or bed nets.
Topics: Drug Combinations; Female; Hospitals; Humans; Longitudinal Studies; Malaria; Malawi; Mosquito Nets; | 2010 |
Bottlenecks for high coverage of intermittent preventive treatment in pregnancy: the case of adolescent pregnancies in rural Burkina Faso.
Topics: Adolescent; Age Distribution; Attitude to Health; Burkina Faso; Drug Combinations; Female; Health Pr | 2010 |
Community management of anti-malarials in Africa and iatrogenic risk.
Topics: Antimalarials; Atovaquone; Child; Community Health Services; Contraindications; Cote d'Ivoire; Diagn | 2011 |
Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites.
Topics: Animals; Artemisinins; Computer Simulation; Directed Molecular Evolution; DNA Copy Number Variations | 2010 |
Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model.
Topics: Animals; Antimalarials; Artemisinins; Chloroquine; Dose-Response Relationship, Drug; Drug Resistance | 2011 |
Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy.
Topics: Antimalarials; Drug Combinations; Female; Humans; Malaria; Placenta; Pregnancy; Pregnancy Complicati | 2010 |
Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Codon; Cross-Se | 2010 |
Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda.
Topics: Adolescent; Adult; Antimalarials; Delivery of Health Care; Drug Combinations; Female; Health Surveys | 2010 |
Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children.
Topics: Antibodies, Protozoan; Antimalarials; Artemisinins; Artesunate; Chemoprevention; Child, Preschool; D | 2010 |
Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi.
Topics: Adolescent; Adult; Anemia; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combination | 2011 |
Drug dispensing practices during implementation of artemisinin-based combination therapy at health facilities in rural Tanzania, 2002-2005.
Topics: Adolescent; Age Factors; Antimalarials; Artemisinins; Artesunate; Case Management; Child; Child, Pre | 2011 |
Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data.
Topics: Adolescent; Adult; Africa South of the Sahara; Antimalarials; Drug Combinations; Female; Humans; Ins | 2011 |
Intermittent preventive treatment to reduce the burden of malaria in children: new evidence on integration and delivery.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Drug Combinations; Female; Humans; Infant; Infant, New | 2011 |
Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination.
Topics: Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Resistance, Multiple; Female | 2011 |
Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance.
Topics: Animals; Antimalarials; Culicidae; Drug Resistance; Hepatocytes; Immunization; Insect Bites and Stin | 2011 |
Molecular epidemiology of Plasmodium vivax anti-folate resistance in India.
Topics: Amino Acid Substitution; Antimalarials; Dihydropteroate Synthase; DNA, Protozoan; Drug Combinations; | 2011 |
Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire.
Topics: Adolescent; Adult; Chemoprevention; Cote d'Ivoire; Cross-Sectional Studies; Drug Combinations; Drug | 2011 |
Modelling the protective efficacy of alternative delivery schedules for intermittent preventive treatment of malaria in infants and children.
Topics: Antimalarials; Child, Preschool; Drug Combinations; Humans; Infant; Malaria; Models, Theoretical; Py | 2011 |
Knowledge of malaria and preventive measures among pregnant women attending antenatal clinics in a rural local government area in Southwestern Nigeria.
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combinations; Femal | 2011 |
Field evaluation of the intermittent preventive treatment of malaria during pregnancy (IPTp) in Benin: evolution of the coverage rate since its implementation.
Topics: Adolescent; Adult; Antimalarials; Benin; Chemoprevention; Child; Drug Combinations; Drug Utilization | 2011 |
Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria and anemia in pregnant women.
Topics: Adolescent; Adult; Anemia; Antimalarials; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pre | 2011 |
Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance.
Topics: Adult; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combinations; Drug Resistance; | 2011 |
The use of intermittent preventive treatment with sulfadoxine-pyrimethamine for preventing malaria in pregnant women.
Topics: Antimalarials; Chemoprevention; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Male; P | 2011 |
Combining community case management and intermittent preventive treatment for malaria.
Topics: Africa; Antimalarials; Case Management; Child; Child, Preschool; Chloroquine; Community Health Servi | 2011 |
[Comparison of efficacy of chloroquine versus sulfadoxine-pyrimethamine in malaria prevention in pregnant women in the Toamasina region (Madagascar)].
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Drug Combinations; Endemic Diseases; Female; Humans; | 2011 |
Utilisation of malaria preventive measures during pregnancy and birth outcomes in Ibadan, Nigeria.
Topics: Adult; Animals; Antimalarials; Attitude to Health; Chloroquine; Drug Combinations; Female; Health Pr | 2011 |
The fitness of drug-resistant malaria parasites in a rodent model: multiplicity of infection.
Topics: Analysis of Variance; Animals; Antimalarials; Biological Evolution; Drug Resistance; Genetic Fitness | 2011 |
Evaluating health workers' potential resistance to new interventions: a role for discrete choice experiments.
Topics: Adult; Aging; Choice Behavior; Drug Combinations; Evaluation Studies as Topic; Female; Ghana; Health | 2011 |
Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2011 |
Management of uncomplicated malaria in children under 13 years of age at a district hospital in Senegal: from official guidelines to usual practices.
Topics: Adolescent; Amodiaquine; Antimalarials; Blood; Child; Child, Preschool; Drug Combinations; Drug Ther | 2011 |
Presumptive treatment to reduce imported malaria among refugees from east Africa resettling in the United States.
Topics: Adolescent; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Combinations; Eth | 2011 |
Intermittent preventive treatment during pregnancy with sulphadoxine-pyrimethamine may promote Plasmodium falciparum gametocytogenesis.
Topics: Adolescent; Adult; Antimalarials; Chi-Square Distribution; Drug Combinations; Drug Therapy, Combinat | 2012 |
Reduced impact of pyrimethamine drug pressure on Plasmodium malariae dihydrofolate reductase gene.
Topics: Africa; Animals; Antimalarials; Cambodia; Drug Combinations; Drug Resistance; Genetic Variation; Hum | 2012 |
Acceptability of coupling intermittent preventive treatment in infants with the expanded programme on immunization in three francophone countries in Africa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Antipyretics; Attitude of Health Personne | 2012 |
Prescription practices and availability of artemisinin monotherapy in India: where do we stand?
Topics: Antimalarials; Artemisinins; Cross-Sectional Studies; Drug Combinations; Drug Resistance; Health Fac | 2011 |
[Evaluation of the use of insecticide-treated nets and intermittent preventive treatment in three health zones in Benin].
Topics: Antimalarials; Benin; Child, Preschool; Drug Administration Schedule; Drug Combinations; Female; Geo | 2012 |
Sulfadoxine-pyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC).
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Congo; Drug Combinations; Drug Resistance; Female; F | 2012 |
Pharmacovigilance of malaria intermittent preventive treatment in infants coupled with routine immunizations in 6 African countries.
Topics: Adverse Drug Reaction Reporting Systems; Africa; Antimalarials; Drug Combinations; Drug-Related Side | 2012 |
The impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on the prevalence of malaria parasitaemia in pregnancy.
Topics: Adult; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Malaria; Para | 2012 |
Mosquito infection studies with Aotus monkeys and humans infected with the Chesson strain of Plasmodiun vivax.
Topics: Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Management; Disease Models, Animal; | 2012 |
A high-coverage artificial chromosome library for the genome-wide screening of drug-resistance genes in malaria parasites.
Topics: Animals; Antimalarials; Chromosomes, Artificial; Cloning, Molecular; Drug Resistance; Gene Library; | 2012 |
Patterns of case management and chemoprevention for malaria-in-pregnancy by public and private sector health providers in Enugu state, Nigeria.
Topics: Adult; Antimalarials; Case Management; Chemoprevention; Chloroquine; Drug Combinations; Female; Heal | 2012 |
Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Ch | 2012 |
Enhanced transmission of drug-resistant parasites to mosquitoes following drug treatment in rodent malaria.
Topics: Animals; Anopheles; DNA Primers; Drug Resistance; Female; Linear Models; Logistic Models; Malaria; M | 2012 |
Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment.
Topics: Anemia; Antimalarials; Child; Child, Preschool; Clinical Trials as Topic; Drug Combinations; Fever; | 2012 |
Estimation of summary protective efficacy using a frailty mixture model for recurrent event time data.
Topics: Algorithms; Antimalarials; Computer Simulation; Drug Combinations; Ghana; Humans; Infant; Malaria; M | 2012 |
The effects of malaria and intermittent preventive treatment during pregnancy on fetal anemia in Malawi.
Topics: Anemia, Neonatal; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Fetal Blood; Fe | 2012 |
Validity of self-reported use of sulphadoxine-pyrimethamine intermittent presumptive treatment during pregnancy (IPTp): a cross-sectional study.
Topics: Adolescent; Adult; Antimalarials; Blood; Chemoprevention; Chromatography, High Pressure Liquid; Cros | 2012 |
The in vivo antimalarial activity of methylene blue combined with pyrimethamine, chloroquine and quinine.
Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhib | 2012 |
In vitro hemolytic effect of sulfadoxine/pyrimethamine and artemether/lumefantrine on malaria parasitized erythrocytes of female patients.
Topics: Adult; Analysis of Variance; Antimanic Agents; Artemether, Lumefantrine Drug Combination; Artemisini | 2012 |
Virulence, drug sensitivity and transmission success in the rodent malaria, Plasmodium chabaudi.
Topics: Animals; Antimalarials; Drug Resistance; Female; Genotype; Malaria; Mice; Mice, Inbred C57BL; Parasi | 2012 |
Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting.
Topics: Advisory Committees; Antimalarials; Drug Combinations; Drug Costs; Drug Resistance; Expert Testimony | 2012 |
Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax.
Topics: Alleles; Amino Acid Sequence; Animals; Antimalarials; Dose-Response Relationship, Drug; Drug Resista | 2002 |
Plasmodium berghei: routine production of pure gametocytes, extracellular gametes, zygotes, and ookinetes.
Topics: Animals; Antimalarials; Centrifugation; Erythrocytes; Female; Germ Cells; Malaria; Mice; Parasitemia | 2002 |
Preventing malaria in pregnancy.
Topics: Antimalarials; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, Paras | 2003 |
Treatment history and treatment dose are important determinants of sulfadoxine-pyrimethamine efficacy in children with uncomplicated malaria in Western Kenya.
Topics: Age Factors; Animals; Antimalarials; Body Weight; Child, Preschool; Dose-Response Relationship, Drug | 2003 |
[Effect of nitroquine on the membrane phospholipid of intraerythrocytic Plasmodium yoelii in vitro].
Topics: Animals; Anopheles; Antimalarials; Cellular Structures; Ethanolamines; Malaria; Membranes; Parasitic | 1999 |
The effect of providing fansidar (sulfadoxine-pyrimethamine) in schools on mortality in school-age children in Malawi.
Topics: Adolescent; Antimalarials; Child; Drug Combinations; Humans; Malaria; Malawi; Pyrimethamine; Sulfado | 2003 |
[Malaria study in the cyclone risk zone: entomological , diagnostic and therapeutic approach in the southeastern region of Madagascar].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anopheles; Antimalarials; Child; Child, Prescho | 2002 |
Malaria in Austria 1990-2000.
Topics: Adolescent; Adult; Age Distribution; Animals; Austria; Chemoprevention; Child; Child, Preschool; Chl | 2003 |
Vendor-to-vendor education to improve malaria treatment by private drug outlets in Bungoma District, Kenya.
Topics: Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Commerce; Drug Combinations | 2003 |
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites.
Topics: Alleles; Animals; Antimalarials; Asia; Drug Resistance; Genetic Variation; Malaria; Malaria, Falcipa | 2003 |
[Limits and weaknesses of intermittent treatment in malaria prevention].
Topics: Antimalarials; Drug Therapy, Combination; Humans; Malaria; Pyrimethamine; Sulfadoxine; World Health | 2003 |
Anaemia in African children: malaria or iron deficiency?
Topics: Africa; Anemia; Anemia, Iron-Deficiency; Antimalarials; Child, Preschool; Drug Combinations; Humans; | 2003 |
Evaluation of the antimalarial properties and standardization of tablets of Azadirachta indica (Meliaceae) in mice.
Topics: Administration, Oral; Animals; Antimalarials; Azadirachta; Chloroquine; Malaria; Mice; Parasitic Sen | 2003 |
Daraprim (50-63) in simian malaria.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1951 |
Daraprim resistance in experimental malarial infections.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1952 |
Daraprim-experimental chemotherapy.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1952 |
Daraprim, clinical trials and pharmacology.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1952 |
Malaria treated with daraprim, including cerebral malaria and high parasitaemia.
Topics: Malaria; Malaria, Cerebral; Parasitemia; Pyrimethamine; Pyrimidines | 1952 |
Treatment of acute malaria with pyrimethamine.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1953 |
TINY tasteless drug now available; daraprim for malaria.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1952 |
Daraprim (B.W. 50-63) in treatment of malaria.
Topics: Humans; Malaria; Pyrimethamine; Pyrimidines | 1953 |
The antimalarial properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, daraprim.
Topics: Antimalarials; Malaria; Pyrimethamine; Pyrimidines | 1953 |
Pyrimethamine (daraprim) as a prophylactic agent against a West African strain of P. falciparum.
Topics: Black People; Humans; Malaria; Malaria, Falciparum; Pyrimethamine; Pyrimidines | 1953 |
Pyrimethamine in treatment of vivax malaria; preliminary report.
Topics: Humans; Malaria; Malaria, Vivax; Pyrimethamine; Pyrimidines | 1953 |
Studies on Plasmodium berghei n. sp. Vincke and Lips, 1948. VI. Reaction of blood-induced infection in albino mice to daraprim 2:4-diamino pyrimidine.
Topics: Albinism, Oculocutaneous; Animals; Lip; Malaria; Mice; Plasmodium; Plasmodium berghei; Pyrimethamine | 1952 |
[Medical prophylaxis with daraprim in rural areas].
Topics: Malaria; Pyrimethamine; Pyrimidines | 1952 |
Pyrimethamine daraprim the treatment of vivax malaria.
Topics: Humans; Malaria; Malaria, Vivax; Pyrimethamine; Pyrimidines | 1953 |
[A new synthetic antimalarial; pyrimethamine].
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1953 |
[Chemotherapy of malaria and the new antimalarials, daraprim and primaquine].
Topics: Antimalarials; Malaria; Primaquine; Pyrimethamine; Quinolines; Uricosuric Agents | 1953 |
The effect of pyrimethamine (daraprim) against Plasmodium gallinaceum infections in chicks.
Topics: Animals; Antimalarials; Chickens; Malaria; Plasmodium gallinaceum; Pyrimethamine | 1953 |
Studies in human malaria. XXXII. The protective and therapeutic effects of pyrimethamine (daraprim) against Chesson strain vivax malaria.
Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Pyrimethamine | 1953 |
Studies in human malaria. XXXIII. The toxicity of pyrimethamine (daraprim) in man.
Topics: Antimalarials; Blood; Malaria; Pyrimethamine | 1953 |
Studies in human malaria. XXXIV. Acquired resistance to pyrimethamine (daraprim) by the Chesson strain of plasmodium vivax.
Topics: Antimalarials; Humans; Malaria; Plasmodium vivax; Pyrimethamine | 1953 |
Relative pyrimethamine insensitivity in a case of falciparum malaria in Jamaica.
Topics: Antimalarials; Humans; Jamaica; Malaria; Malaria, Falciparum; Pyrimethamine | 1953 |
Therapeutic trial of pyrimethamine (daraprim) in human malaria.
Topics: Antimalarials; Malaria; Pyrimethamine | 1953 |
Effect of pyrimethamine in human malaria; suppressive treatment. III.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1953 |
[Preliminary report on the use of daraprim in acute malaria].
Topics: Antimalarials; Malaria; Pyrimethamine | 1953 |
[Experiments in daraprim prevention of malaria among the native population].
Topics: Antimalarials; Biomedical Research; Malaria; Pyrimethamine | 1953 |
[First results of a trail of chemoprophylaxis with malocide against malaria in children in a village of the Upper Volta].
Topics: Antimalarials; Burkina Faso; Chemoprevention; Child; Humans; Malaria; Pyrimethamine | 1953 |
Observations on monthly pyrimethamine (daraprim) prophylaxis in an East African village.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1954 |
Resistance of P. falciparum and P. malariae to pyrimethamine (daraprim) following mass treatment with this drug; a preliminary note.
Topics: Antimalarials; Humans; Malaria; Malaria, Falciparum; Pyrimethamine | 1954 |
Occurrence of pyrimethamine resistant strain of malaria in the Teita District of Kenya.
Topics: Antimalarials; Humans; Kenya; Malaria; Pyrimethamine | 1954 |
A comparison of the antimalarial effects of suppressive doses of chloroquine, amodiaquin, and pyrimethamine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Pyrimethamine | 1954 |
The effect of pyrimethamine on the BI strain of Plasmodium gallinaceum.
Topics: Antimalarials; Humans; Malaria; Plasmodium gallinaceum; Pyrimethamine | 1954 |
Relationship between time of administration, dose, and prophylactic activity of pyrimethamine on sporozoite-induced Plasmodium gallinaceum infections.
Topics: Animals; Antimalarials; Communicable Diseases; Malaria; Plasmodium gallinaceum; Pyrimethamine; Sporo | 1954 |
[Prophylaxis of malaria by a single monthly dose of pyrimethamine].
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1954 |
[Note on the treatment of epidemic malaria by a single dose of pyrimethamine].
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1954 |
A brief summary of trials with pyrimethamine (daraprim) previously undertaken at the Malaria Institute of India.
Topics: Academies and Institutes; Antimalarials; India; Malaria; Pyrimethamine | 1953 |
Preliminary report on the antirelapse properties of pyrimethamine (daraprim) and primaquine.
Topics: Humans; Malaria; Primaquine; Pyrimethamine | 1953 |
Screening of anti-malarials against P. gallinaceum in chicks. III. Synergistic action of pyrimethamine and quinine.
Topics: Animals; Antimalarials; Chickens; Malaria; Pyrimethamine; Quinine | 1953 |
Pyrimethamine (daraprim) in malaria.
Topics: Antimalarials; Chloroquine; Humans; Malaria; Pyrimethamine | 1953 |
A note on clinical trial of pyrimethamine (daraprim) and amodiaquin (camaquin) at the malaria field station, Thirmalapur, Nizamabad district.
Topics: Amodiaquine; Antimalarials; Malaria; Pyrimethamine | 1953 |
Acute malaria treated with pyrimethamine (daraprim).
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1953 |
Therapeutic trials with pyrimethamine (daraprim), resochin, amodiaquin (camoquin) and quinine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Malaria; Pyrimethamine; Quinine | 1953 |
Susceptibility of blood-induced P. cynomolgi infection to pyrimethamine (daraprim), proguanil and bromoguanide.
Topics: Antimalarials; Communicable Diseases; Disease Susceptibility; Humans; Malaria; Proguanil; Pyrimetham | 1953 |
The suppressive treatment of naturally acquired malaria in a rural village with pyrimethamine (daraprim).
Topics: Antimalarials; Environment; Malaria; Pyrimethamine; Rural Population | 1954 |
The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine.
Topics: Amodiaquine; Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Malaria; Pyrimethamine | 1954 |
Effect of pyrimethamine in human malaria. I.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1952 |
Antirelapse treatment with primaquine and pyrimethamine.
Topics: Antimalarials; Humans; Malaria; Primaquine; Pyrimethamine | 1954 |
The apparent transfer of pyrimethamine-resistance from the BI strain of Plasmodium gallinaceum to the M strain.
Topics: Antimalarials; Malaria; Plasmodium gallinaceum; Pyrimethamine | 1954 |
Pyrimethamine in the prophylaxis of malaria.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1955 |
[Malaria prevention in rural areas with pyrimethamine (daraprim)].
Topics: Humans; Malaria; Pyrimethamine | 1954 |
Daraprim as a malaria suppressant.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1954 |
Pyrimethamine in the treatment of malaria.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1955 |
Observation of pyrimethamine (daraprim) as a suppressant of malaria in a small village in Jordan.
Topics: Antimalarials; Environment; Jordan; Malaria; Pyrimethamine | 1955 |
[Preventive effects of daraprim in a native community (Catholic Mission of Huambo, Angola)].
Topics: Angola; Antimalarials; Catholicism; Malaria; Pyrimethamine; Residence Characteristics | 1955 |
Absence of potentiation between quinine and pyrimethamine in infections of Plasmodium gallinaceum in chicks.
Topics: Animals; Antimalarials; Chickens; Humans; Malaria; Plasmodium gallinaceum; Pyrimethamine; Quinine | 1956 |
Transfer of pyrimethamine in human milk.
Topics: Antimalarials; Female; Humans; Malaria; Milk, Human; Pyrimethamine | 1956 |
Transfer of pyrimethamine in human milk.
Topics: Antimalarials; Female; Humans; Malaria; Milk, Human; Pyrimethamine | 1956 |
Transfer of pyrimethamine in human milk.
Topics: Antimalarials; Female; Humans; Malaria; Milk, Human; Pyrimethamine | 1956 |
Transfer of pyrimethamine in human milk.
Topics: Antimalarials; Female; Humans; Malaria; Milk, Human; Pyrimethamine | 1956 |
Suppression of malaria with pyrimethamine in Nigerian schoolchildren.
Topics: Antimalarials; Body Weight; Child; Drug Combinations; Humans; Malaria; Malaria, Falciparum; Pyrimeth | 1956 |
[Malaria prevention with paludrine and daraprim in school children of São Tomé].
Topics: Antimalarials; Child; Humans; Malaria; Proguanil; Pyrimethamine | 1956 |
The response of Plasmodium malariae infections to pyrimethamine (daraprim).
Topics: Antimalarials; Humans; Malaria; Plasmodium malariae; Pyrimethamine | 1957 |
An examination of factors involved in the transfer of pyrimethamine in human milk.
Topics: Antimalarials; Female; Humans; Lactation; Malaria; Milk, Human; Pregnancy; Pyrimethamine | 1957 |
[Treatment of malaria with daraprim].
Topics: Antimalarials; Malaria; Pyrimethamine | 1957 |
[Action of combined primaquine-pyrimethamine. I. Experimental study on pigeons (Columba livia) infected with Plasmodium relictum].
Topics: Animals; Antimalarials; Columbidae; Malaria; Plasmodium; Primaquine; Pyrimethamine | 1957 |
Successful pyrimethamine prophylaxis of malaria in Western Tangan yika.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine | 1957 |
Single dose pyrimethamine treatment of Africans during a malaria epidemic in Tanganyika.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine; Tanzania | 1958 |
Chloroquine or pyrimethamine in salt as a supressive against sporozoite-induced vivax malaria (Chesson strain).
Topics: Animals; Antimalarials; Chloroquine; Humans; Malaria; Malaria, Vivax; Military Personnel; Pyrimetham | 1958 |
The development of pyrimethamine resistance by Plasmodium falciparum.
Topics: Antimalarials; Communicable Diseases; Humans; Malaria; Malaria, Falciparum; Plasmodium falciparum; P | 1959 |
Pyrimethamine resistance in Plasmodium vivax malaria.
Topics: Antimalarials; Blood Transfusion; Fever; Humans; Malaria; Malaria, Vivax; Plasmodium falciparum; Pyr | 1959 |
An attempt to eradicate malaria by the weekly administration of pyrimethamine in areas of out-of-doors transmission in Venezuela.
Topics: Antimalarials; Humans; Malaria; Pyrimethamine; Venezuela | 1959 |
A note on the use of daraprim as a malaria prophylactic in Nigerian troops and their families.
Topics: Antimalarials; Malaria; Pyrimethamine | 1960 |
Field trials with chlorproguanil in the prophylaxis of malaria in Ghana.
Topics: Africa; Antimalarials; Child; Drug Resistance; Ghana; Humans; Infant; Malaria; Malaria, Falciparum; | 1961 |
Prolonged malaria prophylaxis through pyrimethamine in mothers' milk.
Topics: Antimalarials; Female; Humans; Malaria; Milk, Human; Mothers; Pyrimethamine | 1960 |
[Pyrimethamine-primaquine in the treatment of acute malaria. (Study in 20 cases)].
Topics: Antimalarials; Humans; Malaria; Primaquine; Pyrimethamine | 1960 |
[Results of 5 years' mass pyrimethamine prophylaxis (Yangambi, 1955-1960)].
Topics: Antimalarials; Humans; Malaria; Molecular Weight; Pyrimethamine | 1960 |
[The prophylaxis of malaria by addition of chloroquine and pyrimethamine to table salt].
Topics: Chloroquine; Diet; Humans; Malaria; Nutrition Assessment; Nutritional Status; Pyrimethamine; Sodium | 1960 |
Effect of pyrimethamine upon sporogony and pre-erythrocytic schizogony of Laverania falciparum.
Topics: Antimalarials; Liberia; Malaria; Plasmodium falciparum; Pyrimethamine | 1959 |
The appearance of pyrimethamine resistance in Plasmodium falciparum following self-medication by a rural community in Ghana.
Topics: Antimalarials; Drug Combinations; Drug Resistance; Ghana; Malaria; Malaria, Falciparum; Pilot Projec | 1962 |
Nephrosis in Nigerian children. Role of Plasmodium malariae, and effect of antimalarial treatment.
Topics: Antimalarials; Child; Chloroquine; Humans; Malaria; Nephrotic Syndrome; Plasmodium malariae; Primaqu | 1963 |
Studies on the toxicity and action of diaminodiphenyl-sulfone (DDS) in avian and simian malaria.
Topics: Animals; Antimalarials; Birds; Chloroquine; Dapsone; Malaria; Malaria, Avian; Proguanil; Pyrimethami | 1962 |
PYRIMETHAMINE AND SULPHADIAZINE IN TREATMENT OF MALARIA.
Topics: Africa; Africa, Western; Black People; Heart Diseases; Humans; Malaria; Pyrimethamine; Sulfadiazine | 1963 |
BLACKWATER FEVER AFTER THE USE OF CHLOROQUINE-PYRIMETHAMINE.
Topics: Blackwater Fever; Chloroquine; Hemolysis; Humans; Malaria; New Guinea; Pyrimethamine; Quinine; Toxic | 1963 |
[OUR EXPERIENCE WITH THE USE OF DARAPRIM IN HEMOPROPHYLAXIS OF MALARIA IN 1960 AND 1961 IN THE DEVDELIJE REGION].
Topics: Humans; Malaria; Pyrimethamine; Yugoslavia | 1963 |
[MALARIA PREVENTION IN NEW GUINEA WITH DRUGS ADDED TO KITCHEN SALT].
Topics: Chloroquine; DDT; Humans; Malaria; Mosquito Control; New Guinea; Pyrimethamine; Sodium Chloride | 1963 |
DRUG-RESISTANT FALCIPARUM MALARIA FROM CAMBODIA AND MALAYA.
Topics: Animals; Cambodia; Chloroquine; Culicidae; Drug Resistance; Drug Resistance, Microbial; Humans; Mala | 1963 |
CONTROLLED TRIAL OF PYRIMETHAMINE IN PREGNANT WOMEN IN AN AFRICAN VILLAGE.
Topics: Birth Weight; Chloroquine; Female; Humans; Infant; Infant Mortality; Lactose; Malaria; Nigeria; Preg | 1964 |
STUDIES IN THE ACQUISITION OF IMMUNITY OF PLASMODIUM FALCIPARUM INFECTIONS IN AFRICA.
Topics: Adolescent; Africa; Africa, Western; Allergy and Immunology; Child; Chloroquine; Humans; Infant; Mal | 1964 |
FLUORESCENT ANTIBODY STUDIES IN HUMAN MALARIA. II. DEVELOPMENT AND PERSISTENCE OF ANTIBODIES TO PLASMODIUM FALCIPARUM.
Topics: Amodiaquine; Antibodies; Antigen-Antibody Reactions; Chloroquine; Fluorescent Antibody Technique; Hu | 1964 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM THAILAND.
Topics: Amodiaquine; Antimalarials; Asia, Southeastern; Biomedical Research; Chloroquine; Drug Resistance; D | 1964 |
A MALARIA ERADICATION EXPERIMENT IN THE HIGHLANDS OF KIGEZI (UGANDA).
Topics: Chloroquine; DDT; Epidemiology; Humans; Malaria; Pyrimethamine; Uganda | 1964 |
DRUG-RESISTANCE IN FALCIPARUM MALARIA IN SOUTH-EAST ASIA.
Topics: Adolescent; Asia, Southeastern; Child; Chloroquine; Drug Resistance; Drug Resistance, Microbial; Dru | 1964 |
IMMUNOLOGICAL ASPECTS OF A POPULATION UNDER PROPHYLAXIS AGAINST MALARIA.
Topics: Africa; Africa, Western; Antibody Formation; Female; Fluorescent Antibody Technique; gamma-Globulins | 1964 |
[CAMPAIGN AGAINST MALARIA WITH MEDICATED SALT IN NEW GUINEA].
Topics: Chloroquine; Humans; Malaria; New Guinea; Pharmacology; Pyrimethamine; Quinolines; Sodium Chloride | 1964 |
THE CONTROL OF EPIDEMIC MALARIA IN THE HIGHLANDS OF WESTERN KENYA. I. BEFORE THE CAMPAIGN.
Topics: Animals; Anopheles; Drug Therapy; Epidemics; Epidemiology; Humans; Kenya; Malaria; Pyrimethamine | 1964 |
THE CONTROL OF EPIDEMIC MALARIA IN THE HIGHLANDS OF WESTERN KENYA. II. THE CAMPAIGN.
Topics: Animals; Dieldrin; Epidemics; Humans; Kenya; Malaria; Mosquito Control; Pyrimethamine | 1964 |
ROLE OF P-AMINOBENZOIC ACID IN PLASMODIUM BERGHEI INFECTION IN THE MOUSE.
Topics: 4-Aminobenzoic Acid; Aminopterin; Animals; Chloroquine; Folic Acid; Folic Acid Deficiency; Leucovori | 1964 |
THE CONTROL OF EPIDEMIC MALARIA IN THE HIGHLANDS OF WESTERN KENYA. 3. AFTER THE CAMPAIGN.
Topics: Adolescent; Animals; Anopheles; Child; Chloroquine; Communicable Disease Control; Dieldrin; Drug The | 1964 |
THE USE OF MEDICATED SALT IN AN ANTIMALARIA CAMPAIGN IN WEST NEW GUINEA.
Topics: Antimalarials; Chloroquine; Epidemiology; Humans; Indonesia; Malaria; New Guinea; Pyrimethamine; Sod | 1964 |
ANTIMALARIAL EFFECT OF SULPHORTHODIMETHOXINE (FANASIL).
Topics: Antimalarials; Biomedical Research; Child; Delayed-Action Preparations; Drug Therapy; Humans; Malari | 1964 |
APPARENT REFRACTORINESS TO CHLOROQUINE, PYRIMETHAMINE, AND QUININE IN STRAINS OF PLASMODIUM FALCIPARUM FROM VIETNAM.
Topics: Chloroquine; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Humans; Malaria; Military Me | 1965 |
TREATMENT OF ACUTE FALCIPARUM MALARIA WITH SULPHORTHODIMETHOXINE (FANASIL).
Topics: Adolescent; Africa; Africa, Eastern; Antimalarials; Child; Delayed-Action Preparations; Drug Resista | 1965 |
STUDIES ON A STRAIN OF CHLOROQUINE-RESISTANT PLASMODIUM FALCIPARUM FROM VIET-NAM.
Topics: Amodiaquine; Antimalarials; Biomedical Research; Chloroquine; Drug Therapy; Humans; Malaria; Malaria | 1964 |
POTENTIATION OF ACTIVITY OF DIAPHENYLSULFONE AND PYRIMETHAMINE AGAINST PLASMODIUM GALLINACEUM AND PLASMODIUM CYNOMOLGI BASTIANELLII.
Topics: Animals; Dapsone; Drug Resistance; Drug Resistance, Microbial; Haplorhini; Malaria; Pharmacology; Pl | 1964 |
CHLOROQUINE-RESISTANT STRAIN OF PLASMODIUM FALCIPARUM FROM KHAO MAI KHAEO, THAILAND.
Topics: Chloroquine; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Humans; Malaria; Plasmodium | 1965 |
MALARIA IN CHILDHOOD MODERN CONCEPTS OF IMMUNITY, TREATMENT, PROPHYLAXIS.
Topics: Amodiaquine; Child; Chloroquine; Diagnosis; Drug Therapy; Epidemiology; Humans; Infant; Infant, Newb | 1965 |
SOME FEATURES OF MALARIA IN DILI, PORTUGUESE TIMOR, DURING 1963-64.
Topics: Amodiaquine; Anemia; Chloroquine; Clinical Laboratory Techniques; Drug Therapy; Epidemiology; Humans | 1965 |
Treatment of vivax malaria by pyrimethamine (daraprim) and quinine.
Topics: Antimalarials; Disease; Humans; Malaria; Malaria, Vivax; Military Personnel; Pyrimethamine; Quinine | 1955 |
The mode of action of sulphonamides, proguanil and pyrimethamine on Plasmodium gallinaceum.
Topics: Antimalarials; Humans; Malaria; Plasmodium gallinaceum; Proguanil; Pyrimethamine; Sulfadiazine | 1955 |
[Clinical contribution to the determination of the efficacy of pyrimethamine in the prophylaxis and therapy of paludism].
Topics: Antimalarials; Malaria; Pyrimethamine | 1959 |
Administration of pyrimethamine with folic acid and folinic acids in human malaria.
Topics: Antimalarials; Folic Acid; Humans; Leucovorin; Malaria; Pyrimethamine | 1959 |
Potentiation of pyrimethamine by sulphadiazine in human malaria.
Topics: Antimalarials; Malaria; Pyrimethamine; Sulfadiazine; Sulfanilamide; Sulfanilamides; Sulfonamides | 1959 |
Preliminary assessment of the efficacy of mefloquine/-sulphadoxine/ pyrimethamine combination in the treatment of uncomplicated malaria in children in North Eastern Nigeria.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; Infant; Malaria; Mefloquine; Nige | 2001 |
The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.
Topics: Africa, Eastern; Amodiaquine; Antimalarials; Chloroquine; Disease Susceptibility; Drug Combinations; | 2003 |
Diagnosis and treatment of malaria in children.
Topics: Animals; Antimalarials; Atovaquone; Child; Chloroquine; Drug Combinations; Humans; Malaria; Malaria, | 2003 |
Use of antenatal care services and intermittent preventive treatment for malaria among pregnant women in Blantyre District, Malawi.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Cluster Analysis; Drug Administration Schedule; | 2004 |
Daraprim in treatment of malaria; a study of its effects in falciparum and quartan infections in West Africa.
Topics: Africa, Western; Malaria; Pyrimethamine; Pyrimidines | 1952 |
Daraprim (B.W. 50-63) a new antimalarial; trials in human volunteers.
Topics: Antimalarials; Healthy Volunteers; Malaria; Pyrimethamine; Pyrimidines | 1952 |
DARAPRIM in malaria.
Topics: Malaria; Pyrimethamine; Pyrimidines | 1952 |
Effectiveness of intermittent preventive treatment with sulphadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: a hospital-based study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Birth Weight; Cohort Studies; Drug Admi | 2004 |
Artesunate combinations for malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Cost-Benefit Analysis; Drug Combinations; Drug Resistance; | 2004 |
Treating malaria in Africa.
Topics: Africa; Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria; Pyrimethamine; Sulfadoxi | 2004 |
Use of intermittent presumptive treatment and insecticide treated bed nets by pregnant women in four Kenyan districts.
Topics: Adult; Antimalarials; Bedding and Linens; Clinical Competence; Delivery, Obstetric; Drug Administrat | 2004 |
Early treatment during a primary malaria infection modifies the development of cross immunity.
Topics: Animals; Antibodies, Protozoan; Body Weight; Cross Reactions; Gene Expression; Hemoglobins; Immunity | 2004 |
Competitive release of drug resistance following drug treatment of mixed Plasmodium chabaudi infections.
Topics: Animals; Anopheles; Antimalarials; Drug Resistance; Female; Genotype; Insect Vectors; Malaria; Mice; | 2004 |
Linkage group selection: rapid gene discovery in malaria parasites.
Topics: Animals; Anopheles; Crosses, Genetic; Drug Resistance; Female; Genes, Protozoan; Genetic Linkage; Ha | 2005 |
Efficacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, chloroquine-sulfadoxine-pyrimethamine combination, and amodiaquine-sulfadoxine-pyrimethamine combination in Central African children with noncomplicated malaria.
Topics: Amodiaquine; Antimalarials; Central African Republic; Child, Preschool; Chloroquine; Drug Combinatio | 2005 |
The pattern of home treatment of malaria in under-fives in south eastern Nigeria.
Topics: Adult; Antimalarials; Child, Preschool; Chloroquine; Cross-Sectional Studies; Drug Combinations; Fem | 2005 |
Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe District, North-Eastern Tanzania.
Topics: Antimalarials; Delivery of Health Care; Drug Administration Schedule; Drug Combinations; Female; Gui | 2005 |
Effectiveness of antimalarial drugs.
Topics: Africa; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Pyrimethami | 2005 |
Perceptions on use of sulfadoxine-pyrimethamine in pregnancy and the policy implications for malaria control in Uganda.
Topics: Adolescent; Adult; Child; Drug Combinations; Female; Health Policy; Humans; Malaria; Middle Aged; Pr | 2006 |
[Blood levels of sulfadoxine and pyrimethamine, according to the malaria-treatment response, in two municipalities of Antioquia, Colombia].
Topics: Adolescent; Adult; Anti-Infective Agents; Antimalarials; Catchment Area, Health; Child; Child, Presc | 2005 |
Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: cross sectional study.
Topics: Ambulatory Care; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Chlo | 2005 |
Intermittent preventive treatment for malaria in infants: moving forward, cautiously.
Topics: Antimalarials; Chemoprevention; Drug Administration Schedule; Drug Combinations; Humans; Infant; Mal | 2005 |
Amodiaquine and combination chemotherapy for malaria.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Hum | 2005 |
Infectious diseases. Will a preemptive strike against malaria pay off?
Topics: Animals; Antimalarials; Controlled Clinical Trials as Topic; Drug Combinations; Drug Resistance; Fem | 2005 |
How sulfadoxine-pyrimethamine (SP) was perceived in some rural communities after phasing out chloroquine (CQ) as a first-line drug for uncomplicated malaria in Tanzania: lessons to learn towards moving from monotherapy to fixed combination therapy.
Topics: Antimalarials; Attitude to Health; Chloroquine; Drug Combinations; Drug Therapy, Combination; Focus | 2006 |
Improved transfection and new selectable markers for the rodent malaria parasite Plasmodium yoelii.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Electroporation; Female; Green Fluo | 2006 |
A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods.
Topics: Adult; Antimalarials; Bedding and Linens; Child; Chloroquine; DDT; Drug Combinations; Drug Resistanc | 2006 |
Single-dose sulfadoxine-pyrimethamine in intermittent preventive treatment of malaria.
Topics: Antimalarials; Drug Combinations; Humans; Infant; Malaria; Pyrimethamine; Sulfadoxine | 2006 |
Sulfadoxine-pyrimethamine as an anti-malaria preventative in donated blood.
Topics: Antimalarials; Blood Donors; Cross Infection; Drug Approval; Drug Combinations; Global Health; Human | 2006 |
Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antimalarials; Child; Child, Presc | 2006 |
Adherence of community caretakers of children to pre-packaged antimalarial medicines (HOMAPAK) among internally displaced people in Gulu district, Uganda.
Topics: Adult; Antimalarials; Caregivers; Child, Preschool; Chloroquine; Drug Combinations; Drug Packaging; | 2006 |
Simultaneous quantification of alpha-/beta-diastereomers of arteether, sulphadoxine and pyrimethamine: a promising anti-relapse antimalarial therapeutic combination, by liquid chromatography tandem mass spectrometry.
Topics: Animals; Antimalarials; Artemisinins; Chromatography, High Pressure Liquid; Malaria; Male; Pyrimetha | 2006 |
Impact of chloroquine on viral load in breast milk.
Topics: Adult; Anti-HIV Agents; Antimalarials; Breast Feeding; CD4 Lymphocyte Count; Chloroquine; Drug Combi | 2006 |
Intermittent preventive treatment in infants--adjusting expectations and seeing opportunity.
Topics: Antimalarials; Chemoprevention; Drug Combinations; Female; Humans; Infant; Infant, Newborn; Malaria; | 2006 |
Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso.
Topics: Adolescent; Adult; Antimalarials; Bedding and Linens; Burkina Faso; Drug Combinations; Female; Human | 2006 |
Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004.
Topics: Africa; Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Clinical Trials as Topic; Drug Co | 2006 |
Cost-effectiveness study of three antimalarial drug combinations in Tanzania.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2006 |
Amodiaquine, malaria, pregnancy: the old new drug.
Topics: Amodiaquine; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; Ghana; Humans; Mal | 2006 |
Plasmodium yoelii yoelii 17XNL constitutively expressing GFP throughout the life cycle.
Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Drug Resistance; Erythrocytes; Flow Cytom | 2007 |
In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Atovaquone; Disease Models, Animal; Drug Interacti | 2007 |
Malaria. Chloroquine makes a comeback.
Topics: Adult; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malar | 2006 |
Treating malaria at home in Uganda.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Caregivers; Chloroquine; Dev | 2006 |
Similar trends of pyrimethamine resistance-associated mutations in Plasmodium vivax and P. falciparum.
Topics: Alleles; Animals; Antimalarials; DNA, Protozoan; Drug Resistance; Folic Acid Antagonists; Genotype; | 2007 |
Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice.
Topics: Animals; Apoptosis; Chloroquine; Cytokines; Immunologic Factors; Malaria; Mice; Mice, Inbred BALB C; | 2007 |
Home-based management of fever in rural Uganda: community perceptions and provider opinions.
Topics: Adolescent; Adult; Antimalarials; Child, Preschool; Chloroquine; Community Health Services; Communit | 2007 |
Effect of haematinic supplementation and malaria prevention on maternal anaemia and malaria in western Kenya.
Topics: Adult; Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; Folic Acid; Hema | 2007 |
The role of communication between clients and health care providers: implications for adherence to malaria treatment in rural Gambia.
Topics: Antimalarials; Attitude to Health; Child; Child, Preschool; Chloroquine; Communication Barriers; Dru | 2007 |
Intermittent preventive treatment of malaria in pregnancy: the effect of new delivery approaches on access and compliance rates in Uganda.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Child; Delivery of Health Care; Drug Combination | 2007 |
Assessing malaria burden during pregnancy in Mali.
Topics: Adult; Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; Drug Combinations; Female; Huma | 2007 |
Intermittent preventive antimalarial treatment in infants.
Topics: Antimalarials; Humans; Immunization; Infant; Malaria; Pyrimethamine; Sulfadoxine | 2007 |
Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs).
Topics: Antimalarials; Artemisinins; Chloroquine; Drug Therapy; Drug Therapy, Combination; Humans; Malaria; | 2007 |
Ethnographic study of factors influencing compliance to intermittent preventive treatment of malaria during pregnancy among Yao women in rural Malawi.
Topics: Antimalarials; Communication; Drug Combinations; Female; Health Knowledge, Attitudes, Practice; Huma | 2007 |
Battling the malaria iceberg with chloroquine in India.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Delivery of Health Care; Drug Combinations; Dr | 2007 |
A community-based delivery system of intermittent preventive treatment of malaria in pregnancy and its effect on use of essential maternity care at health units in Uganda.
Topics: Adolescent; Adult; Antimalarials; Child; Drug Combinations; Female; Humans; Malaria; Patient Complia | 2007 |
Malaria pharmacovigilance in Africa: lessons from a pilot project in Mpumalanga Province, South Africa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2007 |
Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications.
Topics: Antimalarials; Bedding and Linens; Drug Administration Schedule; Drug Combinations; Humans; Infant; | 2007 |
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Artesunate; Chloroquine; Dapsone; Drug Design; | 2007 |
Health workers perceptions on chloroquine and sulfadoxine/sulfalene pyrimethamine monotherapies: implications for the change to combination therapy of artemether/lumefantrine in Tanzania.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Attitude of Health Pe | 2007 |
Malaria treatment efficacy among people living with HIV: the role of host and parasite factors.
Topics: Adolescent; Adult; Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Dru | 2007 |
Intermittent preventive therapy with sulfadoxine-pyrimethamine during pregnancy: seeking information on optimal dosing frequency.
Topics: Adult; AIDS-Related Opportunistic Infections; Antimalarials; Disease Susceptibility; Drug Administra | 2007 |
Intermittent preventive treatment of malaria during pregnancy in central Mozambique.
Topics: Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Health Policy; Humans; Malar | 2007 |
[Assessing the application of Rwanda's national protocol for uncomplicated malaria treatment in healthcare institutions in Kigali City, Rwanda].
Topics: Adult; Amodiaquine; Antimalarials; Drug Prescriptions; Drug Therapy, Combination; Female; Guideline | 2008 |
Appraisal on the prevalence of malaria and anaemia in pregnancy and factors influencing uptake of intermittent preventive therapy with sulfadoxine-pyrimethamine in Kibaha district, Tanzania.
Topics: Adolescent; Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Humans | 2007 |
A simple technique for the detection of anti-malarial drug formulations and their presence in human urine.
Topics: Amodiaquine; Antimalarials; Biological Assay; Biological Availability; Chloroquine; Chromatography, | 2006 |
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance.
Topics: Algorithms; Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Computer Simulation; Dru | 2008 |
Use of antenatal care, maternity services, intermittent presumptive treatment and insecticide treated bed nets by pregnant women in Luwero district, Uganda.
Topics: Adult; Antimalarials; Bedding and Linens; Cross-Sectional Studies; Delivery of Health Care; Drug Com | 2008 |
Increased Plasmodium falciparum gametocyte production in mixed infections with P. malariae.
Topics: Amodiaquine; Animals; Antimalarials; Child; Drug Combinations; Gametogenesis; Humans; Malaria; Plasm | 2008 |
Effect of a community-based delivery of intermittent preventive treatment of malaria in pregnancy on treatment seeking for malaria at health units in Uganda.
Topics: Adolescent; Adult; Antimalarials; Community Health Services; Drug Administration Schedule; Drug Comb | 2008 |
Can changes in malaria transmission intensity explain prolonged protection and contribute to high protective efficacy of intermittent preventive treatment for malaria in infants?
Topics: Antimalarials; Drug Combinations; Humans; Infant; Malaria; Models, Theoretical; Protective Agents; P | 2008 |
Sudden enlargement of the prostate in a patient taking Fansidar for malaria.
Topics: Aged; Antimalarials; Drug Combinations; Humans; Malaria; Male; Prostatic Hyperplasia; Pyrimethamine; | 2007 |
Treatment of chloroquine-resistant Plasmodium falciparum infections in Vietnam.
Topics: Chloroquine; Dapsone; Humans; Malaria; Military Medicine; Pyrimethamine; Quinacrine; Quinine; Sulfad | 1967 |
Chemotherapy of Plasmodium chabaudi infection in albino mice.
Topics: Aminobenzoates; Animals; Antimalarials; Erythrocytes; Injections, Intraperitoneal; Malaria; Male; Mi | 1967 |
Chemotherapy of sporozoite- and blood-induced Plasmodium berghei infections with selected antimalarial agents.
Topics: Animals; Chloroquine; Cricetinae; Dapsone; Malaria; Mice; Primaquine; Pyrimethamine; Quinine; Rats | 1967 |
Low serum folate among persons taking Fansidar (pyrimethamine plus sulfadoxine) for prophylaxis of malaria.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Drug Combinations; Female; Folic A | 1980 |
Tolerance and haematological findings with antimalarials (chloroquine and Fansidar [pyrimethamine plus sulfadoxine]) in adults and children during field trials in Nigeria.
Topics: Adult; Child; Chloroquine; Drug Combinations; Drug Tolerance; Female; Hemoglobinometry; Humans; Leuk | 1980 |
Fansidar-resistant falciparum malaria in Papua New Guinea.
Topics: Antimalarials; Child, Preschool; Drug Combinations; Humans; Infant; Malaria; Male; New Guinea; Plasm | 1980 |
Single dose therapy with a combination of chloroquine and pyrimethamine (darachlor) in the treatment of malaria. Short communication.
Topics: Administration, Oral; Adult; Child, Preschool; Chloroquine; Drug Therapy, Combination; Humans; Malar | 1981 |
Resistance of Plasmodium falciparum malaria to sulfadoxine-pyrimethamine ('Fansidar') in a refugee camp in Thailand.
Topics: Adolescent; Adult; Cambodia; Child; Drug Combinations; Female; Humans; Malaria; Male; Middle Aged; P | 1981 |
Drug-resistant malaria.
Topics: Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; | 1981 |
Problems with pyrimethamine/sulfadoxine malaria prophylaxis.
Topics: Antimalarials; Drug Combinations; Female; Humans; Malaria; Male; Plasmodium vivax; Pyrimethamine; Su | 1982 |
Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine.
Topics: Aged; Agranulocytosis; Antimalarials; Drug Combinations; Female; Humans; Jaundice; Malaria; Male; Mi | 1982 |
Falciparum malaria despite pyrimethamine/suifadoxine in five tourists to East Africa.
Topics: Adult; Africa, Eastern; Antimalarials; Berlin; Drug Combinations; Female; Humans; Malaria; Male; Mid | 1982 |
Presumptive fatality due to pyrimethamine-sulfadoxine.
Topics: Adult; Agranulocytosis; Humans; Malaria; Male; Pyrimethamine; Sulfadoxine; Sulfanilamides | 1982 |
Teratogenicity of pyrimethamine.
Topics: Abnormalities, Drug-Induced; Adult; Female; Humans; Malaria; Maternal-Fetal Exchange; Pregnancy; Pyr | 1983 |
Pyrimethamine combinations in pregnancy.
Topics: Abnormalities, Drug-Induced; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, Infectious | 1983 |
Pyrimethamine in pregnancy.
Topics: Abnormalities, Drug-Induced; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, Infectious | 1983 |
Genetics of cross-resistance between antifolate drugs in Plasmodium yoelii.
Topics: Animals; Crosses, Genetic; Drug Resistance; Genes; Genetic Linkage; Malaria; Mice; Plasmodium; Pyrim | 1982 |
Suppression of mitogenic lectin-induced blast transformation of human peripheral blood mononuclear cells by pyrimethamine.
Topics: Antigens, Surface; Humans; Immunity, Cellular; Lectins; Lymphocyte Activation; Lymphocyte Culture Te | 1983 |
Long-acting, repository antimalarial agents. Duration of protection in mice and monkeys following administration of pyrimethamine pamoate.
Topics: Acedapsone; Animals; Dapsone; Drug Combinations; Female; Injections, Intramuscular; Macaca fascicula | 1984 |
Comparative drug trial of a sulfadoxine/pyrimethamine and a sulfalene/pyrimethamine combination against Plasmodium falciparum infections in semi-immune populations of Burma.
Topics: Adolescent; Adult; Age Factors; Aged; Anopheles; Blood; Child; Child, Preschool; Drug Administration | 1984 |
[Falciparum malaria in East African tourists in spite of fansidar prevention. A contribution on increased chloroquine and pyrimethamine-sulfadoxine resistance in areas of East Africa].
Topics: Adult; Africa, Eastern; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Erythrocytes; Fe | 1983 |
[Drug-resistant malaria in East Africa].
Topics: Adult; Africa, Eastern; Aged; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Ma | 1983 |
Combined chloroquine/Fansidar-resistant falciparum malaria appears in East Africa.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Comb | 1983 |
Plasmodium berghei: diet and drug dosage regimens influencing selection of drug-resistant parasites in mice.
Topics: 4-Aminobenzoic Acid; Animals; Diet; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Ho | 1983 |
Treatment of chloroquine-resistant malaria during pregnancy.
Topics: Adult; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria; Plasmodium falciparum; Pregn | 1983 |
[Unsuccessful effect of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Tanzania].
Topics: Adult; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodium falciparum; | 1983 |
Treatment of vivax malaria with a single dose of sulphadoxine and pyrimethamine (Fansidar).
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Combinations; Female; Humans; Infant; Malaria; Male | 1983 |
Fansidar resistant Plasmodium falciparum infection in Surinam.
Topics: Antimalarials; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Malaria; Male; Middle | 1983 |
[Chloroquine- and fansidar-resistant falciparum malaria treated with minocycline].
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Male; Minocyclin | 1983 |
Treatment failure of falciparum malaria with Fansidar in Tawau Sabah. January-June, 1982.
Topics: Adult; Antimalarials; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Malaria; Malays | 1983 |
Chloroquine-resistant falciparum malaria from Malawi.
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Malawi; Male; Pl | 1984 |
Cross resistance of pyrimethamine and sulfadoxine to their related compounds in Plasmodium falciparum.
Topics: Animals; Drug Resistance, Microbial; Malaria; Methotrexate; Plasmodium falciparum; Pyrimethamine; Su | 1984 |
[Chloroquine and pyrimethamine/sulfadoxine resistant malaria tropica in a child with diabetes mellitus].
Topics: Adolescent; Chloroquine; Diabetes Mellitus, Type 1; Diagnosis, Differential; Doxycycline; Drug Resis | 1984 |
Probable chloroquine-resistant Plasmodium falciparum malaria in south-western Africa.
Topics: Adult; Africa, Southern; Africa, Western; Animals; Chloroquine; Drug Resistance, Microbial; Humans; | 1984 |
Concomitant resistance to pyrimethamine and cycloguanil of chloroquine-resistant falciparum malaria from East Africa: an in vitro study of 12 isolates.
Topics: Africa, Eastern; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Microbial Sensitivity Tes | 1984 |
The response of Plasmodium vivax to antifols.
Topics: Humans; Malaria; Plasmodium vivax; Proguanil; Pyrimethamine | 1984 |
[Malaria and intestinal parasitosis in Indians of the Nadeb-Maku tribe, State of Amazonas, Brazil].
Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Child, Preschool; Drug Combinations; Feces; Female; | 1984 |
Kenyan chloroquin, fansidar and quninine resistant P. Falciparum.
Topics: Adolescent; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malar | 1984 |
A new in vitro test for pyrimethamine/sulfadoxine susceptibility of Plasmodium falciparum and its correlation with in vivo resistance in Kenya.
Topics: Adolescent; Child; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Kenya; M | 1984 |
Plasmodium falciparum in Haiti: susceptibility to pyrimethamine and sulfadoxine-pyrimethamine.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Female; Hait | 1984 |
Clinical efficacy of sulfadoxine-pyrimethamine in the treatment of falciparum malaria in Sabah, Malaysia.
Topics: Adolescent; Adult; Antimalarials; Child; Drug Combinations; Drug Resistance, Microbial; Female; Foll | 1984 |
[Treatment of malaria. Update].
Topics: Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Malaria; Plasmodium falc | 1984 |
Activities of respository preparations of cycloguanil pamoate and 4,4'-diacetyldiaminodiphenylsulfone, alone and in combination, against infections with Plasmodium cynomolgi in rhesus monkeys.
Topics: Acedapsone; Animals; Antimalarials; Dapsone; Drug Combinations; Drug Resistance, Microbial; Macaca m | 1984 |
The effect of sulphadoxine/pyrimethamine on gametocytes in falciparum malaria.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Humans; | 1984 |
The chemotherapy of rodent malaria XXXV. Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and 'P. berghei NS'.
Topics: Animals; Antimalarials; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Therapy, | 1984 |
Malaria chemoprophylaxis for multiple drug resistant Plasmodium falciparum in Africa: an increasing problem.
Topics: Adult; Africa; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Human | 1984 |
[Plasmodium falciparum and drug resistance].
Topics: Adult; Africa, Eastern; Animals; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Plasmodiu | 1984 |
[Malaria prevention with Fansidar].
Topics: Chloroquine; Double-Blind Method; Drug Combinations; Humans; Malaria; Nigeria; Plasmodium; Pyrimetha | 1983 |
Falciparum malaria resistant to chloroquine and fansidar: implications for prophylaxis.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; M | 1983 |
Falciparum malaria resistant to chloroquine and Fansidar.
Topics: Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falciparum; | 1984 |
Falciparum malaria resistant to chloroquine and Fansidar: implications for prophylaxis.
Topics: Chloroquine; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Malaria; Middle Aged; Pl | 1984 |
Unusual pulmonary reaction during short term prophylaxis with pyrimethamine-sulfadoxine (Fansidar).
Topics: Antimalarials; Drug Combinations; Humans; Lung Diseases; Malaria; Male; Middle Aged; Pyrimethamine; | 1984 |
Jarisch-Herxheimer reaction in falciparum malaria?
Topics: Adult; Antimalarials; Body Temperature; Drug Combinations; Humans; Malaria; Male; Plasmodium falcipa | 1984 |
Management of Plasmodium falciparum malaria.
Topics: Amodiaquine; Anemia; Antimalarials; Brain Diseases; Chloroquine; Drug Resistance; Female; Humans; Hy | 1984 |
Protection against Plasmodium berghei yoelii in chloroquine- and pyrimethamine-treated mice.
Topics: Animals; Chloroquine; Malaria; Mice; Plasmodium; Pyrimethamine | 1984 |
Effects of antimalarial drugs on human natural killer cell activity.
Topics: Antimalarials; B-Lymphocytes; Chloroquine; Humans; Killer Cells, Natural; Lymphocytes; Lymphocytes, | 1983 |
Red cell hypoplasia following dapsone and pyrimethamine.
Topics: Aged; Anemia, Aplastic; Dapsone; Humans; Malaria; Male; Pyrimethamine | 1983 |
Fansidar prophylaxis, therapy, and immune responses in rodent malaria (Plasmodium berghei).
Topics: Animals; Antimalarials; Drug Combinations; Female; Malaria; Mice; Plasmodium berghei; Pyrimethamine; | 1982 |
[Treatment of malaria with a combination of 3 drugs on São Luís Island, Maranhão, Brazil].
Topics: Antimalarials; Brazil; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Plasmodium falciparu | 1981 |
A case of fansidar-resistant Plasmodium falciparum from Tanzania.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; | 1982 |
Fansidar-resistant Plasmodium falciparum infection from Tanzania.
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Ma | 1982 |
[Treatment of malaria with a combination of 3 drugs on the Island of São Luis, Maranhão, Brazil].
Topics: Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; | 1981 |
In vitro assessment of 2-acetylpyridine thiosemicarbazones against chloroquine-resistant Plasmodium falciparum.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Malaria; Mefloquine; Mice; Plasmodium falcipar | 1982 |
Comparison of in vitro pyrimethamine assays and in vivo response to sulphadoxine-pyrimethamine in Plasmodium falciparum from Papua New Guinea.
Topics: Child; Child, Preschool; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Microbial S | 1982 |
[Resistance of Plasmodium falciparum to fansidar, quinine and tetracycline].
Topics: Adolescent; Chloroquine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial | 1982 |
Antimalarial combination available.
Topics: Drug Combinations; Humans; Malaria; Pyrimethamine; Sulfadoxine; Sulfanilamides | 1982 |
Problems encountered with using Fansidar as prophylaxis for malaria.
Topics: Adult; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodium; Pyrimethami | 1982 |
Prevention of malaria in travelers 1982.
Topics: Child; Chloroquine; Drug Resistance, Microbial; Female; Humans; Malaria; Plasmodium; Plasmodium falc | 1982 |
Treatment of malaria.
Topics: Dapsone; Drug Therapy, Combination; Humans; Malaria; Primaquine; Pyrimethamine | 1980 |
Chemoprophylaxis in malaria.
Topics: Chloroquine; Drug Resistance, Microbial; Female; Humans; Malaria; Plasmodium falciparum; Pregnancy; | 1980 |
[A case of chloroquine-resistant (R1) falciparum malaria from the East African Comoros Islands (author's transl)].
Topics: Africa, Eastern; Chloroquine; Humans; Malaria; Male; Plasmodium falciparum; Pyrimethamine; Sulfadoxi | 1980 |
Plasmodium falciparum resistance to pyrimethamine and chlorproguanil -- host or parasite dependent?
Topics: Child; Child, Preschool; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falciparum; Proguan | 1980 |
Malaria prophylaxis in travelers.
Topics: Africa; Antimalarials; Asia; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Infant | 1980 |
Pyrimethamine sensitivity in Plasmodium falciparum: determination in vitro by a modified 48-hour test.
Topics: Adult; Cells, Cultured; Drug Resistance; Female; Humans; Malaria; Middle Aged; Plasmodium falciparum | 1980 |
Malaria in southeast Queensland in 1979.
Topics: Adolescent; Adult; Australia; Child; Child, Preschool; Chloroquine; Dapsone; Female; Humans; Infant; | 1980 |
Plasmodium falciparum strains from Papua New Guinea: culture characteristics and drug sensitivity.
Topics: Adolescent; Adult; Animals; Child, Preschool; Chloroquine; Humans; Malaria; New Guinea; Plasmodium f | 1980 |
Treatment of falciparum malaria with sulfalene-pyrimethamine versus sulfadoxine-pyrimethamine.
Topics: Adolescent; Adult; Aged; Animals; Child; Drug Combinations; Female; Humans; Malaria; Male; Middle Ag | 1980 |
Pyrimethamine susceptibility status of p. falciparum in Karbi-Anglong district of Assam and Adilabad District of Andhra Pradesh.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Humans; India; Infant; Malaria; P | 1980 |
Chloroquine resistant Plasmodium falciparum infection from Lampung and South Sumatra, Indonesia.
Topics: Adult; Chloroquine; Drug Resistance; Humans; Indonesia; Malaria; Male; Plasmodium falciparum; Pyrime | 1981 |
Plasmodium falciparum resistant to fansidar.
Topics: Adolescent; Antimalarials; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Plasmodium f | 1981 |
Blood schizontocidal activity of antibiotics against Plasmodium berghei sensitive as well as resistant to chloroquine, pyrimethamine and primaquine.
Topics: Animals; Anti-Bacterial Agents; Chloroquine; Drug Resistance; Malaria; Mice; Plasmodium berghei; Pri | 1981 |
[Plasmodium falciparum malaria resistant to polychemotherapy. Usefulness of pathogen culture (author's transl)].
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; H | 1981 |
Sustained-release implants in the chemotherapy of experimental rodent malaria I. A comparison of the effects of some antimalarials in polydimethylsiloxane matrices.
Topics: Animals; Antimalarials; Chloroquine; Dimethylpolysiloxanes; Drug Implants; Malaria; Male; Mefloquine | 1981 |
Sustained-release implants in the chemotherapy of experimental rodent malaria II. The effects of sulphadiazine, pyrimethamine and cycloguanil in biodegradable polymer matrices.
Topics: Animals; Biodegradation, Environmental; Drug Implants; Malaria; Male; Mice; Mice, Inbred Strains; Pl | 1981 |
Fansidar resistant falciparum malaria acquired in South East Asia.
Topics: Adult; Antimalarials; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Malaria; Malays | 1981 |
Acute malaria in children in Madang: endemicity, clinical presentation and treatment.
Topics: Amodiaquine; Child, Preschool; Chloroquine; Drug Resistance; Humans; Malaria; Papua New Guinea; Plas | 1981 |
Chloroquine-resistant Plasmodium falciparum malaria in Madang children.
Topics: Child; Child, Preschool; Chloroquine; Drug Resistance; Female; Humans; Infant; Malaria; Male; Papua | 1981 |
Malaria: management of a peripatetic problem.
Topics: Abdomen; Adult; Anemia, Hemolytic, Autoimmune; Anemia, Megaloblastic; Diagnosis, Differential; Femal | 1982 |
Antimalarial activity of cyclosporin A.
Topics: Animals; Antimalarials; Cyclosporins; Drug Interactions; Malaria; Male; Mice; Mice, Inbred Strains; | 1981 |
Ineffective malaria prophylaxis.
Topics: Adult; Drug Combinations; Female; Humans; Malaria; Male; Plasmodium falciparum; Pyrimethamine; Sulfa | 1982 |
The antimalarial activity of N-benzyl-oxydihydrotriazines. IV. The development of resistance to BRL 6231 (4,6-diamino-1,2-dihyydro-2-,2-dimethyl-1-(2,4,5-trichloropropyloxy)-1,3,5 triazine hydrochloride) by Plasmodium berghei.
Topics: Animals; Antimalarials; Drug Resistance; Malaria; Male; Mice; Plasmodium berghei; Pyrimethamine; Tri | 1982 |
Drug-resistant malaria in Africa. A case report and review of the problem and treatment.
Topics: Adult; Chloroquine; Drug Resistance; Drug Therapy, Combination; Humans; Malaria; Male; Plasmodium fa | 1982 |
Adoptive transfer of resistance to Plasmodium berghei with spleen cells and serum from Fansidar-cured mice.
Topics: Animals; Antimalarials; B-Lymphocytes; Drug Combinations; Female; Malaria; Mice; Plasmodium berghei; | 1982 |
Possible sulfadoxine-pyrimethamine resistance in Plasmodium falciparum malaria from Kenya.
Topics: Adult; Antimalarials; Drug Combinations; Drug Resistance, Microbial; Humans; Kenya; Malaria; Male; P | 1982 |
Falciparum malaria resistant to Fansidar (sulphadoxine-pyrimethamine) occurring in three children of the same family.
Topics: Child, Preschool; Drug Combinations; Drug Resistance, Microbial; Humans; Infant; Malaria; Malaysia; | 1982 |
In vitro demonstration of pyrimethamine resistance of "wild" Plasmodium falciparum in The Gambia.
Topics: Animals; Child; Child, Preschool; Drug Resistance, Microbial; Gambia; Humans; Malaria; Plasmodium fa | 1982 |
Indications for the use of Fansidar in malaria.
Topics: Antimalarials; Drug Combinations; Drug Labeling; Humans; Malaria; Pyrimethamine; Sulfadoxine; Sulfan | 1982 |
A pyrimethamine-chloroquine combination for malaria prophylaxis during pregnancy.
Topics: Abnormalities, Drug-Induced; Chloroquine; Drug Combinations; Female; Fetus; Humans; Malaria; Pregnan | 1982 |
[Malaria prophylaxis and therapy].
Topics: Antimalarials; Drug Combinations; Humans; Malaria; Pyrimethamine; Sulfadoxine | 1982 |
The management and treatment of malaria (a personal view).
Topics: Chloroquine; Female; Humans; Malaria; Male; Pregnancy; Pregnancy Complications, Infectious; Proguani | 1980 |
[Malaria chemotherapy].
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Pyrimeth | 1981 |
Haptoglobin polymorphism and its relationship to malaria infections in The Gambia.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Female; Gambia; Haptoglobins; Humans; Infan | 1981 |
Effects of low concentrations of pyrimethamine on human bone marrow cells in vitro: possible implications for malaria prophylaxis.
Topics: Bone Marrow; Bone Marrow Cells; Deoxyuridine; Humans; In Vitro Techniques; Malaria; Pyrimethamine; T | 1981 |
Haemoglobinuria after a single dose treatment with dapsone and pyrimethamine for falciparum malaria in a patient with glucose-6-phosphate dehydrogenase deficiency.
Topics: Child, Preschool; Dapsone; Drug Combinations; Glucosephosphate Dehydrogenase; Glucosephosphate Dehyd | 1981 |
[Observation of therapeutic effect of single-dose combined administration of Qinghaosu, sulphomethoxine, pyrimethamine and primaquine in the treatment of chloroquine-resistant malignant malaria (author's transl)].
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Resistanc | 1981 |
The effect of malarial chemoprophylaxis on immunoglobulin levels of pregnant Nigerian women and the newborn.
Topics: Chloroquine; Female; Fetal Blood; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immu | 1980 |
Malaria treatment in Vanuatu: new national treatment guidelines.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Female; H | 1994 |
Prevention of malaria in travellers from the United Kingdom.
Topics: Adult; Antimalarials; Developing Countries; Drug Combinations; Female; Humans; Malaria; Male; Mefloq | 1993 |
Stage sensitivity of Plasmodium vinckei petteri to quinine, mefloquine, and pyrimethamine.
Topics: Animals; Malaria; Male; Mefloquine; Mice; Plasmodium; Pyrimethamine; Quinine; Time Factors | 1995 |
Self-medication with antimalarial drugs in Dar es Salaam, Tanzania.
Topics: Antimalarials; Chi-Square Distribution; Drug Combinations; Female; Humans; Malaria; Male; Medicine, | 1995 |
[Variation of cholostase enzymes (5'-nucleotidase and alkaline phosphatase) during a specific treatment for malaria in the Gabonese child].
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Antimalarials; Child; Child, Preschool; Drug Combinations; Ga | 1995 |
Malaria in east African refugees resettling to the United States: development of strategies to reduce the risk of imported malaria.
Topics: Africa, Eastern; Centers for Disease Control and Prevention, U.S.; Communicable Disease Control; Dru | 1995 |
The dihydrofolate reductase domain of rodent malarias: point mutations and pyrimethamine resistance.
Topics: Amino Acid Sequence; Animals; Base Sequence; Drug Resistance; Malaria; Molecular Sequence Data; Plas | 1994 |
Effect of pyrimethamine resistance on sporogony in a Plasmodium berghei/Anopheles stephensi model.
Topics: Animals; Anopheles; Drug Resistance; Female; Insect Vectors; Malaria; Mice; Plasmodium berghei; Pyri | 1994 |
[Current possibilities of malaria chemoprophylaxis].
Topics: Africa; Animals; Antimalarials; Contraindications; Developing Countries; Drug Combinations; Humans; | 1994 |
Malaria prophylaxis and treatment.
Topics: Botswana; Chloroquine; Humans; Malaria; Pyrimethamine; Zimbabwe | 1993 |
[Emergency treatment of malaria during travel].
Topics: Antimalarials; Drug Combinations; Emergencies; Humans; Malaria; Mefloquine; Patient Education as Top | 1993 |
How frequent are notified severe cutaneous adverse reactions to Fansidar?
Topics: Adverse Drug Reaction Reporting Systems; Antimalarials; Drug Combinations; Drug Eruptions; Drug Util | 1993 |
Antimalarial activity of novel arylene bis(methylketone) compounds.
Topics: Animals; Antimalarials; Chloroquine; Female; Malaria; Mice; Mice, Inbred Strains; Molecular Structur | 1996 |
Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Topics: Alanine Transaminase; Ammonia; Animals; Antimalarials; Aspartate Aminotransferases; Biomarkers; Brai | 1996 |
Multi-drug resistant malaria in Sri Lanka.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance, Multiple; Humans; Ma | 1996 |
Gene targeting in malaria parasites.
Topics: Animals; Anopheles; Genes, Reporter; Genetic Vectors; Humans; Malaria; Parasitemia; Plasmids; Plasmo | 1997 |
A role for B cells in the development of T cell helper function in a malaria infection in mice.
Topics: Animals; B-Lymphocytes; Chloroquine; Erythrocytes; Female; Genes, Immunoglobulin; Immunoglobulin mu- | 1998 |
Status of ammonia, glutamate, lactate and pyruvate during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Topics: Ammonia; Animals; Antimalarials; Glutamic Acid; Humans; Lactic Acid; Malaria; Mice; Plasmodium yoeli | 1997 |
Effect of intramuscular sulfadoxine-pyrimethamine on pregnant Wistar rats.
Topics: Animals; Antimalarials; Cricetinae; Drug Combinations; Embryo Loss; Female; Folic Acid Antagonists; | 1998 |
Status of urea and related enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Topics: Animals; Antimalarials; Liver; Malaria; Mice; Plasmodium yoelii; Pyrimethamine; Urea | 1997 |
Studies on infections with two strains of Plasmodium inui from Taiwan in rhesus monkeys and different anopheline mosquitoes.
Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Host-Parasite Interactions; Insect Vector | 1998 |
[Chemoprophylaxis of malaria in travelers to endemic zones].
Topics: Antimalarials; Chloroquine; Dapsone; Doxycycline; Drug Resistance; Drug Therapy, Combination; Humans | 1998 |
Use of antimalarial drugs in Mali: policy versus reality.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Consumer Behavior; Data Collection; Drug Combinations | 1998 |
Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Adverse Drug Reaction Reporting Systems; | 1998 |
Adverse effects of antimalarial prophylactic drugs: an important consideration in the risk-benefit equation.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Atovaquone; Azithromycin; Chloroquine; Drug Therapy, | 1998 |
[Evaluation of malaria chemoprevention among 359 pregnant women attending a health center in Dakar].
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Chloroquine; Female; Humans; Malaria; Maternal He | 1997 |
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum | 1998 |
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum | 1998 |
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum | 1998 |
Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Female; HIV Infections; HIV Seroprevalence; Hum | 1998 |
[The proper use of antimalarial drugs currently available].
Topics: Animals; Antimalarials; Chemoprevention; Chloroquine; Contraindications; Drug Combinations; Drug Res | 1998 |
Plasmodium chabaudi: effect of antimalarial drugs on gametocytogenesis.
Topics: Animals; Antimalarials; Chloroquine; Gametogenesis; Malaria; Male; Mefloquine; Mice; Mice, Inbred C5 | 1999 |
Plasmodium cynomolgi: transfection of blood-stage parasites using heterologous DNA constructs.
Topics: Animals; Antimalarials; Disease Models, Animal; DNA Primers; DNA, Protozoan; Drug Resistance; Electr | 1999 |
Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Doxycycline; Erythromycin; | 2000 |
Studies on hepatic mitochondrial cytochrome P-450 during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Topics: Animals; Antimalarials; Cytochrome P-450 Enzyme System; Malaria; Mice; Microsomes, Liver; Mitochondr | 2000 |
Patterns of care for childhood malaria in Zambia.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Fever; Health Care Surveys; | 2000 |
Folic acid antagonists during pregnancy and risk of birth defects.
Topics: Abnormalities, Drug-Induced; Antimalarials; Drug Combinations; Female; Folic Acid Antagonists; Human | 2001 |
Gene targeting in the rodent malaria parasite Plasmodium yoelii.
Topics: Animals; Antimalarials; Gene Deletion; Gene Targeting; Malaria; Mice; Mice, Inbred BALB C; Multienzy | 2001 |
Homology modeling of wild type and pyrimethamine/cycloguanil-cross resistant mutant type Plasmodium falciparum dihydrofolate reductase. A model for antimalarial chemotherapy resistance.
Topics: Amino Acid Sequence; Animals; Antimalarials; Binding Sites; Chickens; Drug Resistance; Folic Acid An | 2001 |
Malaria control in Tanzania.
Topics: Antimalarials; Drug Combinations; Humans; Infant; Malaria; Pyrimethamine; Sulfadoxine; Tanzania | 2001 |
Potent antimalarial activities of polyether antibiotic, X-206.
Topics: Actinomycetales; Animals; Anti-Bacterial Agents; Antimalarials; Artemether; Artemisinins; Artesunate | 2001 |
[Danger of malaria self-treatment. Acute neurologic toxicity of mefloquine and its combination with pyrimethamine-sulfadoxine].
Topics: Adult; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Malaria; Mal | 2001 |
Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience.
Topics: Africa, Eastern; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Geography; Health C | 2001 |
Perception of chloroquine efficacy and alternative treatments for uncomplicated malaria in children in a holoendemic area of Tanzania: implications for the change of treatment policy.
Topics: Adolescent; Adult; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Endemic Diseases | 2001 |
Changing the first line drug for malaria treatment--cost-effectiveness analysis with highly uncertain inter-temporal trade-offs.
Topics: Africa South of the Sahara; Antimalarials; Case Management; Child; Child, Preschool; Chloroquine; Co | 2001 |
African scientists discuss drug-resistant malaria.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance, Multiple; Drug Therapy, Com | 2002 |
Intermittent malaria treatment as a component of the EPI (Expanded Programme on Immunization) schedule in Africa.
Topics: Africa; Anemia; Antimalarials; Drug Administration Schedule; Drug Combinations; Humans; Immunization | 2002 |
Diagnosis of iron deficiency anaemia among Nigerian pregnant women by serum iron/T.I.B.C. determination.
Topics: Anemia, Hypochromic; Blood Cells; Female; Folic Acid; Folic Acid Deficiency; Humans; Iron; Malaria; | 1976 |
Development of effective antisporozoite immunity by natural bites of Plasmodium-berghei-infected mosquitoes in rats under prophylactic treatment with various drug regimens.
Topics: Animals; Antibodies; Chloroquine; Cross Reactions; Culicidae; Malaria; Plasmodium berghei; Primaquin | 1978 |
Comparative studies on dihydrofolate reductases from Plasmodium falciparum and Aotus trivirgatus.
Topics: Animals; Aotus trivirgatus; Erythrocytes; Haplorhini; Hydrogen-Ion Concentration; Malaria; Molecular | 1979 |
Megaloblastic anaemia associated with combined pyrimethamine and co-trimoxazole administration.
Topics: Adult; Anemia, Macrocytic; Anemia, Megaloblastic; Drug Combinations; Drug Therapy, Combination; Fema | 1976 |
Persistence of drug-resistant malaria parasites.
Topics: Animals; Chloroquine; Drug Resistance; Malaria; Mice; Mutation; Plasmodium; Pyrimethamine | 1978 |
Fansidar resistant falciparum malaria in Indonesia.
Topics: Antimalarials; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Male; Middle Aged; Pl | 1979 |
Plasmodium falciparum and Plasmodium vivax infections in the owl monkey (Aotus trivirgatus). II. Responses to chloroquine, quinine, and pyrimethamine.
Topics: Animals; Aotus trivirgatus; Chloroquine; Disease Models, Animal; Dose-Response Relationship, Drug; F | 1978 |
Antimalarial activities of various 9-phenanthrenemethanols with special attention to WR-122,455 and WR-171,669.
Topics: Animals; Antimalarials; Chloroquine; Haplorhini; Humans; Malaria; Phenanthrenes; Plasmodium falcipar | 1978 |
Malaria and beriberi: unresolved military medical problems contributing to the fall of Cambodia.
Topics: Antimalarials; Beriberi; Cambodia; Drug Combinations; Glucosephosphate Dehydrogenase Deficiency; Hem | 1979 |
Studies on the 2,4-diamino-6 substituted quinazolines. I. Antimalarial activities of 2,4-diamino-6-[(3,4-dichlorobenzyl)-nitrosoamino]-quinazoline (CI-679) as exhibited in rhesus monkeys infected with the Ro or Ro/PM strains of Plasmodium cynomolgi.
Topics: Animals; Anopheles; Drug Resistance, Microbial; Female; Haplorhini; Macaca mulatta; Malaria; Male; P | 1979 |
Studies on the 2,4-diamino-6-substituted quinazolines. II. Activities of selected derivatives against infections with various drug-susceptible and drug-resistant strains of Plasmodium falciparum and Plasmodium vivax in owl monkeys.
Topics: Animals; Aotus trivirgatus; Chemical Phenomena; Chemistry; Chloroquine; Drug Resistance, Microbial; | 1979 |
Studies on the 2,4-diamino-6-substituted quinazolines. III. The capacity of sulfadiazine to enhance the activities of WR-158,122 and WR-159,412 against infections with various drug-susceptible and drug-resistant strains of Plasmodium falciparum and Plasmo
Topics: Animals; Aotus trivirgatus; Drug Combinations; Drug Resistance, Microbial; Female; Haplorhini; Malar | 1979 |
[Problems with malaria. Epidemiology, clinical aspects and therapy].
Topics: Drug Resistance, Microbial; Female; Germany, West; Hospitalization; Humans; India; Malaria; Male; Pa | 1979 |
Resistance to antimalarials by Plasmodium falciparum in Burma.
Topics: Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Myanmar; Plasmodium falciparum; Pyrime | 1977 |
Prevention and treatment of malaria.
Topics: Amodiaquine; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Qu | 1977 |
[Chloroquine resistant tropical malaria imported from Surinam].
Topics: Chloroquine; Drug Resistance; Female; Humans; Malaria; Middle Aged; Netherlands; Plasmodium falcipar | 1977 |
[Obscure diagnosis of malaria (author's transl)].
Topics: Adult; Humans; Malaria; Male; Plasmodium vivax; Pyrimethamine | 1977 |
The chemotherapy of rodent malaria, XXVIII. The development of resistance to mefloquine (WR 142,490).
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance, Microbial; Malaria; Mice; Piperidines; P | 1977 |
The influence of acetylator phenotype on the response to sulfalene in individuals with chloroquine-resistant falciparum malaria.
Topics: Acetylation; Adult; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Mala | 1978 |
[Malaria; a summary].
Topics: Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Plasmodium malariae; Plasmodiu | 1978 |
A comparative study of malaria prophylaxis in peninsular Malaysia using chloroquine and a combination of sulphadoxine and pyrimethamine.
Topics: Adult; Child; Child, Preschool; Chloroquine; Drug Combinations; Female; Humans; Leukocyte Count; Mal | 1978 |
Malaria prophylaxis for visitors to Papua New Guinea.
Topics: Dapsone; Drug Therapy, Combination; Humans; Malaria; New Guinea; Plasmodium falciparum; Pyrimethamin | 1978 |
The treatment of malaria.
Topics: Chloroquine; Drug Combinations; Female; Humans; Malaria; Plasmodium falciparum; Pyrimethamine | 1978 |
Clearance of falciparum parasitaemia with a single dose sulfadoxine-pyrimethamine in Vientiane, Laos.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Combinations; Female; Humans; Laos; Malaria; Male; | 1978 |
Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone.
Topics: Acute Disease; Adult; Drug Combinations; Humans; Malaria; Male; Plasmodium vivax; Pyrimethamine; Sul | 1979 |
Falciparum malaria despite chemoprophylaxis.
Topics: Chloroquine; Dapsone; Drug Combinations; Humans; Malaria; Plasmodium falciparum; Pyrimethamine | 1979 |
Fansidar for falciparum malaria.
Topics: Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Sulfadoxine; Sulfanilamides | 1979 |
Treatment of falciparum malaria in Thai children.
Topics: Child; Child, Preschool; Chloroquine; Dose-Response Relationship, Drug; Drug Therapy, Combination; F | 1979 |
Drug-resistant falciparum malaria among the Mayongong Indians in the Brazilian Amazon.
Topics: Adolescent; Adult; Brazil; Child; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Female | 1979 |
Malaria in Australia.
Topics: Australia; Chloroquine; Dapsone; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falciparum; | 1979 |
Possible chloroquine-resistant Plasmodium falciparum in Nigeria.
Topics: Chloroquine; Drug Resistance; Drug Therapy, Combination; Erythrocytes; Humans; Malaria; Male; Middle | 1979 |
Which prophylactic drugs for malaria?
Topics: Humans; Malaria; Plasmodium falciparum; Plasmodium vivax; Proguanil; Pyrimethamine | 1979 |
Chemotherapy of falciparum malaria: regional differences in responsiveness to treatment.
Topics: Adult; Africa, Central; Africa, Western; Asia, Southeastern; Chloroquine; Drug Resistance; Drug Ther | 1979 |
Chloroquine resistance in P. falciparum in Assam State.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India; In | 1979 |
Response to chloroquine with and without pyrimethamine in Plasmodium falciparum in West Bengal, Tripura, Mizoram, Manipur and Arunachal Pradesh.
Topics: Animals; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Pyrimethamine | 1979 |
Quantitative aspects of pyrimethamine-sulfonamide synergism.
Topics: Animals; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Haplorhini; Macaca m | 1977 |
[Malaria is advancing again (author's transl)].
Topics: Aminoquinolines; Humans; Malaria; Pyrimethamine; Quinine; Sulfadoxine; Switzerland; Travel; Tropical | 1979 |
Malaria--a red alert.
Topics: Aged; Child; Chloroquine; Drug Resistance; Drug Therapy, Combination; Health Education; Humans; Mala | 1979 |
Chemoprophylaxis of chloroquine-resistant malaria; an additional note.
Topics: Chloroquine; Drug Resistance; Humans; Malaria; Pyrimethamine; Sulfadoxine | 1979 |
Chemoprophylaxis of malaria.
Topics: Chloroquine; Drug Evaluation; Drug Resistance, Microbial; Malaria; Proguanil; Pyrimethamine | 1977 |
Chloroquine-resistant falciparum malaria from Irian Jaya (Indonesian New Guinea).
Topics: Amodiaquine; Chloroquine; Drug Resistance; Humans; Malaria; Male; Piperidines; Plasmodium falciparum | 1976 |
Physiological and morphological characters in two pyrimethamine-resistant lines of Plasmodium berghei SP11 after cryopreservation.
Topics: Animals; Brain; Drug Resistance; Erythrocytes; Freezing; Malaria; Mice; Plasmodium berghei; Preserva | 1976 |
Chemoprophylaxis of malaria.
Topics: Adult; Antimalarials; Chloroquine; Humans; Malaria; Plasmodium falciparum; Proguanil; Pyrimethamine; | 1976 |
A comparative study of the efficacy of chloroquine and a combination of dapsone and pyrimethamine in the prophylaxis of malaria in Peninsular Malaysia.
Topics: Adult; Child; Chloroquine; Dapsone; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; M | 1976 |
Chemotherapy of Plasmodium vivax in Saimiri and Aotus models.
Topics: Administration, Oral; Animals; Chloroquine; Disease Models, Animal; Drug Combinations; Drug Evaluati | 1975 |
Antiplasmodial efficacy of 2,4--diaminopyrimidine0sylfonamide combinations, especially against chloroquine-resistant malaria.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance, Microb | 1975 |
Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
Topics: Amodiaquine; Animals; Antimalarials; Dapsone; Disease Models, Animal; Dose-Response Relationship, Dr | 1976 |
Chadwick lecture. Cerebral malaria--the quest for suitable experimental models in parasitic diseases of man.
Topics: Africa; Animals; Brain; Brain Diseases; Disease Models, Animal; Drug Resistance; Haplorhini; Humans; | 1976 |
[Chemotherapy and chemoprophylaxis of malaria (author's transl)].
Topics: Adult; Amodiaquine; Antimalarials; Asia, Southeastern; Central America; Child; Chloroquine; Drug Res | 1976 |
Chemoprophylaxis of malaria.
Topics: Antimalarials; Drug Combinations; Humans; Malaria; Pyrimethamine; Sulfadoxine | 1977 |
[Prevention and therapy of malaria and amebiasis].
Topics: Acetamides; Amebiasis; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Emetine; Humans; | 1977 |
[Chemoprophylaxis of malaria].
Topics: Africa; Asia; Chloroquine; Humans; Hungary; Malaria; Proguanil; Pyrimethamine; South America | 1976 |
[Effects of administration of a combination sulfadoxine-pyrimethamine on attacks of malaria in hyperendemic zones].
Topics: Adolescent; Adult; Child; Drug Combinations; Drug Evaluation; Drug Tolerance; Humans; Malaria; Pyrim | 1976 |
Breakthrough in fight against malaria.
Topics: Community Health Workers; Dapsone; Drug Combinations; Drug Evaluation; Humans; Infant; Malaria; Pyri | 1975 |
Host failure in treatment of malaria with sulfalene and pyrimethamine.
Topics: Adult; Amodiaquine; Drug Resistance; Drug Therapy, Combination; Erythrocytes; Humans; Malaria; Male; | 1975 |
Letter: Prevention of chloroquine-resistant falciparum malaria.
Topics: Chloroquine; Dapsone; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Malaria; Plasmo | 1975 |
Falciparum malaria cured by quinine followed by sulfadoxine-pyrimethamine.
Topics: Administration, Oral; Adult; Blood; Drug Combinations; Drug Therapy, Combination; Female; Humans; In | 1975 |
Sulfadoxine and pyrimethamine in the treatment of falciparum malaria in Vietnam.
Topics: Adolescent; Adult; Blood; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, | 1975 |
Chloroquine resistance of Plasmodium falciparum in West Irian and East Kalimantan.
Topics: Adult; Chloroquine; Drug Resistance; Erythrocytes; Humans; Indonesia; Malaria; Male; Plasmodium falc | 1975 |
Some effects of partial malaria suppression in Ugandan children during the first 3 years of life.
Topics: Antibodies; Child, Preschool; Chloroquine; Humans; Infant; Malaria; Plasmodium falciparum; Pyrimetha | 1975 |
Acetylator phenotype and response of individuals infected with a chloroquine-resistant strain of Plasmodium falciparum to sulfalene and pyrimethamine.
Topics: Acetylation; Adult; Chloroquine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Ther | 1975 |
A case of recurrent subacute disseminated intravascular coagulation associated with malarial prophylaxis.
Topics: Anemia, Hemolytic; Autopsy; Disseminated Intravascular Coagulation; Heparin; Humans; Malaria; Male; | 1975 |
Pharmacokinetic rationale for a malarial suppressant administered once monthly.
Topics: Adolescent; Adult; Dosage Forms; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 1975 |
An extended field trial of pyrimethamine combined with dapsone in the prophylaxis of malaria.
Topics: Adolescent; Adult; Child; Child, Preschool; Dapsone; Drug Therapy, Combination; Humans; Infant; Mala | 1975 |
[Use of injectable Fansidar in juvenile malaria in Dakar].
Topics: Adolescent; Child; Child, Preschool; Drug Combinations; Drug Evaluation; Female; Humans; Infant; Mal | 1975 |
A genetic investigation of virulence in a rodent malaria parasite.
Topics: Animals; Clone Cells; Crosses, Genetic; Drug Resistance; Glucose-6-Phosphate Isomerase; Malaria; Mic | 1976 |
Malaria therapy in 452 patients, with special reference to the use of quinine.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Drug Resistance; Drug Therapy, Combination; Female; H | 1992 |
Malarial parasitaemia in febrile children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Bacteremia; Child; Child, Preschool; Female; Fever; Gram-Negative B | 1992 |
Mefloquine plus sulfadoxine and pyrimethamine.
Topics: Animals; Drug Combinations; Drug Resistance; Humans; Malaria; Mefloquine; Plasmodium falciparum; Pyr | 1991 |
Pyrimethamine/sulfadoxine for falciparum malaria.
Topics: Adolescent; Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Malaria; Male; Plasm | 1991 |
Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic for malaria. Part 4. Effects on incidence of malaria infection.
Topics: Bedding and Linens; Blood; Child; Child, Preschool; Cohort Studies; Humans; Incidence; Infant; Insec | 1991 |
[Trends of tissue hypoxia following chemotherapy of acute malaria in mice].
Topics: Animals; Antimalarials; Cell Hypoxia; Drug Combinations; Malaria; Male; Mice; Mice, Inbred Strains; | 1991 |
In vitro sensitivity of southern African reference isolates of Plasmodium falciparum to chloroquine and pyrimethamine.
Topics: Africa, Southern; Animals; Chloroquine; Drug Resistance; Humans; Malaria; Microbial Sensitivity Test | 1991 |
[Prevention and treatment of malaria in expatriates living in Black Africa. Influence of chemoresistance. Investigations conducted in Brazzaville (Congo)].
Topics: Adolescent; Adult; Aged; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; | 1991 |
Resistance to antimalarials by Plasmodium falciparum in Arso PIR, Irian Jaya, Indonesia.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans | 1991 |
[Plasmodium falciparum resistant to sulfadoxine/pyrimethamine in Senegal].
Topics: Adult; Animals; Drug Combinations; Drug Resistance; Female; Humans; Malaria; Plasmodium falciparum; | 1991 |
A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimethamine in Diaoluo area, Hainan Province.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; China; Drug Combinations; Drug Resistance; D | 1991 |
Treatment of malaria with sulfadoxine/pyrimethamine: note of caution.
Topics: Animals; Antimalarials; Drug Combinations; Drug Resistance; Humans; Infant; Malaria; Male; Plasmodiu | 1990 |
Malaria prophylaxis and self-therapy in airline crews.
Topics: Aerospace Medicine; Africa; Animals; Antimalarials; Culicidae; Drug Combinations; Drug Resistance; E | 1990 |
Evidence for specific suppression of gametocytemia by Plasmodium falciparum in residents of hyperendemic Irian Jaya.
Topics: Adolescent; Adult; Animals; Antibodies, Protozoan; Child; Child, Preschool; Drug Combinations; Ethni | 1991 |
Pyrimethamine-sulfadoxine (Fansidar) resistance in a non-immune Kenyan--a case report.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Humans; Kenya; Malar | 1991 |
Problems of chloroquine-resistant P. falciparum in Nigeria: one antimalaria drugs' utilisation in metropolitan Calabar.
Topics: Adult; Animals; Chloroquine; Drug Resistance, Microbial; Educational Status; Female; Humans; Malaria | 1991 |
Application of a simplified in-vivo test system for determining chloroquine resistance in Plasmodium falciparum.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Dose-Response Relationship, Drug; Dru | 1990 |
In vitro and in vivo susceptibility of Plasmodium falciparum isolates from Liberia to pyrimethamine, cycloguanil and chlorcycloguanil.
Topics: Animals; Antimalarials; Dose-Response Relationship, Drug; Drug Resistance; Humans; In Vitro Techniqu | 1990 |
Activities of new acridone alkaloid derivatives against Plasmodium yoelii in vitro.
Topics: Acridines; Acridones; Alkaloids; Animals; Antimalarials; Cell Survival; Chloroquine; Erythrocytes; I | 1990 |
[Imported fever in a 4-year-old boy].
Topics: Africa, Central; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi | 1990 |
Malaria prophylaxis in travellers to tropical Africa.
Topics: Africa; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Humans; Mal | 1990 |
Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria.
Topics: Amino Acid Sequence; Animals; Binding Sites; DNA; Drug Resistance; Humans; Malaria; Models, Structur | 1990 |
Falciparum malaria resistant to quinine and pyrimethamine-sulfadoxine successfully treated with mefloquine.
Topics: Adult; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; Female; Humans; | 1990 |
[Uncomplicated malaria attack in an area with high resistance to chloroquine. 3. The use of second-choice oral drug treatment].
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Re | 1990 |
[Look systematically for malaria in exposed children].
Topics: Adoption; Animals; Child, Preschool; Chloroquine; Emigration and Immigration; Female; Humans; Infant | 1990 |
Efficacies of chloroquine and pyrimethamine-sulphadoxine in a Nigerian population with chloroquine resistant P. falciparum malaria.
Topics: Animals; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Humans; Infant; Malaria; | 1990 |
Isolated malaria outbreak in Somalia: role of chloroquine-resistant Plasmodium falciparum demonstrated in Balcad epidemic.
Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Disease Outbreaks; Dose-Response R | 1990 |
[Combined action of pyronaridine and sulfadoxine/pyrimethamine against Plasmodium berghei ANKA strain in mice].
Topics: Animals; Antimalarials; Drug Synergism; Drug Therapy, Combination; Female; Malaria; Male; Mice; Naph | 1990 |
[Plasmodium falciparum drug resistance in the Congo. Evaluation of surveys carried out from 1985 to 1989].
Topics: Adolescent; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroqui | 1990 |
Chromosomal rearrangements and point mutations in the DHFR-TS gene of Plasmodium chabaudi under antifolate selection.
Topics: Animals; Chromosomes; Cloning, Molecular; Drug Resistance; Malaria; Mice; Mice, Inbred BALB C; Mutat | 1990 |
[Drugs used against protozoan infections in man].
Topics: Amebiasis; Aminoquinolines; Antiprotozoal Agents; Humans; Malaria; Metronidazole; Pneumonia, Pneumoc | 1990 |
Pharmacokinetics of mefloquine in combination with sulfadoxine-pyrimethamine and primaquine in male Thai patients with falciparum malaria.
Topics: Adolescent; Adult; Animals; Drug Resistance; Drug Therapy, Combination; Half-Life; Humans; Malaria; | 1990 |
Microscopic and flow cytophotometric analysis of parasitemia in cultures of Plasmodium falciparum vitally stained with Hoechst 33342--application to studies of antimalarial agents.
Topics: Antimalarials; Benzimidazoles; Chloroquine; Cyclosporins; DNA; Erythrocytes; Flow Cytometry; Fluores | 1986 |
[Chloroquine-resistant Plasmodium falciparum malaria confirmed by semi-micro sensitivity test for chloroquine seen in a person returned from Nigeria to Japan].
Topics: Adult; Animals; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Male; Nigeria; Pla | 1989 |
Stevens-Johnson syndrome due to pyrimethamine/sulfadoxine during presumptive self-therapy of malaria.
Topics: Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Malaria; Medication Error | 1989 |
Oral lichenoid reactions during antimalarial prophylaxis with sulphadoxine-pyrimethamine combination.
Topics: Adult; Drug Therapy, Combination; Humans; Lichen Planus; Malaria; Malaysia; Male; Mouth Diseases; Py | 1989 |
Chemotherapeutic malaria control operation by single dose of Fansidar plus primaquine in North Sumatra, Indonesia.
Topics: Age Factors; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Humans; Indonesi | 1989 |
Mitochondria as the site of action of tetracycline on Plasmodium falciparum.
Topics: 2,4-Dinitrophenol; Animals; Cycloheximide; Dinitrophenols; Electrophoresis, Polyacrylamide Gel; Huma | 1989 |
Antimalarial properties of ebselen.
Topics: Animals; Antimalarials; Antioxidants; Azoles; Cell Line; Humans; Isoindoles; Macrophages; Malaria; M | 1989 |
[Comparative efficacy of alternative treatments in Plasmodium falciparum infections in Zaire].
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Democratic Republic of the Congo; Drug Resist | 1989 |
Malaria prophylaxis--a persisting dilemma.
Topics: Adult; Animals; Female; Humans; Malaria; Male; Middle Aged; Plasmodium falciparum; Pyrimethamine; Qu | 1989 |
[Plasmodium falciparum drug resistance and sulfadoxine-pyrimethamine in Africa].
Topics: Adult; Africa; Animals; Antimalarials; Drug Resistance; Drug Therapy, Combination; Female; France; H | 1989 |
Fansimef in the treatment of malaria.
Topics: Animals; Antimalarials; Drug Combinations; Humans; Malaria; Mefloquine; Plasmodium vivax; Pyrimetham | 1989 |
A focus of high degree chloroquine resistant P. falciparum in Mandla district (M.P.).
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; F | 1989 |
Gametocytocidal and sporontocidal activity of some standard antimalarials on P. berghei (NK 65) infection M. natalensis.
Topics: Animals; Disease Models, Animal; Female; Malaria; Muridae; Plasmodium berghei; Primaquine; Pyrimetha | 1989 |
Chloroquine resistance in Plasmodium falciparum in KwaZulu, 1983-1988.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Malaria; Plasmodium falcipa | 1989 |
Antimalarial and toxic effect of triple combination of pyronaridine, sulfadoxine and pyrimethamine.
Topics: Animals; Antimalarials; Drug Therapy, Combination; Follow-Up Studies; Humans; Malaria; Mice; Naphthy | 1989 |
Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia.
Topics: Animals; Drug Resistance; Drug Therapy, Combination; Humans; Indonesia; Malaria; Parasite Egg Count; | 1989 |
Sulfadoxine specific lymphocyte transformation in a patient with eosinophilic pneumonia induced by sulfadoxine-pyrimethamine (Fansidar).
Topics: Adult; Antimalarials; Drug Combinations; Drug Hypersensitivity; Female; Humans; Lymphocyte Activatio | 1989 |
Curative and preventive treatment of uncomplicated malaria in public health institutions in Cameroon.
Topics: Amodiaquine; Antimalarials; Cameroon; Child; Chloroquine; Drug Combinations; Female; Humans; Malaria | 1989 |
Qinghaosu, mefloquine, and pyrimethamine-sulfadoxine in falciparum malaria.
Topics: Antimalarials; Artemisinins; Drug Combinations; Humans; Malaria; Mefloquine; Pyrimethamine; Quinolin | 1985 |
Qinghaosu, mefloquine, and pyrimethamine-sulfadoxine in falciparum malaria.
Topics: Artemisinins; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Mala | 1985 |
RI quinine-Fansidar resistant falciparum malaria from Malawi.
Topics: Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Malawi; Male; Middle Aged; Plasmodiu | 1985 |
Does chloroquine contribute to the risk of serious adverse reactions to fansidar?
Topics: Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Pyrimethamine; Skin Dise | 1985 |
Plasmodium falciparum resistant to mefloquine plus sulfadoxine/pyrimethamine.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Malaria; Mefloquine; Plasmodium falci | 1986 |
Combination treatment for falciparum prophylaxis.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Malaria; Mefloquine; Plasmodium falci | 1987 |
Compliance with malaria chemoprophylaxis programmes in Zimbabwe.
Topics: Chloroquine; Dapsone; Humans; Malaria; Patient Compliance; Pyrimethamine; Zimbabwe | 1987 |
Plasma concentrations of sulfadoxine in healthy and malaria infected Thai subjects.
Topics: Adolescent; Adult; Antimalarials; Drug Combinations; Half-Life; Humans; Malaria; Male; Pyrimethamine | 1988 |
An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy.
Topics: Antimalarials; Child; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Ma | 1989 |
Falciparum malaria treated with a fixed combination of mefloquine, sulfadoxine and pyrimethamine: a field study in adults in Burma.
Topics: Adolescent; Adult; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Malaria; Male; Mef | 1985 |
Erythroderma resembling sézary syndrome after treatment with Fansidar and chloroquine.
Topics: Antimalarials; Chloroquine; Dermatitis, Exfoliative; Drug Combinations; Humans; Malaria; Male; Middl | 1986 |
[The reliability and side effects of malaria chemoprophylaxis].
Topics: Antimalarials; Drug Combinations; Drug Eruptions; Drug Resistance; Humans; Malaria; Plasmodium falci | 1986 |
Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Eruptions; Eryth | 1986 |
Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar).
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Dermatitis, Exfoliative; Drug Combinations; Ecua | 1987 |
Adverse reactions to sulphadoxine-pyrimethamine in Swedish travellers: implications for prophylaxis.
Topics: Adult; Antimalarials; Drug Combinations; Drug Eruptions; Erythema Multiforme; Female; Humans; Malari | 1987 |
Need for malaria prophylaxis by travelers to areas with chloroquine-resistant Plasmodium falciparum.
Topics: Africa; Animals; Antimalarials; Centers for Disease Control and Prevention, U.S.; Chloroquine; Drug | 1986 |
Leads from the MMWR. Need for malaria prophylaxis by travelers to areas with chloroquine-resistant Plasmodium falciparum.
Topics: Africa; Antimalarials; Centers for Disease Control and Prevention, U.S.; Chloroquine; Drug Combinati | 1986 |
Serial studies on the evolution of drug resistance in malaria in an area of east Africa: findings from 1979 up to 1986.
Topics: Age Factors; Amodiaquine; Animals; Antibodies, Protozoan; Antimalarials; Child; Child, Preschool; Ch | 1988 |
[Evolving visceral malaria: an unusual occurrence in Europeans. Apropos of a case].
Topics: Animals; Antimalarials; Drug Combinations; Female; Humans; Intestinal Diseases, Parasitic; Malaria; | 1988 |
[An imported case of malaria resistant to chloroquine].
Topics: Animals; Cameroon; Child; Child, Preschool; Chloroquine; Doxycycline; Drug Combinations; Drug Resist | 1988 |
The first report of Plasmodium falciparum resistant to chloroquine plus sulphadoxine/pyrimethamine in Rwanda.
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combin | 1988 |
[Chloroquine and fansidar resistance of Plasmodium falciparum now also in Ghana].
Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Ghana; Humans; Malar | 1988 |
Fansimef [Fansidar plus mefloquine] is effective treatment for imported malaria in New Zealand.
Topics: Adolescent; Adult; Animals; Child; Drug Combinations; Female; Humans; Malaria; Male; Mefloquine; Pla | 1988 |
[Efficacy of combined use of pyronaridine, sulfadoxine and pyrimethamine in the treatment of falciparum malaria on Hainan Island].
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Drug Therapy, Combination; Humans; Malaria; Naphth | 1988 |
The combined use of artemether, sulfadoxine and pyrimethamine in the treatment of uncomplicated falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether; Artemisinins; Drug Resistance; Drug Therapy, | 1988 |
Multiple drug resistant Plasmodium falciparum malaria in a pregnant indigenous Zambian woman.
Topics: Adult; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Erythro | 1988 |
Studies on efficacy of treatment with sulfamethoxazole + trimethoprim and sulfalene + pyrimethamine combinations in Plasmodium falciparum malaria of known and unknown resistant status.
Topics: Animals; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; India; Mala | 1988 |
Agranulocytosis associated with the use of amodiaquine for malaria prophylaxis.
Topics: Agranulocytosis; Amodiaquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; Proguan | 1986 |
[Black water fever associated with quinine-MP therapy of a malaria patient].
Topics: Adult; Antimalarials; Blackwater Fever; Drug Combinations; Humans; Malaria; Male; Plasmodium falcipa | 1986 |
Severe orthostatic hypotension during treatment of falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Drug Therapy, Combination; Humans; Hypotension, Or | 1988 |
Sulfadoxine-pyrimethamine resistant malaria from west or central Africa.
Topics: Adult; Africa; Animals; Drug Resistance; Humans; Malaria; Male; Plasmodium falciparum; Pyrimethamine | 1988 |
Death despite malaria prophylaxis.
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; Malaria; | 1988 |
Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar).
Topics: Chemical and Drug Induced Liver Injury; Drug Combinations; Drug Eruptions; Female; Humans; Kidney Di | 1985 |
Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Eruptions; Drug Resistance; Humans; Malaria; Pla | 1985 |
Leads from the MMWR. Revised recommendations for preventing malaria in travelers to areas with chloroquine-resistant Plasmodium falciparum.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Eruptions; Drug Resistance; Humans; Malaria; Pla | 1985 |
Malaria in north-eastern Botswana.
Topics: Botswana; Dapsone; Drug Therapy, Combination; Humans; Malaria; Pyrimethamine; Sulfadoxine; Sulfanila | 1988 |
Observations on early and late post-sporozoite tissue stages in primate malaria. V. The effect of pyrimethamine and proguanil upon tissue hypnozoites and schizonts of Plasmodium cynomolgi bastianellii.
Topics: Animals; Liver; Macaca mulatta; Malaria; Plasmodium; Proguanil; Pyrimethamine | 1988 |
Urinary level of sulfadoxine in falciparum malaria patients after treatment with sulfadoxine-pyrimethamine.
Topics: Animals; Drug Combinations; Humans; Malaria; Male; Plasmodium falciparum; Pyrimethamine; Sulfadoxine | 1988 |
Concurrent chloroquine and Fansidar resistance of Plasmodium falciparum: an imported case from Gabon.
Topics: Animals; Chloroquine; Drug Combinations; Drug Resistance; Gabon; Malaria; Mefloquine; Plasmodium fal | 1988 |
Genetic analysis of the human malaria parasite Plasmodium falciparum.
Topics: Adenosine Deaminase; Animals; Anopheles; Antigens, Protozoan; Chromosomes; Clone Cells; Crosses, Gen | 1987 |
Plasmodium falciparum RI resistance to quinine and sulphadoxine-pyrimethamine in the Solomon Islands.
Topics: Adult; Doxycycline; Drug Combinations; Drug Resistance; Humans; Malaria; Male; Pacific Islands; Plas | 1987 |
Pyrimethamine-sulfadoxine still effective against Plasmodium falciparum in Jayapura, Irian Jaya: RI-type resistance in 2 of 18 patients.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Resistance; Femal | 1987 |
Decreased hepatic elimination of pyrimethamine during malaria infection. Studies in the isolated perfused rat liver.
Topics: Animals; Kinetics; Liver; Malaria; Metabolic Clearance Rate; Plasmodium berghei; Pyrimethamine; Rats | 1987 |
Clinical evaluation of antimalarial regimens in Japan.
Topics: Animals; Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Japan; Malaria; Plasmodium f | 1987 |
Response of Plasmodium falciparum infections to pyrimethamine-sulfadoxine in Thailand.
Topics: Adult; Animals; Child; Drug Combinations; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Sul | 1987 |
Plasmodium falciparum in Kinshasa, Zaire: in vitro drug susceptibility studies.
Topics: Animals; Child; Chloroquine; Democratic Republic of the Congo; Drug Resistance; Humans; Malaria; Pla | 1987 |
A case of Plasmodium falciparum infection resistant to chloroquine.
Topics: Adult; Animals; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Male; Plasmodium f | 1987 |
The activity of drug combinations against established infections of rodent malaria.
Topics: Animals; Antimalarials; Chloroquine; Dapsone; Drug Therapy, Combination; Malaria; Mice; Plasmodium b | 1987 |
Fansidar resistance in the Philippines.
Topics: Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Resistance; Humans; Malaria; Male; | 1987 |
[2 cases of multiresistant Plasmodium falciparum malaria contracted in Douala with atypical clinical presentation].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Cameroon; Chloroquine; Drug Combinations; Dr | 1987 |
[Development of drug resistance in cases of P. falciparum malaria of African origin in a Parisian hospital. Comparison with field data and therapeutic consequences].
Topics: Africa; Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; France | 1987 |
Compared response to chloroquine, fansidar, quinine, and quinidine slow release of infections with Plasmodium falciparum in the Kivu region of Zaire.
Topics: Animals; Antimalarials; Chloroquine; Delayed-Action Preparations; Democratic Republic of the Congo; | 1987 |
Malaria on the Thai-Burmese border: treatment of 5192 patients with mefloquine-sulfadoxine-pyrimethamine.
Topics: Adult; Animals; Antimalarials; Child; Drug Therapy, Combination; Female; Humans; Malaria; Male; Mefl | 1987 |
Report of a case of P. falciparum malaria resistant to chloroquine and combination of sulfalene and pyrimethamine in Delhi.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Mal | 1987 |
Comparative efficacy of alternative primary therapies for Plasmodium falciparum infections in Malawi.
Topics: Amodiaquine; Animals; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Humans; Mal | 1987 |
ELISA tests for dapsone and pyrimethamine and their application in a malaria chemoprophylaxis programme.
Topics: Child, Preschool; Dapsone; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Gambia; Humans; Inf | 1986 |
Reduced efficacy of chemotherapy of Plasmodium chabaudi in T cell-deprived mice.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Lymphocyte Depletion; Malaria; Mice; Mice, Inb | 1987 |
Effects of Fansidar on chloroquine-resistant Plasmodium falciparum in Pakistan.
Topics: Disease Reservoirs; Drug Combinations; Drug Resistance; Humans; Malaria; Pakistan; Plasmodium falcip | 1986 |
The susceptibility of Plasmodium falciparum to sulfadoxine and pyrimethamine: correlation of in vivo and in vitro results.
Topics: Adult; Antimalarials; Drug Combinations; Drug Resistance, Microbial; Humans; In Vitro Techniques; Ma | 1986 |
Adaptation of the Indochina I/CDC strain of Plasmodium falciparum to the squirrel monkey (Saimiri sciureus).
Topics: Animals; Aotus trivirgatus; Cebidae; Chloroquine; Disease Models, Animal; Drug Resistance; Malaria; | 1986 |
Plasmodium falciparum: induction, selection, and characterization of pyrimethamine-resistant mutants.
Topics: Drug Resistance, Microbial; Malaria; Microbial Sensitivity Tests; Mutation; Plasmodium falciparum; P | 1986 |
Sensitivity in vivo of Plasmodium falciparum to chloroquine and pyrimethamine/sulfadoxine in a coastal area of Tanzania.
Topics: Adolescent; Child; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Plasmodium falciparum; P | 1986 |
Imported cases of chloroquine-resistant falciparum malaria in Iran.
Topics: Adolescent; Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combina | 1986 |
[Malaria prevention. Risk of infection in relation to preventive measures].
Topics: Adult; Africa; Antimalarials; Chloroquine; Drug Combinations; Female; Germany, West; Humans; India; | 1986 |
Epidemiology of emergence and spread of drug-resistant falciparum malaria in Southeast Asia.
Topics: Anopheles; Asia, Southeastern; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; I | 1986 |
The efficacy of artemether (qinghaosu) in Plasmodium falciparum and P. vivax in Burma.
Topics: Antimalarials; Artemether; Artemisinins; Chloroquine; Drug Combinations; Humans; Malaria; Plasmodium | 1986 |
[Chloroquine-resistant malignant malaria in Hainan Island: report of 10 years' study].
Topics: China; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Pyrimethamine | 1986 |
Failures of combined chloroquine and Fansidar prophylaxis in American travelers to East Africa.
Topics: Adult; Aged; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Female; Human | 1986 |
Response of Plasmodium falciparum to dihydrofolate reductase inhibitors in Malindi, Kenya.
Topics: Child; Drug Resistance, Microbial; Drug Therapy, Combination; Folic Acid Antagonists; Humans; Kenya; | 1986 |
Concurrent chloroquine- and Fansidar-resistant Plasmodium falciparum: an imported case into Zimbabwe.
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Male; Plasmodium falciparum | 1986 |
Epidemiology of the emergence and spread of drug-resistant falciparum malaria in South-East Asia and Australasia.
Topics: Antimalarials; Asia, Southeastern; Cambodia; Chloroquine; Dapsone; Drug Combinations; Drug Resistanc | 1986 |
Chloroquine-resistant falciparum malaria from East Africa.
Topics: Adult; Africa, Eastern; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, Microbial | 1986 |
A combination of sulfamonomethoxine and pyrimethamine versus other drugs for the treatment of malaria.
Topics: Adolescent; Adult; Aged; Chloroquine; Drug Combinations; Female; Humans; Malaria; Male; Middle Aged; | 1986 |
In vivo and in vitro susceptibility of Plasmodium falciparum to sulphadoxine/pyrimethamine in Liberia, West Africa.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Malaria; Male | 1986 |
Efficacy of malaria prophylaxis in American and Swiss travelers to Kenya.
Topics: Aminoquinolines; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination; Humans; K | 1987 |
Chloroquine and Fansidar prophylaxis--a reply.
Topics: Chloroquine; Drug Combinations; Erythrocytes; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; | 1987 |
Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum.
Topics: Chromatography, Affinity; Drug Resistance; Folic Acid Antagonists; Humans; Kinetics; Malaria; Methot | 1987 |
Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine.
Topics: Adolescent; Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Intes | 1987 |
A case of black water fever treated with peritoneal dialysis and artemether (quinghaosu derivative).
Topics: Artemether; Artemisinins; Blackwater Fever; Humans; Malaria; Middle Aged; Peritoneal Dialysis; Pyran | 1987 |
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis.
Topics: Adolescent; Adult; Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Erythrocyte Cou | 1987 |
Fatal Stevens-Johnson syndrome associated with Fansidar and chloroquine.
Topics: Child, Preschool; Chloroquine; Drug Combinations; Humans; Malaria; Male; Pyrimethamine; Stevens-John | 1986 |
Experiences with malaria chemoprophylaxis.
Topics: Adult; Chloroquine; Humans; Hungary; Malaria; Pyrimethamine; Travel | 1986 |
Accidental overdose of pyrimethamine and sulphadoxine for malaria prophylaxis without adverse effects.
Topics: Antimalarials; Drug Combinations; Female; Humans; Kinetics; Malaria; Male; Medication Errors; Pyrime | 1986 |
[Making good use of mefloquine].
Topics: Adult; Antimalarials; Child; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Mefloqu | 1985 |
Leads from the MMWR. Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria.
Topics: Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Plasmodium falciparum; Pyrimethami | 1985 |
[A case of malaria tropicameningoencephalitis (neuromalaria) with chloroquine and pyrimethamine/sulfadoxine resistance].
Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Therapy, Combination; Hu | 1985 |
Sensitivity of Plasmodium falciparum to antimalarial drugs in Colombia.
Topics: Amodiaquine; Antimalarials; Chloroquine; Colombia; Drug Combinations; Drug Resistance, Microbial; Ge | 1985 |
Chloroquine-resistant falciparum malaria in northern Malawi.
Topics: Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; Malawi; Male; Mi | 1985 |
Development of an in vitro microtest for determining the susceptibility of Plasmodium falciparum to sulfadoxine-pyrimethamine: laboratory investigations and field studies in Port-au-Prince, Haiti.
Topics: Animals; Drug Combinations; Haiti; Humans; Malaria; Microbial Sensitivity Tests; Plasmodium falcipar | 1985 |
In vitro susceptibility of Plasmodium falciparum collected from pyrimethamine-sulfadoxine sensitive and resistant areas in Thailand.
Topics: 4-Aminobenzoic Acid; Animals; Drug Combinations; Humans; Malaria; Microbial Sensitivity Tests; Plasm | 1985 |
Malaria in the province of Takeo, Cambodia.
Topics: Adolescent; Adult; Age Factors; Animals; Cambodia; Child; Child, Preschool; Drug Combinations; Drug | 1985 |
Fansidar for malaria prophylaxis.
Topics: Antimalarials; Drug Combinations; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Sulfadoxine | 1985 |
[The combined use of artemether, sulfadoxine, pyrimethamine and primaquine in the treatment of chloroquine-resistant falciparum malaria].
Topics: Adult; Animals; Antimalarials; Artemether; Artemisinins; Child; Chloroquine; Drug Resistance, Microb | 1985 |
In vivo assessment of the sensitivity of Plasmodium falciparum to sulphadoxine/pyrimethamine combination (Fansidar) in six localities in Tanzania where chloroquine-resistant P. falciparum has been detected.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance, | 1985 |
Decreased red cell deformability and vascular obstruction in falciparum malaria illustrated by a fatal case.
Topics: Blood Viscosity; Cell Survival; Drug Combinations; Erythrocyte Deformability; Erythrocytes; Exchange | 1985 |
Drug-resistant malaria--changing patterns mean difficult decisions.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance, Microbial; Humans | 1985 |
Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria.
Topics: Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Humans; Malaria; Plasmodium falcipar | 1985 |
Fansidar in malaria prophylaxis.
Topics: Antimalarials; Chloroquine; Drug Combinations; Humans; Malaria; Pyrimethamine; Sulfadoxine; Sulfanil | 1985 |
Erythema multiforme (Stevens-Johnson) precipitated by Fansidar.
Topics: Adult; Antimalarials; Drug Combinations; Humans; Malaria; Male; Pyrimethamine; Stevens-Johnson Syndr | 1985 |
Amodiaquine-induced agranulocytosis: drug inhibition of myeloid colonies in the presence of patient's serum.
Topics: Agranulocytosis; Amodiaquine; Bone Marrow Cells; Colony-Forming Units Assay; Dipyrone; Drug Interact | 1985 |
A comparison of the pyrimethamine and cycloguanil sensitivities of the pre-erythrocytic and erythrocytic stages of drug-sensitive and -resistant strains of Plasmodium yoelii.
Topics: Animals; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Malaria; Male; Mice; Plasmodi | 1985 |
[Malaria in 1985: new recommendations].
Topics: Africa; Asia; Chloroquine; Drug Combinations; Humans; Malaria; Pyrimethamine; South America; Sulfado | 1985 |
Boxed warning added to Fansidar labeling.
Topics: Drug Combinations; Humans; Malaria; Product Labeling; Pyrimethamine; Sulfadoxine; Sulfanilamides; Un | 1985 |
A comparison of chloroquine and pyrimethamine as malaria chemoprophylactics in young Nigerian children.
Topics: Antibodies; Chloroquine; Enzyme-Linked Immunosorbent Assay; Ferritins; Folic Acid; Hemodynamics; Hum | 1985 |
[Remarks on the drug prevention of malaria].
Topics: Adult; Antimalarials; Child; Chloroquine; Drug Administration Schedule; Drug Combinations; Drug Resi | 1985 |
Letter: Co-trimoxazole and the blood.
Topics: Administration, Oral; Adult; Anemia, Macrocytic; Blood Cell Count; Drug Therapy, Combination; Female | 1974 |
Sulphonamides in malaria.
Topics: Drug Synergism; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Sulfonamides | 1967 |
Choroquine-resistant Plasmodium falciparum malaria in the United Kingdom.
Topics: Adult; Chloroquine; England; Humans; Malaria; Malaysia; Male; Penicillin Resistance; Penicillins; Pl | 1968 |
Resistant falciparum malaria.
Topics: Asia, Southeastern; Drug Resistance, Microbial; Folic Acid; Humans; Malaria; Plasmodium falciparum; | 1969 |
Drug-resistant malaria.
Topics: Chloroquine; Dapsone; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falciparum; Primaquine | 1969 |
Pyrimethamine-induced leukopenia and thrombocytopenia in a patient with malaria and tropical sprue: case report.
Topics: Adult; Humans; Leukopenia; Malaria; Male; Pyrimethamine; Sprue, Tropical; Thrombocytopenia | 1973 |
Prophylaxis of malaria in man using the sulfone DFD with pyrimethamine.
Topics: Chloroquine; Dapsone; Formaldehyde; Humans; Malaria; Male; Plasmodium falciparum; Plasmodium vivax; | 1973 |
Comparison of precipitation malarial antibodies produced by indigenous immune Gambians and an infected European.
Topics: Antibodies; Antigen-Antibody Reactions; Black People; Blood Protein Electrophoresis; C-Reactive Prot | 1973 |
Experience with mixed infections of Plasmodium falciparum and vivax.
Topics: Antimalarials; Chloroquine; Dapsone; Humans; Malaria; Military Medicine; Plasmodium falciparum; Plas | 1973 |
Response to treatment in man of multi-drug resistant Plasmodium falciparum from Panama.
Topics: Adult; Amodiaquine; Animals; Anopheles; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug | 1974 |
Chemotherapeutic results in a multi-drug resistant strain of Plasmodium falciparum malaria from Vietnam.
Topics: Adult; Alanine Transaminase; Anopheles; Antimalarials; Aspartate Aminotransferases; Dapsone; Drug Re | 1974 |
[Treatment of cerebral malaria with a fansidar-hydergine combination].
Topics: Adolescent; Adult; Antimalarials; Brain Diseases; Child; Child, Preschool; Coma; Drug Combinations; | 1973 |
Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey--model systems for basic biological and chemotherapeutic studies.
Topics: Animal Feed; Animals; Butylamines; Chlorobenzenes; Chloroquine; Colombia; Darkness; Disease Models, | 1973 |
[Prevention and treatment of malaria. 2. Preventive of malaria with folic acid (sulformethoxine-pyrimethamine or sulfamonomethoxine--pyrimethamine compounds)].
Topics: Drug Combinations; Folic Acid Antagonists; Humans; Malaria; Pyrimethamine; Pyrimidines; Sulfanilamid | 1973 |
Resistance to antimalarials.
Topics: Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Pyrimethamine | 1966 |
Coombs'-positive hemolytic disease in malaria.
Topics: Adrenal Cortex Hormones; Adult; Anemia, Hemolytic; Antibodies; Chloroquine; Coombs Test; Drug Erupti | 1968 |
Hospital and field traials of sulformethoxine with pyrimethamine against Malaysian strains of Plasmodium falciparum and P. vivax.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; Female; Human | 1968 |
[Mass treatment with pyrimethamine and primaquine for malaria eradication in Sambú, Panama].
Topics: Humans; Malaria; Panama; Primaquine; Pyrimethamine | 1971 |
The control of malaria among the Orang Asli in West Malaysia.
Topics: Adolescent; Adult; Aged; Asian People; Black People; Child; Child, Preschool; Chloroquine; Ethnicity | 1972 |
Characterization of a drug resistant strain of Plasmodium falciparum from Burma.
Topics: Adult; Amodiaquine; Anopheles; Chloroquine; Drug Resistance, Microbial; Human Experimentation; Human | 1973 |
Generalised pustular drug rash.
Topics: Adult; Aged; Biguanides; Chloramphenicol; Chloroquine; Cross Reactions; Digoxin; Drug Eruptions; Fur | 1973 |
Correspondence: Misuse of fansidar.
Topics: Antimalarials; Dose-Response Relationship, Drug; Malaria; Pyrimethamine | 1973 |
Differences in drug response of the sporogonous cycles of three strains of Plasmodium falciparum in Anopheles stephensi.
Topics: Animals; Anti-Infective Agents; Antimalarials; Culicidae; Drug Resistance, Microbial; Folic Acid Ant | 1970 |
Gametocytocidal and sporontocidal effects of antimalarial drugs on malaria parasites. II. Action of the folic reductase inhibitors, chlorguanide, and pyrimethamine against Plasmodium cynomolgi.
Topics: Administration, Oral; Animals; Anopheles; Blood; Feeding Behavior; Folic Acid Antagonists; Macaca mu | 1974 |
Forty years of malaria control in Natal and Zululand.
Topics: Animals; Anopheles; Chloroquine; DDT; Disease Outbreaks; Emigration and Immigration; Health Educatio | 1974 |
Malaria prophylactic drug trial in Western Nigeria.
Topics: Child; Chloroquine; Drug Evaluation; Humans; Malaria; Nigeria; Pyrimethamine | 1974 |
[Tropical and parasitic diseases].
Topics: Acute Kidney Injury; Amebiasis; Antimalarials; Cholera; Drug Resistance, Microbial; Encephalitis; Gl | 1974 |
[Prevention of malaria].
Topics: Antimalarials; Chloroquine; Humans; Malaria; Proguanil; Pyrimethamine; World Health Organization | 1974 |
Effect of four different types of single-dose treatment with chloroquine and with chloroquine and pyrimethamine on Plasmodium falciparum infections in a semi-immune population in northern Nigeria.
Topics: Adolescent; Child; Child, Preschool; Chloroquine; Drug Combinations; Humans; Infant; Malaria; Nigeri | 1972 |
Response of drug-resistant Plasmodium falciparum to combined therapy in Panama.
Topics: Adult; Amodiaquine; Child; Chloroquine; Drug Resistance, Microbial; Humans; Infant; Malaria; Panama; | 1972 |
Sulphadoxine and pyrimethamine as treatment for acute Plasmodium falciparum malaria.
Topics: Acute Disease; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Military Medicine; Pl | 1972 |
Pyrimethamine resistance in The Gambia: a failure to prevent experimental infection with Plasmodium falciparum in a "non-immune".
Topics: Adult; Anopheles; Child, Preschool; Drug Resistance, Microbial; Gambia; Humans; Malaria; Plasmodium | 1972 |
Quinine infusion for recrudescences of falciparum malaria in Vietnam: a controlled study.
Topics: Dapsone; Humans; Infusions, Parenteral; Malaria; Plasmodium falciparum; Pyrimethamine; Quinine; Recu | 1972 |
[Treatment of malaria].
Topics: Adolescent; Amodiaquine; Child; Child, Preschool; Humans; Infant; Malaria; Plasmodium; Plasmodium fa | 1972 |
Imported malaria in Cape Town.
Topics: Africa; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falciparum; Plasmodium vivax; Pyrime | 1973 |
Experience with mass drug administration as a supplementary attack measure in areas of vivax malaria.
Topics: Anopheles; Chloroquine; DDT; Emergencies; Humans; Insecticide Resistance; Malaria; Mosquito Control; | 1972 |
Recrudescent falciparum malaria in Vietnam.
Topics: Adult; Black People; Dapsone; Fever; Follow-Up Studies; Humans; Malaria; Male; Military Medicine; Pl | 1973 |
A comparative evaluation of sulfalene-trimethoprim and sulphormethoxine-pyrimethamine against falciparum malaria in Thailand.
Topics: Adolescent; Adult; Anti-Infective Agents; Antibodies; Antimalarials; Drug Combinations; Evaluation S | 1973 |
Some haematological and biochemical effects of a malaria control programme in New Guinea.
Topics: Adolescent; Adult; Antimalarials; Blood Group Antigens; Blood Proteins; Child; Child, Preschool; Chl | 1973 |
The chemotherapy of rodent malaria. XVII. Dynamics of drug resistance. 3. Influence of drug combinations on the development of resistance to chloroquine in P. berghei.
Topics: Animals; Chloroquine; Drug Interactions; Drug Resistance, Microbial; Malaria; Mice; Plasmodium bergh | 1973 |
The chemotherapy of rodent malaria. 18. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. 5. The blood schizontocidal action of some newer sulphonamides.
Topics: Animals; Drug Resistance, Microbial; Drug Synergism; Folic Acid Antagonists; Malaria; Mice; Plasmodi | 1973 |
Strain specific immunity to Plasmodium berghei: a new genetic marker.
Topics: Animals; Anopheles; Cross Reactions; Crosses, Genetic; Drug Resistance, Microbial; Erythrocytes; Gen | 1973 |
Characterisation of a drug resistant strain of Plasmodium falciparum from Sabah.
Topics: Adult; Amodiaquine; Borneo; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodi | 1973 |
Synthesis of 5-substituted quinazolines as potential antimalarial agents.
Topics: Animals; Antimalarials; Folic Acid Antagonists; Liver; Malaria; Mice; Plasmodium berghei; Pyrimetham | 1973 |
The evaluation of quinine alone or in combination with tetracycline and pyrimethamine against falciparum malaria in Thailand.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Evaluation Studies as Topic; Female; H | 1973 |
The suppression of Plasmodium falciparum and Plasmodium vivax parasitaemias by a dapsone-pyrimethamine combination.
Topics: Adolescent; Adult; Child; Chloroquine; Dapsone; Drug Combinations; Female; Hematocrit; Humans; Malar | 1973 |
Chloroquine-resistant Falciparum malaria acquired in Vietnam.
Topics: Acute Kidney Injury; Adolescent; Adult; Blood Cell Count; Chloroquine; Dapsone; Drug Resistance, Mic | 1973 |
The evaluation of the presumptive and radical treatments against falciparum malaria in Thailand.
Topics: Adolescent; Adult; Blood; Chloroquine; Drug Evaluation; Female; Humans; Malaria; Male; Plasmodium fa | 1973 |
Malaria in New York City. IV. 1960-1971.
Topics: Adolescent; Adult; Africa, Western; Age Factors; Amodiaquine; Child; Child, Preschool; Chloroquine; | 1974 |
Characteristics of Plasmodium falciparum from the Solomon Islands.
Topics: Anopheles; Blood; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Pacific Islands; Plasmod | 1974 |
Multidrug-resistant strain of Plasmodium falciparum from eastern Colombia.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Colombia; Drug Combinations; Drug Resistance, Microbi | 1974 |
Genetic recombination in Plasmodium berghei.
Topics: Animals; Anopheles; Crosses, Genetic; Drug Resistance, Microbial; Erythrocytes; Glucose-6-Phosphate | 1973 |
Chemotherapeutic activity of combination doses of chloroquine, pyrimethamine, and sulfamethoxy-diazine, a long-acting sulfanilamide, against Plasmodium berghei infections in mice.
Topics: Animals; Chloroquine; Drug Combinations; Malaria; Mice; Plasmodium berghei; Pyrimethamine; Sulfanila | 1973 |
A comparison between the quinine and chloroquine regimens for falciparum malaria in Vietnam.
Topics: Administration, Oral; Chloroquine; Dapsone; Humans; Injections, Intravenous; Malaria; Male; Military | 1974 |
Morphologic and clinical effect of pyrimethamine-sulfonamide combinations (sulformethoxine-pyrimethamine or sulfamonomethoxine-pyrimethamine) on P. vivax and its infection.
Topics: Adolescent; Adult; Child; Drug Combinations; Female; Fever; Humans; Malaria; Male; Middle Aged; Ovum | 1974 |
Considerations on the use of sulphones and sulphonamides with a pyrimidine derivative.
Topics: Adult; Amodiaquine; Child; Dapsone; Drug Combinations; Drug Resistance, Microbial; Humans; Malaria; | 1974 |
Chemotherapy of rodent malaria: transfer of resistance vs mutation.
Topics: Animals; Blood; Cell Division; Chloroquine; Cricetinae; Drug Resistance, Microbial; Erythrocytes; Ex | 1974 |
Editorial: Drugs for prevention of malaria.
Topics: Antimalarials; Drug Resistance, Microbial; Drug Synergism; Humans; Malaria; Plasmodium falciparum; P | 1974 |
Some pharmacological aspects of antimalarial drugs.
Topics: Antimalarials; Chloroquine; Dapsone; Drug Resistance, Microbial; Humans; Malaria; Plasmodium falcipa | 1974 |
[Cerebral tropical malaria with blackwater fever. A current diagnostic and therapeutic problem].
Topics: Acute Kidney Injury; Adult; Blackwater Fever; Brain Diseases; Chloroquine; Disseminated Intravascula | 1974 |
[Treatment of drug-resistant malaria: animal experiments].
Topics: Amodiaquine; Animals; Chloroquine; Drug Evaluation, Preclinical; Drug Resistance; Drug Therapy, Comb | 1974 |
Recrudescence, poor response or resistance to quinine of falciparum malaria in Thailand.
Topics: Administration, Oral; Adult; Chloroquine; Drug Combinations; Drug Resistance, Microbial; Humans; Inj | 1974 |
[Malaria prevention for Swedish tourists in West-Africa].
Topics: Africa, Western; Antimalarials; Biguanides; Chloroquine; Drug Resistance; Humans; Malaria; Plasmodiu | 1974 |
Prevention of drug resistance in rodent malaria by the use of drug mixtures.
Topics: Animals; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; Malaria; Mice; Microbia | 1974 |
Studies on the characterization of plasmodium vivax strains from Central America.
Topics: Animals; Central America; Chloroquine; Haplorhini; Humans; Lincomycin; Malaria; Plasmodium vivax; Pr | 1972 |
Maternal anaemia and fetal birthweight.
Topics: Anemia; Anemia, Sickle Cell; Birth Weight; Blood Transfusion; Body Height; Chloroquine; Embryonic an | 1973 |
Letter: Delayed attacks of malaria in visitors to the tropics.
Topics: Chloroquine; Humans; Malaria; Pyrimethamine; Time Factors; Travel; Tropical Climate | 1973 |
[Antimetabolites of folic acid metabolism with chemotherapeutic activity against rodent malaria (Plasmodium vinckei)].
Topics: Aminopterin; Animals; Cycloheximide; Female; Folic Acid; Folic Acid Antagonists; Hydantoins; Malaria | 1973 |
Dihydrogolate reductase in Plasmodium lophurae and duckling erythrocytes.
Topics: Animals; Ducks; Erythrocytes; Folic Acid Antagonists; Hydrogen-Ion Concentration; Malaria; Molecular | 1974 |
Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquine-resistant Plasmodium falciparum from Thailand.
Topics: Adult; Chloroquine; Humans; Malaria; Male; Middle Aged; Plasmodium falciparum; Primaquine; Proguanil | 1967 |
Treatment of acute falciparum malaria with sulfalene and trimethoprim.
Topics: Chloroquine; Folic Acid Antagonists; Humans; Malaria; Male; Plasmodium falciparum; Pyrimethamine; Py | 1968 |
[Resistance in Protozoa].
Topics: Antiprotozoal Agents; Chloroquine; Drug Synergism; Malaria; Plasmodium; Pyrimethamine; Trypanosoma | 1967 |
Antimalarial effects of sulphormethoxine, diaphenylsulphone and separate combinations of these with pyrimethamine: a review of preliminary investigations carried out in Tanzania.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Dapsone; Drug Hypersensitivity; Drug Resistanc | 1968 |
[Treatment of "P. falciparum" malaria by delayed-action sulfonamides].
Topics: Antimalarials; Chloroquine; Delayed-Action Preparations; Drug Synergism; Humans; Malaria; Plasmodium | 1967 |
Apparent chloroquine-resistant falciparum malaria from coastal Brazil.
Topics: Brazil; Chloroquine; Drug Resistance, Microbial; Geography; Humans; Malaria; Male; Plasmodium falcip | 1968 |
Early experiences in the treatment of falciparum malaria from Southeast Asia.
Topics: Asia, Southeastern; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Military Medicin | 1968 |
Acute renal failure in Plasmodium falciparum malaria. Treatment of peritoneal dialysis.
Topics: Acute Kidney Injury; Adult; Creatinine; Electrocardiography; Humans; Kinetics; Malaria; Male; Milita | 1968 |
The sporogonous of Plasmodium vivax in Anopheles mosquitoes as a system for evaluating the prophylactic and curative capabilities of potential antimalarial compounds.
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Malaria; Naphthoquinones; Oxytetracycline; Penicilli | 1968 |
Chloroquine-pyrimethamine-sulfisoxazole therapy of Plasmodium falciparum malaria. An alternative to quinine.
Topics: Chloroquine; Dapsone; Drug Resistance, Microbial; Fever; Humans; Malaria; Male; Military Medicine; P | 1969 |
Studies on the relationship between fluorescent antibody response and ecology of malaria in Malaysia.
Topics: Adolescent; Adult; Anopheles; Child; Child, Preschool; Chloroquine; Ecology; Fluorescent Antibody Te | 1968 |
A clinical view of the biology of Plasmodia.
Topics: Antimalarials; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Plasmodium; Plasmodium falc | 1969 |
Acute falciparum malaria. Field experience with quinine-pyrimethamine combined therapy.
Topics: Chloroquine; Humans; Malaria; Military Medicine; Plasmodium falciparum; Plasmodium vivax; Primaquine | 1969 |
Response to drugs of South American strains of Plasmodium falciparum.
Topics: Chloroquine; Drug Resistance, Microbial; Drug Synergism; Fever; Humans; Malaria; Plasmodium falcipar | 1968 |
Combined pyrimethamine-quinine therapy for chloroquine-resistant P. falciparum infections.
Topics: Adolescent; Adult; Agranulocytosis; Anemia, Hemolytic; Chloroquine; Clinical Laboratory Techniques; | 1969 |
Antimalarial activity of Kelfizina-trimethoprim and Kelfizina-pyrimethamine versus chloroquine in field trials in Nigeria.
Topics: Adolescent; Adult; Child; Child, Preschool; Chloroquine; Folic Acid Antagonists; Humans; Infant; Mal | 1969 |
Combination therapy of malaria.
Topics: Chloroquine; Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Sulfisoxazole | 1969 |
Enhanced sensitivity of P. falciparum to sulphalene as a consequence of resistance to pyrimethamine.
Topics: Drug Resistance, Microbial; Folic Acid; Humans; Malaria; Male; Plasmodium falciparum; Pyrimethamine; | 1969 |
Pituitary-adrenal function in acute falciparum malaria.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Aldosterone; Humans; Malaria; Male; Metyrapone; Military | 1969 |
Fatal transfusion malaria.
Topics: Blood Volume; Chloroquine; Chorea; Dehydration; Dexamethasone; Humans; Malaria; Male; Middle Aged; N | 1969 |
Therapy of natural falciparum malaria with combinations of antifolic drugs in non-immune subjects.
Topics: Adult; Disease Outbreaks; Drug Synergism; Female; Folic Acid Antagonists; Humans; Infant; Malaria; M | 1970 |
Fatal pulmonary edema as a complication of acute falciparum malaria.
Topics: Adolescent; Adult; Cephalosporins; Chloroquine; Digitalis Glycosides; Humans; Hypersensitivity; Mala | 1970 |
Response of Laotian malaria strains to chemotherapy.
Topics: Adult; Antimalarials; Asian People; Chloroquine; Drug Resistance, Microbial; Humans; Japan; Laos; Ma | 1970 |
Studies on the chemotherapy of malaria. II. Pyrimethamine resistance in The Gambia.
Topics: Carrier State; Child; Child, Preschool; Dapsone; Drug Resistance, Microbial; Erythrocytes; Female; G | 1970 |
Folic acid deficiency complicating malaria.
Topics: Anemia, Macrocytic; Bone Marrow Examination; Diet; Erythrocyte Count; Folic Acid; Folic Acid Antagon | 1970 |
Experience with an insecticide-drug combination and observations on suppressive chloroquine-pyrimethamine treatment.
Topics: Child; Chloroquine; DDT; Humans; Malaria; Malaysia; Mosquito Control; Plasmodium falciparum; Plasmod | 1971 |
Malaria at Nam Ngum Dam construction site in Laos. I. Suppression with combinations of sulfonamides and pyrimethamine.
Topics: Chloroquine; Female; Humans; Laos; Leukopenia; Malaria; Male; Plasmodium falciparum; Plasmodium mala | 1971 |
Malaria revisited.
Topics: Chloroquine; Humans; Malaria; Military Medicine; Plasmodium falciparum; Plasmodium vivax; Primaquine | 1971 |
Curative and suppressive treatment of P. falciparum malaria with oral and parenteral Fansidar.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Child; Child, Preschool; Chloroquine; Dapson | 1971 |
Malaria resistant to chloroquine and sulphamethoxine-pyrimethamine.
Topics: Adult; Aniline Compounds; Chloroquine; Drug Resistance, Microbial; Drug Synergism; Humans; Malaria; | 1971 |
Malaria suppression and prophylaxis on a Malaysian rubber estate: sulformethoxine-pyrimethamine single monthly dose vs chloroquine single weekly dose.
Topics: Adolescent; Adult; Aged; Blood; Child; Child, Preschool; Chloroquine; Drug Combinations; Female; Hum | 1971 |
Acquired decrease in sensitivity to quinine observed during studies with a strain of chloroquine-resistant Plasmodium falciparum.
Topics: Adult; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodium falciparum; Pyrime | 1967 |
Clinical experience with sulphadiazine and pyrimethamine in the treatment of persons experimentally infected with chloroquine-resistant Plasmodium falciparum.
Topics: Adult; Antimalarials; Body Temperature; Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Ma | 1967 |
Activities of trimethoprim against infections with pyrimethamine susceptible and resistant strains of Plasmodium cynomolgi.
Topics: Animals; Folic Acid Antagonists; Haplorhini; Malaria; Plasmodium; Pyrimethamine; Pyrimidines | 1969 |
Human malaria (Plasmodium falciparum) in owl monkeys (Aotus trivirgatus).
Topics: Anemia; Animals; Antimalarials; Blood Coagulation; Haplorhini; Malaria; Myocardium; Plasmodium falci | 1969 |
The activities of chlorinated lincomycin derivatives against infections with Plasmodium cynomolgi in Macaca mulatta.
Topics: Animals; Anopheles; Antimalarials; Blood Bactericidal Activity; Chlorine; Haplorhini; Lincomycin; Ma | 1970 |
[Chemotherapeutic activity of standard antimalarials in a simplified test for Plasmodium vinckey infection in the NMPI mouse].
Topics: Animals; Antimalarials; Chloroquine; Long-Term Care; Malaria; Mice; Plasmodium; Primaquine; Pyrimeth | 1970 |
Exotic holidays and malaria.
Topics: Holidays; Humans; Malaria; Proguanil; Protective Clothing; Pyrimethamine | 1972 |
[Causal preventive activity of standard antimalarials in rodent malaria (Plasmodium berghei yoelii)].
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Malaria; Mice; Mice, Inbred Strains; Plasmodium; Pri | 1972 |
The role of drugs in a malaria program.
Topics: Amodiaquine; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Malaria; Primaqui | 1972 |
The chemotherapy of rodent malaria. XIV. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. 4. The response of normal and drug-resistant strains of Plasmodium berghei.
Topics: Animals; Chloroquine; Drug Resistance, Microbial; Folic Acid Antagonists; Malaria; Male; Mice; Prima | 1971 |
Potentiating action of sulfalene-pyrimethamine mixtures against drug-resistant strains of Plasmodium berghei.
Topics: Animals; Drug Combinations; Drug Resistance, Microbial; Drug Synergism; Injections, Intraperitoneal; | 1971 |
Malaria in childhood.
Topics: Child, Preschool; Chloroquine; Female; Humans; Infant; Malaria; Male; Nigeria; Pyrimethamine | 1971 |
[Effectiveness of trypanocides berenil and pentamidine in rodent malaria (Plasmodium vinckei)].
Topics: Acetates; Amidines; Animals; Antimalarials; Azo Compounds; Chloroquine; Cresols; Glycine; Malaria; P | 1971 |
Treatment of malaria infection.
Topics: Folic Acid Antagonists; Humans; Malaria; Pyrimethamine; Sulfonamides; Sulfones | 1969 |
The treatment of acute malaria with sulforthomidine and a combination of sulforthomidine and pyrimethamine.
Topics: Child; Child, Preschool; Drug Synergism; Humans; In Vitro Techniques; Malaria; Pyrimethamine; Sulfon | 1966 |
Preliminary studies on the anti-malarial activity of SDDS (2-sulfamoyl-4, 4'-diaminodiphenylsulfone) against Plasmodium berghei and Plasmodium gallinaceum.
Topics: Animals; Antimalarials; Chickens; Injections, Subcutaneous; Malaria; Malaria, Avian; Mice; Plasmodiu | 1967 |
[Initial results with Ro 6-4793-1 in malaria].
Topics: Antimalarials; Humans; Malaria; Plasmodium; Pyrimethamine; Sulfanilamides | 1968 |
[Initial results with the use of Ro 6-4793-1 in the treatment of malaria].
Topics: Adolescent; Adult; Antimalarials; Brazil; Humans; Malaria; Male; Middle Aged; Pyrimethamine; Sulfona | 1968 |
Heterophile antibodies, M-antiglobulins, immunoglobulins and acute phase proteins in pregnancy in Nigeria.
Topics: Antibodies; Antibodies, Anti-Idiotypic; C-Reactive Protein; Ceruloplasmin; Chloroquine; Female; Huma | 1970 |
Malaria in Laos. II. Peripheral leucocyte counts during long-term administration of combined folic inhibitors (pyrimethamine with sulformethoxine or sulfamonomethoxine).
Topics: Adenine; Administration, Oral; Aniline Compounds; Asian People; Drug Combinations; Folic Acid Antago | 1971 |
Resistance to cycloguanil pamoate (CI-501) by falciparum malaria in West Pakistan.
Topics: Adolescent; Antimalarials; Child; Child, Preschool; Female; Humans; Infant; Malaria; Male; Pakistan; | 1965 |
The effect of biweekly administration of 50 mg pyrimethamine in prevention of falciparum and vivax malaria.
Topics: China; Humans; Malaria; Plasmodium falciparum; Plasmodium vivax; Pyrimethamine | 1965 |
The evaluation of sulfonamides, alone or in combination with pyrimethamine, in the treatment of multi-resistant falciparum malaria.
Topics: Humans; Malaria; Plasmodium falciparum; Pyrimethamine; Sulfadiazine; Sulfonamides | 1966 |
Management of chloroquine resistant falciparum malaria.
Topics: Adult; Brain Diseases; Chloroquine; Dapsone; Dexamethasone; Drug Resistance, Microbial; Edema; Human | 1967 |
Some recent results on the chemotherapy of amebiasis, coccidiosis, and malaria.
Topics: Amebiasis; Animals; Animals, Domestic; Anti-Bacterial Agents; Coccidiosis; Emetine; Malaria; Pyrimet | 1969 |
Plasmodium vinckei: production of chloroquine-resistant strain.
Topics: Animals; Antimalarials; Arsenicals; Chloroquine; Cytoplasm; Drug Resistance, Microbial; Malaria; Met | 1969 |
Single step production of pyrimethamine-resistant P. berghei.
Topics: Animals; Cricetinae; Drug Resistance, Microbial; Malaria; Male; Mice; Plasmodium; Primaquine; Pyrime | 1970 |
Altered dihydrofolate reductase associated with drug-resistance transfer between rodent plasmodia.
Topics: Animals; Drug Resistance, Microbial; Genetics, Microbial; Kinetics; Malaria; Microbial Sensitivity T | 1970 |
Altered dihydrofolate reductase associated with a pyrimethamine-resistant Plasmodium berghei berghei produced in a single step.
Topics: Animals; Cricetinae; Drug Resistance, Microbial; Malaria; Mice; Plasmodium; Pyrimethamine; Tetrahydr | 1970 |
[Treatment of malaria with pyrimethamine-sulformethoxine in association].
Topics: Antimalarials; Humans; Malaria; Pyrimethamine; Pyrimidines; Sulfonamides | 1970 |
Drug sensitivity of exo-erythrocytic stages in pyrimethamine-resistant Plasmodium berghei.
Topics: Animals; Antimalarials; Drug Resistance, Microbial; Malaria; Male; Mice; Microbial Sensitivity Tests | 1970 |
The chemotherapy of rodent malaria. IX. Causal prophylaxis. I. A method for demonstrating drug action on exo-erythrocytic stages.
Topics: Animals; Antimalarials; Chloroquine; Dapsone; Malaria; Male; Mice; Plasmodium; Primaquine; Proguanil | 1970 |
The effects of pyrimethamine and sulphormethoxine on the pre-erythrocytic and sporogonous cycle of Plasmodium berghei berghei.
Topics: Animals; Malaria; Mice; Plasmodium; Pyrimethamine; Pyrimidines; Rats; Sulfur; Time Factors | 1970 |
The action of sulphonamide-folic reductase inhibitor combinations against normal and drug-resistant strains of rodent malaria.
Topics: Animals; Folic Acid Antagonists; Malaria; Mice; Proguanil; Pyrimethamine; Pyrimidines; Sulfadimethox | 1971 |
Malaria chemoprophylaxis.
Topics: Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Emigration and Immigration; Female; Huma | 1971 |
Resistant malaria.
Topics: Child; Dapsone; Drug Resistance, Microbial; Drug Synergism; Humans; Malaria; Pyrimethamine; Pyrimidi | 1971 |
Barrier spraying at the Kelantan side of the Thai-Malaysia border.
Topics: Anopheles; Child; Chloroquine; DDT; Dieldrin; Housing; Humans; Insect Vectors; Insecticide Resistanc | 1971 |
[Prophylaxis versus suppression of malaria].
Topics: Chloroquine; Humans; Malaria; Proguanil; Pyrimethamine | 1967 |
[Studies on resistance formation toward Plasmodium berghei in mice].
Topics: Animals; Breeding; Female; Malaria; Male; Mice; Plasmodium; Pyrimethamine; Rodent Diseases | 1967 |
Chloroquine-resistant falciparum malaria.
Topics: Chloroquine; Humans; Malaria; Military Medicine; Pyrimethamine; Quinine; Vietnam | 1967 |
The prevention of megaloblastic anaemia in pregnancy in Nigeria.
Topics: Anemia, Hypochromic; Anemia, Macrocytic; Female; Folic Acid; Hemolysis; Humans; Malaria; Nigeria; Pr | 1968 |
Medical problems from Vietnam.
Topics: Dapsone; Humans; Malaria; Military Medicine; Pyrimethamine; Quinine; Vietnam | 1968 |
Medical problems from Vietnam.
Topics: Amebiasis; Humans; Malaria; Military Medicine; Pyrimethamine; Quinine; Vietnam | 1968 |
Pyrimethamine-resistant strains of human malaria.
Topics: Drug Resistance, Microbial; Humans; Malaria; Male; Plasmodium; Pyrimethamine | 1968 |
Chemotherapy of malaria.
Topics: Drug Resistance, Microbial; Humans; Malaria; Proguanil; Pyrimethamine; Quinolines | 1968 |
Characteristics and cross-resistance patterns of chloroquine-resistant Plasmodium berghei infections in mice.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Dapsone; Drug Resistance, Microbial; Female; Hemat | 1968 |
Treatment of malaria.
Topics: Humans; Malaria; Pyrimethamine; Sulfonamides | 1968 |
Common anaemia in rural Gambia. 3. A spontaneously remitting anaemia possibly precipitated by malarial parasitaemia.
Topics: Adolescent; Anemia; Child; Child, Preschool; Female; Gambia; Hemoglobins; Humans; Infant; Infant, Ne | 1968 |
The chemotherapy of rodent malaria. VI. The action of some sulphonamides alone or with folic reductase inhibitors against malaria vectors and parasites. I. Introduction and anti-vector studies.
Topics: Animals; Anopheles; Female; Insect Vectors; Insecticides; Malaria; Mice; Pyrimethamine; Sucrose; Sul | 1968 |
Malaria--the British point of view.
Topics: Chloroquine; Drug Resistance, Microbial; Humans; Malaria; Malaysia; Military Medicine; Proguanil; Py | 1969 |
Drug-resistance transfer among rodent plasmodia. 1. Acquisition of resistance to pyrimethamine by a drug-sensitive strain of Plasmodium berghei in the course of its concomitant development with a pyrimethamine-resistant P. vinckei strain.
Topics: Animals; Cricetinae; Drug Resistance, Microbial; Malaria; Mice; Plasmodium; Pyrimethamine | 1969 |
Of men, malaria and megaloblasts.
Topics: Anemia, Macrocytic; Bone Marrow Diseases; Folic Acid Antagonists; Humans; Malaria; Pyrimethamine; Th | 1969 |
Comparative response of various rodent malarias to chemotherapy.
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Malaria; Male; Mice; Pyrimethamine | 1969 |
Cerebral malaria following blood transfusion.
Topics: Adult; Brain Diseases; Chloroquine; Communicable Disease Control; Disease Reservoirs; Humans; Malari | 1969 |
Pyrimethamine effect on folate metabolism.
Topics: Bone Marrow; Bone Marrow Cells; Culture Techniques; Folic Acid; Folic Acid Antagonists; Humans; Mala | 1969 |
Drug resistance in Plasmodium berghei Vincke and Lips, 1948. II. Triazine resistance.
Topics: Animals; Dapsone; In Vitro Techniques; Malaria; Mice; Plasmodium; Primaquine; Proguanil; Pyrimethami | 1965 |
Drug resistance in Plasmodium berghei Vincke and Lips, 1948. I. Chloroquine resistance.
Topics: Amodiaquine; Animals; Chloroquine; Dapsone; Malaria; Mice; Plasmodium; Primaquine; Proguanil; Pyrime | 1965 |
Daraclor trial.
Topics: Child; Child, Preschool; Chloroquine; Female; Humans; Infant; Infant, Newborn; Malaria; Male; Pyrime | 1966 |
[Pyrimethamine therapy combined with paraaminobenzoic acid-free diet in experimental malaria infection(Plasmodium berghei)].
Topics: Aminobenzoates; Animals; Erythrocytes; Malaria; Mice; Microscopy, Electron; Milk; Plasmodium; Pyrime | 1966 |